=== Generating (published_papers) ===
=== Generating (teaching_experience) ===
=== Generating (misc) ===
=== Generating (research_projects) ===
=== Generating (books_etc) ===
=== Generating (industrial_property_rights) ===
=== Generating (awards) ===
=== Generating (presentations) ===
==== begin registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/published_papers.jsonl) ====
line:1, {"insert":{"user_id":"B000320827","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38364549","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=407189","label":"url"}],"paper_title":{"en":"The binding selectivity of quercetin and its structure-related polyphenols to human serum albumin using a fluorescent dye cocktail for multiplex drug-site mapping.","ja":"The binding selectivity of quercetin and its structure-related polyphenols to human serum albumin using a fluorescent dye cocktail for multiplex drug-site mapping."},"authors":{"en":[{"name":"Mukai Rie"},{"name":"Okuyama Hitomi"},{"name":"Uchimura Miku"},{"name":"Sakao Kozue"},{"name":"Matsuhiro Miyu"},{"name":"Ikeda-Imafuku Mayumi"},{"name":"Ishima Yu"},{"name":"Nishikawa Miyu"},{"name":"Ikushiro Shinichi"},{"name":"Tai Akihiro"}],"ja":[{"name":"向井 理恵"},{"name":"奥山 仁美"},{"name":"Uchimura Miku"},{"name":"Sakao Kozue"},{"name":"松廣 美優"},{"name":"Ikeda-Imafuku Mayumi"},{"name":"異島 優"},{"name":"Nishikawa Miyu"},{"name":"Ikushiro Shinichi"},{"name":"田井 章博"}]},"description":{"en":"Human serum albumin (HSA) is a serum protein that carries flavonoids in blood circulation. In this report, the binding selectivity and strength of interactions to HSA-binding sites (sites I or II) by flavonoids were evaluated using competition experiments and the specific fluorescent dyes, dansylamide and BD140. Most tested flavonoids bound site I preferentially, with the binding strength dependent on the mother structure in the order flavonol > flavone > flavanone > flavan 3-ols. Glycosylation or glucuronidation reduced the binding of quercetin to site I of HSA, whereas sulfation increased binding. Quercetin 7-sulfate showed the strongest binding and molecular docking simulations supported this observation. Prenylation at any position or glucuronidation and sulfation at the C-4' or C-7 position of quercetin facilitated stronger binding to site II. The binding affinity of flavonoids toward site I correlated with the partition coefficient value (logP), whereas no corresponding correlation was observed for site II.","ja":"Human serum albumin (HSA) is a serum protein that carries flavonoids in blood circulation. In this report, the binding selectivity and strength of interactions to HSA-binding sites (sites I or II) by flavonoids were evaluated using competition experiments and the specific fluorescent dyes, dansylamide and BD140. Most tested flavonoids bound site I preferentially, with the binding strength dependent on the mother structure in the order flavonol > flavone > flavanone > flavan 3-ols. Glycosylation or glucuronidation reduced the binding of quercetin to site I of HSA, whereas sulfation increased binding. Quercetin 7-sulfate showed the strongest binding and molecular docking simulations supported this observation. Prenylation at any position or glucuronidation and sulfation at the C-4' or C-7 position of quercetin facilitated stronger binding to site II. The binding affinity of flavonoids toward site I correlated with the partition coefficient value (logP), whereas no corresponding correlation was observed for site II."},"publication_date":"2024-04","publication_name":{"en":"Bioorganic Chemistry","ja":"Bioorganic Chemistry"},"volume":"Vol.145","starting_page":"107184","ending_page":"107184","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bioorg.2024.107184"],"issn":["1090-2120"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:2, {"insert":{"user_id":"B000320827","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/119211","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405317","label":"url"}],"paper_title":{"en":"Human hair keratin responds to oxidative stress via reactive sulfur and supersulfides","ja":"Human hair keratin responds to oxidative stress via reactive sulfur and supersulfides"},"authors":{"en":[{"name":"Hirai Takeru"},{"name":"Ikeda-Imafuku Mayumi"},{"name":"Tasaka Nanami"},{"name":"Victor Tuan Giam Chuang"},{"name":"Ming Xian"},{"name":"Ishida Tatsuhiro"},{"name":"Akaike Takaaki"},{"name":"Ishima Yu"}],"ja":[{"name":"平井 傑琉"},{"name":"池田 真由美"},{"name":"田坂 菜々美"},{"name":"Victor Tuan Giam Chuang"},{"name":"Ming Xian"},{"name":"石田 竜弘"},{"name":"Akaike Takaaki"},{"name":"異島 優"}]},"publication_date":"2024-04","publication_name":{"en":"Advances in Redox Research","ja":"Advances in Redox Research"},"volume":"Vol.10","starting_page":"100091","ending_page":"100091","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.arres.2023.100091"],"issn":["2667-1379"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:3, {"insert":{"user_id":"B000320827","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405320","label":"url"}],"paper_title":{"en":"Peritoneal B Cells Play a Role in The Production of Anti-Polyethylene Glycol (PEG) IgM Against Intravenously Injected siRNA-PEGylated Liposome Complexes","ja":"Peritoneal B Cells Play a Role in The Production of Anti-Polyethylene Glycol (PEG) IgM Against Intravenously Injected siRNA-PEGylated Liposome Complexes"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Amr S Abu Lila"},{"name":"Kitayama Yuka"},{"name":"Abe Ryo"},{"name":"Takata Haruka"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Amr S Abu Lila"},{"name":"北山 由佳"},{"name":"阿部 遼"},{"name":"髙田 春風"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2024-02","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.47","number":"No.2","starting_page":"469","ending_page":"477","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b23-00733"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:4, {"insert":{"user_id":"B000320827","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/119400","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38256961","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050582385450085504/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405319","label":"url"}],"paper_title":{"en":"Acute kidney injury caused by rhabdomyolysis is ameliorated by serum albumin-based supersulfides donors through antioxidative pathways","ja":"Acute kidney injury caused by rhabdomyolysis is ameliorated by serum albumin-based supersulfides donors through antioxidative pathways"},"authors":{"en":[{"name":"Ikeda-Imafuku Mayumi"},{"name":"Fukuta Tatsuya"},{"name":"Victor Tuan Giam Chuang"},{"name":"Sawa Tomohiro"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"池田 真由美"},{"name":"福田 達也"},{"name":"Victor Tuan Giam Chuang"},{"name":"Sawa Tomohiro"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"description":{"en":"Oxidative stress is responsible for the onset and progression of various kinds of diseases including rhabdomyolysis-induced acute kidney injury (AKI). Antioxidants are, therefore, thought to aid in the recovery of illnesses linked to oxidative stress. Supersulfide species have been shown to have substantial antioxidative activity; however, due to their limited bioavailability, few supersulfide donors have had their actions evaluated in vivo. In this study, human serum albumin (HSA) and N-acetyl-L-cysteine polysulfides (NACSn), which have polysulfides in an oxidized form, were conjugated to create a supersulfide donor. HSA is chosen to be a carrier of NACSn because of its extended blood circulation and high level of biocompatibility. In contrast to a supersulfide donor containing reduced polysulfide in HSA, the NACSn-conjugated HSAs exhibited stronger antioxidant activity than HSA and free NACSn without being uptaken by the cells in vitro. The supersulfide donor reduced the levels of blood urea nitrogen and serum creatinine significantly in a mouse model of rhabdomyolysis-induced AKI. Supersulfide donors significantly reduced the expression of oxidative stress markers in the kidney. These results indicate that the developed supersulfide donor has the therapeutic effect on rhabdomyolysis-induced AKI.","ja":"Oxidative stress is responsible for the onset and progression of various kinds of diseases including rhabdomyolysis-induced acute kidney injury (AKI). Antioxidants are, therefore, thought to aid in the recovery of illnesses linked to oxidative stress. Supersulfide species have been shown to have substantial antioxidative activity; however, due to their limited bioavailability, few supersulfide donors have had their actions evaluated in vivo. In this study, human serum albumin (HSA) and N-acetyl-L-cysteine polysulfides (NACSn), which have polysulfides in an oxidized form, were conjugated to create a supersulfide donor. HSA is chosen to be a carrier of NACSn because of its extended blood circulation and high level of biocompatibility. In contrast to a supersulfide donor containing reduced polysulfide in HSA, the NACSn-conjugated HSAs exhibited stronger antioxidant activity than HSA and free NACSn without being uptaken by the cells in vitro. The supersulfide donor reduced the levels of blood urea nitrogen and serum creatinine significantly in a mouse model of rhabdomyolysis-induced AKI. Supersulfide donors significantly reduced the expression of oxidative stress markers in the kidney. These results indicate that the developed supersulfide donor has the therapeutic effect on rhabdomyolysis-induced AKI."},"publication_date":"2024-01-18","publication_name":{"en":"Pharmaceuticals","ja":"Pharmaceuticals"},"volume":"Vol.17","number":"No.1","starting_page":"128","ending_page":"128","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/ph17010128"],"issn":["1424-8247"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:5, {"insert":{"user_id":"B000320827","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37579503","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85169045394&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402793","label":"url"}],"paper_title":{"en":"Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticle for the Treatment of Hepatitis","ja":"Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticle for the Treatment of Hepatitis"},"authors":{"en":[{"name":"Yasuda Kengo"},{"name":"Maeda Hitoshi"},{"name":"Kinoshita Ryo"},{"name":"Minayoshi Yuki"},{"name":"Mizuta Yuki"},{"name":"Nakamura Yuka"},{"name":"Imoto Shuhei"},{"name":"Nishi Koji"},{"name":"Yamasaki Keishi"},{"name":"Sakuragi Mina"},{"name":"Nakamura Teruya"},{"name":"Ikeda-Imafuku Mayumi"},{"name":"Iwao Yasunori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"Iwakiri Yasuko"},{"name":"Otagiri Masaki"},{"name":"Watanabe Hiroshi"},{"name":"Maruyama Toru"}],"ja":[{"name":"Yasuda Kengo"},{"name":"Maeda Hitoshi"},{"name":"木下 遼"},{"name":"Minayoshi Yuki"},{"name":"Mizuta Yuki"},{"name":"Nakamura Yuka"},{"name":"Imoto Shuhei"},{"name":"Nishi Koji"},{"name":"Yamasaki Keishi"},{"name":"Sakuragi Mina"},{"name":"Nakamura Teruya"},{"name":"池田 真由美"},{"name":"Iwao Yasunori"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"Iwakiri Yasuko"},{"name":"Otagiri Masaki"},{"name":"Watanabe Hiroshi"},{"name":"Maruyama Toru"}]},"description":{"en":"Hepatitis is an inflammation of the liver caused by the inadequate elimination of reactive oxygen species (ROS) derived from Kupffer cells. Edaravone is clinically used as an antioxidant but shows poor liver distribution. Herein, we report on the design of a Kupffer cell-oriented nanoantioxidant based on a disulfide cross-linked albumin nanoparticle containing encapsulated edaravone (EeNA) as a therapeutic for the treatment of hepatitis. Since the edaravone is bound to albumin, this results in a soluble and stable form of edaravone in water. Exchanging the intramolecular disulfide bonds to intermolecular disulfide bridges of albumin molecules allowed the preparation of a redox responsive albumin nanoparticle that is stable in the blood circulation but can release drugs into cells. Consequently, EeNA was fabricated by the nanoscale self-assembly of edaravone and albumin nanoparticles without the additives that are contained in commercially available edaravone preparations. EeNA retained its nanostructure under serum conditions, but the encapsulated edaravone was released efficiently under intracellular reducing conditions in macrophages. The EeNA was largely distributed in the liver and subsequently internalized into Kupffer cells within 60 min after injection in a concanavalin-A-induced hepatitis mouse. The survival rate of the hepatitis mice was significantly improved by EeNA due to the suppression of liver necrosis and oxidative stress by scavenging excessive ROS. Moreover, even through the postadministration, EeNA showed an excellent hepatoprotective action as well. In conclusion, EeNA has the potential for use as a nanotherapeutic against various types of hepatitis because of its Kupffer cell targeting ability and redox characteristics.","ja":"Hepatitis is an inflammation of the liver caused by the inadequate elimination of reactive oxygen species (ROS) derived from Kupffer cells. Edaravone is clinically used as an antioxidant but shows poor liver distribution. Herein, we report on the design of a Kupffer cell-oriented nanoantioxidant based on a disulfide cross-linked albumin nanoparticle containing encapsulated edaravone (EeNA) as a therapeutic for the treatment of hepatitis. Since the edaravone is bound to albumin, this results in a soluble and stable form of edaravone in water. Exchanging the intramolecular disulfide bonds to intermolecular disulfide bridges of albumin molecules allowed the preparation of a redox responsive albumin nanoparticle that is stable in the blood circulation but can release drugs into cells. Consequently, EeNA was fabricated by the nanoscale self-assembly of edaravone and albumin nanoparticles without the additives that are contained in commercially available edaravone preparations. EeNA retained its nanostructure under serum conditions, but the encapsulated edaravone was released efficiently under intracellular reducing conditions in macrophages. The EeNA was largely distributed in the liver and subsequently internalized into Kupffer cells within 60 min after injection in a concanavalin-A-induced hepatitis mouse. The survival rate of the hepatitis mice was significantly improved by EeNA due to the suppression of liver necrosis and oxidative stress by scavenging excessive ROS. Moreover, even through the postadministration, EeNA showed an excellent hepatoprotective action as well. In conclusion, EeNA has the potential for use as a nanotherapeutic against various types of hepatitis because of its Kupffer cell targeting ability and redox characteristics."},"publication_date":"2023-08-14","publication_name":{"en":"ACS Nano","ja":"ACS Nano"},"volume":"Vol.17","number":"No.17","starting_page":"16668","ending_page":"16681","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/acsnano.3c02877"],"issn":["1936-086X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:6, {"insert":{"user_id":"B000320827","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37355210","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402792","label":"url"}],"paper_title":{"en":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route","ja":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route"},"authors":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Yamade Rina"},{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"Emam Abdallah Emam Sherif"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"山出 莉奈"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Modifying the surface of nanoparticles with polyethylene glycol (PEG) is a commonly used approach for improving the in vitro stability of nanoparticles such as liposomes and increasing their circulation half-lives. We have demonstrated that, in certain conditions, an intravenous (i.v.) injection of PEGylated liposomes (PEG-Lip) induced anti-PEG IgM antibodies, which led to rapid clearance of second doses in mice. SARS-CoV-2 vaccines, composed of mRNA-containing PEGylated lipid nanoparticles, have been widely administered as intramuscular (i.m.) injections, so it is important to determine if PEGylated formulations can induce anti-PEG antibodies. If the favorable properties that PEGylation imparts to therapeutic nanoparticles are to be widely applicable this should apply to various routes of administration. However, there are few reports on the effect of different administration routes on the in vivo production of anti-PEG IgM. In this study, we investigated anti-PEG IgM production in mice following i.m., intraperitoneal (i.p.) and subcutaneous (s.c.) administration of PEG-Lip. PEG-Lip appeared to induce anti-PEG IgM by all the tested routes of administration, although the lipid dose causing maximum responses varied. Splenectomy attenuated the anti-PEG IgM production for all routes of administration, suggesting that splenic immune cells may have contributed to anti-PEG IgM production. Interestingly, in vitro experiments indicated that not only splenic cells but also cells in the peritoneal cavity induced anti-PEG IgM following incubation with PEG-Lip. These observations confirm previous experiments that have shown that measurable amounts of PEG-Lip administered i.p., i.m. or s.c. are absorbed to some extent into the blood circulation, where they can be distributed to the spleen and/or peritoneal cavity, and are recognized by B cells, triggering anti-PEG IgM production. The results obtained in this study have important implications for developing efficient PEGylated nanoparticular delivery system.","ja":"Modifying the surface of nanoparticles with polyethylene glycol (PEG) is a commonly used approach for improving the in vitro stability of nanoparticles such as liposomes and increasing their circulation half-lives. We have demonstrated that, in certain conditions, an intravenous (i.v.) injection of PEGylated liposomes (PEG-Lip) induced anti-PEG IgM antibodies, which led to rapid clearance of second doses in mice. SARS-CoV-2 vaccines, composed of mRNA-containing PEGylated lipid nanoparticles, have been widely administered as intramuscular (i.m.) injections, so it is important to determine if PEGylated formulations can induce anti-PEG antibodies. If the favorable properties that PEGylation imparts to therapeutic nanoparticles are to be widely applicable this should apply to various routes of administration. However, there are few reports on the effect of different administration routes on the in vivo production of anti-PEG IgM. In this study, we investigated anti-PEG IgM production in mice following i.m., intraperitoneal (i.p.) and subcutaneous (s.c.) administration of PEG-Lip. PEG-Lip appeared to induce anti-PEG IgM by all the tested routes of administration, although the lipid dose causing maximum responses varied. Splenectomy attenuated the anti-PEG IgM production for all routes of administration, suggesting that splenic immune cells may have contributed to anti-PEG IgM production. Interestingly, in vitro experiments indicated that not only splenic cells but also cells in the peritoneal cavity induced anti-PEG IgM following incubation with PEG-Lip. These observations confirm previous experiments that have shown that measurable amounts of PEG-Lip administered i.p., i.m. or s.c. are absorbed to some extent into the blood circulation, where they can be distributed to the spleen and/or peritoneal cavity, and are recognized by B cells, triggering anti-PEG IgM production. The results obtained in this study have important implications for developing efficient PEGylated nanoparticular delivery system."},"publication_date":"2023-08","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.360","starting_page":"285","ending_page":"292","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2023.06.027"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:7, {"insert":{"user_id":"B000320827","type":"published_papers","id":"41379369"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36805860","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393938","label":"url"}],"paper_title":{"en":"Ionic liquid-based transcutaneous peptide antitumor vaccine; therapeutic effect in a mouse tumor model","ja":"Ionic liquid-based transcutaneous peptide antitumor vaccine; therapeutic effect in a mouse tumor model"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Matsuzaki Takaaki"},{"name":"Fukuda Shoishiro"},{"name":"Yoshioka Chihiro"},{"name":"Shimazaki Yuna"},{"name":"Takese Shunsuke"},{"name":"Yamanaka Katsuhiro"},{"name":"Nakae Takashi"},{"name":"Ishibashi Masaki"},{"name":"Hamamoto Hidetoshi"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"松﨑 隆朗"},{"name":"福田 翔一郎"},{"name":"吉岡 千尋"},{"name":"島﨑 優奈"},{"name":"竹瀬 俊輔"},{"name":"Yamanaka Katsuhiro"},{"name":"Nakae Takashi"},{"name":"Ishibashi Masaki"},{"name":"Hamamoto Hidetoshi"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Traditional vaccinations need to be injected with needles, and since some people have a strong aversion to needles, a needle-free alternative delivery system is important. In this study, we employed ionic liquids (ILs) for transcutaneous delivery of cancer antigen-derived peptides to obtain anticancer therapeutic effects in a needle-free manner. ILs successfully increased the in vitro skin permeability of a peptide from Wilms tumor 1 (WT1), one of the more promising cancer antigens, plus or minus an adjuvant, resiquimod (R848), a toll-like receptor 7 agonist. In vivo studies demonstrated that concomitant transcutaneous delivery of WT1 peptide and R848 by ILs induced WT1-specific cytotoxic T lymphocyte (CTL) in mice, resulting in tumor growth inhibition in Lewis lung carcinoma-bearing mice. Interestingly, administrating R848 in ILs before WT1 peptides in ILs increased tumor growth inhibition effects compared to co-administration of both. We found that the prior application of R848 increased the infiltration of leukocytes in the skin and that subsequent delivery of WT1 peptides was more likely to induce WT1-specific CTL. Furthermore, sequential immunization with IL-based formulations was applicable to different types of peptides and cancer models without induction of skin irritation. IL-based transcutaneous delivery of cancer antigen-derived peptides and adjuvants, either alone or together, could be a novel approach to needle-free cancer therapeutic vaccines.","ja":"Traditional vaccinations need to be injected with needles, and since some people have a strong aversion to needles, a needle-free alternative delivery system is important. In this study, we employed ionic liquids (ILs) for transcutaneous delivery of cancer antigen-derived peptides to obtain anticancer therapeutic effects in a needle-free manner. ILs successfully increased the in vitro skin permeability of a peptide from Wilms tumor 1 (WT1), one of the more promising cancer antigens, plus or minus an adjuvant, resiquimod (R848), a toll-like receptor 7 agonist. In vivo studies demonstrated that concomitant transcutaneous delivery of WT1 peptide and R848 by ILs induced WT1-specific cytotoxic T lymphocyte (CTL) in mice, resulting in tumor growth inhibition in Lewis lung carcinoma-bearing mice. Interestingly, administrating R848 in ILs before WT1 peptides in ILs increased tumor growth inhibition effects compared to co-administration of both. We found that the prior application of R848 increased the infiltration of leukocytes in the skin and that subsequent delivery of WT1 peptides was more likely to induce WT1-specific CTL. Furthermore, sequential immunization with IL-based formulations was applicable to different types of peptides and cancer models without induction of skin irritation. IL-based transcutaneous delivery of cancer antigen-derived peptides and adjuvants, either alone or together, could be a novel approach to needle-free cancer therapeutic vaccines."},"publication_date":"2023-03","publication_name":{"en":"The AAPS Journal","ja":"The AAPS Journal"},"volume":"Vol.25","number":"No.2","starting_page":"27","ending_page":"27","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1208/s12248-023-00790-w"],"issn":["1550-7416"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:8, {"insert":{"user_id":"B000320827","type":"published_papers","id":"41053474"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393469","label":"url"}],"paper_title":{"en":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","ja":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice"},"authors":{"en":[{"name":"Ibrahim Mohamed"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Elgarhy Omar Helmy"},{"name":"Sarhan Hatem A"},{"name":"Hussein Amal K"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Ibrahim Mohamed"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"Elgarhy Omar Helmy"},{"name":"Sarhan Hatem A"},{"name":"Hussein Amal K"},{"name":"石田 竜弘"}]},"publication_date":"2023-02-01","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.354","starting_page":"260","ending_page":"267","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2023.01.012"],"issn":["0168-3659"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:9, {"insert":{"user_id":"B000320827","type":"published_papers","id":"40510326"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118017","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392886","label":"url"}],"paper_title":{"en":"FTY720 reduces lipid accumulation by upregulating ABCA1 through liver X receptor and sphingosine kinase 2 signaling in macrophages","ja":"FTY720 reduces lipid accumulation by upregulating ABCA1 through liver X receptor and sphingosine kinase 2 signaling in macrophages"},"authors":{"en":[{"name":"Tachibana Kohki"},{"name":"Kusumoto Kohshi"},{"name":"Ogawa Mai"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"Okuhira Keiichiro"}],"ja":[{"name":"立花 洸季"},{"name":"楠本 嵩志"},{"name":"小川 真依"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"奥平 桂一郎"}]},"publication_date":"2022-11-23","publication_name":{"en":"International Journal of Molecular Sciences","ja":"International Journal of Molecular Sciences"},"volume":"Vol.23","starting_page":"14617","ending_page":"14617","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/ijms232314617"],"issn":["1422-0067"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:10, {"insert":{"user_id":"B000320827","type":"published_papers","id":"39507274"},"force":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390856583390911232/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387846","label":"url"}],"paper_title":{"en":"A maleimide-terminally modified PEGylated liposome induced the accelerated blood clearance independent of the production of anti-PEG IgM antibodies","ja":"A maleimide-terminally modified PEGylated liposome induced the accelerated blood clearance independent of the production of anti-PEG IgM antibodies"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Yamazaki Nio"},{"name":"Chuang V"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"山﨑 仁王"},{"name":"Chuang V"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"}]},"publication_date":"2022-10-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.45","number":"No.10","starting_page":"1518","ending_page":"1524","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b22-00389"],"issn":["0918-6158"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:11, {"insert":{"user_id":"B000320827","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397281","label":"url"}],"paper_title":{"en":"アルブミンのボリスルフィドによる新たな生体恒常性維持機構","ja":"アルブミンのボリスルフィドによる新たな生体恒常性維持機構"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"publication_date":"2022-09-01","publication_name":{"en":"人工血液","ja":"人工血液"},"volume":"Vol.30","starting_page":"59","ending_page":"64","languages":["jpn"],"referee":true,"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:12, {"insert":{"user_id":"B000320827","type":"published_papers","id":"39656555"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35988781","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=389908","label":"url"}],"paper_title":{"en":"Oral administration of sodium bicarbonate can enhance the therapeutic outcome of Doxil® via neutralizing the acidic tumor microenvironment","ja":"Oral administration of sodium bicarbonate can enhance the therapeutic outcome of Doxil® via neutralizing the acidic tumor microenvironment"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Ikeda Ai"},{"name":"Tagami Maho"},{"name":"Matsuo Nana"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Eshima K"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"池田 愛"},{"name":"田神 舞帆"},{"name":"松尾 菜々"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"Eshima K"},{"name":"石田 竜弘"}]},"description":{"en":"The pH of the tumor microenvironment in solid tumors is reported to be more acidic than that of normal tissues. The pH is controlled by over-expression of several transporters that are associated with the progression, angiogenesis, and metastasis of solid tumors. Antitumor effects of weak-base anticancer agents, such as doxorubicin (DXR), could be reduced in an acidic environment because of increases in the ionized form of the drug under these conditions, reducing its membrane penetrability. In our previous studies, we demonstrated that oral administration of sodium bicarbonate (NaHCO) can neutralize the acidic tumor microenvironment and enhance the effects of small molecule anticancer drugs. However, it is not known whether or not increasing the tumor pH by oral administration of NaHCO leads to enhanced antitumor effects of lipidic nanoparticle formulations of weak-base anticancer drugs, such as Doxil®. In this study, we investigated the antitumor efficacy of Doxil® in combination with oral administration of NaHCO in a Colon26 tumor-bearing mouse model. NaHCO clearly enhanced the tumor-growth inhibitory effect of Doxil® without exacerbating any systemic side effects. In vitro studies indicated that high levels of DXR were internalized into cells at neutral pH. These studies demonstrate that the neutralization of acidic tumor microenvironment by an oral administration of NaHCO could be a promising approach to enhance the therapeutic outcomes of Doxil®.","ja":"The pH of the tumor microenvironment in solid tumors is reported to be more acidic than that of normal tissues. The pH is controlled by over-expression of several transporters that are associated with the progression, angiogenesis, and metastasis of solid tumors. Antitumor effects of weak-base anticancer agents, such as doxorubicin (DXR), could be reduced in an acidic environment because of increases in the ionized form of the drug under these conditions, reducing its membrane penetrability. In our previous studies, we demonstrated that oral administration of sodium bicarbonate (NaHCO) can neutralize the acidic tumor microenvironment and enhance the effects of small molecule anticancer drugs. However, it is not known whether or not increasing the tumor pH by oral administration of NaHCO leads to enhanced antitumor effects of lipidic nanoparticle formulations of weak-base anticancer drugs, such as Doxil®. In this study, we investigated the antitumor efficacy of Doxil® in combination with oral administration of NaHCO in a Colon26 tumor-bearing mouse model. NaHCO clearly enhanced the tumor-growth inhibitory effect of Doxil® without exacerbating any systemic side effects. In vitro studies indicated that high levels of DXR were internalized into cells at neutral pH. These studies demonstrate that the neutralization of acidic tumor microenvironment by an oral administration of NaHCO could be a promising approach to enhance the therapeutic outcomes of Doxil®."},"publication_date":"2022-08-18","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.350","starting_page":"414","ending_page":"420","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2022.08.031"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:13, {"insert":{"user_id":"B000320827","type":"published_papers","id":"36905618"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117224","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=385361","label":"url"}],"paper_title":{"en":"Development of a nanocarrier-based splenic B cell-targeting system for loading antigens in vitro","ja":"Development of a nanocarrier-based splenic B cell-targeting system for loading antigens in vitro"},"authors":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2022-07-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.45","number":"No.7","starting_page":"926","ending_page":"933","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b22-00222"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:14, {"insert":{"user_id":"B000320827","type":"published_papers","id":"36366795"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384285","label":"url"}],"paper_title":{"en":"Development of an antigen delivery system for a B cell-targeted vaccine as an alternative to dendritic cell-targeted vaccines","ja":"Development of an antigen delivery system for a B cell-targeted vaccine as an alternative to dendritic cell-targeted vaccines"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Kawaguchi Yoshino"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"川口 桂乃"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2022-05-01","publication_name":{"en":"Chemical & Pharmaceutical Bulletin","ja":"Chemical & Pharmaceutical Bulletin"},"volume":"Vol.70","number":"No.5","starting_page":"341","ending_page":"350","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/cpb.c22-00047"],"issn":["1347-5223"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:15, {"insert":{"user_id":"B000320827","type":"published_papers","id":"36164913"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383648","label":"url"}],"paper_title":{"en":"Subvisible particles derived by dropping stress enhance anti-PEG antibody production and clearance of PEGylated proteins in mice","ja":"Subvisible particles derived by dropping stress enhance anti-PEG antibody production and clearance of PEGylated proteins in mice"},"authors":{"en":[{"name":"Nakajima Takaki"},{"name":"Nagano Kazuya"},{"name":"Fukuda Yuka"},{"name":"Ishima Yu"},{"name":"Shibata Hiroko"},{"name":"Isaka Ryo"},{"name":"Zhang Tian-Qi"},{"name":"Haga Yuya"},{"name":"Higashisaka Kazuma"},{"name":"Tsujino Hirofumi"},{"name":"Ishida Tatsuhiro"},{"name":"Ishii-Watabe Akiko"},{"name":"Tsutsumi Yasuo"}],"ja":[{"name":"Nakajima Takaki"},{"name":"Nagano Kazuya"},{"name":"福田 悠花"},{"name":"異島 優"},{"name":"Shibata Hiroko"},{"name":"Isaka Ryo"},{"name":"Zhang Tian-Qi"},{"name":"Haga Yuya"},{"name":"Higashisaka Kazuma"},{"name":"Tsujino Hirofumi"},{"name":"石田 竜弘"},{"name":"Ishii-Watabe Akiko"},{"name":"Tsutsumi Yasuo"}]},"publication_date":"2022-05-01","publication_name":{"en":"Journal of Pharmaceutical Sciences","ja":"Journal of Pharmaceutical Sciences"},"volume":"Vol.111","number":"No.5","starting_page":"1363","ending_page":"1369","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.xphs.2022.01.023"],"issn":["0022-3549"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:16, {"insert":{"user_id":"B000320827","type":"published_papers","id":"36292762"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35124114","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384078","label":"url"}],"paper_title":{"en":"A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes","ja":"A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes"},"authors":{"en":[{"name":"El Sayed Marwa"},{"name":"Shimizu Taro"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"Alaaeldin Eman"},{"name":"Kamal Amal"},{"name":"Sarhan Hatem"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"El Sayed Marwa"},{"name":"清水 太郎"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"Alaaeldin Eman"},{"name":"Kamal Amal"},{"name":"Sarhan Hatem"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"The presence of anti-polyethylene glycol (PEG) antibodies in the systemic circulation might have potential implications for the therapeutic activity of PEGylated products in vivo in the clinic. In order to study the effect of pre-existing anti-PEG antibodies on the in vivo fate and the therapeutic efficiency of PEGylated therapeutics, we developed a BALB/c mouse model by virtue of the intraperitoneal (i.p.) inoculation of hybridoma cells (HIK-M09 and HIK-M11), secreting monoclonal anti-PEG IgM, mimicking the presence of pre-existing anti-PEG antibodies in the blood. In the model, the titers of anti-PEG IgM in the blood increased as a function of hybridoma cells numbers and time after i.p. inoculation. The in vivo levels of anti-PEG IgM decreased in a dose-dependent manner, following i.v. administration of empty PEGylated liposomes. C26 tumor-bearing mice with measurable levels of anti-PEG IgM, receiving i.v. injection of DiR-labeled empty PEGylated liposomes, showed lower levels of liposomal tumor accumulation and higher levels of liver and spleen accumulation, compared to C26 tumor-bearing mice without measurable anti-PEG IgM. This specifies that the presence of anti-PEG IgM in the murine circulation induced accelerated blood clearance of PEGylated liposomes and reduced their tumor accumulation. The biodistribution and antitumor efficacy of commercially available doxorubicin (DXR)-containing PEGylated liposomes, Doxil®, were scrutinized in the anti-PEG IgM mouse model. In C26 tumor-bearing mice having circulating anti-PEG IgM, at 24 h after injection almost no DXR was observed in blood and tumor, and increased DXR accumulation was observed in spleen and liver, compared to tumor-bearing mice with no circulating anti-PEG IgM. The antitumor efficacy of Doxil® was significantly compromised in the C26 tumor-bearing mice in the presence of anti-PEG IgM. These results demonstrate that the anti-PEG IgM mouse model could be a useful prognostic indicator for the therapeutic effectiveness of different formulations of PEGylated therapeutics in pre-clinical studies.","ja":"The presence of anti-polyethylene glycol (PEG) antibodies in the systemic circulation might have potential implications for the therapeutic activity of PEGylated products in vivo in the clinic. In order to study the effect of pre-existing anti-PEG antibodies on the in vivo fate and the therapeutic efficiency of PEGylated therapeutics, we developed a BALB/c mouse model by virtue of the intraperitoneal (i.p.) inoculation of hybridoma cells (HIK-M09 and HIK-M11), secreting monoclonal anti-PEG IgM, mimicking the presence of pre-existing anti-PEG antibodies in the blood. In the model, the titers of anti-PEG IgM in the blood increased as a function of hybridoma cells numbers and time after i.p. inoculation. The in vivo levels of anti-PEG IgM decreased in a dose-dependent manner, following i.v. administration of empty PEGylated liposomes. C26 tumor-bearing mice with measurable levels of anti-PEG IgM, receiving i.v. injection of DiR-labeled empty PEGylated liposomes, showed lower levels of liposomal tumor accumulation and higher levels of liver and spleen accumulation, compared to C26 tumor-bearing mice without measurable anti-PEG IgM. This specifies that the presence of anti-PEG IgM in the murine circulation induced accelerated blood clearance of PEGylated liposomes and reduced their tumor accumulation. The biodistribution and antitumor efficacy of commercially available doxorubicin (DXR)-containing PEGylated liposomes, Doxil®, were scrutinized in the anti-PEG IgM mouse model. In C26 tumor-bearing mice having circulating anti-PEG IgM, at 24 h after injection almost no DXR was observed in blood and tumor, and increased DXR accumulation was observed in spleen and liver, compared to tumor-bearing mice with no circulating anti-PEG IgM. The antitumor efficacy of Doxil® was significantly compromised in the C26 tumor-bearing mice in the presence of anti-PEG IgM. These results demonstrate that the anti-PEG IgM mouse model could be a useful prognostic indicator for the therapeutic effectiveness of different formulations of PEGylated therapeutics in pre-clinical studies."},"publication_date":"2022-03-05","publication_name":{"en":"International Journal of Pharmaceutics","ja":"International Journal of Pharmaceutics"},"volume":"Vol.615","starting_page":"121539","ending_page":"121539","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijpharm.2022.121539"],"issn":["1873-3476"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:17, {"insert":{"user_id":"B000320827","type":"published_papers","id":"39728153"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117445","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35432956","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85123466355&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391150","label":"url"}],"paper_title":{"en":"8-Prenylnaringenin tissue distribution and pharmacokinetics in mice and its binding to human serum albumin and cellular uptake in human embryonic kidney cells.","ja":"8-Prenylnaringenin tissue distribution and pharmacokinetics in mice and its binding to human serum albumin and cellular uptake in human embryonic kidney cells."},"authors":{"en":[{"name":"Tanaka Yoshiaki"},{"name":"Okuyama Hitomi"},{"name":"Nishikawa Miyu"},{"name":"Ikushiro Shin-ichi"},{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Ukawa Yuichi"},{"name":"Oe Kenichi"},{"name":"Terao Junji"},{"name":"Mukai Rie"}],"ja":[{"name":"Tanaka Yoshiaki"},{"name":"Okuyama Hitomi"},{"name":"Nishikawa Miyu"},{"name":"Ikushiro Shin-ichi"},{"name":"Ikeda Mayumi"},{"name":"異島 優"},{"name":"Ukawa Yuichi"},{"name":"Oe Kenichi"},{"name":"寺尾 純二"},{"name":"向井 理恵"}]},"description":{"en":"8-Prenylnaringenin (8-PN), a hop flavonoid, is a promising food substance with health benefits. Compared with nonprenylated naringenin, 8-PN exhibits stronger estrogenic activity and prevents muscle atrophy. Moreover, 8-PN prevents hot flushes and bone loss. Considering that prenylation reportedly improves the bioavailability of flavonoids, we compared the parameters related to the bioavailability [pharmacokinetics and tissue distribution in C57/BL6 mice, binding affinity to human serum albumin (HSA), and cellular uptake in HEK293 cells] of 8-PN and its mother (non-prenylated) compound naringenin. C57/BL6 mice were fed an 8-PN or naringenin mixed diet for 22 days. The amount of 8-PN (nmol/g tissue) in the kidneys (16.8 ± 9.20), liver (14.8 ± 2.58), muscles (3.33 ± 0.60), lungs (2.07 ± 0.68), pancreas (1.80 ± 0.38), heart (1.71 ± 0.27), spleen (1.36 ± 0.29), and brain (0.31 ± 0.09) was higher than that of naringenin. A pharmacokinetic study in mice demonstrated that the of 8-PN (50 mg/kg body weight) was lower than that of naringenin; however, the plasma concentration of 8-PN 8 h after ingestion was higher than that of naringenin. The binding affinity of 8-PN to HSA and cellular uptake in HEK293 cells were higher than those of naringenin. 8-PN bioavailability features assessed in mouse or human model experiments were obviously different from those of naringenin.","ja":"8-Prenylnaringenin (8-PN), a hop flavonoid, is a promising food substance with health benefits. Compared with nonprenylated naringenin, 8-PN exhibits stronger estrogenic activity and prevents muscle atrophy. Moreover, 8-PN prevents hot flushes and bone loss. Considering that prenylation reportedly improves the bioavailability of flavonoids, we compared the parameters related to the bioavailability [pharmacokinetics and tissue distribution in C57/BL6 mice, binding affinity to human serum albumin (HSA), and cellular uptake in HEK293 cells] of 8-PN and its mother (non-prenylated) compound naringenin. C57/BL6 mice were fed an 8-PN or naringenin mixed diet for 22 days. The amount of 8-PN (nmol/g tissue) in the kidneys (16.8 ± 9.20), liver (14.8 ± 2.58), muscles (3.33 ± 0.60), lungs (2.07 ± 0.68), pancreas (1.80 ± 0.38), heart (1.71 ± 0.27), spleen (1.36 ± 0.29), and brain (0.31 ± 0.09) was higher than that of naringenin. A pharmacokinetic study in mice demonstrated that the of 8-PN (50 mg/kg body weight) was lower than that of naringenin; however, the plasma concentration of 8-PN 8 h after ingestion was higher than that of naringenin. The binding affinity of 8-PN to HSA and cellular uptake in HEK293 cells were higher than those of naringenin. 8-PN bioavailability features assessed in mouse or human model experiments were obviously different from those of naringenin."},"publication_date":"2022-01-22","publication_name":{"en":"Food Science & Nutrition","ja":"Food Science & Nutrition"},"volume":"Vol.10","number":"No.4","starting_page":"1070","ending_page":"1080","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/fsn3.2733"],"issn":["2048-7177"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:18, {"insert":{"user_id":"B000320827","type":"published_papers","id":"35684140"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34980774","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390290617368317184/","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85123166599&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382877","label":"url"}],"paper_title":{"en":"Using Bio-Layer Interferometry to evaluate anti-PEG antibody-mediated complement activation","ja":"Using Bio-Layer Interferometry to evaluate anti-PEG antibody-mediated complement activation"},"authors":{"en":[{"name":"Mahmoud Mostafa M"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Abdelkader H"},{"name":"Ishima Yu"},{"name":"Farghaly Aly U"},{"name":"Sarhan H A"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Mahmoud Mostafa M"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"Abdelkader H"},{"name":"異島 優"},{"name":"Farghaly Aly U"},{"name":"Sarhan H A"},{"name":"石田 竜弘"}]},"description":{"en":"The purpose of this study was to develop a Bio-layer interferometry (BLI) system that could be an alternative approach for the direct evaluation of anti-polyethylene glycol (PEG) immunoglobulin M (IgM)-mediated complement activation of the accelerated blood clearance (ABC) phenomenon. Complement activation is well known to play an important role in the clearance of PEGylated and non-PEGylated nanomedicines following intravenous injection. This complement system is also thought to be responsible for the ABC phenomenon wherein repeated injections of PEGylated products are bound by anti-PEG antibodies. This study used three different sources of anti-PEG antibodies: HIK-M09 monoclonal antibodies (mAbs); HIK-M11 mAbs; and antiserum containing polyclonal anti-PEG IgMs. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy (polyethylene glycol)-2000] (mPEG-DSPE) was immobilized as an antigen on aminopropyl silane biosensor chips of BLI. All anti-PEG IgMs in the sources increased the signals (thickness of the layer around the sensor tip) regarding binding of anti-PEG antibodies to PEG on the chips. In all anti-PEG IgM sources, further increases in the signals were observed when incubated in naïve mouse serum, which is a complement source, but not in heat inactivated (56 °C, 30 min) mouse serum, which abolishes complement activity. These findings show that the complement activation mediated via anti-PEG IgMs, which occurred on the sensor chips, was detected via BLI analysis. The complement activation induced by all anti-PEG IgM sources was confirmed via conventional enzyme-linked immunosorbent assay (ELISA), which is the conventional mode for detection of complement activation. Our study results show that BLI is a simple alternative method for the detection of complement activation.","ja":"The purpose of this study was to develop a Bio-layer interferometry (BLI) system that could be an alternative approach for the direct evaluation of anti-polyethylene glycol (PEG) immunoglobulin M (IgM)-mediated complement activation of the accelerated blood clearance (ABC) phenomenon. Complement activation is well known to play an important role in the clearance of PEGylated and non-PEGylated nanomedicines following intravenous injection. This complement system is also thought to be responsible for the ABC phenomenon wherein repeated injections of PEGylated products are bound by anti-PEG antibodies. This study used three different sources of anti-PEG antibodies: HIK-M09 monoclonal antibodies (mAbs); HIK-M11 mAbs; and antiserum containing polyclonal anti-PEG IgMs. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy (polyethylene glycol)-2000] (mPEG-DSPE) was immobilized as an antigen on aminopropyl silane biosensor chips of BLI. All anti-PEG IgMs in the sources increased the signals (thickness of the layer around the sensor tip) regarding binding of anti-PEG antibodies to PEG on the chips. In all anti-PEG IgM sources, further increases in the signals were observed when incubated in naïve mouse serum, which is a complement source, but not in heat inactivated (56 °C, 30 min) mouse serum, which abolishes complement activity. These findings show that the complement activation mediated via anti-PEG IgMs, which occurred on the sensor chips, was detected via BLI analysis. The complement activation induced by all anti-PEG IgM sources was confirmed via conventional enzyme-linked immunosorbent assay (ELISA), which is the conventional mode for detection of complement activation. Our study results show that BLI is a simple alternative method for the detection of complement activation."},"publication_date":"2022-01-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.45","number":"No.1","starting_page":"129","ending_page":"135","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b21-00772"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:19, {"insert":{"user_id":"B000320827","type":"published_papers","id":"35997017"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383343","label":"url"}],"paper_title":{"en":"I.p.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors","ja":"I.p.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors"},"authors":{"en":[{"name":"Ando-Matsuoka Rie"},{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Maeda Noriyuki"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 里英"},{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Maeda Noriyuki"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2022-01","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.341","starting_page":"524","ending_page":"532","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2021.12.004"],"issn":["0168-3659"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:20, {"insert":{"user_id":"B000320827","type":"published_papers","id":"33247701"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116618","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=377858","label":"url"}],"paper_title":{"en":"The therapeutic effect of HSA dimer-doxorubicin complex against human pancreatic tumour","ja":"The therapeutic effect of HSA dimer-doxorubicin complex against human pancreatic tumour"},"authors":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Chuang T.G. Victor"},{"name":"Watanabe Hiroshi"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Okuhira Keiichiro"},{"name":"Otagiri Masaki"},{"name":"Ishida Tatsuhiro"},{"name":"Maruyama Toru"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"Chuang T.G. Victor"},{"name":"Watanabe Hiroshi"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"奥平 桂一郎"},{"name":"Otagiri Masaki"},{"name":"石田 竜弘"},{"name":"Maruyama Toru"}]},"publication_date":"2021-08-05","publication_name":{"en":"Pharmaceutics","ja":"Pharmaceutics"},"volume":"Vol.13","number":"No.8","starting_page":"1209","ending_page":"1209","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/pharmaceutics13081209"],"issn":["1999-4923"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:21, {"insert":{"user_id":"B000320827","type":"published_papers","id":"32904113"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116603","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376567","label":"url"}],"paper_title":{"en":"Doxorubicin embedded into nanofibrillated bacterial cellulose (NFBC) produces a promising therapeutic outcome for peritoneally metastatic gastric cancer in mice models via intraperitoneal direct injection","ja":"Doxorubicin embedded into nanofibrillated bacterial cellulose (NFBC) produces a promising therapeutic outcome for peritoneally metastatic gastric cancer in mice models via intraperitoneal direct injection"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Mochizuki Takashi"},{"name":"Lila Abu Ali Ahmed Selim Amr"},{"name":"Akagi Shunsuke"},{"name":"Tajima Kenji"},{"name":"Fujita Kenji"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Matsushima Tokuo"},{"name":"Kusano Takatomo"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"望月 啓志"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"赤木 俊介"},{"name":"Tajima Kenji"},{"name":"藤田 研司"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"Matsushima Tokuo"},{"name":"Kusano Takatomo"},{"name":"石田 竜弘"}]},"publication_date":"2021-06-28","publication_name":{"en":"Nanomaterials","ja":"Nanomaterials"},"volume":"Vol.11","starting_page":"1697","ending_page":"1697","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/nano11071697"],"issn":["2079-4991"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:22, {"insert":{"user_id":"B000320827","type":"published_papers","id":"32439560"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33957196","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85105280797&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375385","label":"url"}],"paper_title":{"en":"Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice","ja":"Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice"},"authors":{"en":[{"name":"Sherif Emam Abdallah Emam"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Takata Haruka"},{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Sherif Emam Abdallah Emam"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"髙田 春風"},{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Recently, there is an increasing interest in exosomes or extracellular vesicles as potential candidates for delivering RNAs, proteins, genes, and anticancer agents. Engineering of exosome properties is rapidly evolving as a means of expanding exosome applications. PEGylation of exosomes is a technique used to improve their in vivo stability, circulation half-lives, and sometimes to allow the binding targeting ligands to the exosome exterior. According to FDA guidelines for the development of PEGylated proteins, immunological responses to PEGylated molecules and particles should be examined. In this study, we prepared PEGylated exosomes and investigated the production of anti-PEG IgM antibodies after single i.v. injections in mice. In addition, we monitored blood concentrations and tumor accumulation of a second dose of PEGylated exosomes administered after the initial dose. Single injections of PEGylated exosomes in mice induced anti-PEG IgM production in a T cell-dependent manner. The anti-PEG IgM production decreased when the injection dose of PEGylated exosomes was further increased. Anti-PEG IgM induced by injection of PEGylated exosomes decreased blood concentrations of a second dose of PEGylated exosomes and suppressed their tumor accumulation in a C26 murine colorectal cancer model. Initial injection doses of either PEGylated liposomes or PEGylated ovalbumin (PEG-OVA), both of them induced anti-PEG IgM production, also decreased the blood concentration of PEGylated exosomes. Interestingly, anti-PEG IgM induced by injection of PEGylated exosomes did not affect the blood concentration of PEG-OVA. These results imply the importance of monitoring anti-PEG IgM when repeat PEGylated exosome doses are required and/or when PEGylated exosomes are used together with other PEGylated therapeutics.","ja":"Recently, there is an increasing interest in exosomes or extracellular vesicles as potential candidates for delivering RNAs, proteins, genes, and anticancer agents. Engineering of exosome properties is rapidly evolving as a means of expanding exosome applications. PEGylation of exosomes is a technique used to improve their in vivo stability, circulation half-lives, and sometimes to allow the binding targeting ligands to the exosome exterior. According to FDA guidelines for the development of PEGylated proteins, immunological responses to PEGylated molecules and particles should be examined. In this study, we prepared PEGylated exosomes and investigated the production of anti-PEG IgM antibodies after single i.v. injections in mice. In addition, we monitored blood concentrations and tumor accumulation of a second dose of PEGylated exosomes administered after the initial dose. Single injections of PEGylated exosomes in mice induced anti-PEG IgM production in a T cell-dependent manner. The anti-PEG IgM production decreased when the injection dose of PEGylated exosomes was further increased. Anti-PEG IgM induced by injection of PEGylated exosomes decreased blood concentrations of a second dose of PEGylated exosomes and suppressed their tumor accumulation in a C26 murine colorectal cancer model. Initial injection doses of either PEGylated liposomes or PEGylated ovalbumin (PEG-OVA), both of them induced anti-PEG IgM production, also decreased the blood concentration of PEGylated exosomes. Interestingly, anti-PEG IgM induced by injection of PEGylated exosomes did not affect the blood concentration of PEG-OVA. These results imply the importance of monitoring anti-PEG IgM when repeat PEGylated exosome doses are required and/or when PEGylated exosomes are used together with other PEGylated therapeutics."},"publication_date":"2021-06-10","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.334","starting_page":"327","ending_page":"334","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2021.05.001"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:23, {"insert":{"user_id":"B000320827","type":"published_papers","id":"32234603"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33896187","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374835","label":"url"}],"paper_title":{"en":"Incorporating gangliosides into PEGylated cationic liposomes that complexed DNA attenuates anti-PEG antibody production, but not anti-DNA antibody production in mice","ja":"Incorporating gangliosides into PEGylated cationic liposomes that complexed DNA attenuates anti-PEG antibody production, but not anti-DNA antibody production in mice"},"authors":{"en":[{"name":"Milad Reda Qelliny"},{"name":"Shimizu Taro"},{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"Emam Abdallah Emam Sherif"},{"name":"Takata Haruka"},{"name":"Zeinab M. A. Fathalla"},{"name":"Amal K. Hussein"},{"name":"Khaled A. Khaled"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Milad Reda Qelliny"},{"name":"清水 太郎"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"髙田 春風"},{"name":"Zeinab M. A. Fathalla"},{"name":"Amal K. Hussein"},{"name":"Khaled A. Khaled"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Gangliosides (glycosphingolipids) reduce antibody production by inhibiting B-cell receptor (BCR) signaling. We have shown that a copresentation of gangliosides and polyethylene glycol (PEG) on the same liposomes suppresses anti-PEG IgM production in mice. In addition, we recently observed that pDNA incorporated in PEGylated cationic liposomes (PCLs) induces anti-DNA IgM, which could be a hurdle to the development of efficient gene delivery systems. Therefore, the focus of this study was to determine if the copresentation of gangliosides and DNA on the same PCL would suppress antibody production against DNA. PCLs including DNA induced both anti-PEG IgM production and anti-DNA IgM production. The extent of anti-PEG and anti-DNA IgM production was likely dependent on the immunogenicity of the complexed DNA. Treatment of clodronate-containing liposomes, which causes a depletion of phagocytic cells, suppressed anti-PEG IgM production from PCLs that did not include DNA but failed to suppress anti-PEG IgM production from PCLs that complexed DNA (PCLD). Both anti-PEG IgM and anti-DNA IgM was induced in T-cell-deficient nude mice as well as in normal mice following treatment with PCLs and PCLD, respectively. These results indicate that phagocytic cells contribute to anti-PEG IgM production but not to anti-DNA IgM production, while T-cells do not contribute to any form of antibody production. The copresentation of gangliosides and DNA significantly reduced anti-PEG IgM production but unfortunately did not reduce anti-DNA IgM production. It appears that the immunosuppressive effect of gangliosides, presumably via the CD22 signaling pathway, is limited only to anti-PEG immunity.","ja":"Gangliosides (glycosphingolipids) reduce antibody production by inhibiting B-cell receptor (BCR) signaling. We have shown that a copresentation of gangliosides and polyethylene glycol (PEG) on the same liposomes suppresses anti-PEG IgM production in mice. In addition, we recently observed that pDNA incorporated in PEGylated cationic liposomes (PCLs) induces anti-DNA IgM, which could be a hurdle to the development of efficient gene delivery systems. Therefore, the focus of this study was to determine if the copresentation of gangliosides and DNA on the same PCL would suppress antibody production against DNA. PCLs including DNA induced both anti-PEG IgM production and anti-DNA IgM production. The extent of anti-PEG and anti-DNA IgM production was likely dependent on the immunogenicity of the complexed DNA. Treatment of clodronate-containing liposomes, which causes a depletion of phagocytic cells, suppressed anti-PEG IgM production from PCLs that did not include DNA but failed to suppress anti-PEG IgM production from PCLs that complexed DNA (PCLD). Both anti-PEG IgM and anti-DNA IgM was induced in T-cell-deficient nude mice as well as in normal mice following treatment with PCLs and PCLD, respectively. These results indicate that phagocytic cells contribute to anti-PEG IgM production but not to anti-DNA IgM production, while T-cells do not contribute to any form of antibody production. The copresentation of gangliosides and DNA significantly reduced anti-PEG IgM production but unfortunately did not reduce anti-DNA IgM production. It appears that the immunosuppressive effect of gangliosides, presumably via the CD22 signaling pathway, is limited only to anti-PEG immunity."},"publication_date":"2021-06-07","publication_name":{"en":"Molecular Pharmaceutics","ja":"Molecular Pharmaceutics"},"volume":"Vol.18","number":"No.6","starting_page":"2406","ending_page":"2415","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/acs.molpharmaceut.1c00255"],"issn":["1543-8384"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:24, {"insert":{"user_id":"B000320827","type":"published_papers","id":"32065133"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374661","label":"url"}],"paper_title":{"en":"Increasing tumor extracellular pH by an oral alkalinizing agent improves antitumor responses of anti-PD-1 antibody: Implication of relationships between serum bicarbonate concentrations, urinary pH, and therapeutic outcomes","ja":"Increasing tumor extracellular pH by an oral alkalinizing agent improves antitumor responses of anti-PD-1 antibody: Implication of relationships between serum bicarbonate concentrations, urinary pH, and therapeutic outcomes"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Emam Abdallah Emam Sherif"},{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Kiyoshi Eshima"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"Sherif Emam Abdallah Emam"},{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"Kiyoshi Eshima"},{"name":"石田 竜弘"}]},"publication_date":"2021-06-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.44","number":"No.6","starting_page":"844","ending_page":"852","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b21-00076"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:25, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31973250"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374432","label":"url"}],"paper_title":{"en":"Reduction-responsive and Multi-drug Deliverable Albumin Nanoparticles: an antitumor drug to Abraxane® against Human Pancreatic Tumor-Bearing Mice","ja":"Reduction-responsive and Multi-drug Deliverable Albumin Nanoparticles: an antitumor drug to Abraxane® against Human Pancreatic Tumor-Bearing Mice"},"authors":{"en":[{"name":"Hirakawa Naoki"},{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Nakano Ryuto"},{"name":"Victor Tuan Giam Chuang"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"平川 尚樹"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"中野 琉人"},{"name":"Victor Tuan Giam Chuang"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"石田 竜弘"}]},"publication_date":"2021-05-17","publication_name":{"en":"ACS Applied Bio Materials","ja":"ACS Applied Bio Materials"},"volume":"Vol.4","number":"No.5","starting_page":"4302","ending_page":"4309","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/acsabm.1c00110"],"issn":["2576-6422"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:26, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31973251"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374431","label":"url"}],"paper_title":{"en":"Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: a possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies","ja":"Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: a possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies"},"authors":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Kawaguchi Yoshino"},{"name":"Ueda Hiro"},{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"川口 桂乃"},{"name":"上田 大"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2021-05-15","publication_name":{"en":"International Journal of Pharmaceutics","ja":"International Journal of Pharmaceutics"},"volume":"Vol.601","starting_page":"120529","ending_page":"120529","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijpharm.2021.120529"],"issn":["0378-5173"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:27, {"insert":{"user_id":"B000320827","type":"published_papers","id":"32225139"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374827","label":"url"}],"paper_title":{"en":"Evidence for delivery of Abraxane® via a denatured-albumin transport system","ja":"Evidence for delivery of Abraxane® via a denatured-albumin transport system"},"authors":{"en":[{"name":"Hama Maichi"},{"name":"Ishima Yu"},{"name":"Chuang V"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"濵 眞壱"},{"name":"異島 優"},{"name":"Chuang V"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"publication_date":"2021-05-05","publication_name":{"en":"ACS Applied Materials & Interfaces","ja":"ACS Applied Materials & Interfaces"},"volume":"Vol.13","number":"No.17","starting_page":"19736","ending_page":"19744","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/acsami.1c03065"],"issn":["1944-8244"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:28, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31562212"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373441","label":"url"}],"paper_title":{"en":"Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model","ja":"Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model"},"authors":{"en":[{"name":"Akagi Shunsuke"},{"name":"ANDO Hidenori"},{"name":"Fujita Kenji"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Tajima Kenji"},{"name":"Matsushima Tokuo"},{"name":"Kusano Takatomo"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"赤木 俊介"},{"name":"安藤 英紀"},{"name":"藤田 研司"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"Tajima Kenji"},{"name":"Matsushima Tokuo"},{"name":"Kusano Takatomo"},{"name":"石田 竜弘"}]},"publication_date":"2021-03","publication_name":{"en":"International Journal of Biological Macromolecules","ja":"International Journal of Biological Macromolecules"},"volume":"Vol.174","starting_page":"494","ending_page":"501","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijbiomac.2021.01.201"],"issn":["0141-8130"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:29, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31396057"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373094","label":"url"}],"paper_title":{"en":"Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes","ja":"Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Watanabe Yuki"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"渡邉 優希"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2021-02-12","publication_name":{"en":"Vaccine","ja":"Vaccine"},"volume":"Vol.39","number":"No.7","starting_page":"1131","ending_page":"1139","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.vaccine.2021.01.008"],"issn":["0264-410X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:30, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512911"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371851","label":"url"}],"paper_title":{"en":"Complement activation induced by PEG enhances humoral immune responses against antigens encapsulated in PEG-modified liposomes","ja":"Complement activation induced by PEG enhances humoral immune responses against antigens encapsulated in PEG-modified liposomes"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Awata Mizuki"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Yoshioka Chihiro"},{"name":"Kawaguchi Yoshino"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"粟田 瑞月"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"吉岡 千尋"},{"name":"川口 桂乃"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2021-01-10","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.329","starting_page":"1046","ending_page":"1053","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2020.10.033"],"issn":["0168-3659"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:31, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31853993"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116466","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33396604","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374278","label":"url"}],"paper_title":{"en":"Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin","ja":"Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin"},"authors":{"en":[{"name":"Tsukigawa Kenji"},{"name":"Imoto Shuhei"},{"name":"Yamasaki Keishi"},{"name":"Nishi Koji"},{"name":"Tsutsumi Toshihiko"},{"name":"Yokoyama Shoko"},{"name":"Ishima Yu"},{"name":"Otagiri Masaki"}],"ja":[{"name":"Tsukigawa Kenji"},{"name":"Imoto Shuhei"},{"name":"Yamasaki Keishi"},{"name":"Nishi Koji"},{"name":"Tsutsumi Toshihiko"},{"name":"Yokoyama Shoko"},{"name":"異島 優"},{"name":"Otagiri Masaki"}]},"publication_date":"2020-12-30","publication_name":{"en":"Pharmaceuticals","ja":"Pharmaceuticals"},"volume":"Vol.14","number":"No.1","starting_page":"22","ending_page":"22","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/ph14010022"],"issn":["1424-8247"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:32, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512910"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116247","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371854","label":"url"}],"paper_title":{"en":"Adjuvant antitumor immunity contributes to the overall antitumor effect of PEGylated liposomal doxorubicin (Doxil®) in C26 tumor-bearing immunocompetent mice","ja":"Adjuvant antitumor immunity contributes to the overall antitumor effect of PEGylated liposomal doxorubicin (Doxil®) in C26 tumor-bearing immunocompetent mice"},"authors":{"en":[{"name":"Takayama Takuma"},{"name":"Shimizu Taro"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Kanazawa Yuki"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"高山 拓磨"},{"name":"清水 太郎"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"金沢 有希"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2020-10-19","publication_name":{"en":"Pharmaceutics","ja":"Pharmaceutics"},"volume":"Vol.12","number":"No.10","starting_page":"990","ending_page":"990","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/pharmaceutics12100990"],"issn":["1999-4923"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:33, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512904"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32879214","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366419","label":"url"}],"paper_title":{"en":"Pegfilgrastim (PEG-G-CSF) induces anti-polyethylene glycol (PEG) IgM via a T cell-dependent mechanism","ja":"Pegfilgrastim (PEG-G-CSF) induces anti-polyethylene glycol (PEG) IgM via a T cell-dependent mechanism"},"authors":{"en":[{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Protein-based therapeutics are beginning to be widely used in various clinical settings. Conjugation of polyethylene glycol (PEGylation) to protein therapeutics improves their circulation half-lives in the body. However, we and other groups observed that the initial dose of some PEGylated protein-based therapeutics may induce anti-PEG antibodies (primarily immunoglobulin M (IgM)), resulting in the accelerated clearance of a second dose. The mechanism behind the induction of anti-PEG IgM by PEGylated protein-based therapeutics is still unclear. In this study, we found that Pegfilgrastim (PEG-G-CSF, the PEGylated form of the recombinant human granulocyte colony-stimulating factor) induced anti-PEG IgM in mice when administered via either intravenous or subcutaneous administration. However, the anti-PEG IgM induction is diminished both in athymic nude mice lacking T cells and in splenectomized mice. In addition, anti-PEG IgM production was significantly diminished in the cyclophosphamide-treated mice depleted of B-cells. These results indicate that anti-PEG IgM production by Pegfilgrastim occurs in spleen in a T cell-dependent manner, which differs from anti-PEG IgM induced by PEGylated liposomes. However, B cells, both marginal zone and follicular, are essential for anti-PEG IgM production in both PEGylated preparations.","ja":"Protein-based therapeutics are beginning to be widely used in various clinical settings. Conjugation of polyethylene glycol (PEGylation) to protein therapeutics improves their circulation half-lives in the body. However, we and other groups observed that the initial dose of some PEGylated protein-based therapeutics may induce anti-PEG antibodies (primarily immunoglobulin M (IgM)), resulting in the accelerated clearance of a second dose. The mechanism behind the induction of anti-PEG IgM by PEGylated protein-based therapeutics is still unclear. In this study, we found that Pegfilgrastim (PEG-G-CSF, the PEGylated form of the recombinant human granulocyte colony-stimulating factor) induced anti-PEG IgM in mice when administered via either intravenous or subcutaneous administration. However, the anti-PEG IgM induction is diminished both in athymic nude mice lacking T cells and in splenectomized mice. In addition, anti-PEG IgM production was significantly diminished in the cyclophosphamide-treated mice depleted of B-cells. These results indicate that anti-PEG IgM production by Pegfilgrastim occurs in spleen in a T cell-dependent manner, which differs from anti-PEG IgM induced by PEGylated liposomes. However, B cells, both marginal zone and follicular, are essential for anti-PEG IgM production in both PEGylated preparations."},"publication_date":"2020-09-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.43","number":"No.9","starting_page":"1393","ending_page":"1397","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b20-00345"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:34, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512905"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32519877","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366420","label":"url"}],"paper_title":{"en":"Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of peginterferon alfa-2a (Pegasys®) in mice","ja":"Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of peginterferon alfa-2a (Pegasys®) in mice"},"authors":{"en":[{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Hondoh Eri"},{"name":"Shimizu Taro"},{"name":"Takata Haruka"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Sherif Emam Abdallah Emam"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"本藤 栄里"},{"name":"清水 太郎"},{"name":"髙田 春風"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"PEGylation had been used successfully to improve the circulation half-lives and some physicochemical properties of protein therapeutics. However, anti-polyethylene glycol (anti-PEG) antibodies, either pre-existing or treatment-induced, can negatively affect the pharmacokinetics and pharmacological efficacy of PEGylated proteins. We have examined anti-PEG immune responses in mice for peginterferon alfa-2a (Pegasys), a clinically approved PEGylated protein therapeutic, at both the recommended dose (equivalent to 3 μg/kg in mice) and at higher doses (150 μg/kg) for single or repeated subcutaneous (s.c.) administrations. The effect of treatment-induced anti-PEG IgM on serum concentrations of Pegasys, following repeated administrations, was evaluated. In addition, the effect of pre-existing anti-PEG IgM elicited by a different PEGylated protein, PEG-OVA, on the systemic clearance of Pegasys, was investigated. At a s.c. dose of 3 μg/kg, single injections of Pegasys barely elicited anti-PEG immune responses. Four repeated doses of 150 μg/kg Pegasys elicited anti-PEG IgM production, depending on dose frequency, and triggered the rapid clearance of subsequent doses. In addition, anti-PEG-IgM produced in response to prior administration of PEG-OVA caused a rapid blood clearance of Pegasys. Our results, therefore, underscore the importance of screening for both pre-existing and treatment-induced anti-PEG antibodies in patients prior to and during treatment with PEGylated protein drugs.","ja":"PEGylation had been used successfully to improve the circulation half-lives and some physicochemical properties of protein therapeutics. However, anti-polyethylene glycol (anti-PEG) antibodies, either pre-existing or treatment-induced, can negatively affect the pharmacokinetics and pharmacological efficacy of PEGylated proteins. We have examined anti-PEG immune responses in mice for peginterferon alfa-2a (Pegasys), a clinically approved PEGylated protein therapeutic, at both the recommended dose (equivalent to 3 μg/kg in mice) and at higher doses (150 μg/kg) for single or repeated subcutaneous (s.c.) administrations. The effect of treatment-induced anti-PEG IgM on serum concentrations of Pegasys, following repeated administrations, was evaluated. In addition, the effect of pre-existing anti-PEG IgM elicited by a different PEGylated protein, PEG-OVA, on the systemic clearance of Pegasys, was investigated. At a s.c. dose of 3 μg/kg, single injections of Pegasys barely elicited anti-PEG immune responses. Four repeated doses of 150 μg/kg Pegasys elicited anti-PEG IgM production, depending on dose frequency, and triggered the rapid clearance of subsequent doses. In addition, anti-PEG-IgM produced in response to prior administration of PEG-OVA caused a rapid blood clearance of Pegasys. Our results, therefore, underscore the importance of screening for both pre-existing and treatment-induced anti-PEG antibodies in patients prior to and during treatment with PEGylated protein drugs."},"publication_date":"2020-08-03","publication_name":{"en":"Molecular Pharmaceutics","ja":"Molecular Pharmaceutics"},"volume":"Vol.17","number":"No.8","starting_page":"2964","ending_page":"2970","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/acs.molpharmaceut.0c00366"],"issn":["1543-8392"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:35, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512906"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32278827","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85083399688&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=364762","label":"url"}],"paper_title":{"en":"Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon","ja":"Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon"},"authors":{"en":[{"name":"El Sayed M M"},{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Kawaguchi Yoshino"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Alaaeldin E"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Kamal A"},{"name":"Sarhan H A"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"El Sayed M M"},{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"川口 桂乃"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Alaaeldin E"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"Kamal A"},{"name":"Sarhan H A"},{"name":"石田 竜弘"}]},"description":{"en":"The accelerated blood clearance (ABC) phenomenon, caused in large degree via in vivo anti-PEG IgM production, is one of obstacles for development of PEGylated liposome and protein formulations, due to decreased efficiency and/or side effects such as anaphylaxis upon repeat administrations. We have shown in murine ABC models that splenectomy suppressed the level of anti-PEG IgM production induced by PEGylated liposomes, indicating that murine splenic B cells play an important role in its production. However, splenectomy did not completely inhibit production of anti-PEG IgM, suggesting that other cells may contribute to its production in the ABC phenomenon. In this study, we examined the contribution of hepatosplenic phagocytic cells to anti-PEG IgM production and clearance of PEGylated liposomes during the ABC phenomenon. Depletion of hepatosplenic phagocytic cells by pretreatment of mice with clodronate-containing non-PEGylated liposomes suppressed anti-PEG IgM production to a considerable degree, without a change in the number of splenic B cells, and attenuated the enhanced clearance of second dose of PEGylated liposomes. These results suggest that hepatosplenic phagocytic cells, in addition to splenic B cells, contribute to the production of anti-PEG IgM and the ABC phenomenon against PEGylated liposomes. The mechanism whereby splenic B cells interact with hepatosplenic phagocytic cells to produce anti-PEG IgM, upon administration of an initial dose of PEGylated liposomes remains to be elucidated.","ja":"The accelerated blood clearance (ABC) phenomenon, caused in large degree via in vivo anti-PEG IgM production, is one of obstacles for development of PEGylated liposome and protein formulations, due to decreased efficiency and/or side effects such as anaphylaxis upon repeat administrations. We have shown in murine ABC models that splenectomy suppressed the level of anti-PEG IgM production induced by PEGylated liposomes, indicating that murine splenic B cells play an important role in its production. However, splenectomy did not completely inhibit production of anti-PEG IgM, suggesting that other cells may contribute to its production in the ABC phenomenon. In this study, we examined the contribution of hepatosplenic phagocytic cells to anti-PEG IgM production and clearance of PEGylated liposomes during the ABC phenomenon. Depletion of hepatosplenic phagocytic cells by pretreatment of mice with clodronate-containing non-PEGylated liposomes suppressed anti-PEG IgM production to a considerable degree, without a change in the number of splenic B cells, and attenuated the enhanced clearance of second dose of PEGylated liposomes. These results suggest that hepatosplenic phagocytic cells, in addition to splenic B cells, contribute to the production of anti-PEG IgM and the ABC phenomenon against PEGylated liposomes. The mechanism whereby splenic B cells interact with hepatosplenic phagocytic cells to produce anti-PEG IgM, upon administration of an initial dose of PEGylated liposomes remains to be elucidated."},"publication_date":"2020-07-10","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.323","starting_page":"102","ending_page":"109","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2020.04.011"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:36, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31858357"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32380091","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85084408610&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374318","label":"url"}],"paper_title":{"en":"Changes in redox state of albumin before and after kidney transplantation in patients with end-stage renal disease","ja":"Changes in redox state of albumin before and after kidney transplantation in patients with end-stage renal disease"},"authors":{"en":[{"name":"Tanaka Ryota"},{"name":"Imafuku Tadashi"},{"name":"Suzuki Yosuke"},{"name":"Nishida Kento"},{"name":"Matsusaka Kotaro"},{"name":"Shin Toshitaka"},{"name":"Sato Yuhki"},{"name":"Ishima Yu"},{"name":"Watanabe Hiroshi"},{"name":"Mimata Hiromitsu"},{"name":"Maruyama Toru"},{"name":"Itoh Hiroki"}],"ja":[{"name":"Tanaka Ryota"},{"name":"Imafuku Tadashi"},{"name":"Suzuki Yosuke"},{"name":"Nishida Kento"},{"name":"Matsusaka Kotaro"},{"name":"Shin Toshitaka"},{"name":"Sato Yuhki"},{"name":"異島 優"},{"name":"Watanabe Hiroshi"},{"name":"Mimata Hiromitsu"},{"name":"Maruyama Toru"},{"name":"Itoh Hiroki"}]},"description":{"en":"Cardiovascular disease is one of the major causes of death in patients with end-stage kidney disease who have undergone kidney transplantation. Since the complication of cardiovascular disease in patients with chronic kidney disease is strongly linked to oxidative stress, understanding the oxidative stress condition after kidney transplantation would be of great importance for the prevention of cardiovascular disease. This study examined whether improvement of renal function after kidney transplantation has an impact on the redox state of the Cys34 residue of albumin that reflects the level of oxidative stress in blood. We enrolled 23 patients with end-stage renal failure who received kidney transplantation. All patients were followed for 180 days after transplantation. The fractions of albumin isoforms were determined by the electrospray ionization time-of-flight mass spectrometry (ESI-TOFMS) method. Serum creatinine decreased significantly immediately after kidney transplantation, suggesting successful transplantations. The ESI-TOFMS method identified three albumin isoforms cysteinylated at the Cys34 residue (Cys-Cys34-albumin) and the three corresponding albumin isoforms without Cys34 cysteinylation. The fraction of total Cys-Cys34-albumin decreased transiently after kidney transplantation, and was followed by an elevation at day 7 and gradual decrease thereafter until day 180. Meanwhile, reduced albumin concentration did not change until day 14 after kidney transplantation, then showed a significant increase compared to pre-transplant level at day 30 and remained stably elevated until day 180. Actual reduced albumin levels were found to exceed pre-transplant levels on or after day 30 following kidney transplantation unlike immediate restoration of renal function. Renal function was recovered immediately following kidney transplantation, but reduced albumen concentration increased above the pre-transplant levels only from day 30 after transplantation.","ja":"Cardiovascular disease is one of the major causes of death in patients with end-stage kidney disease who have undergone kidney transplantation. Since the complication of cardiovascular disease in patients with chronic kidney disease is strongly linked to oxidative stress, understanding the oxidative stress condition after kidney transplantation would be of great importance for the prevention of cardiovascular disease. This study examined whether improvement of renal function after kidney transplantation has an impact on the redox state of the Cys34 residue of albumin that reflects the level of oxidative stress in blood. We enrolled 23 patients with end-stage renal failure who received kidney transplantation. All patients were followed for 180 days after transplantation. The fractions of albumin isoforms were determined by the electrospray ionization time-of-flight mass spectrometry (ESI-TOFMS) method. Serum creatinine decreased significantly immediately after kidney transplantation, suggesting successful transplantations. The ESI-TOFMS method identified three albumin isoforms cysteinylated at the Cys34 residue (Cys-Cys34-albumin) and the three corresponding albumin isoforms without Cys34 cysteinylation. The fraction of total Cys-Cys34-albumin decreased transiently after kidney transplantation, and was followed by an elevation at day 7 and gradual decrease thereafter until day 180. Meanwhile, reduced albumin concentration did not change until day 14 after kidney transplantation, then showed a significant increase compared to pre-transplant level at day 30 and remained stably elevated until day 180. Actual reduced albumin levels were found to exceed pre-transplant levels on or after day 30 following kidney transplantation unlike immediate restoration of renal function. Renal function was recovered immediately following kidney transplantation, but reduced albumen concentration increased above the pre-transplant levels only from day 30 after transplantation."},"publication_date":"2020-07","publication_name":{"en":"Clinical Biochemistry","ja":"Clinical Biochemistry"},"volume":"Vol.81","starting_page":"20","ending_page":"26","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.clinbiochem.2020.04.010"],"issn":["1873-2933"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:37, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512907"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32376372","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=365548","label":"url"}],"paper_title":{"en":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice","ja":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice"},"authors":{"en":[{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"Lila Abu Ali Ahmed Selim Amr"},{"name":"Emam Abdallah Emam Sherif"},{"name":"Shimizu Taro"},{"name":"Takata Haruka"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"Lila Abu Ali Ahmed Selim Amr"},{"name":"Emam Abdallah Emam Sherif"},{"name":"清水 太郎"},{"name":"髙田 春風"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Pegfilgrastimis a recombinant PEGylated human granulocyte colony-stimulating factor (G-CSF) analog filgrastim (trade names Neulasta® or G-Lasta®) that stimulates the production of white blood cells (neutrophils). It is employed as an alternative to filgrastim (G-CSF) for chemotherapy-induced neutropenia in patients due to its longer half-life. In clinical settings, PEG-G-CSF is administered to cancer patients via both the s.c. and i.v. routes. In a murine study, we showed that, regardless of administration route, initial doses of PEG-G-CSF above 0.06 mg/kg elicited anti-PEG immune response in a dose-dependent manner. I.v. administration elicited higher levels of anti-PEG IgM than the s.c. route. Initial doses of PEG-G-CSF (6 mg/kg) that were high enough to trigger production of anti-PEG IgM, did not trigger the accelerated clearance of a lower subsequent dose (0.06 mg/kg) that was similar to i.v. clinical doses of PEG-G-CSF, but when the subsequent dose of PEG-G-CSF was raised to (6 mg/kg), the initial dose triggered the accelerated clearance of the second dose via an anti-PEG IgM-mediated complement activation. Similar observations were noted when an increased PEG-OVA dose was given as the second dose, indicating that pre-existing and/or treatment-induced anti-PEG antibodies might compromise the therapeutic activity and/or reduce tolerance of other PEGylated formulations. To the best of our knowledge, this is the first report to suggest the induction of the ABC phenomenon upon repeated injections of pegfilgrastim. In the clinic, cancer patients, receiving multiple cycles of chemotherapy, receive multiple cycles of pegfilgrastim to avoid infections and substantial morbidity. The ABC phenomenon to pegfilgrastim appears to be the cause of loss of clinical benefit of sequential treatments with pegfilgrastim in patients.","ja":"Pegfilgrastimis a recombinant PEGylated human granulocyte colony-stimulating factor (G-CSF) analog filgrastim (trade names Neulasta® or G-Lasta®) that stimulates the production of white blood cells (neutrophils). It is employed as an alternative to filgrastim (G-CSF) for chemotherapy-induced neutropenia in patients due to its longer half-life. In clinical settings, PEG-G-CSF is administered to cancer patients via both the s.c. and i.v. routes. In a murine study, we showed that, regardless of administration route, initial doses of PEG-G-CSF above 0.06 mg/kg elicited anti-PEG immune response in a dose-dependent manner. I.v. administration elicited higher levels of anti-PEG IgM than the s.c. route. Initial doses of PEG-G-CSF (6 mg/kg) that were high enough to trigger production of anti-PEG IgM, did not trigger the accelerated clearance of a lower subsequent dose (0.06 mg/kg) that was similar to i.v. clinical doses of PEG-G-CSF, but when the subsequent dose of PEG-G-CSF was raised to (6 mg/kg), the initial dose triggered the accelerated clearance of the second dose via an anti-PEG IgM-mediated complement activation. Similar observations were noted when an increased PEG-OVA dose was given as the second dose, indicating that pre-existing and/or treatment-induced anti-PEG antibodies might compromise the therapeutic activity and/or reduce tolerance of other PEGylated formulations. To the best of our knowledge, this is the first report to suggest the induction of the ABC phenomenon upon repeated injections of pegfilgrastim. In the clinic, cancer patients, receiving multiple cycles of chemotherapy, receive multiple cycles of pegfilgrastim to avoid infections and substantial morbidity. The ABC phenomenon to pegfilgrastim appears to be the cause of loss of clinical benefit of sequential treatments with pegfilgrastim in patients."},"publication_date":"2020-07","publication_name":{"en":"European Journal of Pharmaceutics and Biopharmaceutics","ja":"European Journal of Pharmaceutics and Biopharmaceutics"},"volume":"Vol.152","starting_page":"56","ending_page":"62","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ejpb.2020.04.026"],"issn":["1873-3441"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:38, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31867757"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116252","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374334","label":"url"}],"paper_title":{"en":"The DsbA-L gene is associated with respiratory function of the elderly via its adiponectin multimeric or antioxidant properties","ja":"The DsbA-L gene is associated with respiratory function of the elderly via its adiponectin multimeric or antioxidant properties"},"authors":{"en":[{"name":"Oniki Kentaro"},{"name":"Nohara Hirofumi"},{"name":"Nakashima Ryunosuke"},{"name":"Obata Yui"},{"name":"Muto Narumi"},{"name":"Sakamoto Yuki"},{"name":"Ueno-Shuto Keiko"},{"name":"Imafuku Tadashi"},{"name":"Ishima Yu"},{"name":"Watanabe Hiroshi"},{"name":"Maruyama Toru"},{"name":"Otake Koji"},{"name":"Ogata Yasuhiro"},{"name":"Suico Ann Mary"},{"name":"Kai Hirofumi"},{"name":"Shuto Tsuyoshi"},{"name":"Saruwatari Junji"}],"ja":[{"name":"Oniki Kentaro"},{"name":"Nohara Hirofumi"},{"name":"Nakashima Ryunosuke"},{"name":"Obata Yui"},{"name":"Muto Narumi"},{"name":"Sakamoto Yuki"},{"name":"Ueno-Shuto Keiko"},{"name":"Imafuku Tadashi"},{"name":"異島 優"},{"name":"Watanabe Hiroshi"},{"name":"Maruyama Toru"},{"name":"Otake Koji"},{"name":"Ogata Yasuhiro"},{"name":"Suico Ann Mary"},{"name":"Kai Hirofumi"},{"name":"Shuto Tsuyoshi"},{"name":"Saruwatari Junji"}]},"publication_date":"2020-04-06","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"Vol.10","starting_page":"5973","ending_page":"5973","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41598-020-62872-5"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:39, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512908"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115605","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32283709","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85083281974&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=364894","label":"url"}],"paper_title":{"en":"A unique gene-silencing approach, using an intelligent RNA expression device (iRed), results in minimal immune stimulation when given by local intrapleural injection in malignant pleural mesothelioma","ja":"A unique gene-silencing approach, using an intelligent RNA expression device (iRed), results in minimal immune stimulation when given by local intrapleural injection in malignant pleural mesothelioma"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Saito-Tarashima Noriko"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Kinjoh Nozomi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Minakawa Noriaki"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"田良島 典子"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"金城 望"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"南川 典昭"},{"name":"石田 竜弘"}]},"description":{"en":"We have recently introduced an intelligent RNA expression device (iRed), comprising the minimum essential components needed to transcribe short hairpin RNA (shRNA) in cells. Use of iRed efficiently produced shRNA molecules after transfection into cells and alleviated the innate immune stimulation following intravenous injection. To study the usefulness of iRed for local injection, the engineered iRed encoding luciferase shRNA (Luc iRed), complexed with cationic liposomes (Luc iRed/liposome-complexes), was intrapleurally injected into an orthotopic mesothelioma mouse model. Luc iRed/liposome-complexes markedly suppressed the expression of a luciferase marker gene in pleurally disseminated mesothelioma cells. The suppressive efficiency was correlated with the expression level of shRNA within the mesothelioma cells. In addition, intrapleural injection of iRed/liposome-complexes did not induce IL-6 production in the pleural space and consequently in the blood compartment, although plasmid DNA (pDNA) or dsDNA (the natural construct for iRed) in the formulation did. Local delivery of iRed could augment the in vivo gene silencing effect without eliciting pronounced innate immune stimulation. Our results might hold promise for widespread utilization of iRed as an RNAi-based therapeutic for intracelial malignant cancers.","ja":"We have recently introduced an intelligent RNA expression device (iRed), comprising the minimum essential components needed to transcribe short hairpin RNA (shRNA) in cells. Use of iRed efficiently produced shRNA molecules after transfection into cells and alleviated the innate immune stimulation following intravenous injection. To study the usefulness of iRed for local injection, the engineered iRed encoding luciferase shRNA (Luc iRed), complexed with cationic liposomes (Luc iRed/liposome-complexes), was intrapleurally injected into an orthotopic mesothelioma mouse model. Luc iRed/liposome-complexes markedly suppressed the expression of a luciferase marker gene in pleurally disseminated mesothelioma cells. The suppressive efficiency was correlated with the expression level of shRNA within the mesothelioma cells. In addition, intrapleural injection of iRed/liposome-complexes did not induce IL-6 production in the pleural space and consequently in the blood compartment, although plasmid DNA (pDNA) or dsDNA (the natural construct for iRed) in the formulation did. Local delivery of iRed could augment the in vivo gene silencing effect without eliciting pronounced innate immune stimulation. Our results might hold promise for widespread utilization of iRed as an RNAi-based therapeutic for intracelial malignant cancers."},"publication_date":"2020-04-01","publication_name":{"en":"Molecules","ja":"Molecules"},"volume":"Vol.25","number":"No.7","starting_page":"1725","ending_page":"1725","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/molecules25071725"],"issn":["1420-3049"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:40, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512909"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31794135","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85076101146&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360737","label":"url"}],"paper_title":{"en":"Albumin domain mutants with enhanced Aβ binding capacity identified by phage display analysis for application in various peripheral Aβ elimination approaches of Alzheimer's disease treatment","ja":"Albumin domain mutants with enhanced Aβ binding capacity identified by phage display analysis for application in various peripheral Aβ elimination approaches of Alzheimer's disease treatment"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Minomo Ai"},{"name":"Victor Tuan Giam Chuang"},{"name":"Fukuda Tetsuya"},{"name":"Kusumoto Kohshi"},{"name":"Okuhira Keiichiro"},{"name":"Suwa Yoshiaki"},{"name":"Watanabe Hiroshi"},{"name":"Ishida Tatsuhiro"},{"name":"Morioka Hiroshi"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"}],"ja":[{"name":"異島 優"},{"name":"Minomo Ai"},{"name":"Victor Tuan Giam Chuang"},{"name":"Fukuda Tetsuya"},{"name":"楠本 嵩志"},{"name":"奥平 桂一郎"},{"name":"Suwa Yoshiaki"},{"name":"Watanabe Hiroshi"},{"name":"石田 竜弘"},{"name":"Morioka Hiroshi"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"}]},"description":{"en":"Deposition of amyloid protein, particularly Aβ , is a major contributor to the onset of Alzheimer's disease (AD). However, almost no deposition of Aβ in the peripheral tissues could be found. Human serum albumin (HSA), the most abundant protein in the blood, has been reported to inhibit amyloid formation through binding Aβ, which is believed to play an important role in the peripheral clearance of Aβ. We identified the Aβ binding site on HSA and developed HSA mutants with high binding capacities for Aβ using a phage display method. HSA fragment 187-385 (Domain II) was found to exhibit the highest binding capacity for Aβ compared with the other two HSA fragments. To elucidate the sequence that forms the binding site for Aβ on Domain II, a random screening of Domain II display phage biopanning was constructed. A number of mutants with higher Aβ binding capacities than the wild type were identified. These mutants exhibited stronger scavenging abilities than the wild type, as revealed via in vitro equilibrium dialysis of Aβ experiments. These findings provide useful basic data for developing a safer alternative therapy than Aβ vaccines and for application in plasma exchange as well as extracorporeal dialysis.","ja":"Deposition of amyloid protein, particularly Aβ , is a major contributor to the onset of Alzheimer's disease (AD). However, almost no deposition of Aβ in the peripheral tissues could be found. Human serum albumin (HSA), the most abundant protein in the blood, has been reported to inhibit amyloid formation through binding Aβ, which is believed to play an important role in the peripheral clearance of Aβ. We identified the Aβ binding site on HSA and developed HSA mutants with high binding capacities for Aβ using a phage display method. HSA fragment 187-385 (Domain II) was found to exhibit the highest binding capacity for Aβ compared with the other two HSA fragments. To elucidate the sequence that forms the binding site for Aβ on Domain II, a random screening of Domain II display phage biopanning was constructed. A number of mutants with higher Aβ binding capacities than the wild type were identified. These mutants exhibited stronger scavenging abilities than the wild type, as revealed via in vitro equilibrium dialysis of Aβ experiments. These findings provide useful basic data for developing a safer alternative therapy than Aβ vaccines and for application in plasma exchange as well as extracorporeal dialysis."},"publication_date":"2020-04","publication_name":{"en":"IUBMB life","ja":"IUBMB life"},"volume":"Vol.72","number":"No.4","starting_page":"641","ending_page":"651","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/iub.2203"],"issn":["1521-6551"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:41, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31867758"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31924689","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374335","label":"url"}],"paper_title":{"en":"Carbon Monoxide Rescues the Developmental Lethality of Experimental Rat Models of Rhabdomyolysis-Induced Acute Kidney Injury","ja":"Carbon Monoxide Rescues the Developmental Lethality of Experimental Rat Models of Rhabdomyolysis-Induced Acute Kidney Injury"},"authors":{"en":[{"name":"Taguchi Kazuaki"},{"name":"Ogaki Shigeru"},{"name":"Nagasaki Taisei"},{"name":"Yanagisawa Hiroki"},{"name":"Nishida Kento"},{"name":"Maeda Hitoshi"},{"name":"Enoki Yuki"},{"name":"Matsumoto Kazuaki"},{"name":"Sekijima Hidehisa"},{"name":"Ooi Kazuya"},{"name":"Ishima Yu"},{"name":"Watanabe Hiroshi"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"Taguchi Kazuaki"},{"name":"Ogaki Shigeru"},{"name":"Nagasaki Taisei"},{"name":"Yanagisawa Hiroki"},{"name":"Nishida Kento"},{"name":"Maeda Hitoshi"},{"name":"Enoki Yuki"},{"name":"Matsumoto Kazuaki"},{"name":"Sekijima Hidehisa"},{"name":"Ooi Kazuya"},{"name":"異島 優"},{"name":"Watanabe Hiroshi"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"description":{"en":"Many victims, after being extricated from a collapsed building as the result of a disaster, suffer from disaster nephrology, a term that is referred to as the crush syndrome (CS). Recommended treatments, which include dialysis or the continuous administration of massive amounts of fluid are not usually easy in cases of such mass natural disasters. In the present study, we examined the therapeutic performance of a biomimetic carbon monoxide (CO) delivery system, CO-enriched red blood cells (CO-RBCs), on experimental animal models of an acute kidney injury (AKI) induced by traumatic and nontraumatic rhabdomyolysis, including CS and rhabdomyolysis with massive hemorrhage shock. A single CO-RBC treatment was found to effectively suppress the pathogenesis of AKI with the mortality in these model rats being improved. In addition, in further studies using glycerol-induced rhabdomyolysis model rats, the pathogenesis of which is similar to that for the CS, AKI and mortality were also reduced as the result of a CO-RBC treatment. Furthermore, CO-RBCs were found to have renoprotective effects via the suppression of subsequent heme protein-associated renal oxidative injury; the oxidation of myoglobin in the kidneys, the generation of reactive oxygen species by free heme produced from degraded-cytochrome P450 and hemoglobin-associated renal injury. Because CO-RBCs can be prepared and used at both hospitals and at a disaster site, these findings suggest that CO-RBCs have the potential for use as a novel cell therapy against both nontraumatic and traumatic rhabdomyolysis including CS-induced AKI. SIGNIFICANCE STATEMENT: After mass natural and man-made disasters, people who are trapped in collapsed buildings are in danger of acute kidney injury (AKI), including crush syndrome (CS)-related AKI. This paper reports that carbon monoxide-enriched red blood cells (CO-RBCs), which can be prepared at both hospitals and disaster sites, dramatically suppressed the pathogenesis of CS-related AKI, thus improving mortality via suppressing heme protein-associated renal injuries. CO-RBCs have the potential for serving as a practical therapeutic agent against disaster nephrology associated with the CS.","ja":"Many victims, after being extricated from a collapsed building as the result of a disaster, suffer from disaster nephrology, a term that is referred to as the crush syndrome (CS). Recommended treatments, which include dialysis or the continuous administration of massive amounts of fluid are not usually easy in cases of such mass natural disasters. In the present study, we examined the therapeutic performance of a biomimetic carbon monoxide (CO) delivery system, CO-enriched red blood cells (CO-RBCs), on experimental animal models of an acute kidney injury (AKI) induced by traumatic and nontraumatic rhabdomyolysis, including CS and rhabdomyolysis with massive hemorrhage shock. A single CO-RBC treatment was found to effectively suppress the pathogenesis of AKI with the mortality in these model rats being improved. In addition, in further studies using glycerol-induced rhabdomyolysis model rats, the pathogenesis of which is similar to that for the CS, AKI and mortality were also reduced as the result of a CO-RBC treatment. Furthermore, CO-RBCs were found to have renoprotective effects via the suppression of subsequent heme protein-associated renal oxidative injury; the oxidation of myoglobin in the kidneys, the generation of reactive oxygen species by free heme produced from degraded-cytochrome P450 and hemoglobin-associated renal injury. Because CO-RBCs can be prepared and used at both hospitals and at a disaster site, these findings suggest that CO-RBCs have the potential for use as a novel cell therapy against both nontraumatic and traumatic rhabdomyolysis including CS-induced AKI. SIGNIFICANCE STATEMENT: After mass natural and man-made disasters, people who are trapped in collapsed buildings are in danger of acute kidney injury (AKI), including crush syndrome (CS)-related AKI. This paper reports that carbon monoxide-enriched red blood cells (CO-RBCs), which can be prepared at both hospitals and disaster sites, dramatically suppressed the pathogenesis of CS-related AKI, thus improving mortality via suppressing heme protein-associated renal injuries. CO-RBCs have the potential for serving as a practical therapeutic agent against disaster nephrology associated with the CS."},"publication_date":"2020-03","publication_name":{"en":"The Journal of Pharmacology and Experimental Therapeutics","ja":"The Journal of Pharmacology and Experimental Therapeutics"},"volume":"Vol.372","number":"No.3","starting_page":"355","ending_page":"365","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1124/jpet.119.262485"],"issn":["1521-0103"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:42, {"insert":{"user_id":"B000320827","type":"published_papers","id":"31867759"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374336","label":"url"}],"paper_title":{"en":"Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model","ja":"Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model"},"authors":{"en":[{"name":"Maeda Hitoshi"},{"name":"Minayoshi Yuki"},{"name":"Ichimizu Shota"},{"name":"Mizuta Yuki"},{"name":"Nagasaki Taisei"},{"name":"Matsusaka Kotaro"},{"name":"Oshiro Shun"},{"name":"Oniki Kentaro"},{"name":"Saruwatari Junji"},{"name":"Ishima Yu"},{"name":"Watanabe Hiroshi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"Maeda Hitoshi"},{"name":"Minayoshi Yuki"},{"name":"Ichimizu Shota"},{"name":"Mizuta Yuki"},{"name":"Nagasaki Taisei"},{"name":"Matsusaka Kotaro"},{"name":"Oshiro Shun"},{"name":"Oniki Kentaro"},{"name":"Saruwatari Junji"},{"name":"異島 優"},{"name":"Watanabe Hiroshi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"publication_date":"2020-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.43","number":"No.1","starting_page":"93","ending_page":"101","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b19-00599"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:43, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512912"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31629787","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85073758566&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360421","label":"url"}],"paper_title":{"en":"Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues","ja":"Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues"},"authors":{"en":[{"name":"Sherif Emam Abdallah Emam"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Mahdy M"},{"name":"Ghazy E"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Sherif Emam Abdallah Emam"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"Mahdy M"},{"name":"Ghazy E"},{"name":"石田 竜弘"}]},"description":{"en":"Exosomes are gaining increasing attention as drug delivery vehicles due to their low toxicity and ability to functionally transfer biological cargos between cells. However, the therapeutic applicability of exosomes is partially hampered by a lack of cell-type specificity. In this study, therefore, we investigated the impact of cell-type tropism on the in vivo systemic delivery of exosomes to tumor tissues. Exosomes derived from murine colorectal cancer cells (C26) (C26-Exos) and murine melanoma cells (B16BL6) (B16BL6-Exos) were collected. In vitro cellular uptake of either autologous (C26) or allogeneic (B16BL6) exosomes by C26 tumor cells was determined. In vivo tumor accumulation of each type of exosomes in mice bearing C26 tumors was monitored with an in vivo imaging system (IVIS). In in vitro studies, autologous C26-Exos were more efficiently taken up by C26 cancer cells, compared to allogeneic B16BL6-Exos. For in vivo studies, exosomes were modified with surface polyethylene glycol (PEG) to improve their circulation lifetimes. Although both types of PEGylated exosomes accumulated in C26-tumor tissue, autologous exosomes were preferentially accumulated within C26-tumor tissue compared to allogeneic exosomes. The increased tumor accumulation of autologous PEGylated exosomes was accompanied by the preferential uptake of exosomes by not only C26-tumor cells but also tumor-associated immune cells. This study implies that cancer cell-type tropism is an important factor in the achievement of tumor cell targeting with cancer cell-derived exosomes.","ja":"Exosomes are gaining increasing attention as drug delivery vehicles due to their low toxicity and ability to functionally transfer biological cargos between cells. However, the therapeutic applicability of exosomes is partially hampered by a lack of cell-type specificity. In this study, therefore, we investigated the impact of cell-type tropism on the in vivo systemic delivery of exosomes to tumor tissues. Exosomes derived from murine colorectal cancer cells (C26) (C26-Exos) and murine melanoma cells (B16BL6) (B16BL6-Exos) were collected. In vitro cellular uptake of either autologous (C26) or allogeneic (B16BL6) exosomes by C26 tumor cells was determined. In vivo tumor accumulation of each type of exosomes in mice bearing C26 tumors was monitored with an in vivo imaging system (IVIS). In in vitro studies, autologous C26-Exos were more efficiently taken up by C26 cancer cells, compared to allogeneic B16BL6-Exos. For in vivo studies, exosomes were modified with surface polyethylene glycol (PEG) to improve their circulation lifetimes. Although both types of PEGylated exosomes accumulated in C26-tumor tissue, autologous exosomes were preferentially accumulated within C26-tumor tissue compared to allogeneic exosomes. The increased tumor accumulation of autologous PEGylated exosomes was accompanied by the preferential uptake of exosomes by not only C26-tumor cells but also tumor-associated immune cells. This study implies that cancer cell-type tropism is an important factor in the achievement of tumor cell targeting with cancer cell-derived exosomes."},"publication_date":"2019-12","publication_name":{"en":"European Journal of Pharmaceutics and Biopharmaceutics","ja":"European Journal of Pharmaceutics and Biopharmaceutics"},"volume":"Vol.145","starting_page":"27","ending_page":"34","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ejpb.2019.10.005"],"issn":["0939-6411"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:44, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512913"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115036","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31609087","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359929","label":"url"}],"paper_title":{"en":"A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in peritoneally disseminated xenograft model","ja":"A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in peritoneally disseminated xenograft model"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Fukushima M"},{"name":"Eshima K"},{"name":"Hasui Taichi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Huang C"},{"name":"Wada H"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"Fukushima M"},{"name":"Eshima K"},{"name":"蓮井 太一"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"Huang C"},{"name":"Wada H"},{"name":"石田 竜弘"}]},"description":{"en":"In advanced gastric cancer, peritoneal dissemination is a life-threatening mode of metastasis. Since the treatment options with conventional chemotherapy remain limited, any novel therapeutic strategy that could control such metastasis would improve the outcome of treatment. We recently developed a unique RNA interference therapeutic regimen (DFP-10825) consisting of short hairpin RNA against thymidylate synthase (TS shRNA) and cationic liposomes. The treatment with DFP-10825 has shown remarkable antitumor activity in peritoneally disseminated human ovarian cancer-bearing mice via intraperitoneal administration. In this study, we expanded DFP-10825 to the treatment of peritoneally disseminated gastric cancer. DFP-10825 was administered intraperitoneally into mice with intraperitoneally implanted human gastric cancer cells (MKN45 or NCI-N87). Antitumor activity and host survival benefits were monitored. Intraperitoneal distribution of fluorescence-labeled DFP-10825 was monitored in this MKN45 peritoneally disseminated mouse model. Intraperitoneal injection of DFP-10825 suppressed tumor growth in two peritoneally disseminated cancer models (MKN45 and NCI-N87) and increased the survival time of the MKN45 model without severe side effects. Throughout the treatment regimen, no significant body weight loss was associated with the administration of DFP-10825. Interestingly, after intraperitoneal injection, fluorescence-labeled DFP-10825 retained for more than 72 hours in the peritoneal cavity and selectively accumulated in disseminated tumors. Intraperitoneal injection of DFP-10825 demonstrated effective antitumor activity without systemic severe adverse effects via the selective delivery of RNAi molecules into disseminated tumors in the peritoneal cavity. Our current study indicates that DFP-10825 could become an alternative option to improve the outcomes of patients with peritoneally disseminated gastric cancer.","ja":"In advanced gastric cancer, peritoneal dissemination is a life-threatening mode of metastasis. Since the treatment options with conventional chemotherapy remain limited, any novel therapeutic strategy that could control such metastasis would improve the outcome of treatment. We recently developed a unique RNA interference therapeutic regimen (DFP-10825) consisting of short hairpin RNA against thymidylate synthase (TS shRNA) and cationic liposomes. The treatment with DFP-10825 has shown remarkable antitumor activity in peritoneally disseminated human ovarian cancer-bearing mice via intraperitoneal administration. In this study, we expanded DFP-10825 to the treatment of peritoneally disseminated gastric cancer. DFP-10825 was administered intraperitoneally into mice with intraperitoneally implanted human gastric cancer cells (MKN45 or NCI-N87). Antitumor activity and host survival benefits were monitored. Intraperitoneal distribution of fluorescence-labeled DFP-10825 was monitored in this MKN45 peritoneally disseminated mouse model. Intraperitoneal injection of DFP-10825 suppressed tumor growth in two peritoneally disseminated cancer models (MKN45 and NCI-N87) and increased the survival time of the MKN45 model without severe side effects. Throughout the treatment regimen, no significant body weight loss was associated with the administration of DFP-10825. Interestingly, after intraperitoneal injection, fluorescence-labeled DFP-10825 retained for more than 72 hours in the peritoneal cavity and selectively accumulated in disseminated tumors. Intraperitoneal injection of DFP-10825 demonstrated effective antitumor activity without systemic severe adverse effects via the selective delivery of RNAi molecules into disseminated tumors in the peritoneal cavity. Our current study indicates that DFP-10825 could become an alternative option to improve the outcomes of patients with peritoneally disseminated gastric cancer."},"publication_date":"2019-12","publication_name":{"en":"Cancer Medicine","ja":"Cancer Medicine"},"volume":"Vol.8","number":"No.17","starting_page":"7313","ending_page":"7321","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/cam4.2598"],"issn":["2045-7634"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:45, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512914"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354919","label":"url"}],"paper_title":{"en":"PEG修飾リポソームに対する免疫応答","ja":"PEG修飾リポソームに対する免疫応答"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2019-11-01","publication_name":{"en":"人工血液","ja":"人工血液"},"volume":"Vol.27","starting_page":"37","ending_page":"43","languages":["jpn"],"referee":true,"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:46, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512915"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31288036","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85070505990&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363411","label":"url"}],"paper_title":{"en":"α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents","ja":"α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents"},"authors":{"en":[{"name":"Matsusaka Kotaro"},{"name":"Ishima Yu"},{"name":"Maeda Hitoshi"},{"name":"Kinoshita Ryo"},{"name":"Ichimizu Shota"},{"name":"Taguchi Kazuaki"},{"name":"Giam Chuang Tuan Victor"},{"name":"Nishi Koji"},{"name":"Yamasaki Keishi"},{"name":"Otagiri Masaki"},{"name":"Watanabe Hiroshi"},{"name":"Maruyama Toru"}],"ja":[{"name":"Matsusaka Kotaro"},{"name":"異島 優"},{"name":"Maeda Hitoshi"},{"name":"木下 遼"},{"name":"Ichimizu Shota"},{"name":"Taguchi Kazuaki"},{"name":"Giam Chuang Tuan Victor"},{"name":"Nishi Koji"},{"name":"Yamasaki Keishi"},{"name":"Otagiri Masaki"},{"name":"Watanabe Hiroshi"},{"name":"Maruyama Toru"}]},"description":{"en":"Nanosize plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α-acid glycoprotein (AGP) for this role because it is a nanosize plasma protein and binds a variety of anticancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human serum albumin, which was already established as a cancer DDS carrier. AGP is possibly being incorporated into tumor cells via endocytosis pathways. Moreover, a synthetic AGP-derived peptide which possesses a high ability to form an α-helix, as deduced from the primary structure of AGP, was also taken up by the tumor cells. AGP loaded with anticancer agents, such as paclitaxel or nitric oxide, efficiently induced tumor cell death. These results suggest that AGP has the potential to be a novel DDS carrier for anticancer agents.","ja":"Nanosize plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α-acid glycoprotein (AGP) for this role because it is a nanosize plasma protein and binds a variety of anticancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human serum albumin, which was already established as a cancer DDS carrier. AGP is possibly being incorporated into tumor cells via endocytosis pathways. Moreover, a synthetic AGP-derived peptide which possesses a high ability to form an α-helix, as deduced from the primary structure of AGP, was also taken up by the tumor cells. AGP loaded with anticancer agents, such as paclitaxel or nitric oxide, efficiently induced tumor cell death. These results suggest that AGP has the potential to be a novel DDS carrier for anticancer agents."},"publication_date":"2019-11","publication_name":{"en":"Journal of Pharmaceutical Sciences","ja":"Journal of Pharmaceutical Sciences"},"volume":"Vol.108","number":"No.11","starting_page":"3592","ending_page":"3598","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.xphs.2019.07.002"],"issn":["1520-6017"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:47, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512916"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31082432","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85065581511&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352004","label":"url"}],"paper_title":{"en":"Cell-penetrating mechanism of intracellular targeting albumin: Contribution of macropinocytosis induction and endosomal escape","ja":"Cell-penetrating mechanism of intracellular targeting albumin: Contribution of macropinocytosis induction and endosomal escape"},"authors":{"en":[{"name":"Ichimizu S"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Hamasaki K"},{"name":"Ikegami K"},{"name":"Chuang V"},{"name":"Kinoshita Ryo"},{"name":"Nishida K"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"Seki T"},{"name":"Katsuki H"},{"name":"Futaki S"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Ichimizu S"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Hamasaki K"},{"name":"Ikegami K"},{"name":"Chuang V"},{"name":"木下 遼"},{"name":"Nishida K"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"Seki T"},{"name":"Katsuki H"},{"name":"Futaki S"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"We recently developed a cell-penetrating drug carrier composed of albumin (HSA) combined with palmitoyl-cyclic-(D-Arg). While it is possible that the palmitoyl-cyclic-(D-Arg)/HSA enters the cell mainly via macropinocytosis, the mechanism responsible for the induction of macropinocytosis and endosomal escape remain unknown. We report herein that palmitoyl-cyclic-(D-Arg)/HSA might interact with heparan sulfate proteoglycan and the chemokine receptor CXCR4 followed by multiple activations of the PKC/PI3K/JNK/mTOR signaling pathways to induce macropinocytosis. This result was further confirmed by a co-treatment with 70 kDa dextran, a macropinocytosis marker. Using liposomes that mimic endosomes, the leakage of 5,6-carboxyfluorescein from liposome was observed in the presence of palmitoyl-cyclic-(D-Arg)/HSA only in the case of the anionic late endosome-like liposomes but not the neutral early endosome-like liposomes. Heparin largely inhibited this leakage, suggesting the importance of electrostatic interactions between palmitoyl-cyclic-(D-Arg)/HSA and the late-endosomal membrane. Immunofluorescence staining and Western blotting data indicated that the intact HSA could be transferred from endosomes to the cytosol. These collective data suggest that the palmitoyl-cyclic-(D-Arg)/HSA is internalized via macropinocytosis and intact HSA is released from the late endosomes to the cytoplasm before the endosomes fuse with lysosomes. Palmitoyl-cyclic-(D-Arg)/HSA not only functions as an intracellular drug delivery carrier but also as an inducer of macropinocytosis.","ja":"We recently developed a cell-penetrating drug carrier composed of albumin (HSA) combined with palmitoyl-cyclic-(D-Arg). While it is possible that the palmitoyl-cyclic-(D-Arg)/HSA enters the cell mainly via macropinocytosis, the mechanism responsible for the induction of macropinocytosis and endosomal escape remain unknown. We report herein that palmitoyl-cyclic-(D-Arg)/HSA might interact with heparan sulfate proteoglycan and the chemokine receptor CXCR4 followed by multiple activations of the PKC/PI3K/JNK/mTOR signaling pathways to induce macropinocytosis. This result was further confirmed by a co-treatment with 70 kDa dextran, a macropinocytosis marker. Using liposomes that mimic endosomes, the leakage of 5,6-carboxyfluorescein from liposome was observed in the presence of palmitoyl-cyclic-(D-Arg)/HSA only in the case of the anionic late endosome-like liposomes but not the neutral early endosome-like liposomes. Heparin largely inhibited this leakage, suggesting the importance of electrostatic interactions between palmitoyl-cyclic-(D-Arg)/HSA and the late-endosomal membrane. Immunofluorescence staining and Western blotting data indicated that the intact HSA could be transferred from endosomes to the cytosol. These collective data suggest that the palmitoyl-cyclic-(D-Arg)/HSA is internalized via macropinocytosis and intact HSA is released from the late endosomes to the cytoplasm before the endosomes fuse with lysosomes. Palmitoyl-cyclic-(D-Arg)/HSA not only functions as an intracellular drug delivery carrier but also as an inducer of macropinocytosis."},"publication_date":"2019-06-28","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.304","starting_page":"156","ending_page":"163","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2019.05.015"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:48, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512917"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31015002","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85064496754&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352003","label":"url"}],"paper_title":{"en":"A simplified method for manufacturing RNAi therapeutics for local administration","ja":"A simplified method for manufacturing RNAi therapeutics for local administration"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Fukushima M"},{"name":"Matsuoka Rie"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Huang C"},{"name":"Wada H"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Fukushima M"},{"name":"松岡 里英"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"Huang C"},{"name":"Wada H"},{"name":"石田 竜弘"}]},"description":{"en":"RNA interference (RNAi) is one of the most promising strategies for cancer therapeutics. The successful translation of RNAi therapeutics to a clinic setting requires a delivery system that is efficient and simple to upscale. In this study, we devised a simple industrial method to manufacture lipoplex, which includes short hairpin RNA against the expression of thymidylate synthase (TS shRNA) - a key molecule for DNA biosynthesis. An aqueous solution of TS shRNA was gently mixed with either a precursor of cationic liposome (Presome DF-1) or a cationic lipid mixture in an o/w emulsion. This solution was subsequently lyophilized under optimal conditions to obtain either FD-lipoplex-1 or FD-lipoplex-2, respectively. With this method, a lipoplex in activated form was obtained via a simple \"one-step\" hydration with saline. Both forms of FD-lipoplex showed physicochemical properties comparable to those of conventional lipoplex. FD-lipoplexes stably retained TS shRNA within their formulations in the presence of tumor ascites fluid. Intraperitoneal treatment with either FD-lipoplex-1 or FD-lipoplex-2 provided a therapeutic level of efficacy comparable to that of conventional lipoplex in the treatment of a peritoneal disseminated gastric cancer mouse model. Collectively, established freeze-drying-based methods for RNAi-therapeutic preparation could realistically be used in a clinical setting for the treatment of patients with peritoneal disseminated cancer.","ja":"RNA interference (RNAi) is one of the most promising strategies for cancer therapeutics. The successful translation of RNAi therapeutics to a clinic setting requires a delivery system that is efficient and simple to upscale. In this study, we devised a simple industrial method to manufacture lipoplex, which includes short hairpin RNA against the expression of thymidylate synthase (TS shRNA) - a key molecule for DNA biosynthesis. An aqueous solution of TS shRNA was gently mixed with either a precursor of cationic liposome (Presome DF-1) or a cationic lipid mixture in an o/w emulsion. This solution was subsequently lyophilized under optimal conditions to obtain either FD-lipoplex-1 or FD-lipoplex-2, respectively. With this method, a lipoplex in activated form was obtained via a simple \"one-step\" hydration with saline. Both forms of FD-lipoplex showed physicochemical properties comparable to those of conventional lipoplex. FD-lipoplexes stably retained TS shRNA within their formulations in the presence of tumor ascites fluid. Intraperitoneal treatment with either FD-lipoplex-1 or FD-lipoplex-2 provided a therapeutic level of efficacy comparable to that of conventional lipoplex in the treatment of a peritoneal disseminated gastric cancer mouse model. Collectively, established freeze-drying-based methods for RNAi-therapeutic preparation could realistically be used in a clinical setting for the treatment of patients with peritoneal disseminated cancer."},"publication_date":"2019-06-10","publication_name":{"en":"International Journal of Pharmaceutics","ja":"International Journal of Pharmaceutics"},"volume":"Vol.564","starting_page":"256","ending_page":"262","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijpharm.2019.04.054"],"issn":["1873-3476"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:49, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512918"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31002935","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85064481198&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352002","label":"url"}],"paper_title":{"en":"Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivo","ja":"Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivo"},"authors":{"en":[{"name":"Doi Yusuke"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"土井 祐輔"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Liposomal anticancer drugs have been developed with improved clinical effects and reduced side effects. We have developed a PEGylated liposomal formulation of oxaliplatin that has anticancer effects in animal models of colorectal cancer with a favorable toxicity profile. To move this formulation into clinical development, a formulation that is stable during long term storage is needed, which has similar pharmacokinetics and therapeutic activity against solid tumors to the original formulation. In this study, we found that PEGylated liposomal oxaliplatin showed no changes in particle size after long term storage (12 months at 2-8 °C), but phospholipid degradation had occurred. Hence, the stored formulation had compromised membrane integrity, resulting in decreased in vivo circulation times of the liposomes. To improve the stability during long-term storage, a screening study to obtain an appropriate stabilizer was carried out. The buffer 2-morpholinoethansulfonic acid (MES) attenuated not only phospholipid degradation but also oxaliplatin degradation, unlike most other excipients. After 12 months storage at 2-8 °C in the presence of MES only slight degradation of phospholipids in PEGylated liposomal oxaliplatin occurred, resulting in similar in vivo pharmacokinetic profiles of the encapsulated oxaliplatin to the original formulation. Long term stability of PEGylated liposomal oxaliplatin was achieved by addition of MES, resulting in long circulation half-lives in vivo, a property which would be expected to lead to increased suppression of tumor growth and reduced side effects. Our formulation may now be suitable for clinical development.","ja":"Liposomal anticancer drugs have been developed with improved clinical effects and reduced side effects. We have developed a PEGylated liposomal formulation of oxaliplatin that has anticancer effects in animal models of colorectal cancer with a favorable toxicity profile. To move this formulation into clinical development, a formulation that is stable during long term storage is needed, which has similar pharmacokinetics and therapeutic activity against solid tumors to the original formulation. In this study, we found that PEGylated liposomal oxaliplatin showed no changes in particle size after long term storage (12 months at 2-8 °C), but phospholipid degradation had occurred. Hence, the stored formulation had compromised membrane integrity, resulting in decreased in vivo circulation times of the liposomes. To improve the stability during long-term storage, a screening study to obtain an appropriate stabilizer was carried out. The buffer 2-morpholinoethansulfonic acid (MES) attenuated not only phospholipid degradation but also oxaliplatin degradation, unlike most other excipients. After 12 months storage at 2-8 °C in the presence of MES only slight degradation of phospholipids in PEGylated liposomal oxaliplatin occurred, resulting in similar in vivo pharmacokinetic profiles of the encapsulated oxaliplatin to the original formulation. Long term stability of PEGylated liposomal oxaliplatin was achieved by addition of MES, resulting in long circulation half-lives in vivo, a property which would be expected to lead to increased suppression of tumor growth and reduced side effects. Our formulation may now be suitable for clinical development."},"publication_date":"2019-06-10","publication_name":{"en":"International Journal of Pharmaceutics","ja":"International Journal of Pharmaceutics"},"volume":"Vol.564","starting_page":"237","ending_page":"243","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijpharm.2019.04.042"],"issn":["1873-3476"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:50, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512919"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30768131","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363473","label":"url"}],"paper_title":{"en":"Involvement of SAPK/JNK Signaling Pathway in Copper Enhanced Zinc-Induced Neuronal Cell Death","ja":"Involvement of SAPK/JNK Signaling Pathway in Copper Enhanced Zinc-Induced Neuronal Cell Death"},"authors":{"en":[{"name":"Tanaka Ken-Ichiro"},{"name":"Shimoda Mikako"},{"name":"Kasai Misato"},{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Kawahara Masahiro"}],"ja":[{"name":"Tanaka Ken-Ichiro"},{"name":"Shimoda Mikako"},{"name":"Kasai Misato"},{"name":"池田 真由美"},{"name":"異島 優"},{"name":"Kawahara Masahiro"}]},"description":{"en":"Zinc (Zn) plays an important role in many organisms in various physiological functions such as cell division, immune mechanisms and protein synthesis. However, excessive Zn release is induced in pathological situations and causes neuronal cell death. Previously, we reported that Cu ions (Cu2+) markedly exacerbates Zn2+-induced neuronal cell death by potentiating oxidative stress and the endoplasmic reticulum stress response. In contrast, the stress-activated protein kinase/c-Jun amino-terminal kinase (SAPK/JNK) signaling pathway is important in neuronal cell death. Thus, in this study, we focused on the SAPK/JNK signaling pathway and examined its involvement in Cu2+/Zn2+-induced neurotoxicity. Initially, we examined expression of factors involved in the SAPK/JNK signaling pathway. Accordingly, we found that phosphorylated (ie, active) forms of SAPK/JNK (p46 and p54) are increased by CuCl2 and ZnCl2 co-treatment in hypothalamic neuronal mouse cells (GT1-7 cells). Downstream factors of SAPK/JNK, phospho-c-Jun, and phospho-activating transcription factor 2 are also induced by CuCl2 and ZnCl2 co-treatment. Moreover, an inhibitor of the SAPK/JNK signaling pathway, SP600125, significantly suppressed neuronal cell death and activation of the SAPK/JNK signaling pathway induced by CuCl2 and ZnCl2 cotreatment. Finally, we examined involvement of oxidative stress in activation of the SAPK/JNK signaling pathway, and found that human serum albumin-thioredoxin fusion protein, an antioxidative protein, suppresses activation of the SAPK/JNK signaling pathway. On the basis of these results, our findings suggest that activation of ZnCl2-dependent SAPK/JNK signaling pathway is important in neuronal cell death, and CuCl2-induced oxidative stress triggers the activation of this pathway.","ja":"Zinc (Zn) plays an important role in many organisms in various physiological functions such as cell division, immune mechanisms and protein synthesis. However, excessive Zn release is induced in pathological situations and causes neuronal cell death. Previously, we reported that Cu ions (Cu2+) markedly exacerbates Zn2+-induced neuronal cell death by potentiating oxidative stress and the endoplasmic reticulum stress response. In contrast, the stress-activated protein kinase/c-Jun amino-terminal kinase (SAPK/JNK) signaling pathway is important in neuronal cell death. Thus, in this study, we focused on the SAPK/JNK signaling pathway and examined its involvement in Cu2+/Zn2+-induced neurotoxicity. Initially, we examined expression of factors involved in the SAPK/JNK signaling pathway. Accordingly, we found that phosphorylated (ie, active) forms of SAPK/JNK (p46 and p54) are increased by CuCl2 and ZnCl2 co-treatment in hypothalamic neuronal mouse cells (GT1-7 cells). Downstream factors of SAPK/JNK, phospho-c-Jun, and phospho-activating transcription factor 2 are also induced by CuCl2 and ZnCl2 co-treatment. Moreover, an inhibitor of the SAPK/JNK signaling pathway, SP600125, significantly suppressed neuronal cell death and activation of the SAPK/JNK signaling pathway induced by CuCl2 and ZnCl2 cotreatment. Finally, we examined involvement of oxidative stress in activation of the SAPK/JNK signaling pathway, and found that human serum albumin-thioredoxin fusion protein, an antioxidative protein, suppresses activation of the SAPK/JNK signaling pathway. On the basis of these results, our findings suggest that activation of ZnCl2-dependent SAPK/JNK signaling pathway is important in neuronal cell death, and CuCl2-induced oxidative stress triggers the activation of this pathway."},"publication_date":"2019-05-01","publication_name":{"en":"Toxicological Sciences","ja":"Toxicological Sciences"},"volume":"Vol.169","number":"No.1","starting_page":"293","ending_page":"302","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/toxsci/kfz043"],"issn":["1096-0929"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:51, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512920"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115606","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31052207","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85065659717&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351999","label":"url"}],"paper_title":{"en":"Distribution of Polysulfide in Human Biological Fluids and Their. Association with Amylase and Sperm Activities","ja":"Distribution of Polysulfide in Human Biological Fluids and Their. Association with Amylase and Sperm Activities"},"authors":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Chuang VTG"},{"name":"Sakai Maki"},{"name":"Osafune Hiroki"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otagiri M"},{"name":"Akaike T"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"Chuang VTG"},{"name":"酒井 真紀"},{"name":"長船 裕輝"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otagiri M"},{"name":"Akaike T"},{"name":"石田 竜弘"}]},"description":{"en":"Intracellular polysulfide could regulate the redox balance via its anti-oxidant activity. However, the existence of polysulfide in biological fluids still remains unknown. Recently, we developed a quantitative analytical method for polysulfide and discovered that polysulfide exists in plasma and responds to oxidative stress. In this study, we confirmed the presence of polysulfide in other biological fluids, such as semen and nasal discharge. The levels of polysulfide in these biological fluids from healthy volunteers ( = 9) with identical characteristics were compared. Additionally, the circadian rhythm of plasma polysulfide was also investigated. The polysulfide levels detected from nasal discharge and seminal fluid were approximately 400 and 600 μM, respectively. No correlation could be found between plasma polysulfide and the polysulfide levels of tear, saliva, and nasal discharge. On the other hand, seminal polysulfide was positively correlated with plasma polysulfide, and almost all polysulfide contained in semen was found in seminal fluid. Intriguingly, saliva and seminal polysulfide strongly correlated with salivary amylase and sperm activities, respectively. These results provide a foundation for scientific breakthroughs in various research areas like infertility and the digestive system process.","ja":"Intracellular polysulfide could regulate the redox balance via its anti-oxidant activity. However, the existence of polysulfide in biological fluids still remains unknown. Recently, we developed a quantitative analytical method for polysulfide and discovered that polysulfide exists in plasma and responds to oxidative stress. In this study, we confirmed the presence of polysulfide in other biological fluids, such as semen and nasal discharge. The levels of polysulfide in these biological fluids from healthy volunteers ( = 9) with identical characteristics were compared. Additionally, the circadian rhythm of plasma polysulfide was also investigated. The polysulfide levels detected from nasal discharge and seminal fluid were approximately 400 and 600 μM, respectively. No correlation could be found between plasma polysulfide and the polysulfide levels of tear, saliva, and nasal discharge. On the other hand, seminal polysulfide was positively correlated with plasma polysulfide, and almost all polysulfide contained in semen was found in seminal fluid. Intriguingly, saliva and seminal polysulfide strongly correlated with salivary amylase and sperm activities, respectively. These results provide a foundation for scientific breakthroughs in various research areas like infertility and the digestive system process."},"publication_date":"2019-04-30","publication_name":{"en":"Molecules","ja":"Molecules"},"volume":"Vol.24","number":"No.9","starting_page":"1689","ending_page":"1689","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/molecules24091689"],"issn":["1420-3049"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:52, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512921"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116302","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32123826","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345876","label":"url"}],"paper_title":{"en":"S-Nitrosated alpha-1-acid glycoprotein exhibits antibacterial activity against multidrug-resistant bacteria strains and synergistically enhances the effect of antibiotics","ja":"S-Nitrosated alpha-1-acid glycoprotein exhibits antibacterial activity against multidrug-resistant bacteria strains and synergistically enhances the effect of antibiotics"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Watanabe Kaori"},{"name":"Chuang T. G. Victor"},{"name":"Takeda Iyo"},{"name":"Kuroda Teruo"},{"name":"Ogawa Wakano"},{"name":"Watanabe Hiroshi"},{"name":"Iwao Yasunori"},{"name":"Ishida Tatsuhiro"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"異島 優"},{"name":"Watanabe Kaori"},{"name":"Chuang T. G. Victor"},{"name":"Takeda Iyo"},{"name":"Kuroda Teruo"},{"name":"Ogawa Wakano"},{"name":"Watanabe Hiroshi"},{"name":"Iwao Yasunori"},{"name":"石田 竜弘"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"publication_date":"2019-03","publication_name":{"en":"FASEB BioAdvances","ja":"FASEB BioAdvances"},"volume":"Vol.1","number":"No.3","starting_page":"137","ending_page":"150","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1096/fba.1018"],"issn":["2573-9832"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:53, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512922"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30280273","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85054175366&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345958","label":"url"}],"paper_title":{"en":"A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics","ja":"A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Awata Mizuki"},{"name":"Kubo Yukiyo"},{"name":"Mima Yu"},{"name":"Hashimoto Yosuke"},{"name":"ANDO Hidenori"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"粟田 瑞月"},{"name":"久保 幸代"},{"name":"美馬 優"},{"name":"橋本 洋佑"},{"name":"安藤 英紀"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Immunogenicity of PEGylated proteins and nanomedicines represents a potential impediment against their development and use in clinical settings. The purpose of this study is to develop a method for detecting anti-PEG immunity of PEGylated proteins and/or nanomedicines using flow cytometry. The binding of fluorescence-labeled mPEG-modified liposomes to HIK-G11 cells, PEG-specific hybridoma cells, or spleen cells was evaluated by flow cytometry for detecting immunogenicity of PEGylated therapeutics. The fluorescence-labeled methoxy PEG (mPEG)-modified liposomes were efficiently bound to HIK-G11 cells. Such staining with fluorescence-labeled mPEG-modified liposomes was significantly inhibited in the presence of either non-labeled mPEG-modified liposomes or mPEG-modified ovalbumin (OVA) but not polyglycerol-modified liposomes. In addition, we found that mPEG-modified liposomes, highly immunogenic, caused proliferation of PEG-specific cells, while hydroxyl PEG-modified liposomes, less immunogenic, scarcely caused. Furthermore, after intravenous injection of mPEG-modified liposomes, the percentage of PEG-specific cells in the splenocytes, as determined by flow cytometry, corresponded well with the production level of anti-PEG antibodies, as determined by ELISA. PEG-specific B cell assay we introduced may become a useful method to detect an anti-PEG immune response against PEGylated therapeutics and clarify the mechanism for anti-PEG immune responses.","ja":"Immunogenicity of PEGylated proteins and nanomedicines represents a potential impediment against their development and use in clinical settings. The purpose of this study is to develop a method for detecting anti-PEG immunity of PEGylated proteins and/or nanomedicines using flow cytometry. The binding of fluorescence-labeled mPEG-modified liposomes to HIK-G11 cells, PEG-specific hybridoma cells, or spleen cells was evaluated by flow cytometry for detecting immunogenicity of PEGylated therapeutics. The fluorescence-labeled methoxy PEG (mPEG)-modified liposomes were efficiently bound to HIK-G11 cells. Such staining with fluorescence-labeled mPEG-modified liposomes was significantly inhibited in the presence of either non-labeled mPEG-modified liposomes or mPEG-modified ovalbumin (OVA) but not polyglycerol-modified liposomes. In addition, we found that mPEG-modified liposomes, highly immunogenic, caused proliferation of PEG-specific cells, while hydroxyl PEG-modified liposomes, less immunogenic, scarcely caused. Furthermore, after intravenous injection of mPEG-modified liposomes, the percentage of PEG-specific cells in the splenocytes, as determined by flow cytometry, corresponded well with the production level of anti-PEG antibodies, as determined by ELISA. PEG-specific B cell assay we introduced may become a useful method to detect an anti-PEG immune response against PEGylated therapeutics and clarify the mechanism for anti-PEG immune responses."},"publication_date":"2018-11","publication_name":{"en":"Pharmaceutical Research","ja":"Pharmaceutical Research"},"volume":"Vol.35","number":"No.11","starting_page":"223","ending_page":"223","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s11095-018-2505-3"],"issn":["1573-904X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:54, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512923"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30333124","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345866","label":"url"}],"paper_title":{"en":"A novel platform for cancer vaccines: Antigen-selective delivery to splenic marginal zone B cells via repeated injections of PEGylated liposomes","ja":"A novel platform for cancer vaccines: Antigen-selective delivery to splenic marginal zone B cells via repeated injections of PEGylated liposomes"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Kawaguchi Yoshino"},{"name":"Shimazaki Yuna"},{"name":"Mima Yu"},{"name":"Hashimoto Yosuke"},{"name":"Okuhira Keiichiro"},{"name":"Storm G"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"川口 桂乃"},{"name":"島崎 優奈"},{"name":"美馬 優"},{"name":"橋本 洋佑"},{"name":"奥平 桂一郎"},{"name":"Storm G"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Treating cancer with vaccines has been a challenge. In this study, we introduce a novel Ag delivery platform for cancer vaccines that delivers an encapsulated Ag to splenic marginal zone B (MZ-B) cells via the aid of a PEGylated liposome (PL) system. Splenic MZ-B cells have recently attracted interest as alternative APCs. In mice, preimmunization with empty (no Ag encapsulation) PLs triggered the efficient delivery of a subsequent dose of Ag-containing PLs, injected 3 d later, to the spleen compared with a single dose of Ag-containing PLs. In addition, immunization with empty PLs allowed three subsequent sequential injections of OVA-PLs to efficiently induce a CTL response against OVA-expressing murine thymoma (EG7-OVA) cells and resulted in in vivo growth inhibition of subsequently inoculated EG7-OVA cells. However, these sequential treatments require repeated immunizations to achieve their antitumor effect. Therefore, to improve the antitumor effect of our novel vaccine system, an adjuvant, -galactosylceramide (GC), was incorporated into the OVA-PLs (GC/OVA-PLs). As expected, the incorporation of GC reduced the required number of immunizations with OVA-PLs to the point that a single immunization treatment with empty PLs and an injection of GC/OVA-PL efficiently triggered a potent CTL induction, resulting in a rejection of the development and a suppression of the growth of tumors that had already developed s.c. Results of this study indicate that a novel Ag delivery platform that grants efficient Ag delivery to splenic MZ-B cells shows promise as a therapeutic modality for conquering tumor growth and/or progression.","ja":"Treating cancer with vaccines has been a challenge. In this study, we introduce a novel Ag delivery platform for cancer vaccines that delivers an encapsulated Ag to splenic marginal zone B (MZ-B) cells via the aid of a PEGylated liposome (PL) system. Splenic MZ-B cells have recently attracted interest as alternative APCs. In mice, preimmunization with empty (no Ag encapsulation) PLs triggered the efficient delivery of a subsequent dose of Ag-containing PLs, injected 3 d later, to the spleen compared with a single dose of Ag-containing PLs. In addition, immunization with empty PLs allowed three subsequent sequential injections of OVA-PLs to efficiently induce a CTL response against OVA-expressing murine thymoma (EG7-OVA) cells and resulted in in vivo growth inhibition of subsequently inoculated EG7-OVA cells. However, these sequential treatments require repeated immunizations to achieve their antitumor effect. Therefore, to improve the antitumor effect of our novel vaccine system, an adjuvant, -galactosylceramide (GC), was incorporated into the OVA-PLs (GC/OVA-PLs). As expected, the incorporation of GC reduced the required number of immunizations with OVA-PLs to the point that a single immunization treatment with empty PLs and an injection of GC/OVA-PL efficiently triggered a potent CTL induction, resulting in a rejection of the development and a suppression of the growth of tumors that had already developed s.c. Results of this study indicate that a novel Ag delivery platform that grants efficient Ag delivery to splenic MZ-B cells shows promise as a therapeutic modality for conquering tumor growth and/or progression."},"publication_date":"2018-10-17","publication_name":{"en":"The Journal of Immunology","ja":"The Journal of Immunology"},"volume":"Vol.201","number":"No.10","starting_page":"2969","ending_page":"2976","languages":["eng"],"referee":true,"identifiers":{"doi":["10.4049/jimmunol.1701351"],"issn":["1550-6606"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:55, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512924"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114955","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30262875","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85054056121&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345956","label":"url"}],"paper_title":{"en":"Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways","ja":"Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways"},"authors":{"en":[{"name":"Sherif Emam Abdallah Emam"},{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Mahdy M"},{"name":"Ghazy F"},{"name":"Sagawa I"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"Mahdy M"},{"name":"Ghazy F"},{"name":"Sagawa I"},{"name":"石田 竜弘"}]},"description":{"en":"We recently showed that in vitro incubation of cells with liposomes of varying compositions can increase exosome secretion and increase the yield of harvested exosomes (extracellular vesicles, EVs). This might foster their potential therapeutic implementations. In the current study, we investigated the surface proteins and the uptake of the harvested exosomes (EVs) to see if the incubation of cells with liposomes would change the biological properties of these exosomes (EVs). Interestingly, exosomes (EVs) induced by solid cationic liposomes lacked some major exosome marker proteins such as CD9, flotillin-1, annexin-A2 and EGF, and subsequently had lower levels of cellular uptake upon re-incubation with donor cancer cells. However, exosomes (EVs) induced under normal condition and by fluid cationic liposomes, displayed the entire spectrum of proteins, and exhibited higher uptake by the donor cancer cells. Although endocytosis was the major uptake pathway of exosomes (EVs) by tumor cells, endocytosis could occur via more than one mechanism. Higher exosome uptake was observed in donor B16BL6 cells than in allogeneic C26 cells, indicating that donor cells might interact specifically with their exosomes (EVs) and avidly internalize them. Taken together, these results suggest a technique for controlling the characteristics of secreted exosomes (EVs) by incubating donor cancer cells with liposomes of varying physiochemical properties.","ja":"We recently showed that in vitro incubation of cells with liposomes of varying compositions can increase exosome secretion and increase the yield of harvested exosomes (extracellular vesicles, EVs). This might foster their potential therapeutic implementations. In the current study, we investigated the surface proteins and the uptake of the harvested exosomes (EVs) to see if the incubation of cells with liposomes would change the biological properties of these exosomes (EVs). Interestingly, exosomes (EVs) induced by solid cationic liposomes lacked some major exosome marker proteins such as CD9, flotillin-1, annexin-A2 and EGF, and subsequently had lower levels of cellular uptake upon re-incubation with donor cancer cells. However, exosomes (EVs) induced under normal condition and by fluid cationic liposomes, displayed the entire spectrum of proteins, and exhibited higher uptake by the donor cancer cells. Although endocytosis was the major uptake pathway of exosomes (EVs) by tumor cells, endocytosis could occur via more than one mechanism. Higher exosome uptake was observed in donor B16BL6 cells than in allogeneic C26 cells, indicating that donor cells might interact specifically with their exosomes (EVs) and avidly internalize them. Taken together, these results suggest a technique for controlling the characteristics of secreted exosomes (EVs) by incubating donor cancer cells with liposomes of varying physiochemical properties."},"publication_date":"2018-09-27","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"Vol.8","number":"No.1","starting_page":"14493","ending_page":"14493","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41598-018-32861-w"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:56, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512925"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29962402","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85049360539&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339527","label":"url"}],"paper_title":{"en":"Doxorubicin expands in vivo secretion of circulating exosome in mice","ja":"Doxorubicin expands in vivo secretion of circulating exosome in mice"},"authors":{"en":[{"name":"Sherif Emam Abdallah Emam"},{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Kobayashi Shinya"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"小林 真也"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Modulation of tumor immunity is a known factor in the antitumor activity of many chemotherapeutic agents. Exosomes are extracellular nanometric vesicles that are released by almost all types of cells, which includes cancer cells. These vesicles play a crucial role in tumor immunity. Many in vitro studies have reproduced the aggressive secretion of exosomes following treatment with conventional anticancer drugs. Nevertheless, how chemotherapeutic agents including nanomedicines such as Doxil affect the in vivo secretion of exosomes is yet to be elucidated. In this study, the effect of intravenous injection of either free doxorubicin (DXR) or liposomal DXR formulation (Doxil) on exosome secretion was evaluated in BALB/c mice. Exosomes were isolated from serum by using an ExoQuick™ kit. Free DXR treatment markedly increased serum exosome levels in a post-injection time-dependent manner, while Doxil treatment did not. Exosomal size distribution and marker protein expressions (CD9, CD63, and TSG101) were studied. The physical/biological characteristics of treatment-induced exosomes were comparable to those of control mice. Interestingly, splenectomy significantly suppressed the copious exosomal secretions induced by free DXR. Collectively, our results indicate that conventional anticancer agents induce the secretion of circulating exosomes, presumably via stimulating immune cells of the spleen. As far as we know, this study represents the first report indicating that conventional chemotherapeutics may induce exosome secretion which might, in turn, contribute partly to the antitumor effect of chemotherapeutic agents.","ja":"Modulation of tumor immunity is a known factor in the antitumor activity of many chemotherapeutic agents. Exosomes are extracellular nanometric vesicles that are released by almost all types of cells, which includes cancer cells. These vesicles play a crucial role in tumor immunity. Many in vitro studies have reproduced the aggressive secretion of exosomes following treatment with conventional anticancer drugs. Nevertheless, how chemotherapeutic agents including nanomedicines such as Doxil affect the in vivo secretion of exosomes is yet to be elucidated. In this study, the effect of intravenous injection of either free doxorubicin (DXR) or liposomal DXR formulation (Doxil) on exosome secretion was evaluated in BALB/c mice. Exosomes were isolated from serum by using an ExoQuick™ kit. Free DXR treatment markedly increased serum exosome levels in a post-injection time-dependent manner, while Doxil treatment did not. Exosomal size distribution and marker protein expressions (CD9, CD63, and TSG101) were studied. The physical/biological characteristics of treatment-induced exosomes were comparable to those of control mice. Interestingly, splenectomy significantly suppressed the copious exosomal secretions induced by free DXR. Collectively, our results indicate that conventional anticancer agents induce the secretion of circulating exosomes, presumably via stimulating immune cells of the spleen. As far as we know, this study represents the first report indicating that conventional chemotherapeutics may induce exosome secretion which might, in turn, contribute partly to the antitumor effect of chemotherapeutic agents."},"publication_date":"2018-07-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.41","number":"No.7","starting_page":"1078","ending_page":"1083","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b18-00202"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:57, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512926"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115074","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29569850","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=356613","label":"url"}],"paper_title":{"en":"Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status","ja":"Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status"},"authors":{"en":[{"name":"Oniki K"},{"name":"Watanabe T"},{"name":"Kudo M"},{"name":"Izuka T"},{"name":"Ono T"},{"name":"Matsuda K"},{"name":"Sakamoto Y"},{"name":"Nagaoka K"},{"name":"Imafuku T"},{"name":"Ishima Yu"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otake K"},{"name":"Ogata Y"},{"name":"Saruwatari J"}],"ja":[{"name":"Oniki K"},{"name":"Watanabe T"},{"name":"Kudo M"},{"name":"Izuka T"},{"name":"Ono T"},{"name":"Matsuda K"},{"name":"Sakamoto Y"},{"name":"Nagaoka K"},{"name":"Imafuku T"},{"name":"異島 優"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otake K"},{"name":"Ogata Y"},{"name":"Saruwatari J"}]},"description":{"en":"Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity. Disulfide bond-forming oxidoreductase A-like protein (DsbA-L) is known to be a key molecule in protection against obesity and obesity-induced inflammation. In the present study, we used a modeling and simulation approach in an attempt to develop body mass index (BMI) and BMI-based NAFLD prediction models incorporating the DsbA-L polymorphism to predict the BMI and NAFLD in 341 elderly subjects. A nonlinear mixed-effect model best represented the sigmoidal relationship between the BMI and the logit function of the probability of NAFLD prevalence. The final models for BMI and NAFLD showed that DsbA-L rs1917760 polymorphism, age, and gender were associated with the BMI, whereas gender, patatin-like phospholipase 3 rs738409 polymorphism, HbA1c, and high-density and low-density lipoprotein cholesterol levels were associated with the risk of NAFLD. This information may aid in the genetic-based prevention of obesity and NAFLD in the general elderly population.","ja":"Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity. Disulfide bond-forming oxidoreductase A-like protein (DsbA-L) is known to be a key molecule in protection against obesity and obesity-induced inflammation. In the present study, we used a modeling and simulation approach in an attempt to develop body mass index (BMI) and BMI-based NAFLD prediction models incorporating the DsbA-L polymorphism to predict the BMI and NAFLD in 341 elderly subjects. A nonlinear mixed-effect model best represented the sigmoidal relationship between the BMI and the logit function of the probability of NAFLD prevalence. The final models for BMI and NAFLD showed that DsbA-L rs1917760 polymorphism, age, and gender were associated with the BMI, whereas gender, patatin-like phospholipase 3 rs738409 polymorphism, HbA1c, and high-density and low-density lipoprotein cholesterol levels were associated with the risk of NAFLD. This information may aid in the genetic-based prevention of obesity and NAFLD in the general elderly population."},"publication_date":"2018-06","publication_name":{"en":"CPT: Pharmacometrics & Systems Pharmacology","ja":"CPT: Pharmacometrics & Systems Pharmacology"},"volume":"Vol.7","number":"No.6","starting_page":"384","ending_page":"393","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/psp4.12292"],"issn":["2163-8306"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:58, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512927"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29462689","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85042257067&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336344","label":"url"}],"paper_title":{"en":"A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes","ja":"A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Fujita Risako"},{"name":"Awata Mizuki"},{"name":"Kawanishi Munehira"},{"name":"Hashimoto Yosuke"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"藤田 理紗子"},{"name":"粟田 瑞月"},{"name":"川西 宗平"},{"name":"橋本 洋佑"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Surface decoration of liposomes with polyethylene glycol (PEG), PEGylation, is recognized as a method to bestow liposomes with a prolonged circulation time following intravenous administration. However, many reports have emphasized that a first dose of PEGylated liposomes (PL) elicits an anti-PEG IgM antibody response that can trigger a rapid systemic clearance of a second dose of PL via a phenomenon that is referred to as \"accelerated blood clearance (ABC).\" Such a phenomenon is usually observed with PL that has been modified with methoxy-PEG. In the current study, we introduced various functional groups, methoxy (OCH), amino (NH), carboxyl (COOH), and hydroxyl (OH), at the chain ends of PEG to investigate the effect on anti-PEG IgM induction. Among different PEG-modified liposomes, hydroxyl PEG-modified liposomes (PL-OH) efficiently attenuated the anti-PEG IgM response in vitro. In addition, PL-OH was less recognizable by anti-PEG IgM compared with other PLs. These findings raised the possibility that PL-OH could attenuate/abrogate elicitation of the ABC phenomenon. Nonetheless, upon repeated intravenous injection, PL-OH triggered the enhanced clearance of a subsequently injected second dose. Furthermore, in vitro studies have demonstrated that, as a complement activator, PL-OH is stronger than PL-OCH and induces further complement activation in the presence of anti-PEG IgM, which was the predominant contributor to the rapid clearance of a second dose of PL-OH. Our results suggest that the screening of complement activation by polymer-modified products in tandem with anti-polymer antibody production should be a prerequisite in the development of polymers that might enhance the therapeutic efficacy of nanocarriers.","ja":"Surface decoration of liposomes with polyethylene glycol (PEG), PEGylation, is recognized as a method to bestow liposomes with a prolonged circulation time following intravenous administration. However, many reports have emphasized that a first dose of PEGylated liposomes (PL) elicits an anti-PEG IgM antibody response that can trigger a rapid systemic clearance of a second dose of PL via a phenomenon that is referred to as \"accelerated blood clearance (ABC).\" Such a phenomenon is usually observed with PL that has been modified with methoxy-PEG. In the current study, we introduced various functional groups, methoxy (OCH), amino (NH), carboxyl (COOH), and hydroxyl (OH), at the chain ends of PEG to investigate the effect on anti-PEG IgM induction. Among different PEG-modified liposomes, hydroxyl PEG-modified liposomes (PL-OH) efficiently attenuated the anti-PEG IgM response in vitro. In addition, PL-OH was less recognizable by anti-PEG IgM compared with other PLs. These findings raised the possibility that PL-OH could attenuate/abrogate elicitation of the ABC phenomenon. Nonetheless, upon repeated intravenous injection, PL-OH triggered the enhanced clearance of a subsequently injected second dose. Furthermore, in vitro studies have demonstrated that, as a complement activator, PL-OH is stronger than PL-OCH and induces further complement activation in the presence of anti-PEG IgM, which was the predominant contributor to the rapid clearance of a second dose of PL-OH. Our results suggest that the screening of complement activation by polymer-modified products in tandem with anti-polymer antibody production should be a prerequisite in the development of polymers that might enhance the therapeutic efficacy of nanocarriers."},"publication_date":"2018-06","publication_name":{"en":"European Journal of Pharmaceutics and Biopharmaceutics","ja":"European Journal of Pharmaceutics and Biopharmaceutics"},"volume":"Vol.127","starting_page":"142","ending_page":"149","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ejpb.2018.02.019"],"issn":["1873-3441"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:59, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512928"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29530390","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=356623","label":"url"}],"paper_title":{"en":"Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery","ja":"Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery"},"authors":{"en":[{"name":"Ichimizu S"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Hamasaki K"},{"name":"Nakamura Y"},{"name":"Chuang VTG"},{"name":"Kinoshita R"},{"name":"Nishida K"},{"name":"Tanaka R"},{"name":"Enoki Y"},{"name":"Ishima Yu"},{"name":"Kuniyasu A"},{"name":"Kobashigawa Y"},{"name":"Morioka H"},{"name":"Futaki S"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Ichimizu S"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Hamasaki K"},{"name":"Nakamura Y"},{"name":"Chuang VTG"},{"name":"木下 遼"},{"name":"Nishida K"},{"name":"Tanaka R"},{"name":"Enoki Y"},{"name":"異島 優"},{"name":"Kuniyasu A"},{"name":"Kobashigawa Y"},{"name":"Morioka H"},{"name":"Futaki S"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Human serum albumin (HSA) is a superior carrier for delivering extracellular drugs. However, the development of a cell-penetrating HSA remains a great challenge due to its low membrane permeability. We report herein on the design of a series of palmitoyl-poly-arginine peptides (CPPs) and an evaluation of their cell-penetrating effects after forming a complex with HSA for use in intracellular drug delivery. The palmitoyl CPPs forms a stable complex with HSA by anchoring itself to the high affinity palmitate binding sites of HSA. Among the CPPs evaluated, a cyclic polypeptide composed of D-dodecaarginines, palmitoyl-cyclic-(D-Arg) was the most effective for facilitating the cellular uptake of HSA by HeLa cells. Such a superior cell-penetrating capability is primarily mediated by macropinocytosis. The effect of the CPP on pharmacological activity was examined using three drugs loaded in HSA via three different methods: a) an HSA-paclitaxel complex, b) an HSA-doxorubicin covalent conjugate and c) an HSA-thioredoxin fusion protein. The results showed that cell-penetrating efficiency was increased with a corresponding and significant enhancement in pharmacological activity. In conclusion, palmitoyl-cyclic-(D-Arg)/HSA is a versatile cell-penetrating drug delivery system with great potential for use as a nano-carrier for a wide diversity of pharmaceutical applications.","ja":"Human serum albumin (HSA) is a superior carrier for delivering extracellular drugs. However, the development of a cell-penetrating HSA remains a great challenge due to its low membrane permeability. We report herein on the design of a series of palmitoyl-poly-arginine peptides (CPPs) and an evaluation of their cell-penetrating effects after forming a complex with HSA for use in intracellular drug delivery. The palmitoyl CPPs forms a stable complex with HSA by anchoring itself to the high affinity palmitate binding sites of HSA. Among the CPPs evaluated, a cyclic polypeptide composed of D-dodecaarginines, palmitoyl-cyclic-(D-Arg) was the most effective for facilitating the cellular uptake of HSA by HeLa cells. Such a superior cell-penetrating capability is primarily mediated by macropinocytosis. The effect of the CPP on pharmacological activity was examined using three drugs loaded in HSA via three different methods: a) an HSA-paclitaxel complex, b) an HSA-doxorubicin covalent conjugate and c) an HSA-thioredoxin fusion protein. The results showed that cell-penetrating efficiency was increased with a corresponding and significant enhancement in pharmacological activity. In conclusion, palmitoyl-cyclic-(D-Arg)/HSA is a versatile cell-penetrating drug delivery system with great potential for use as a nano-carrier for a wide diversity of pharmaceutical applications."},"publication_date":"2018-05-10","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.277","starting_page":"23","ending_page":"34","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2018.02.037"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:60, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512929"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29709910","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85046668949&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336279","label":"url"}],"paper_title":{"en":"A novel strategy to increase the yield of exosomes (extracellular vesicles) for an expansion of basic research","ja":"A novel strategy to increase the yield of exosomes (extracellular vesicles) for an expansion of basic research"},"authors":{"en":[{"name":"Sherif Emam Abdallah Emam"},{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Shimizu Taro"},{"name":"Ukawa Masami"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Mahdy M A"},{"name":"Ghazy F S"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"清水 太郎"},{"name":"鵜川 真実"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"Mahdy M A"},{"name":"Ghazy F S"},{"name":"石田 竜弘"}]},"description":{"en":"Exosomes are tiny extracellular vesicles that are usually harvested in small quantities. Such small yield has been an obstacle for the expansion of the basic research regarding exosome analysis and applications in drug delivery. To increase exosome yield, we attempted to stimulate tumor cells via the addition of liposomes in vitro. Neutral, cationic-bare or PEGylated liposomes were incubated with four different tumor cell lines. The stimulatory effect of liposomal formulations on exosome secretion and cellular uptake propensity of the collected exosome by mother cells or different cells was evaluated. Both neutral and cationic-bare liposomes enhanced exosome secretion in a dose-dependent manner. Fluid cationic liposomes provided the strongest stimulation. Surprisingly, the PEGylation of bare liposomes diminished exosome secretion. Exosomes harvested in the presence of fluid cationic liposomes showed increased cellular uptake, but solid cationic liposomes did not. Our findings indicate that the physicochemical properties of liposomes determine whether they will act as a stimulant or as a depressant on exosome secretion from tumor cells. Liposomal stimulation may be a useful strategy to increase exosome yield, although further preparation to increase the purity of exosomes may be needed. In addition, fine-tuning of the biological properties of induced exosomes could be achieved via controlling the physicochemical properties of the stimulant liposomes.","ja":"Exosomes are tiny extracellular vesicles that are usually harvested in small quantities. Such small yield has been an obstacle for the expansion of the basic research regarding exosome analysis and applications in drug delivery. To increase exosome yield, we attempted to stimulate tumor cells via the addition of liposomes in vitro. Neutral, cationic-bare or PEGylated liposomes were incubated with four different tumor cell lines. The stimulatory effect of liposomal formulations on exosome secretion and cellular uptake propensity of the collected exosome by mother cells or different cells was evaluated. Both neutral and cationic-bare liposomes enhanced exosome secretion in a dose-dependent manner. Fluid cationic liposomes provided the strongest stimulation. Surprisingly, the PEGylation of bare liposomes diminished exosome secretion. Exosomes harvested in the presence of fluid cationic liposomes showed increased cellular uptake, but solid cationic liposomes did not. Our findings indicate that the physicochemical properties of liposomes determine whether they will act as a stimulant or as a depressant on exosome secretion from tumor cells. Liposomal stimulation may be a useful strategy to increase exosome yield, although further preparation to increase the purity of exosomes may be needed. In addition, fine-tuning of the biological properties of induced exosomes could be achieved via controlling the physicochemical properties of the stimulant liposomes."},"publication_date":"2018-05-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.41","number":"No.5","starting_page":"733","ending_page":"742","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b17-00919"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:61, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512930"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115087","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29688069","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85053734891&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=346483","label":"url"}],"paper_title":{"en":"Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions","ja":"Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions"},"authors":{"en":[{"name":"Minayoshi Yuki"},{"name":"Maeda Hitoshi"},{"name":"Yanagisawa Hiroki"},{"name":"Hamasaki Keisuke"},{"name":"Mizuta Yuki"},{"name":"Nishida Kento"},{"name":"Kinoshita Ryo"},{"name":"Enoki Yuki"},{"name":"Imafuku Tadasi"},{"name":"Chuang Victor Tuan Giam"},{"name":"Koga Tomoaki"},{"name":"Fujiwara Yukiko"},{"name":"Takeya Motohiro"},{"name":"Sonoda Kayoko"},{"name":"Wakayama Tomohiro"},{"name":"Taguchi Kazuaki"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"Iwakiri Yasuko"},{"name":"Tanaka Motohiko"},{"name":"Sasaki Yutaka"},{"name":"Watanabe Hiroshi"},{"name":"Otagiri Masako"},{"name":"Maruyama Toru"}],"ja":[{"name":"Minayoshi Yuki"},{"name":"Maeda Hitoshi"},{"name":"Yanagisawa Hiroki"},{"name":"Hamasaki Keisuke"},{"name":"Mizuta Yuki"},{"name":"Nishida Kento"},{"name":"木下 遼"},{"name":"Enoki Yuki"},{"name":"Imafuku Tadasi"},{"name":"Chuang Victor Tuan Giam"},{"name":"Koga Tomoaki"},{"name":"Fujiwara Yukiko"},{"name":"Takeya Motohiro"},{"name":"Sonoda Kayoko"},{"name":"Wakayama Tomohiro"},{"name":"Taguchi Kazuaki"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"Iwakiri Yasuko"},{"name":"Tanaka Motohiko"},{"name":"Sasaki Yutaka"},{"name":"Watanabe Hiroshi"},{"name":"Otagiri Masako"},{"name":"Maruyama Toru"}]},"description":{"en":"Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on the preparation of a Kupffer cell targeting type-I interferon, an albumin-IFNα2b fusion protein that contains highly mannosylated N-linked oligosaccharide chains, Man-HSA(D494N)-IFNα2b, attached by combining albumin fusion technology and site-directed mutagenesis. The presence of this unique oligosaccharide permits the protein to be efficiently, rapidly and preferentially distributed to Kupffer cells. Likewise IFNα2b, Man-HSA(D494N)-IFNα2b caused a significant induction in the mRNA levels of IL-10, IL-1Ra, PD-L1 in RAW264.7 cells and mouse isolated Kupffer cells, and these inductions were largely inhibited by blocking the interferon receptor. These data indicate that Man-HSA(D494N)-IFNα2b retained the biological activities of type-I interferon. Man-HSA(D494N)-IFNα2b significantly inhibited liver injury in Concanavalin A (Con-A)-induced hepatitis model mice, and consequently improved their survival rate. Moreover, the post-administration of Man-HSA(D494N)-IFNα2b at 2 h after the Con-A challenge also exerted hepato-protective effects. In conclusion, this proof-of-concept study demonstrates the therapeutic effectiveness and utility of Kupffer cell targeting type-I interferon against hepatitis via its anti-inflammatory and immunomodulatory actions.","ja":"Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on the preparation of a Kupffer cell targeting type-I interferon, an albumin-IFNα2b fusion protein that contains highly mannosylated N-linked oligosaccharide chains, Man-HSA(D494N)-IFNα2b, attached by combining albumin fusion technology and site-directed mutagenesis. The presence of this unique oligosaccharide permits the protein to be efficiently, rapidly and preferentially distributed to Kupffer cells. Likewise IFNα2b, Man-HSA(D494N)-IFNα2b caused a significant induction in the mRNA levels of IL-10, IL-1Ra, PD-L1 in RAW264.7 cells and mouse isolated Kupffer cells, and these inductions were largely inhibited by blocking the interferon receptor. These data indicate that Man-HSA(D494N)-IFNα2b retained the biological activities of type-I interferon. Man-HSA(D494N)-IFNα2b significantly inhibited liver injury in Concanavalin A (Con-A)-induced hepatitis model mice, and consequently improved their survival rate. Moreover, the post-administration of Man-HSA(D494N)-IFNα2b at 2 h after the Con-A challenge also exerted hepato-protective effects. In conclusion, this proof-of-concept study demonstrates the therapeutic effectiveness and utility of Kupffer cell targeting type-I interferon against hepatitis via its anti-inflammatory and immunomodulatory actions."},"publication_date":"2018-04-24","publication_name":{"en":"Drug Delivery","ja":"Drug Delivery"},"volume":"Vol.25","number":"No.1","starting_page":"1067","ending_page":"1077","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1080/10717544.2018.1464083"],"issn":["1521-0464"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:62, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512931"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115707","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29040960","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85042682163&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334157","label":"url"}],"paper_title":{"en":"A Novel S-Sulfhydrated Human Serum Albumin Preparation Suppresses Melanin Synthesis","ja":"A Novel S-Sulfhydrated Human Serum Albumin Preparation Suppresses Melanin Synthesis"},"authors":{"en":[{"name":"Ikeda, M"},{"name":"Ishima Yu"},{"name":"Kinoshita, R"},{"name":"Chuang, V"},{"name":"Tasaka, N"},{"name":"Matsuo, N"},{"name":"Watanabe, H"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"},{"name":"Otagiri, M"},{"name":"Maruyama, T"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"Chuang, V"},{"name":"田坂 菜々美"},{"name":"松尾 菜々"},{"name":"Watanabe, H"},{"name":"清水 太郎"},{"name":"石田 竜弘"},{"name":"Otagiri, M"},{"name":"Maruyama, T"}]},"publication_date":"2018-04","publication_name":{"en":"Redox Biology","ja":"Redox Biology"},"volume":"Vol.14","starting_page":"354","ending_page":"360","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.redox.2017.10.007"],"issn":["2213-2317"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:63, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512932"},"force":{"see_also":[{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85034079918&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334834","label":"url"}],"paper_title":{"en":"Dual Therapeutic Effects of an Albumin-based Nitric Oxide Donor on Two Experimental Models of Chronic Kidney Disease","ja":"Dual Therapeutic Effects of an Albumin-based Nitric Oxide Donor on Two Experimental Models of Chronic Kidney Disease"},"authors":{"en":[{"name":"Oshiro S"},{"name":"Ishima Yu"},{"name":"Hitoshi M"},{"name":"Honda N"},{"name":"Jing B"},{"name":"Kinoshita Ryo"},{"name":"Ikeda Mayumi"},{"name":"Iwao Y"},{"name":"Imafuku T"},{"name":"Nishida K"},{"name":"Miyamura S"},{"name":"Watanabe H"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Oshiro S"},{"name":"異島 優"},{"name":"Hitoshi M"},{"name":"Honda N"},{"name":"Jing B"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"Iwao Y"},{"name":"Imafuku T"},{"name":"Nishida K"},{"name":"Miyamura S"},{"name":"Watanabe H"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"publication_date":"2018-03","publication_name":{"en":"Journal of Pharmaceutical Sciences","ja":"Journal of Pharmaceutical Sciences"},"volume":"Vol.107","number":"No.3","starting_page":"848","ending_page":"855","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.xphs.2017.10.023"],"issn":["0022-3549"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:64, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512933"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29287147","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85041697937&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=335639","label":"url"}],"paper_title":{"en":"Intratumoral visualization of oxaliplatin within a liposomal formulation using X-ray fluorescence spectrometry","ja":"Intratumoral visualization of oxaliplatin within a liposomal formulation using X-ray fluorescence spectrometry"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Tanaka Masao"},{"name":"Doi Yusuke"},{"name":"Terada Yasuko"},{"name":"Yagi Naoto"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"田中 真生"},{"name":"土井 祐輔"},{"name":"Terada Yasuko"},{"name":"Yagi Naoto"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Microsynchrotron radiation X-ray fluorescence spectrometry (-SR-XRF) is an X-ray procedure that utilizes synchrotron radiation as an excitation source. -SR-XRF is a rapid, nondestructive technique that allows mapping and quantification of metals and biologically important elements in cell or tissue samples. Generally, the intratumor distribution of nanocarrier-based therapeutics is assessed by tracing the distribution of a labeled nanocarrier within tumor tissue, rather than by tracing the encapsulated drug. Instead of targeting the delivery vehicle, we employed -SR-XRF to visualize the intratumoral microdistribution of oxaliplatin (l-OHP) encapsulated within PEGylated liposomes. Tumor-bearing mice were intravenously injected with either l-OHP-containing PEGylated liposomes (l-OHP liposomes) or free l-OHP. The intratumor distribution of l-OHP within tumor sections was determined by detecting the fluorescence of platinum atoms, which are the main elemental components of l-OHP. The l-OHP in the liposomal formulation was localized near the tumor vessels and accumulated in tumors at concentrations greater than those seen with the free form, which is consistent with the results of our previous study that focused on fluorescent labeling of PEGylated liposomes. In addition, repeated administration of l-OHP liposomes substantially enhanced the tumor accumulation and/or intratumor distribution of a subsequent dose of l-OHP liposomes, presumably via improvements in tumor vascular permeability, which is also consistent with our previous results. In conclusion, -SR-XRF imaging efficiently and directly traced the intratumor distribution of the active pharmaceutical ingredient l-OHP encapsulated in liposomes within tumor tissue. -SR-XRF imaging could be a powerful means for estimating tissue distribution and even predicting the pharmacological effect of nanocarrier-based anticancer metal compounds.","ja":"Microsynchrotron radiation X-ray fluorescence spectrometry (-SR-XRF) is an X-ray procedure that utilizes synchrotron radiation as an excitation source. -SR-XRF is a rapid, nondestructive technique that allows mapping and quantification of metals and biologically important elements in cell or tissue samples. Generally, the intratumor distribution of nanocarrier-based therapeutics is assessed by tracing the distribution of a labeled nanocarrier within tumor tissue, rather than by tracing the encapsulated drug. Instead of targeting the delivery vehicle, we employed -SR-XRF to visualize the intratumoral microdistribution of oxaliplatin (l-OHP) encapsulated within PEGylated liposomes. Tumor-bearing mice were intravenously injected with either l-OHP-containing PEGylated liposomes (l-OHP liposomes) or free l-OHP. The intratumor distribution of l-OHP within tumor sections was determined by detecting the fluorescence of platinum atoms, which are the main elemental components of l-OHP. The l-OHP in the liposomal formulation was localized near the tumor vessels and accumulated in tumors at concentrations greater than those seen with the free form, which is consistent with the results of our previous study that focused on fluorescent labeling of PEGylated liposomes. In addition, repeated administration of l-OHP liposomes substantially enhanced the tumor accumulation and/or intratumor distribution of a subsequent dose of l-OHP liposomes, presumably via improvements in tumor vascular permeability, which is also consistent with our previous results. In conclusion, -SR-XRF imaging efficiently and directly traced the intratumor distribution of the active pharmaceutical ingredient l-OHP encapsulated in liposomes within tumor tissue. -SR-XRF imaging could be a powerful means for estimating tissue distribution and even predicting the pharmacological effect of nanocarrier-based anticancer metal compounds."},"publication_date":"2018-02-05","publication_name":{"en":"Molecular Pharmaceutics","ja":"Molecular Pharmaceutics"},"volume":"Vol.15","number":"No.2","starting_page":"403","ending_page":"409","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/acs.molpharmaceut.7b00762"],"issn":["1543-8392"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:65, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512934"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29217175","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85037534004&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=335200","label":"url"}],"paper_title":{"en":"Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens","ja":"Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Kawanishi Munehira"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"川西 宗平"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Polyethylene glycol (PEG) is an attractive tool for the development of nanoparticle-based cancer therapy since it endows nanoparticles with extended-circulation properties. Nevertheless, recent reports have revealed that intravenous injection of either PEGylated liposomes (SLs) or PEGylated lipoplex (PLpx) could elicit an anti-PEG immunoglobulin (IgM) response in a T cell-independent (TI) manner that would substantially compromise the in vivo fate of PEGylated products upon repeated administration. In the same context, viral or bacterial infections trigger the production of polyreactive IgM that binds both self and foreign antigens. The polyreactivity of IgM elicited by SLs or PLpx, to bacteria and other polymers, however, is yet to be elucidated. In this study, the polyreactivity of IgM elicited by SLs or PLpx was challenged against different bacteria (TI antigens) and against synthetic polymer composed of repetitive structures (PVP-360 or FITC-dextran). Results demonstrated that anti-PEG IgM elicited by either SLs or PLpx showed no reactivity to various bacteria examined, while the IgM showed remarkable reactivity to both PVP-360 and FITC-dextran. In addition, interestingly, anti-PEG IgM elicited by either SLs or PLpx showed no antinuclear antibody-like immune reactivity, and, therefore, treatment with either SLs or PLpx was not expected to exacerbate autoimmune diseases such as systemic lupus erythematosus. Collectively, our findings could provide information supporting the safety of PEGylated nanoparticle-based pharmaceutics, particularly in patients with autoimmune diseases.","ja":"Polyethylene glycol (PEG) is an attractive tool for the development of nanoparticle-based cancer therapy since it endows nanoparticles with extended-circulation properties. Nevertheless, recent reports have revealed that intravenous injection of either PEGylated liposomes (SLs) or PEGylated lipoplex (PLpx) could elicit an anti-PEG immunoglobulin (IgM) response in a T cell-independent (TI) manner that would substantially compromise the in vivo fate of PEGylated products upon repeated administration. In the same context, viral or bacterial infections trigger the production of polyreactive IgM that binds both self and foreign antigens. The polyreactivity of IgM elicited by SLs or PLpx, to bacteria and other polymers, however, is yet to be elucidated. In this study, the polyreactivity of IgM elicited by SLs or PLpx was challenged against different bacteria (TI antigens) and against synthetic polymer composed of repetitive structures (PVP-360 or FITC-dextran). Results demonstrated that anti-PEG IgM elicited by either SLs or PLpx showed no reactivity to various bacteria examined, while the IgM showed remarkable reactivity to both PVP-360 and FITC-dextran. In addition, interestingly, anti-PEG IgM elicited by either SLs or PLpx showed no antinuclear antibody-like immune reactivity, and, therefore, treatment with either SLs or PLpx was not expected to exacerbate autoimmune diseases such as systemic lupus erythematosus. Collectively, our findings could provide information supporting the safety of PEGylated nanoparticle-based pharmaceutics, particularly in patients with autoimmune diseases."},"publication_date":"2018-01-28","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.270","starting_page":"114","ending_page":"119","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2017.12.002"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:66, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512935"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29122608","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85032951371&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=335211","label":"url"}],"paper_title":{"en":"Thioredoxin-Albumin Fusion Protein Prevents Copper enhanced Zinc-induced Neurotoxicity via Its Antioxidative activity","ja":"Thioredoxin-Albumin Fusion Protein Prevents Copper enhanced Zinc-induced Neurotoxicity via Its Antioxidative activity"},"authors":{"en":[{"name":"Tanaka K"},{"name":"Shimoda M"},{"name":"Chuang V"},{"name":"Nishida K"},{"name":"Kawahara M"},{"name":"Ishida Tatsuhiro"},{"name":"Otagiri M"},{"name":"Maruyama T"},{"name":"Ishima Yu"}],"ja":[{"name":"Tanaka K"},{"name":"Shimoda M"},{"name":"Chuang V"},{"name":"Nishida K"},{"name":"Kawahara M"},{"name":"石田 竜弘"},{"name":"Otagiri M"},{"name":"Maruyama T"},{"name":"異島 優"}]},"description":{"en":"Zinc (Zn) is a co-factor for a vast number of enzymes, and functions as a regulator for immune mechanism and protein synthesis. However, excessive Zn release induced in pathological situations such as stroke or transient global ischemia is toxic. Previously, we demonstrated that the interaction of Zn and copper (Cu) is involved in the pathogenesis of Alzheimer's disease and vascular dementia. Furthermore, oxidative stress has been shown to play a significant role in the pathogenesis of various metal ions induced neuronal death. Thioredoxin-Albumin fusion (HSA-Trx) is a derivative of thioredoxin (Trx), an antioxidative protein, with improved plasma retention and stability of Trx. In this study, we examined the effect of HSA-Trx on Cu/Zn-induced neurotoxicity. Firstly, HSA-Trx was found to clearly suppress Cu/Zn-induced neuronal cell death in mouse hypothalamic neuronal cells (GT1-7 cells). Moreover, HSA-Trx markedly suppressed Cu/Zn-induced ROS production and the expression of oxidative stress related genes, such as heme oxygenase-1. In contrast, HSA-Trx did not affect the intracellular levels of both Cu and Zn after Cu/Zn treatment. Finally, HSA-Trx was found to significantly suppress endoplasmic reticulum (ER) stress response induced by Cu/Zn treatment in a dose dependent manner. These results suggest that HSA-Trx counteracted Cu/Zn-induced neurotoxicity by suppressing the production of ROS via interfering the related gene expressions, in addition to the highly possible radical scavenging activity of the fusion protein. Based on these findings, HSA-Trx has great potential as a promising therapeutic agent for the treatment of refractory neurological diseases.","ja":"Zinc (Zn) is a co-factor for a vast number of enzymes, and functions as a regulator for immune mechanism and protein synthesis. However, excessive Zn release induced in pathological situations such as stroke or transient global ischemia is toxic. Previously, we demonstrated that the interaction of Zn and copper (Cu) is involved in the pathogenesis of Alzheimer's disease and vascular dementia. Furthermore, oxidative stress has been shown to play a significant role in the pathogenesis of various metal ions induced neuronal death. Thioredoxin-Albumin fusion (HSA-Trx) is a derivative of thioredoxin (Trx), an antioxidative protein, with improved plasma retention and stability of Trx. In this study, we examined the effect of HSA-Trx on Cu/Zn-induced neurotoxicity. Firstly, HSA-Trx was found to clearly suppress Cu/Zn-induced neuronal cell death in mouse hypothalamic neuronal cells (GT1-7 cells). Moreover, HSA-Trx markedly suppressed Cu/Zn-induced ROS production and the expression of oxidative stress related genes, such as heme oxygenase-1. In contrast, HSA-Trx did not affect the intracellular levels of both Cu and Zn after Cu/Zn treatment. Finally, HSA-Trx was found to significantly suppress endoplasmic reticulum (ER) stress response induced by Cu/Zn treatment in a dose dependent manner. These results suggest that HSA-Trx counteracted Cu/Zn-induced neurotoxicity by suppressing the production of ROS via interfering the related gene expressions, in addition to the highly possible radical scavenging activity of the fusion protein. Based on these findings, HSA-Trx has great potential as a promising therapeutic agent for the treatment of refractory neurological diseases."},"publication_date":"2018-01-15","publication_name":{"en":"International Journal of Pharmaceutics","ja":"International Journal of Pharmaceutics"},"volume":"Vol.535","number":"No.1-2","starting_page":"140","ending_page":"147","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijpharm.2017.11.012"],"issn":["1873-3476"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:67, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512936"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28843775","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85028595242&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334854","label":"url"}],"paper_title":{"en":"Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-B signaling pathway in secondary hyperparathyroidism","ja":"Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-B signaling pathway in secondary hyperparathyroidism"},"authors":{"en":[{"name":"Watanabe Hiroshi"},{"name":"Sugimoto Ryusei"},{"name":"Ikegami Komei"},{"name":"Enoki Yuki"},{"name":"Imafuku Tadashi"},{"name":"Fujimura Rui"},{"name":"Bi Jing"},{"name":"Nishida Kento"},{"name":"Sakaguchi Yoshiaki"},{"name":"Murata Michiya"},{"name":"Maeda Hitoshi"},{"name":"Hirata Kenshiro"},{"name":"Jingami Sachiko"},{"name":"Ishima Yu"},{"name":"Tanaka Motoko"},{"name":"Matsushita Kazutaka"},{"name":"Komaba Hirotaka"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"Watanabe Hiroshi"},{"name":"Sugimoto Ryusei"},{"name":"Ikegami Komei"},{"name":"Enoki Yuki"},{"name":"Imafuku Tadashi"},{"name":"Fujimura Rui"},{"name":"Bi Jing"},{"name":"Nishida Kento"},{"name":"Sakaguchi Yoshiaki"},{"name":"Murata Michiya"},{"name":"Maeda Hitoshi"},{"name":"Hirata Kenshiro"},{"name":"Jingami Sachiko"},{"name":"異島 優"},{"name":"Tanaka Motoko"},{"name":"Matsushita Kazutaka"},{"name":"Komaba Hirotaka"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"description":{"en":"Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models. In SHPT rats, hepatic and intestinal CYP3A expression was suppressed, but the changes were recovered by the administration of the calcimimetic cinacalcet, a PTH suppressor. Under the same experimental conditions, a pharmacokinetic study using orally administered midazolam, a substrate for CYP3A, showed that the AUC was increased by 5 times in SHPT rats, but that was partially recovered by a cinacalcet treatment. This was directly tested in rat primary hepatocytes and intestinal Caco-2 cells where the expression of the CYP3A protein was down-regulated by PTH (1-34). In Caco-2 cells, PTH (1-34) down-regulated the expression of CYP3A mRNA, but an inactive PTH derivative (13-34) had no effect. 8-Bromo-cyclic adenosine monophosphate, a membrane-permeable cAMP analog, reduced mRNA expression of CYP3A whereas the inhibitors of PI3K, NF-κB, PKC and PKA reversed the PTH-induced CYP3A down-regulation. These results suggest that PTH down-regulates CYP3A through multiple signaling pathways, including the PI3K/PKC/PKA/NF-κB pathway after the elevation of intracellular cAMP, and the effect of PTH can be prevented by cinacalcet treatment.","ja":"Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models. In SHPT rats, hepatic and intestinal CYP3A expression was suppressed, but the changes were recovered by the administration of the calcimimetic cinacalcet, a PTH suppressor. Under the same experimental conditions, a pharmacokinetic study using orally administered midazolam, a substrate for CYP3A, showed that the AUC was increased by 5 times in SHPT rats, but that was partially recovered by a cinacalcet treatment. This was directly tested in rat primary hepatocytes and intestinal Caco-2 cells where the expression of the CYP3A protein was down-regulated by PTH (1-34). In Caco-2 cells, PTH (1-34) down-regulated the expression of CYP3A mRNA, but an inactive PTH derivative (13-34) had no effect. 8-Bromo-cyclic adenosine monophosphate, a membrane-permeable cAMP analog, reduced mRNA expression of CYP3A whereas the inhibitors of PI3K, NF-κB, PKC and PKA reversed the PTH-induced CYP3A down-regulation. These results suggest that PTH down-regulates CYP3A through multiple signaling pathways, including the PI3K/PKC/PKA/NF-κB pathway after the elevation of intracellular cAMP, and the effect of PTH can be prevented by cinacalcet treatment."},"publication_date":"2017-12-01","publication_name":{"en":"Biochemical Pharmacology","ja":"Biochemical Pharmacology"},"volume":"Vol.145","starting_page":"192","ending_page":"201","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bcp.2017.08.016"],"issn":["1873-2968"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:68, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512937"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28966257","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85030774993&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334831","label":"url"}],"paper_title":{"en":"Recombinant Human Serum Albumin Containing 3 Copies of Domain I, Has Significant in Vitro Antioxidative Capacity Compared to the Wild-Type","ja":"Recombinant Human Serum Albumin Containing 3 Copies of Domain I, Has Significant in Vitro Antioxidative Capacity Compared to the Wild-Type"},"authors":{"en":[{"name":"Matsushita Sadaharu"},{"name":"Nishi Koji"},{"name":"Iwao Yasunori"},{"name":"Ishima Yu"},{"name":"Watanabe Hiroshi"},{"name":"Taguchi Kazuaki"},{"name":"Yamasaki Keishi"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"}],"ja":[{"name":"Matsushita Sadaharu"},{"name":"Nishi Koji"},{"name":"Iwao Yasunori"},{"name":"異島 優"},{"name":"Watanabe Hiroshi"},{"name":"Taguchi Kazuaki"},{"name":"Yamasaki Keishi"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"}]},"description":{"en":"Human serum albumin (HSA), the most abundant protein in serum, functions as carrier of drugs and contributes to maintaining serum colloid osmotic pressure. We report herein on the preparation of a genetic recombinant HSA, in which domains II and III were changed to domain I (triple domain I; TDI). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that the purity of the TDI was equivalent to that of the wild type (WT). Both far- and near-UV circular dichroism (CD) spectra of the TDI showed that its structural characteristics were similar to the WT. Ligand binding capacity was examined by an ultrafiltration method using 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) and ketoprofen as markers for site I and site II, respectively. The binding capacity of TDI for both ligands was lower than that for the wild type. TDI significantly suppressed the oxidation of dihydrorhodamine 123 (DRD) by HO compared to the WT. Our current results suggest that TDI has great potential for further development as HSA a product having antioxidative functions.","ja":"Human serum albumin (HSA), the most abundant protein in serum, functions as carrier of drugs and contributes to maintaining serum colloid osmotic pressure. We report herein on the preparation of a genetic recombinant HSA, in which domains II and III were changed to domain I (triple domain I; TDI). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that the purity of the TDI was equivalent to that of the wild type (WT). Both far- and near-UV circular dichroism (CD) spectra of the TDI showed that its structural characteristics were similar to the WT. Ligand binding capacity was examined by an ultrafiltration method using 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) and ketoprofen as markers for site I and site II, respectively. The binding capacity of TDI for both ligands was lower than that for the wild type. TDI significantly suppressed the oxidation of dihydrorhodamine 123 (DRD) by HO compared to the WT. Our current results suggest that TDI has great potential for further development as HSA a product having antioxidative functions."},"publication_date":"2017-10-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.40","number":"No.10","starting_page":"1813","ending_page":"1817","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b17-00528"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:69, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512938"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114913","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28608457","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85020393296&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334855","label":"url"}],"paper_title":{"en":"Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction","ja":"Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction"},"authors":{"en":[{"name":"Enoki Yuki"},{"name":"Watanabe Hiroshi"},{"name":"Arake Riho"},{"name":"Fujimura Rui"},{"name":"Ishiodori Kana"},{"name":"Imafuku Tadashi"},{"name":"Nishida Kento"},{"name":"Sugimoto Ryusei"},{"name":"Nagao Saori"},{"name":"Miyamura Shigeyuki"},{"name":"Ishima Yu"},{"name":"Tanaka Motoko"},{"name":"Matsushita Kazutaka"},{"name":"Komaba Hirotaka"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"Enoki Yuki"},{"name":"Watanabe Hiroshi"},{"name":"Arake Riho"},{"name":"Fujimura Rui"},{"name":"Ishiodori Kana"},{"name":"Imafuku Tadashi"},{"name":"Nishida Kento"},{"name":"Sugimoto Ryusei"},{"name":"Nagao Saori"},{"name":"Miyamura Shigeyuki"},{"name":"異島 優"},{"name":"Tanaka Motoko"},{"name":"Matsushita Kazutaka"},{"name":"Komaba Hirotaka"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"description":{"en":"Chronic kidney disease (CKD) patients experience skeletal muscle wasting and decreased exercise endurance. Our previous study demonstrated that indoxyl sulfate (IS), a uremic toxin, accelerates skeletal muscle atrophy. The purpose of this study was to examine the issue of whether IS causes mitochondria dysfunction and IS-targeted intervention using AST-120, which inhibits IS accumulation, or mitochondria-targeted intervention using L-carnitine or teneligliptin, a dipeptidyl peptidase-4 inhibitor which retains mitochondria function and alleviates skeletal muscle atrophy and muscle endurance in chronic kidney disease mice. The in vitro effect of IS on mitochondrial status was evaluated using mouse myofibroblast cells (C2C12 cell). The mice were divided into sham or 5/6-nephrectomized (CKD) mice group. Chronic kidney disease mice were also randomly assigned to non-treatment group and AST-120, L-carnitine, or teneligliptin treatment groups. In C2C12 cells, IS induced mitochondrial dysfunction by decreasing the expression of PGC-1α and inducing autophagy in addition to decreasing mitochondrial membrane potential. Co-incubation with an anti-oxidant, ascorbic acid, L-carnitine, or teneligliptine restored the values to their original state. In CKD mice, the body and skeletal muscle weights were decreased compared with sham mice. Compared with sham mice, the expression of interleukin-6 and atrophy-related factors such as myostatin and atrogin-1 was increased in the skeletal muscle of CKD mice, whereas muscular Akt phosphorylation was decreased. In addition, a reduced exercise capacity was observed for the CKD mice, which was accompanied by a decreased expression of muscular PCG-1α and increased muscular autophagy, as reflected by decreased mitochondria-rich type I fibres. An AST-120 treatment significantly restored these changes including skeletal muscle weight observed in CKD mice to the sham levels accompanied by a reduction in IS levels. An L-carnitine or teneligliptin treatment also restored them to the sham levels without changing IS level. Our results indicate that IS induces mitochondrial dysfunction in skeletal muscle cells and provides a potential therapeutic strategy such as IS-targeted and mitochondria-targeted interventions for treating CKD-induced muscle atrophy and decreased exercise endurance.","ja":"Chronic kidney disease (CKD) patients experience skeletal muscle wasting and decreased exercise endurance. Our previous study demonstrated that indoxyl sulfate (IS), a uremic toxin, accelerates skeletal muscle atrophy. The purpose of this study was to examine the issue of whether IS causes mitochondria dysfunction and IS-targeted intervention using AST-120, which inhibits IS accumulation, or mitochondria-targeted intervention using L-carnitine or teneligliptin, a dipeptidyl peptidase-4 inhibitor which retains mitochondria function and alleviates skeletal muscle atrophy and muscle endurance in chronic kidney disease mice. The in vitro effect of IS on mitochondrial status was evaluated using mouse myofibroblast cells (C2C12 cell). The mice were divided into sham or 5/6-nephrectomized (CKD) mice group. Chronic kidney disease mice were also randomly assigned to non-treatment group and AST-120, L-carnitine, or teneligliptin treatment groups. In C2C12 cells, IS induced mitochondrial dysfunction by decreasing the expression of PGC-1α and inducing autophagy in addition to decreasing mitochondrial membrane potential. Co-incubation with an anti-oxidant, ascorbic acid, L-carnitine, or teneligliptine restored the values to their original state. In CKD mice, the body and skeletal muscle weights were decreased compared with sham mice. Compared with sham mice, the expression of interleukin-6 and atrophy-related factors such as myostatin and atrogin-1 was increased in the skeletal muscle of CKD mice, whereas muscular Akt phosphorylation was decreased. In addition, a reduced exercise capacity was observed for the CKD mice, which was accompanied by a decreased expression of muscular PCG-1α and increased muscular autophagy, as reflected by decreased mitochondria-rich type I fibres. An AST-120 treatment significantly restored these changes including skeletal muscle weight observed in CKD mice to the sham levels accompanied by a reduction in IS levels. An L-carnitine or teneligliptin treatment also restored them to the sham levels without changing IS level. Our results indicate that IS induces mitochondrial dysfunction in skeletal muscle cells and provides a potential therapeutic strategy such as IS-targeted and mitochondria-targeted interventions for treating CKD-induced muscle atrophy and decreased exercise endurance."},"publication_date":"2017-10","publication_name":{"en":"Journal of Cachexia, Sarcopenia and Muscle","ja":"Journal of Cachexia, Sarcopenia and Muscle"},"volume":"Vol.8","number":"No.5","starting_page":"735","ending_page":"747","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/jcsm.12202"],"issn":["2190-6009"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:70, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512939"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28414103","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324411","label":"url"}],"paper_title":{"en":"Apoptosis induction of Poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition","ja":"Apoptosis induction of Poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition"},"authors":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Chuang Victor"},{"name":"Ikeda Tsuyoshi"},{"name":"Kinoshita Ryo"},{"name":"Watanabe Hiroshi"},{"name":"Ishida Tatsuhiro"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"Chuang Victor"},{"name":"Ikeda Tsuyoshi"},{"name":"木下 遼"},{"name":"Watanabe Hiroshi"},{"name":"石田 竜弘"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"description":{"en":"Poly-S-nitrosated human serum albumin (Poly-SNO-HSA) delivered and accumulated nitric oxide (NO) in tumors and induces apoptosis. Tumor hypoxia is strongly associated with malignant progression and tumor resistance to therapy. In this study, we examined the cytotoxic effect of Poly-SNO-HSA under hypoxia on the murine colon 26 adenocarcinoma (C26) cells in vitro and in vivo. Under hypoxia, at about 4 times LD50 dose of Poly-SNO-HSA in vitro, the reactive oxygen species production was hindered but apoptotic cells were induced via cGMP pathway as the effect was suppressed by a soluble guanylate cyclase inhibitor, NS2028. The apoptosis induction effect of low dose Poly-SNO-HSA on C26 cells in vitro under hypoxia can be restored by a phosphodiesterase 5 (PDE5) inhibitor, vardenafil. In C26-bearing mice, Poly-SNO-HSA/vardenafil combination treatment significantly suppressed the tumor volume compared with Poly-SNO-HSA or vardenafil treatment alone. Furthermore, the core tumor tissues showed increased expression of caspase-3 than the non-core tissue. The expression of caspase-3 appeared to overlap with the hypoxic zone of tumor tissues. Similar results were also obtained when the experiments were repeated using Epimedium extract, a natural herbal supplement with PDE5 inhibition activity. In conclusion, Poly-SNO-HSA/PDE5 inhibitors combination therapy is a promising approach for enhancing the anticancer therapeutic effects of Poly-SNO-HSA against not only anti-cancer drug resistance but also hypoxic stress related solid tumor resistance.","ja":"Poly-S-nitrosated human serum albumin (Poly-SNO-HSA) delivered and accumulated nitric oxide (NO) in tumors and induces apoptosis. Tumor hypoxia is strongly associated with malignant progression and tumor resistance to therapy. In this study, we examined the cytotoxic effect of Poly-SNO-HSA under hypoxia on the murine colon 26 adenocarcinoma (C26) cells in vitro and in vivo. Under hypoxia, at about 4 times LD50 dose of Poly-SNO-HSA in vitro, the reactive oxygen species production was hindered but apoptotic cells were induced via cGMP pathway as the effect was suppressed by a soluble guanylate cyclase inhibitor, NS2028. The apoptosis induction effect of low dose Poly-SNO-HSA on C26 cells in vitro under hypoxia can be restored by a phosphodiesterase 5 (PDE5) inhibitor, vardenafil. In C26-bearing mice, Poly-SNO-HSA/vardenafil combination treatment significantly suppressed the tumor volume compared with Poly-SNO-HSA or vardenafil treatment alone. Furthermore, the core tumor tissues showed increased expression of caspase-3 than the non-core tissue. The expression of caspase-3 appeared to overlap with the hypoxic zone of tumor tissues. Similar results were also obtained when the experiments were repeated using Epimedium extract, a natural herbal supplement with PDE5 inhibition activity. In conclusion, Poly-SNO-HSA/PDE5 inhibitors combination therapy is a promising approach for enhancing the anticancer therapeutic effects of Poly-SNO-HSA against not only anti-cancer drug resistance but also hypoxic stress related solid tumor resistance."},"publication_date":"2017-09-30","publication_name":{"en":"Nitric Oxide: Biology and Chemistry","ja":"Nitric Oxide: Biology and Chemistry"},"volume":"Vol.69","starting_page":"28","ending_page":"34","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.niox.2017.04.005"],"issn":["1089-8611"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:71, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512940"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28651144","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85021192830&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325199","label":"url"}],"paper_title":{"en":"Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-Nitrosated Human Serum Albumin Dimer","ja":"Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-Nitrosated Human Serum Albumin Dimer"},"authors":{"en":[{"name":"Kinoshita, Ryo"},{"name":"Ishima Yu"},{"name":"Chuang T.G. Victor"},{"name":"Nakamura, Hideaki"},{"name":"Fang, Jun"},{"name":"Watanabe, Hiroshi"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishida Tatsuhiro"},{"name":"Maeda, Hiroshi"},{"name":"Otagiri, Masaki"},{"name":"Maruyama, Toru"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"Chuang T.G. Victor"},{"name":"Nakamura, Hideaki"},{"name":"Fang, Jun"},{"name":"Watanabe, Hiroshi"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"石田 竜弘"},{"name":"Maeda, Hiroshi"},{"name":"Otagiri, Masaki"},{"name":"Maruyama, Toru"}]},"description":{"en":"In the latest trend of anticancer chemotherapy research, there were many macromolecular anticancer drugs developed based on enhanced permeability and retention (EPR) effect, such as albumin bound paclitaxel nanoparticle (nab- PTX, also called Abraxane). However, cancers with low vascular permeability posed a challenge for these EPR based therapeutic systems. Augmenting the intrinsic EPR effect with an intrinsic vascular modulator such as nitric oxide (NO) could be a promising strategy. S-nitrosated human serum albumin dimer (SNO-HSA Dimer) shown promising activity previously was evaluated for the synergistic effect when used as a pretreatment agent in nab-PTX therapy against various tumor models. In the high vascular permeability C26 murine colon cancer subcutaneous inoculation model, SNO-HSA Dimer enhanced tumor selectivity of nab-PTX, and attenuated myelosuppression. SNO-HSA Dimer also augmented the tumor growth inhibition of nab-PTX in low vascular permeability B16 murine melanoma subcutaneous inoculation model. Furthermore, nab-PTX therapy combined with SNO-HSA Dimer showed higher antitumor activity and improved survival rate of SUIT2 human pancreatic cancer orthotopic model. In conclusion, SNO-HSA Dimer could enhance the therapeutic effect of nab-PTX even in low vascular permeability or intractable pancreatic cancers. The possible underlying mechanisms of action of SNO-HSA Dimer were discussed.","ja":"In the latest trend of anticancer chemotherapy research, there were many macromolecular anticancer drugs developed based on enhanced permeability and retention (EPR) effect, such as albumin bound paclitaxel nanoparticle (nab- PTX, also called Abraxane). However, cancers with low vascular permeability posed a challenge for these EPR based therapeutic systems. Augmenting the intrinsic EPR effect with an intrinsic vascular modulator such as nitric oxide (NO) could be a promising strategy. S-nitrosated human serum albumin dimer (SNO-HSA Dimer) shown promising activity previously was evaluated for the synergistic effect when used as a pretreatment agent in nab-PTX therapy against various tumor models. In the high vascular permeability C26 murine colon cancer subcutaneous inoculation model, SNO-HSA Dimer enhanced tumor selectivity of nab-PTX, and attenuated myelosuppression. SNO-HSA Dimer also augmented the tumor growth inhibition of nab-PTX in low vascular permeability B16 murine melanoma subcutaneous inoculation model. Furthermore, nab-PTX therapy combined with SNO-HSA Dimer showed higher antitumor activity and improved survival rate of SUIT2 human pancreatic cancer orthotopic model. In conclusion, SNO-HSA Dimer could enhance the therapeutic effect of nab-PTX even in low vascular permeability or intractable pancreatic cancers. The possible underlying mechanisms of action of SNO-HSA Dimer were discussed."},"publication_date":"2017-09","publication_name":{"en":"Biomaterials","ja":"Biomaterials"},"volume":"Vol.140","starting_page":"162","ending_page":"169","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.biomaterials.2017.06.021"],"issn":["1878-5905"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:72, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512941"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112372","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28643902","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325157","label":"url"}],"paper_title":{"en":"Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model","ja":"Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nishio Miho"},{"name":"Doi Yusuke"},{"name":"ANDO Hidenori"},{"name":"Ukawa Masami"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"西尾 美穂"},{"name":"土井 祐輔"},{"name":"安藤 英紀"},{"name":"鵜川 真実"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Immune modulation of the tumor microenvironment has been reported to participate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we reported that liposomal encapsulation of oxaliplatin (l-OHP) within PEGylated liposomes conferred a superior antitumor efficacy to free l-OHP in murine colorectal carcinoma-bearing mice through permitting preferential accumulation of the encapsulated drug within tumor tissue. However, the contribution of the immune-modulatory properties of liposomal l-OHP and/or free l-OHP to the overall antitumor efficacy was not elucidated. In the present study, therefore, we investigated the effect of liposomal encapsulation of l-OHP within PEGylated liposomes on the antitumor immunity in both immunocompetent and immunodeficient mice. Liposomal l-OHP significantly suppressed the growth of tumors implanted in immunocompetent mice, but not in immunodeficient mice. In immunocompetent mice, liposomal l-OHP increased the tumor MHC-1 level and preserved antitumor immunity through decreasing the number of immune suppressor cells, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, which collectively suppress CD8(+) T cell-mediated tumor cells killing. In contrast, free l-OHP ruined antitumor immunity. These results suggest that the antitumor efficacy of liposomal l-OHP is attributed, on the one hand, to its immunomodulatory effect on tumor immune microenvironment that is superior to that of free l-OHP, and on the other hand, to its direct cytotoxic effect on tumor cells.","ja":"Immune modulation of the tumor microenvironment has been reported to participate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we reported that liposomal encapsulation of oxaliplatin (l-OHP) within PEGylated liposomes conferred a superior antitumor efficacy to free l-OHP in murine colorectal carcinoma-bearing mice through permitting preferential accumulation of the encapsulated drug within tumor tissue. However, the contribution of the immune-modulatory properties of liposomal l-OHP and/or free l-OHP to the overall antitumor efficacy was not elucidated. In the present study, therefore, we investigated the effect of liposomal encapsulation of l-OHP within PEGylated liposomes on the antitumor immunity in both immunocompetent and immunodeficient mice. Liposomal l-OHP significantly suppressed the growth of tumors implanted in immunocompetent mice, but not in immunodeficient mice. In immunocompetent mice, liposomal l-OHP increased the tumor MHC-1 level and preserved antitumor immunity through decreasing the number of immune suppressor cells, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, which collectively suppress CD8(+) T cell-mediated tumor cells killing. In contrast, free l-OHP ruined antitumor immunity. These results suggest that the antitumor efficacy of liposomal l-OHP is attributed, on the one hand, to its immunomodulatory effect on tumor immune microenvironment that is superior to that of free l-OHP, and on the other hand, to its direct cytotoxic effect on tumor cells."},"publication_date":"2017-07-14","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"Vol.108","number":"No.9","starting_page":"1864","ending_page":"1869","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/cas.13305"],"issn":["1349-7006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:73, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512942"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28411626","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85017155399&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324410","label":"url"}],"paper_title":{"en":"Quantitative determination of polysulfide in albumins, plasma proteins and biological fluid samples using a novel combined assays approach","ja":"Quantitative determination of polysulfide in albumins, plasma proteins and biological fluid samples using a novel combined assays approach"},"authors":{"en":[{"name":"Ikeda, Mayumi"},{"name":"Ishima Yu"},{"name":"Shibata, Akitomo"},{"name":"Chuang T.G. Victor"},{"name":"Sawa, Tomohiro"},{"name":"Ihara, Hideshi"},{"name":"Watanabe, Hiroshi"},{"name":"Xian, Ming"},{"name":"Ouchi, Yuya"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ukawa Masami"},{"name":"Ishida Tatsuhiro"},{"name":"Akaike, T"},{"name":"Otagiri, M"},{"name":"Maruyama, T"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"Shibata, Akitomo"},{"name":"Chuang T.G. Victor"},{"name":"Sawa, Tomohiro"},{"name":"Ihara, Hideshi"},{"name":"Watanabe, Hiroshi"},{"name":"Xian, Ming"},{"name":"Ouchi, Yuya"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"鵜川 真実"},{"name":"石田 竜弘"},{"name":"Akaike, T"},{"name":"Otagiri, M"},{"name":"Maruyama, T"}]},"description":{"en":"Hydrogen sulfide (H2S) signaling involves polysulfide (RSSnSR') formation on various proteins. However, the current lack of sensitive polysulfide detection assays poses methodological challenges for understanding sulfane sulfur homeostasis and signaling. We developed a novel combined assay by modifying Sulfide Antioxidant Buffer (SAOB) to produce an \"Elimination Method of Sulfide from Polysulfide\" (EMSP) treatment solution that liberates sulfide, followed with methylene blue (MB) sulfide detection assay. The combined EMSP-MB sulfide detection assay performed on low molecular weight sulfur species showed that sulfide was produced from trisulfide compounds such as glutathione trisulfide and diallyl trisulfide, but not from the thiol compounds such as cysteine, cystine and glutathione. In the case of plasma proteins, this novel combined detection assay revealed that approximately 14.7, 1.7, 3.9, 3.7 sulfide mol/mol released from human serum albumin, 1-anti-trypsin, 1-acid glycoprotein and ovalbumin, respectively, suggesting that serum albumin is a major pool of polysulfide in human blood circulation. Taken together with the results of albumins of different species, the liberated sulfide has a good correlation with cysteine instead of methionine, indicating the site of incorporation of polysulfide is cysteine. With this novel sulfide detention assay, approximately 8,000, 120 and 1100 M of polysulfide concentrations was quantitated in human healthy plasma, saliva and tear, respectively. Our promising polysulfide specific detection assay can be a very important tool because quantitative determination of polysulfide sheds light on the functional consequence of protein-bound cysteine polysulfide and expands the research area of reactive oxygen to reactive polysulfide species.","ja":"Hydrogen sulfide (H2S) signaling involves polysulfide (RSSnSR') formation on various proteins. However, the current lack of sensitive polysulfide detection assays poses methodological challenges for understanding sulfane sulfur homeostasis and signaling. We developed a novel combined assay by modifying Sulfide Antioxidant Buffer (SAOB) to produce an \"Elimination Method of Sulfide from Polysulfide\" (EMSP) treatment solution that liberates sulfide, followed with methylene blue (MB) sulfide detection assay. The combined EMSP-MB sulfide detection assay performed on low molecular weight sulfur species showed that sulfide was produced from trisulfide compounds such as glutathione trisulfide and diallyl trisulfide, but not from the thiol compounds such as cysteine, cystine and glutathione. In the case of plasma proteins, this novel combined detection assay revealed that approximately 14.7, 1.7, 3.9, 3.7 sulfide mol/mol released from human serum albumin, 1-anti-trypsin, 1-acid glycoprotein and ovalbumin, respectively, suggesting that serum albumin is a major pool of polysulfide in human blood circulation. Taken together with the results of albumins of different species, the liberated sulfide has a good correlation with cysteine instead of methionine, indicating the site of incorporation of polysulfide is cysteine. With this novel sulfide detention assay, approximately 8,000, 120 and 1100 M of polysulfide concentrations was quantitated in human healthy plasma, saliva and tear, respectively. Our promising polysulfide specific detection assay can be a very important tool because quantitative determination of polysulfide sheds light on the functional consequence of protein-bound cysteine polysulfide and expands the research area of reactive oxygen to reactive polysulfide species."},"publication_date":"2017-05-29","publication_name":{"en":"Analytica Chimica Acta","ja":"Analytica Chimica Acta"},"volume":"Vol.969","starting_page":"18","ending_page":"25","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.aca.2017.03.027"],"issn":["1873-4324"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:74, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512943"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27988213","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85008450574&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325115","label":"url"}],"paper_title":{"en":"Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism","ja":"Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism"},"authors":{"en":[{"name":"Sugimoto Ryusei"},{"name":"Watanabe Hiroshi"},{"name":"Ikegami Komei"},{"name":"Enoki Yuki"},{"name":"Imafuku Tadashi"},{"name":"Sakaguchi Yoshiaki"},{"name":"Murata Michiya"},{"name":"Nishida Kento"},{"name":"Miyamura Shigeyuki"},{"name":"Ishima Yu"},{"name":"Tanaka Motoko"},{"name":"Matsushita Kazutaka"},{"name":"Komaba Hirotaka"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"Sugimoto Ryusei"},{"name":"Watanabe Hiroshi"},{"name":"Ikegami Komei"},{"name":"Enoki Yuki"},{"name":"Imafuku Tadashi"},{"name":"Sakaguchi Yoshiaki"},{"name":"Murata Michiya"},{"name":"Nishida Kento"},{"name":"Miyamura Shigeyuki"},{"name":"異島 優"},{"name":"Tanaka Motoko"},{"name":"Matsushita Kazutaka"},{"name":"Komaba Hirotaka"},{"name":"Fukagawa Masafumi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"description":{"en":"Hyperuricemia occurs with increasing frequency among patients with hyperparathyroidism. However, the molecular mechanism by which the serum parathyroid hormone (PTH) affects serum urate levels remains unknown. This was studied in uremic rats with secondary hyperparathyroidism where serum urate levels were found to be increased and urate excretion in the intestine and kidney decreased, presumably due to down-regulation of the expression of the urate exporter ABCG2 in intestinal and renal epithelial membranes. These effects were prevented by administration of the calcimimetic cinacalcet, a PTH suppressor, suggesting that PTH may down-regulate ABCG2 expression. This was directly tested in intestinal Caco-2 cells where the expression of ABCG2 on the plasma membrane was down-regulated by PTH (1-34) while its mRNA level remained unchanged. Interestingly, an inactive PTH derivative (13-34) had no effect, suggesting that a posttranscriptional regulatory system acts through the PTH receptor to regulate ABCG2 plasma membrane expression. As found in an animal study, additional clinical investigations showed that treatment with cinacalcet resulted in significant reductions in serum urate levels together with decreases in PTH levels in patients with secondary hyperparathyroidism undergoing dialysis. Thus, PTH down-regulates ABCG2 expression on the plasma membrane to suppress intestinal and renal urate excretion, and the effects of PTH can be prevented by cinacalcet treatment.","ja":"Hyperuricemia occurs with increasing frequency among patients with hyperparathyroidism. However, the molecular mechanism by which the serum parathyroid hormone (PTH) affects serum urate levels remains unknown. This was studied in uremic rats with secondary hyperparathyroidism where serum urate levels were found to be increased and urate excretion in the intestine and kidney decreased, presumably due to down-regulation of the expression of the urate exporter ABCG2 in intestinal and renal epithelial membranes. These effects were prevented by administration of the calcimimetic cinacalcet, a PTH suppressor, suggesting that PTH may down-regulate ABCG2 expression. This was directly tested in intestinal Caco-2 cells where the expression of ABCG2 on the plasma membrane was down-regulated by PTH (1-34) while its mRNA level remained unchanged. Interestingly, an inactive PTH derivative (13-34) had no effect, suggesting that a posttranscriptional regulatory system acts through the PTH receptor to regulate ABCG2 plasma membrane expression. As found in an animal study, additional clinical investigations showed that treatment with cinacalcet resulted in significant reductions in serum urate levels together with decreases in PTH levels in patients with secondary hyperparathyroidism undergoing dialysis. Thus, PTH down-regulates ABCG2 expression on the plasma membrane to suppress intestinal and renal urate excretion, and the effects of PTH can be prevented by cinacalcet treatment."},"publication_date":"2017-03","publication_name":{"en":"Kidney International","ja":"Kidney International"},"volume":"Vol.91","number":"No.3","starting_page":"658","ending_page":"670","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.kint.2016.09.041"],"issn":["0085-2538"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:75, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512944"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28154250","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85011265928&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325114","label":"url"}],"paper_title":{"en":"Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers","ja":"Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers"},"authors":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"description":{"en":"Biomacromolecules (>40 kDa) have been developed as drug delivery system (DDS) carriers of low-molecular weight drugs to promote these drugs' uptake by cancer tissues via enhanced permeability and retention (EPR) effects. Human serum albumin (HSA) has been found to accumulate in cancer tissues via this EPR effect. HSA is the most abundant protein in serum, which performs essential physiological functions such as the transportation of many endogenous and exogenous ligands. Nitric oxide (NO) is a very small ligand of HSA; it is a unique and diffusible molecular messenger that plays a central role in mammalian physiology. Although the in vivo half-life of NO is extremely short, HSA could prolong the half-life of NO via S-nitrosation at the position of Cys-34. S-Nitrosated HSA (mono-SNO-HSA) is called an 'Endogenous NO traffic protein,' due to the highly stable S-nitroso form in circulating blood, and to the efficiency of S-transnitrosation in cells that require NO. Mono-SNO-HSA possesses a very strong cytoprotective action via the induction of heme oxygenase-1. On the other hand, HSA reinforced with approximately seven NO molecules (poly-SNO-HSA), which we developed by means of chemical modification, possesses multiple anticancer activities. Our previous data clarified that the high expression of protein disulfide isomerase on the surface of cancer cells plays a very important role in the anticancer action of poly-SNO-HSA. In this review, we focus on the advantage of poly-SNO-HSA in treating intractable cancers from the viewpoint of drug delivery systems and drug resistance.","ja":"Biomacromolecules (>40 kDa) have been developed as drug delivery system (DDS) carriers of low-molecular weight drugs to promote these drugs' uptake by cancer tissues via enhanced permeability and retention (EPR) effects. Human serum albumin (HSA) has been found to accumulate in cancer tissues via this EPR effect. HSA is the most abundant protein in serum, which performs essential physiological functions such as the transportation of many endogenous and exogenous ligands. Nitric oxide (NO) is a very small ligand of HSA; it is a unique and diffusible molecular messenger that plays a central role in mammalian physiology. Although the in vivo half-life of NO is extremely short, HSA could prolong the half-life of NO via S-nitrosation at the position of Cys-34. S-Nitrosated HSA (mono-SNO-HSA) is called an 'Endogenous NO traffic protein,' due to the highly stable S-nitroso form in circulating blood, and to the efficiency of S-transnitrosation in cells that require NO. Mono-SNO-HSA possesses a very strong cytoprotective action via the induction of heme oxygenase-1. On the other hand, HSA reinforced with approximately seven NO molecules (poly-SNO-HSA), which we developed by means of chemical modification, possesses multiple anticancer activities. Our previous data clarified that the high expression of protein disulfide isomerase on the surface of cancer cells plays a very important role in the anticancer action of poly-SNO-HSA. In this review, we focus on the advantage of poly-SNO-HSA in treating intractable cancers from the viewpoint of drug delivery systems and drug resistance."},"publication_date":"2017-02-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.40","number":"No.2","starting_page":"128","ending_page":"134","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b16-00867"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:76, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512945"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27666483","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84989831563&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325118","label":"url"}],"paper_title":{"en":"Human serum albumin hydropersulfide is a potent reactive oxygen species scavenger in oxidative stress conditions such as chronic kidney disease","ja":"Human serum albumin hydropersulfide is a potent reactive oxygen species scavenger in oxidative stress conditions such as chronic kidney disease"},"authors":{"en":[{"name":"Shibata Akitomo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"Sato Hirokazu"},{"name":"Imafuku Tadashi"},{"name":"Chuang T. G. Victor"},{"name":"Ouchi Yuya"},{"name":"Abe Takaya"},{"name":"Watanabe Hiroshi"},{"name":"Ishida Tatsuhiro"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"Shibata Akitomo"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"Sato Hirokazu"},{"name":"Imafuku Tadashi"},{"name":"Chuang T. G. Victor"},{"name":"Ouchi Yuya"},{"name":"Abe Takaya"},{"name":"Watanabe Hiroshi"},{"name":"石田 竜弘"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"description":{"en":"Recently, hydropersulfide (RSSH) was found to exist in mammalian tissues and fluids. Cysteine hydropersulfide can be found in free cysteine residues as well as in proteins, and it has potent antioxidative activity. Human serum albumin (HSA) is the most abundant protein in mammalian serum. HSA possesses a free thiol group in Cys-34 that could be a site for hydropersulfide formation. HSA hydropersulfide of high purity as a positive control was prepared by treatment of HSA with Na2S. The presence of HSA hydropersulfide was confirmed by spectroscopy and ESI-TOFMS analysis where molecular weights of HSA hydropersulfide by increments of approximately 32 Da (Sulfur atom) were detected. The fluorescent probe results showed that Alexa Fluor 680 conjugated maleimide (Red-Mal) was a suitable assay and bromotrimethylammoniumbimane bromide appeared to be a selective reagent for hydropersulfide. The effect of oxidative stress related disease on the existence of albumin hydropersulfides was examined in rat 5/6 nephrectomy model of chronic kidney disease (CKD). Interestingly, the level of hydropersulfides in rat 5/6 nephrectomy model serum was decreased by a uremic toxin that increases oxidative stress in rat 5/6 nephrectomy model. Furthermore, we demonstrated that the levels of HSA hydropersulfide in human subjects were reduced in CKD but restored by hemodialysis using Red-Mal assay. We conclude that HSA hydropersulfide could potentially play an important role in biological anti-oxidative defense, and it is a promising diagnostic and therapeutic marker of oxidative diseases.","ja":"Recently, hydropersulfide (RSSH) was found to exist in mammalian tissues and fluids. Cysteine hydropersulfide can be found in free cysteine residues as well as in proteins, and it has potent antioxidative activity. Human serum albumin (HSA) is the most abundant protein in mammalian serum. HSA possesses a free thiol group in Cys-34 that could be a site for hydropersulfide formation. HSA hydropersulfide of high purity as a positive control was prepared by treatment of HSA with Na2S. The presence of HSA hydropersulfide was confirmed by spectroscopy and ESI-TOFMS analysis where molecular weights of HSA hydropersulfide by increments of approximately 32 Da (Sulfur atom) were detected. The fluorescent probe results showed that Alexa Fluor 680 conjugated maleimide (Red-Mal) was a suitable assay and bromotrimethylammoniumbimane bromide appeared to be a selective reagent for hydropersulfide. The effect of oxidative stress related disease on the existence of albumin hydropersulfides was examined in rat 5/6 nephrectomy model of chronic kidney disease (CKD). Interestingly, the level of hydropersulfides in rat 5/6 nephrectomy model serum was decreased by a uremic toxin that increases oxidative stress in rat 5/6 nephrectomy model. Furthermore, we demonstrated that the levels of HSA hydropersulfide in human subjects were reduced in CKD but restored by hemodialysis using Red-Mal assay. We conclude that HSA hydropersulfide could potentially play an important role in biological anti-oxidative defense, and it is a promising diagnostic and therapeutic marker of oxidative diseases."},"publication_date":"2016-10-21","publication_name":{"en":"Biochemical and Biophysical Research Communications","ja":"Biochemical and Biophysical Research Communications"},"volume":"Vol.479","number":"No.3","starting_page":"578","ending_page":"583","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bbrc.2016.09.113"],"issn":["0006-291X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:77, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512946"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26777880","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84963977250&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325120","label":"url"}],"paper_title":{"en":"Mutants and molecular dockings reveal that the primary L-thyroxine binding site in human serum albumin is not the one which can cause familial dysalbuminemic hyperthyroxinemia","ja":"Mutants and molecular dockings reveal that the primary L-thyroxine binding site in human serum albumin is not the one which can cause familial dysalbuminemic hyperthyroxinemia"},"authors":{"en":[{"name":"Kragh-Hansen U"},{"name":"Minchiotti L"},{"name":"Coletta A"},{"name":"Bienk K"},{"name":"Galliano M"},{"name":"Schiøtt B"},{"name":"Iwao Y"},{"name":"Ishima Yu"},{"name":"Otagiri M"}],"ja":[{"name":"Kragh-Hansen U"},{"name":"Minchiotti L"},{"name":"Coletta A"},{"name":"Bienk K"},{"name":"Galliano M"},{"name":"Schiøtt B"},{"name":"Iwao Y"},{"name":"異島 優"},{"name":"Otagiri M"}]},"description":{"en":"Natural mutations of R218 in human serum albumin (HSA) result in an increased affinity for L-thyroxine and lead to the autosomal dominant condition of familial dysalbuminemic hyperthyroxinemia. Binding was studied by equilibrium dialysis and computer modeling. Ten of 32 other isoforms tested had modified high-affinity hormone binding. L-thyroxine has been reported to bind to four sites (Tr) in HSA; Tr1 and Tr4 are placed in the N-terminal and C-terminal part of the protein, respectively. Site-directed mutagenesis gave new information about all the sites. It is widely assumed that Tr1 is the primary hormone site, and that this site, on a modified form, is responsible for the above syndrome, but the binding experiments with the genetic variants and displacement studies with marker ligands indicated that the primary site is Tr4. This new assignment of the high-affinity site was strongly supported by results of MM-PBSA analyses and by molecular docking performed on relaxed protein structure. However, dockings also revealed that mutating R218 for a smaller amino acid increases the affinity of Tr1 to such an extent that it can become the high-affinity site. Placing the high-affinity binding site (Tr4) and the one which can result in familial dysalbuminemic hyperthyroxinemia (Tr1) in two very different parts of HSA is not trivial, because in this way persons with and without the syndrome can have different types of interactions, and thereby complications, when given albumin-bound drugs. The molecular information is also useful when designing drugs based on L-thyroxine analogues.","ja":"Natural mutations of R218 in human serum albumin (HSA) result in an increased affinity for L-thyroxine and lead to the autosomal dominant condition of familial dysalbuminemic hyperthyroxinemia. Binding was studied by equilibrium dialysis and computer modeling. Ten of 32 other isoforms tested had modified high-affinity hormone binding. L-thyroxine has been reported to bind to four sites (Tr) in HSA; Tr1 and Tr4 are placed in the N-terminal and C-terminal part of the protein, respectively. Site-directed mutagenesis gave new information about all the sites. It is widely assumed that Tr1 is the primary hormone site, and that this site, on a modified form, is responsible for the above syndrome, but the binding experiments with the genetic variants and displacement studies with marker ligands indicated that the primary site is Tr4. This new assignment of the high-affinity site was strongly supported by results of MM-PBSA analyses and by molecular docking performed on relaxed protein structure. However, dockings also revealed that mutating R218 for a smaller amino acid increases the affinity of Tr1 to such an extent that it can become the high-affinity site. Placing the high-affinity binding site (Tr4) and the one which can result in familial dysalbuminemic hyperthyroxinemia (Tr1) in two very different parts of HSA is not trivial, because in this way persons with and without the syndrome can have different types of interactions, and thereby complications, when given albumin-bound drugs. The molecular information is also useful when designing drugs based on L-thyroxine analogues."},"publication_date":"2016-04","publication_name":{"en":"Biochimica et Biophysica Acta (BBA) - General Subjects","ja":"Biochimica et Biophysica Acta (BBA) - General Subjects"},"volume":"Vol.1860","number":"No.4","starting_page":"648","ending_page":"660","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bbagen.2016.01.001"],"issn":["0304-4165"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:78, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512947"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26928399","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84964453424&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325119","label":"url"}],"paper_title":{"en":"Comparison of Posttranslational Modification and the Functional Impairment of Human Serum Albumin in Commercial Preparations","ja":"Comparison of Posttranslational Modification and the Functional Impairment of Human Serum Albumin in Commercial Preparations"},"authors":{"en":[{"name":"Miyamura S"},{"name":"Imafuku T"},{"name":"Anraku M"},{"name":"Taguchi K"},{"name":"Yamasaki K"},{"name":"Tominaga Y"},{"name":"Maeda H"},{"name":"Ishima Yu"},{"name":"Watanabe H"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Miyamura S"},{"name":"Imafuku T"},{"name":"Anraku M"},{"name":"Taguchi K"},{"name":"Yamasaki K"},{"name":"Tominaga Y"},{"name":"Maeda H"},{"name":"異島 優"},{"name":"Watanabe H"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"On account of its long circulating half-life, human serum albumin (HSA) is susceptible to posttranslational modifications that can alter its functions. Here, we comprehensively compared the degree of posttranslational modifications with the functional impairment of HSA derived from 5 different commercially available albumin preparations and clarified their relationships. We used electrospray ionization-time of flight mass spectrometry to evaluate the degree of posttranslational modification of the entire HSA molecule that was associated with disease development and found that the fraction of Cys34-cysteinylated HSA (Cys-Cys34-HSA), a major form of oxidative modification, varied substantially among the albumin preparations. Meanwhile, no remarkable difference was found in the degree of glycated or N-terminal truncated HSA among the preparations tested. The nonosmotic pressure maintenance functions of HSA, such as its antioxidative and ligand-binding activities significantly differed among the preparations. Interestingly, the alternations of these functions showed a significantly negative correlation only with the Cys-Cys34-HSA fraction. These findings suggest that the Cys-Cys34-HSA fraction, as estimated by electrospray ionization-time of flight mass spectrometry can be used as a predictive marker for the functional impairment of albumin preparations and that it would be preferable to use albumin preparations with higher contents of functionally effective albumin that correspond to a lower degree of cysteinylation of Cys34 in clinical practice.","ja":"On account of its long circulating half-life, human serum albumin (HSA) is susceptible to posttranslational modifications that can alter its functions. Here, we comprehensively compared the degree of posttranslational modifications with the functional impairment of HSA derived from 5 different commercially available albumin preparations and clarified their relationships. We used electrospray ionization-time of flight mass spectrometry to evaluate the degree of posttranslational modification of the entire HSA molecule that was associated with disease development and found that the fraction of Cys34-cysteinylated HSA (Cys-Cys34-HSA), a major form of oxidative modification, varied substantially among the albumin preparations. Meanwhile, no remarkable difference was found in the degree of glycated or N-terminal truncated HSA among the preparations tested. The nonosmotic pressure maintenance functions of HSA, such as its antioxidative and ligand-binding activities significantly differed among the preparations. Interestingly, the alternations of these functions showed a significantly negative correlation only with the Cys-Cys34-HSA fraction. These findings suggest that the Cys-Cys34-HSA fraction, as estimated by electrospray ionization-time of flight mass spectrometry can be used as a predictive marker for the functional impairment of albumin preparations and that it would be preferable to use albumin preparations with higher contents of functionally effective albumin that correspond to a lower degree of cysteinylation of Cys34 in clinical practice."},"publication_date":"2016-03","publication_name":{"en":"Journal of Pharmaceutical Sciences","ja":"Journal of Pharmaceutical Sciences"},"volume":"Vol.105","number":"No.3","starting_page":"1043","ending_page":"1049","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.xphs.2015.12.015"],"issn":["1520-6017"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:79, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512948"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26725666","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325121","label":"url"}],"paper_title":{"en":"Human Serum Albumin as Carrier in Drug Delivery Systems","ja":"Human Serum Albumin as Carrier in Drug Delivery Systems"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"Maruyama T"}]},"description":{"en":"Recently, human serum albumin (HSA) has emerged as a versatile carrier for therapeutic agents against diabetes, cancer, and infectious diseases. Market-approved products include fatty acid derivatives of human insulin for diabetes and the paclitaxel-HSA nanoparticle for various cancers such as metastatic breast cancer and advanced pancreatic cancer. In this review, we focus on the next-generation approach including HSA-binding bioactive gas such as nitric oxide (NO) for treating ischemic/reperfusion injury, cancer, and bacterial infection. To date, pharmacologically active compounds that release NO within the body, such as organic nitrates, have been used as therapeutic agents, but their efficacy is significantly limited by unwanted side effects. Therefore, novel NO donors with better pharmacological and pharmacokinetic properties are highly desirable. The S-nitrosothiol fraction in plasma is largely composed of endogenous S-nitrosated HSA (SNO-HSA), which is why we are investigating whether this albumin form can be therapeutically useful. Recently, we have developed SNO-HSA analogues such as SNO-HSA with many conjugated SNO groups (poly-SNO-HSA) prepared using chemical modification. Unexpectedly, we found striking inverse effects between poly-SNO-HSA and SNO-HSA. Despite the fact that SNO-HSA inhibits apoptosis, poly-SNO-HSA possesses very strong pro-apoptotic effects against tumor cells. Furthermore, poly-SNO-HSA can reduce or even completely eliminate the multidrug resistance often developed by cancer cells. In this review, we put forward the possibility that poly-SNO-HSA can be used as a safe, effective multifunctional antitumor agent.","ja":"Recently, human serum albumin (HSA) has emerged as a versatile carrier for therapeutic agents against diabetes, cancer, and infectious diseases. Market-approved products include fatty acid derivatives of human insulin for diabetes and the paclitaxel-HSA nanoparticle for various cancers such as metastatic breast cancer and advanced pancreatic cancer. In this review, we focus on the next-generation approach including HSA-binding bioactive gas such as nitric oxide (NO) for treating ischemic/reperfusion injury, cancer, and bacterial infection. To date, pharmacologically active compounds that release NO within the body, such as organic nitrates, have been used as therapeutic agents, but their efficacy is significantly limited by unwanted side effects. Therefore, novel NO donors with better pharmacological and pharmacokinetic properties are highly desirable. The S-nitrosothiol fraction in plasma is largely composed of endogenous S-nitrosated HSA (SNO-HSA), which is why we are investigating whether this albumin form can be therapeutically useful. Recently, we have developed SNO-HSA analogues such as SNO-HSA with many conjugated SNO groups (poly-SNO-HSA) prepared using chemical modification. Unexpectedly, we found striking inverse effects between poly-SNO-HSA and SNO-HSA. Despite the fact that SNO-HSA inhibits apoptosis, poly-SNO-HSA possesses very strong pro-apoptotic effects against tumor cells. Furthermore, poly-SNO-HSA can reduce or even completely eliminate the multidrug resistance often developed by cancer cells. In this review, we put forward the possibility that poly-SNO-HSA can be used as a safe, effective multifunctional antitumor agent."},"publication_date":"2016-01-01","publication_name":{"en":"Journal of the Pharmaceutical Society of Japan","ja":"Journal of the Pharmaceutical Society of Japan"},"volume":"Vol.136","number":"No.1","starting_page":"39","ending_page":"47","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/yakushi.15-00227-1"],"issn":["1347-5231"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:80, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512949"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26302904","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325123","label":"url"}],"paper_title":{"en":"S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes","ja":"S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Ikeda Mayumi"},{"name":"Kragh-Hansen U"},{"name":"Fang J"},{"name":"Nakamura H"},{"name":"Chuang VT"},{"name":"Tanaka R"},{"name":"Maeda H"},{"name":"Kodama A"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"Kragh-Hansen U"},{"name":"Fang J"},{"name":"Nakamura H"},{"name":"Chuang VT"},{"name":"Tanaka R"},{"name":"Maeda H"},{"name":"Kodama A"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"The enhanced permeability and retention (EPR) effect is a unique phenomenon of solid tumors, and it can serve as a basis for the development of macromolecular anticancer therapy. We have previously found that recombinant human serum albumin dimer, and especially its S-nitrosated form (SNO-HSA-Dimer), is an enhancer of the EPR effect. In this study, we investigated the influence of SNO-HSA-Dimer on the anti-tumor effect of two types of macromolecular anti-tumor drugs, namely N-(2-hydroxypropyl)methacrylamide polymer conjugated with zinc protoporphyrin, which forms micelles and can be used for fluorescence studies. The other was PEGylated liposomal doxorubicin (Doxil), a typical example of a stealth liposome approved for medical usage. In mice having C26 tumors with highly permeable vasculature, SNO-HSA-Dimer increases tumor accumulation of the drugs by a factor 3-4 and thereby their anti-tumor effects. Experiments with Evans blue revealed increased EPR effect in all parts of the tumor. Furthermore, SNO-HSA-Dimer improves the anti-metastatic effects of Doxil and reduces its minor uptake in non-tumorous organs such as liver and kidney. Tumor accumulation of Doxil in B16 tumors, which are characterized by a low permeable vasculature, increased even more (6-fold) in the presence of SNO-HSA-Dimer, and the improved accumulation lead to decreased tumor volume and increased survival of the animals. The administration of SNO-HSA-Dimer itself is safe, because it has no effect on blood pressure, heart rate or on several biochemical parameters. The present findings indicate that SNO-HSA-Dimer is promising for enhancing the EPR effect and consequently the specific, therapeutic effects of macromolecular anticancer drugs.","ja":"The enhanced permeability and retention (EPR) effect is a unique phenomenon of solid tumors, and it can serve as a basis for the development of macromolecular anticancer therapy. We have previously found that recombinant human serum albumin dimer, and especially its S-nitrosated form (SNO-HSA-Dimer), is an enhancer of the EPR effect. In this study, we investigated the influence of SNO-HSA-Dimer on the anti-tumor effect of two types of macromolecular anti-tumor drugs, namely N-(2-hydroxypropyl)methacrylamide polymer conjugated with zinc protoporphyrin, which forms micelles and can be used for fluorescence studies. The other was PEGylated liposomal doxorubicin (Doxil), a typical example of a stealth liposome approved for medical usage. In mice having C26 tumors with highly permeable vasculature, SNO-HSA-Dimer increases tumor accumulation of the drugs by a factor 3-4 and thereby their anti-tumor effects. Experiments with Evans blue revealed increased EPR effect in all parts of the tumor. Furthermore, SNO-HSA-Dimer improves the anti-metastatic effects of Doxil and reduces its minor uptake in non-tumorous organs such as liver and kidney. Tumor accumulation of Doxil in B16 tumors, which are characterized by a low permeable vasculature, increased even more (6-fold) in the presence of SNO-HSA-Dimer, and the improved accumulation lead to decreased tumor volume and increased survival of the animals. The administration of SNO-HSA-Dimer itself is safe, because it has no effect on blood pressure, heart rate or on several biochemical parameters. The present findings indicate that SNO-HSA-Dimer is promising for enhancing the EPR effect and consequently the specific, therapeutic effects of macromolecular anticancer drugs."},"publication_date":"2015-11-10","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.217","starting_page":"1","ending_page":"9","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2015.08.036"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:81, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512950"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26232728","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325125","label":"url"}],"paper_title":{"en":"Kupffer cell inactivation by carbon monoxide bound to red blood cells preserves hepatic cytochrome P450 via anti-oxidant and anti-inflammatory effects exerted through the HMGB1/TLR-4 pathway during resuscitation from hemorrhagic shock","ja":"Kupffer cell inactivation by carbon monoxide bound to red blood cells preserves hepatic cytochrome P450 via anti-oxidant and anti-inflammatory effects exerted through the HMGB1/TLR-4 pathway during resuscitation from hemorrhagic shock"},"authors":{"en":[{"name":"Ogaki S"},{"name":"Taguchi K"},{"name":"Maeda H"},{"name":"Watanabe H"},{"name":"Ishima Yu"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Ogaki S"},{"name":"Taguchi K"},{"name":"Maeda H"},{"name":"Watanabe H"},{"name":"異島 優"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Red blood cell (RBC) transfusions for controlling hemorrhaging induce systemic ischemia reperfusion, resulting in a decrease in hepatic cytochrome P450 (CYP) levels. Carbon monoxide (CO), when bound to red blood cells (CO-RBC) has the potential to protect the hepatic CYP protein to produce a resuscitative effect in a hemorrhagic shock rat model. The aim of this study was to investigate the mechanism by which CO-RBC resuscitation from a massive hemorrhage protects against a decrease in hepatic CYP. In the early phase (∼1h) after a hemorrhage and RBC resuscitation, hepatic CYP protein levels were significantly decreased with increasing hepatic free heme levels, but were maintained by a pre-treatment of gadolinium chloride (GdCl3), a Kupffer cell inhibitor, and Trolox, an anti-oxidant agent, as well as CO-RBC resuscitation. Under these conditions, the production of reactive oxygen species (ROS) derived from activated Kupffer cells was increased, but this increase was suppressed by CO-RBC resuscitation. At a late phase (6∼24h), CYP mRNA levels decreased after hemorrhage and RBC resuscitation, but not in the case of CO-RBC resuscitation. The increases in plasma IL-6 and TNF-α levels were decreased by CO-RBC resuscitation via the suppression of the toll-like receptor-4 (TLR-4) and the expression of the high mobility group box-1 (HMGB-1). Hepatic CYP protection after a hemorrhage and CO-RBC resuscitation can be attributed to the inactivation of Kupffer cells, resulting in the suppression of ROS production in the early phase and the suppression of inflammatory cytokine production via the TLR-4/HMGB-1signal pathway in the late phase.","ja":"Red blood cell (RBC) transfusions for controlling hemorrhaging induce systemic ischemia reperfusion, resulting in a decrease in hepatic cytochrome P450 (CYP) levels. Carbon monoxide (CO), when bound to red blood cells (CO-RBC) has the potential to protect the hepatic CYP protein to produce a resuscitative effect in a hemorrhagic shock rat model. The aim of this study was to investigate the mechanism by which CO-RBC resuscitation from a massive hemorrhage protects against a decrease in hepatic CYP. In the early phase (∼1h) after a hemorrhage and RBC resuscitation, hepatic CYP protein levels were significantly decreased with increasing hepatic free heme levels, but were maintained by a pre-treatment of gadolinium chloride (GdCl3), a Kupffer cell inhibitor, and Trolox, an anti-oxidant agent, as well as CO-RBC resuscitation. Under these conditions, the production of reactive oxygen species (ROS) derived from activated Kupffer cells was increased, but this increase was suppressed by CO-RBC resuscitation. At a late phase (6∼24h), CYP mRNA levels decreased after hemorrhage and RBC resuscitation, but not in the case of CO-RBC resuscitation. The increases in plasma IL-6 and TNF-α levels were decreased by CO-RBC resuscitation via the suppression of the toll-like receptor-4 (TLR-4) and the expression of the high mobility group box-1 (HMGB-1). Hepatic CYP protection after a hemorrhage and CO-RBC resuscitation can be attributed to the inactivation of Kupffer cells, resulting in the suppression of ROS production in the early phase and the suppression of inflammatory cytokine production via the TLR-4/HMGB-1signal pathway in the late phase."},"publication_date":"2015-10-01","publication_name":{"en":"Biochemical Pharmacology","ja":"Biochemical Pharmacology"},"volume":"Vol.97","number":"No.3","starting_page":"310","ending_page":"319","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bcp.2015.07.035"],"issn":["1873-2968"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:82, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512951"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26412311","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84942754053&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325122","label":"url"}],"paper_title":{"en":"Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury","ja":"Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury"},"authors":{"en":[{"name":"Nishida K"},{"name":"Watanabe H"},{"name":"Ogaki S"},{"name":"Kodama A"},{"name":"Tanaka R"},{"name":"Imafuku T"},{"name":"Ishima Yu"},{"name":"Chuang VT"},{"name":"Toyoda M"},{"name":"Kondoh M"},{"name":"Wu Q"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Nishida K"},{"name":"Watanabe H"},{"name":"Ogaki S"},{"name":"Kodama A"},{"name":"Tanaka R"},{"name":"Imafuku T"},{"name":"異島 優"},{"name":"Chuang VT"},{"name":"Toyoda M"},{"name":"Kondoh M"},{"name":"Wu Q"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Rhabdomyolysis-associated acute kidney injury (AKI) is a serious life-threatening condition. As such, more effective strategies are needed for its prevention. Thioredoxin-1 (Trx), a redox-active and macrophage migration inhibitory factor (MIF) modulating protein, has a short retention time in the blood. We examined the renoprotective effect of long acting Trx that was genetically fused with human serum albumin (HSA-Trx) against glycerol-induced AKI. An intravenous HSA-Trx pre-treatment attenuated the glycerol-induced decline in renal function, compared to a PBS, HSA or Trx alone. HSA-Trx caused a reduction in the tubular injuries and in the number of apoptosis-positive tubular cells. Renal superoxide, 8-hydroxy deoxyguanosine, nitrotyrosine and the plasma Cys34-cysteinylated albumin were clearly suppressed by the HSA-Trx treatment. Prior to decreasing TNF-α and IL-6, HSA-Trx suppressed an increase of plasma MIF level. In LLC-PK1 cells, HSA-Trx decreased the level of reactive oxygen species and lactate dehydrogenase release induced by myoglobin. HSA-Trx treatment resulted in a threefold increase in the survival of lethal glycerol-treated mice. The post-administration of HSA-Trx at 1 and 3 hr after glycerol injection exerted a significant renoprotective effect. These results suggest HSA-Trx has potential for use in the treatment of rhabdomyolysis-associated AKI via its extended effects of modulating oxidative stress and MIF.","ja":"Rhabdomyolysis-associated acute kidney injury (AKI) is a serious life-threatening condition. As such, more effective strategies are needed for its prevention. Thioredoxin-1 (Trx), a redox-active and macrophage migration inhibitory factor (MIF) modulating protein, has a short retention time in the blood. We examined the renoprotective effect of long acting Trx that was genetically fused with human serum albumin (HSA-Trx) against glycerol-induced AKI. An intravenous HSA-Trx pre-treatment attenuated the glycerol-induced decline in renal function, compared to a PBS, HSA or Trx alone. HSA-Trx caused a reduction in the tubular injuries and in the number of apoptosis-positive tubular cells. Renal superoxide, 8-hydroxy deoxyguanosine, nitrotyrosine and the plasma Cys34-cysteinylated albumin were clearly suppressed by the HSA-Trx treatment. Prior to decreasing TNF-α and IL-6, HSA-Trx suppressed an increase of plasma MIF level. In LLC-PK1 cells, HSA-Trx decreased the level of reactive oxygen species and lactate dehydrogenase release induced by myoglobin. HSA-Trx treatment resulted in a threefold increase in the survival of lethal glycerol-treated mice. The post-administration of HSA-Trx at 1 and 3 hr after glycerol injection exerted a significant renoprotective effect. These results suggest HSA-Trx has potential for use in the treatment of rhabdomyolysis-associated AKI via its extended effects of modulating oxidative stress and MIF."},"publication_date":"2015-09-28","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"Vol.5","starting_page":"14471","ending_page":"14471","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/srep14471"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:83, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512952"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26277392","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325124","label":"url"}],"paper_title":{"en":"Nitration of indoxyl sulfate facilitates its cytotoxicity in human renal proximal tubular cells via expression of heme oxygenase-1","ja":"Nitration of indoxyl sulfate facilitates its cytotoxicity in human renal proximal tubular cells via expression of heme oxygenase-1"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Narisoko T"},{"name":"Kragh-Hansen U"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"Narisoko T"},{"name":"Kragh-Hansen U"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Peroxynitrite, the reaction product of superoxide [Formula: see text] and nitric oxide (NO), nitrates tyrosine residues, unsaturated fatty acids, cyclic guanosine monophosphate and other phenolics. We report herein that indoxyl sulfate (IS) is also nitrated by peroxynitrite in vitro and forms 2-nitro-IS, as determined from spectral characteristics and (1)H-NMR. IS is one of the very important uremic toxins that accelerate the progression of chronic kidney disease via various mechanisms. However, cell viability experiments with human proximal tubular cells show that the cytotoxicity of 2-nitro-IS is several-fold higher than that of IS. The explanation for this finding seems to be that 2-nitro-IS induces a much more pronounced generation of intracellular reactive oxygen species (ROS) than IS. Results with inhibitors revealed that an organic anion transporter, several intracellular enzymes and nonprotein-bound iron ions are reasons for this finding. Most importantly, however, as detected by immunofluorescence and Western blotting, 2-nitro-IS induces the expression of heme oxygenase-1 and thereby the formation of ROS; most probably through the Fenton reaction. The final result of the increased amounts of ROS is death of the kidney cells. Thus, nitration of uremic toxins by peroxynitrite may help us to understand the initiation and progress of chronic kidney diseases.","ja":"Peroxynitrite, the reaction product of superoxide [Formula: see text] and nitric oxide (NO), nitrates tyrosine residues, unsaturated fatty acids, cyclic guanosine monophosphate and other phenolics. We report herein that indoxyl sulfate (IS) is also nitrated by peroxynitrite in vitro and forms 2-nitro-IS, as determined from spectral characteristics and (1)H-NMR. IS is one of the very important uremic toxins that accelerate the progression of chronic kidney disease via various mechanisms. However, cell viability experiments with human proximal tubular cells show that the cytotoxicity of 2-nitro-IS is several-fold higher than that of IS. The explanation for this finding seems to be that 2-nitro-IS induces a much more pronounced generation of intracellular reactive oxygen species (ROS) than IS. Results with inhibitors revealed that an organic anion transporter, several intracellular enzymes and nonprotein-bound iron ions are reasons for this finding. Most importantly, however, as detected by immunofluorescence and Western blotting, 2-nitro-IS induces the expression of heme oxygenase-1 and thereby the formation of ROS; most probably through the Fenton reaction. The final result of the increased amounts of ROS is death of the kidney cells. Thus, nitration of uremic toxins by peroxynitrite may help us to understand the initiation and progress of chronic kidney diseases."},"publication_date":"2015-09-25","publication_name":{"en":"Biochemical and Biophysical Research Communications","ja":"Biochemical and Biophysical Research Communications"},"volume":"Vol.465","number":"No.3","starting_page":"481","ending_page":"487","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bbrc.2015.08.043"],"issn":["1090-2104"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:84, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512953"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26086073","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84939222427&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325126","label":"url"}],"paper_title":{"en":"Pleiotropic Effects of Levofloxacin, Fluoroquinolone Antibiotics, against Influenza Virus-Induced Lung Injury","ja":"Pleiotropic Effects of Levofloxacin, Fluoroquinolone Antibiotics, against Influenza Virus-Induced Lung Injury"},"authors":{"en":[{"name":"Enoki Y"},{"name":"Ishima Yu"},{"name":"Tanaka R"},{"name":"Sato K"},{"name":"Kimachi K"},{"name":"Shirai T"},{"name":"Watanabe H"},{"name":"Chuang VT"},{"name":"Fujiwara Y"},{"name":"Takeya M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Enoki Y"},{"name":"異島 優"},{"name":"Tanaka R"},{"name":"Sato K"},{"name":"Kimachi K"},{"name":"Shirai T"},{"name":"Watanabe H"},{"name":"Chuang VT"},{"name":"Fujiwara Y"},{"name":"Takeya M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Reactive oxygen species (ROS) and nitric oxide (NO) are major pathogenic molecules produced during viral lung infections, including influenza. While fluoroquinolones are widely used as antimicrobial agents for treating a variety of bacterial infections, including secondary infections associated with the influenza virus, it has been reported that they also function as anti-oxidants against ROS and as a NO regulator. Therefore, we hypothesized that levofloxacin (LVFX), one of the most frequently used fluoroquinolone derivatives, may attenuate pulmonary injuries associated with influenza virus infections by inhibiting the production of ROS species such as hydroxyl radicals and neutrophil-derived NO that is produced during an influenza viral infection. The therapeutic impact of LVFX was examined in a PR8 (H1N1) influenza virus-induced lung injury mouse model. ESR spin-trapping experiments indicated that LVFX showed scavenging activity against neutrophil-derived hydroxyl radicals. LVFX markedly improved the survival rate of mice that were infected with the influenza virus in a dose-dependent manner. In addition, the LVFX treatment resulted in a dose-dependent decrease in the level of 8-hydroxy-2'-deoxyguanosine (a marker of oxidative stress) and nitrotyrosine (a nitrative marker) in the lungs of virus-infected mice, and the nitrite/nitrate ratio (NO metabolites) and IFN-γ in BALF. These results indicate that LVFX may be of substantial benefit in the treatment of various acute inflammatory disorders such as influenza virus-induced pneumonia, by inhibiting inflammatory cell responses and suppressing the overproduction of NO in the lungs.","ja":"Reactive oxygen species (ROS) and nitric oxide (NO) are major pathogenic molecules produced during viral lung infections, including influenza. While fluoroquinolones are widely used as antimicrobial agents for treating a variety of bacterial infections, including secondary infections associated with the influenza virus, it has been reported that they also function as anti-oxidants against ROS and as a NO regulator. Therefore, we hypothesized that levofloxacin (LVFX), one of the most frequently used fluoroquinolone derivatives, may attenuate pulmonary injuries associated with influenza virus infections by inhibiting the production of ROS species such as hydroxyl radicals and neutrophil-derived NO that is produced during an influenza viral infection. The therapeutic impact of LVFX was examined in a PR8 (H1N1) influenza virus-induced lung injury mouse model. ESR spin-trapping experiments indicated that LVFX showed scavenging activity against neutrophil-derived hydroxyl radicals. LVFX markedly improved the survival rate of mice that were infected with the influenza virus in a dose-dependent manner. In addition, the LVFX treatment resulted in a dose-dependent decrease in the level of 8-hydroxy-2'-deoxyguanosine (a marker of oxidative stress) and nitrotyrosine (a nitrative marker) in the lungs of virus-infected mice, and the nitrite/nitrate ratio (NO metabolites) and IFN-γ in BALF. These results indicate that LVFX may be of substantial benefit in the treatment of various acute inflammatory disorders such as influenza virus-induced pneumonia, by inhibiting inflammatory cell responses and suppressing the overproduction of NO in the lungs."},"publication_date":"2015-06-18","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"Vol.10","number":"No.6","starting_page":"e0130248","ending_page":"e0130248","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0130248"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:85, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512954"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25398242","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325131","label":"url"}],"paper_title":{"en":"Polythiol-Containing, Recombinant Mannosylated-Albumin Is a Superior CD68+/CD206+ Kupffer Cell-Targeted Nanoantioxidant for Treatment of Two Acute Hepatitis Models","ja":"Polythiol-Containing, Recombinant Mannosylated-Albumin Is a Superior CD68+/CD206+ Kupffer Cell-Targeted Nanoantioxidant for Treatment of Two Acute Hepatitis Models"},"authors":{"en":[{"name":"Maeda H"},{"name":"Hirata K"},{"name":"Watanabe H"},{"name":"Ishima Yu"},{"name":"Chuang VT"},{"name":"Taguchi K"},{"name":"Inatsu A"},{"name":"Kinoshita M"},{"name":"Tanaka M"},{"name":"Sasaki Y"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Maeda H"},{"name":"Hirata K"},{"name":"Watanabe H"},{"name":"異島 優"},{"name":"Chuang VT"},{"name":"Taguchi K"},{"name":"Inatsu A"},{"name":"Kinoshita M"},{"name":"Tanaka M"},{"name":"Sasaki Y"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Since reactive oxygen species (ROS) derived from Kupffer cells (KC), especially CD68(+) KC, play a key role in the induction of hepatic oxidative stress and injuries, we developed a polythiolated- and mannosylated human serum albumin (SH-Man-HSA), which functions as a novel nanoantioxidant for delivering thiol to CD68(+) KC. In vitro electron paramagnetic resonance coupled with pharmacokinetics and immunohistochemical studies showed that SH-Man-HSA possessed powerful radical-scavenging activity and rapidly and selectively delivered thiols to the liver via mannose receptor (CD206) on CD68(+) cells. SH-Man-HSA significantly improved the survival rate of concanavalin-A (Con-A)-treated mice. Moreover, SH-Man-HSA exhibited excellent hepatoprotective functions, not by decreasing tumor necrosis factor or interferon-γ production that is closely associated with Con-A-induced hepatitis, but by suppressing ROS production. Interestingly, the protective effect of SH-Man-HSA was superior to N-acetyl cysteine (NAC). This could be attributed to the difference in the inhibition of hepatic oxidative stress between the two antioxidants depending on their potential for thiol delivery to the liver. Similar results were also observed for acetaminophen (APAP)-induced hepatopathy models. Flow cytometric data further confirmed that an increase in F4/80(+)/ROS(+) cells was dramatically decreased by SH-Man-HSA. The administration of SH-Man-HSA at 4 hours following a Con-A or APAP injection also exhibited a profound hepatoprotective action against these hepatitis models, whereas this was not observed for NAC. It can be concluded therefore that SH-Man-HSA has great potential for use in a rescue therapy for hepatopathy as a nanoantioxidant because of its ability to efficiently and rapidly deliver thiols to CD68(+)/CD206(+) KC.","ja":"Since reactive oxygen species (ROS) derived from Kupffer cells (KC), especially CD68(+) KC, play a key role in the induction of hepatic oxidative stress and injuries, we developed a polythiolated- and mannosylated human serum albumin (SH-Man-HSA), which functions as a novel nanoantioxidant for delivering thiol to CD68(+) KC. In vitro electron paramagnetic resonance coupled with pharmacokinetics and immunohistochemical studies showed that SH-Man-HSA possessed powerful radical-scavenging activity and rapidly and selectively delivered thiols to the liver via mannose receptor (CD206) on CD68(+) cells. SH-Man-HSA significantly improved the survival rate of concanavalin-A (Con-A)-treated mice. Moreover, SH-Man-HSA exhibited excellent hepatoprotective functions, not by decreasing tumor necrosis factor or interferon-γ production that is closely associated with Con-A-induced hepatitis, but by suppressing ROS production. Interestingly, the protective effect of SH-Man-HSA was superior to N-acetyl cysteine (NAC). This could be attributed to the difference in the inhibition of hepatic oxidative stress between the two antioxidants depending on their potential for thiol delivery to the liver. Similar results were also observed for acetaminophen (APAP)-induced hepatopathy models. Flow cytometric data further confirmed that an increase in F4/80(+)/ROS(+) cells was dramatically decreased by SH-Man-HSA. The administration of SH-Man-HSA at 4 hours following a Con-A or APAP injection also exhibited a profound hepatoprotective action against these hepatitis models, whereas this was not observed for NAC. It can be concluded therefore that SH-Man-HSA has great potential for use in a rescue therapy for hepatopathy as a nanoantioxidant because of its ability to efficiently and rapidly deliver thiols to CD68(+)/CD206(+) KC."},"publication_date":"2015-02-01","publication_name":{"en":"The Journal of Pharmacology and Experimental Therapeutics","ja":"The Journal of Pharmacology and Experimental Therapeutics"},"volume":"Vol.352","number":"No.2","starting_page":"244","ending_page":"257","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1124/jpet.114.219493"],"issn":["1521-0103"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:86, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512955"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25457681","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325128","label":"url"}],"paper_title":{"en":"Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy via the generation of nitric oxide","ja":"Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy via the generation of nitric oxide"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Inoue A"},{"name":"Fang J"},{"name":"Kinoshita R"},{"name":"Ikeda M"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"Inoue A"},{"name":"Fang J"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"Watanabe H"},{"name":"Maeda H"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Autophagy is one of the major causes of drug resistance. For example, the angiogenesis inhibitor bevacizumab shows only transient and short-term therapeutic effects, whereas long-term therapeutic benefits are rarely observed, probably due to hypoxia-induced autophagy. Nitric oxide (NO) is an important molecule with multiple functions, and it has recently been reported to function as a regulator of autophagy. Therefore, a reasonable therapeutic strategy for overcoming drug resistance by NO would involve it being directly delivered to the tumor. Here, we investigated the inhibitory effect of NO on autophagy by using a macromolecular NO donor S-nitrosated human serum albumin (SNO-HSA) with a high degree of NO loading and tumor targeting potential. In colon 26 (C26) cells, SNO-HSA significantly suppressed hypoxia-induced autophagy by inhibiting the phosphorylation of JNK1 and the expression of its downstream molecule Beclin1. The effect of SNO-HSA was also confirmed in vivo by combining it with Bev. In C26-bearing mice, significant suppression of tumor growth as well as lung metastasis was achieved in the combination group compared to the SNO-HSA or bevacizumab alone group. Similar to the in vitro experiments, the immunostaining of tumor tissues clearly showed that SNO-HSA inhibited the autophagy of tumor cells induced by bevacizumab treatment. In addition to other known antitumor effects of SNO-HSA, that is, the induction of apoptosis and the inhibition of multidrug efflux pumps, these data may open alternate strategies for cancer chemotherapy by taking advantage of the ability of SNO-HSA to suppress autophagy-mediated drug resistance and enhance the efficacy of chemotherapy.","ja":"Autophagy is one of the major causes of drug resistance. For example, the angiogenesis inhibitor bevacizumab shows only transient and short-term therapeutic effects, whereas long-term therapeutic benefits are rarely observed, probably due to hypoxia-induced autophagy. Nitric oxide (NO) is an important molecule with multiple functions, and it has recently been reported to function as a regulator of autophagy. Therefore, a reasonable therapeutic strategy for overcoming drug resistance by NO would involve it being directly delivered to the tumor. Here, we investigated the inhibitory effect of NO on autophagy by using a macromolecular NO donor S-nitrosated human serum albumin (SNO-HSA) with a high degree of NO loading and tumor targeting potential. In colon 26 (C26) cells, SNO-HSA significantly suppressed hypoxia-induced autophagy by inhibiting the phosphorylation of JNK1 and the expression of its downstream molecule Beclin1. The effect of SNO-HSA was also confirmed in vivo by combining it with Bev. In C26-bearing mice, significant suppression of tumor growth as well as lung metastasis was achieved in the combination group compared to the SNO-HSA or bevacizumab alone group. Similar to the in vitro experiments, the immunostaining of tumor tissues clearly showed that SNO-HSA inhibited the autophagy of tumor cells induced by bevacizumab treatment. In addition to other known antitumor effects of SNO-HSA, that is, the induction of apoptosis and the inhibition of multidrug efflux pumps, these data may open alternate strategies for cancer chemotherapy by taking advantage of the ability of SNO-HSA to suppress autophagy-mediated drug resistance and enhance the efficacy of chemotherapy."},"publication_date":"2015-02","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"Vol.106","number":"No.2","starting_page":"194","ending_page":"200","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/cas.12577"],"issn":["1349-7006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:87, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512956"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25692011","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325127","label":"url"}],"paper_title":{"en":"p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress","ja":"p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress"},"authors":{"en":[{"name":"Watanabe H"},{"name":"Miyamoto Y"},{"name":"Enoki Y"},{"name":"Ishima Yu"},{"name":"Kadowaki D"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Tanaka M"},{"name":"Matsushita K"},{"name":"Mori Y"},{"name":"Kakuta T"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Watanabe H"},{"name":"Miyamoto Y"},{"name":"Enoki Y"},{"name":"異島 優"},{"name":"Kadowaki D"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Tanaka M"},{"name":"Matsushita K"},{"name":"Mori Y"},{"name":"Kakuta T"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"The major cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease. Here, p-Cresyl sulfate (PCS), a uremic toxin, is considered to be a risk factor for cardiovascular disease in CKD. However, our understanding of the vascular toxicity induced by PCS and its mechanism is incomplete. The purpose of this study was to determine whether PCS enhances the production of reactive oxygen species (ROS) in vascular endothelial and smooth muscle cells, resulting in cytotoxicity. PCS exhibited pro-oxidant properties in human umbilical vein endothelial cells (HUVEC) and aortic smooth muscle cells (HASMC) by enhancing NADPH oxidase expression. PCS also up-regulates the mRNA levels and the protein secretion of monocyte chemotactic protein-1 (MCP-1) in HUVEC. In HASMC, PCS increased the mRNA levels of alkaline phosphatase (ALP), osteopontin (OPN), core-binding factor alpha 1, and ALP activity. The knockdown of Nox4, a subunit of NADPH oxidase, suppressed the cell toxicity induced by PCS. The vascular damage induced by PCS was largely suppressed in the presence of probenecid, an inhibitor of organic anion transporters (OAT). In PCS-overloaded 5/6-nephrectomized rats, plasma MCP-1 levels, OPN expression, and ALP activity of the aortic arch were increased, accompanied by the induction of Nox4 expression. Collectively, the vascular toxicity of PCS can be attributed to its intracellular accumulation via OAT, which results in an enhanced NADPH oxidase expression and increased ROS production. In conclusion, we found for the first time that PCS could play an important role in the development of cardiovascular disease by inducing vascular toxicity in the CKD condition.","ja":"The major cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease. Here, p-Cresyl sulfate (PCS), a uremic toxin, is considered to be a risk factor for cardiovascular disease in CKD. However, our understanding of the vascular toxicity induced by PCS and its mechanism is incomplete. The purpose of this study was to determine whether PCS enhances the production of reactive oxygen species (ROS) in vascular endothelial and smooth muscle cells, resulting in cytotoxicity. PCS exhibited pro-oxidant properties in human umbilical vein endothelial cells (HUVEC) and aortic smooth muscle cells (HASMC) by enhancing NADPH oxidase expression. PCS also up-regulates the mRNA levels and the protein secretion of monocyte chemotactic protein-1 (MCP-1) in HUVEC. In HASMC, PCS increased the mRNA levels of alkaline phosphatase (ALP), osteopontin (OPN), core-binding factor alpha 1, and ALP activity. The knockdown of Nox4, a subunit of NADPH oxidase, suppressed the cell toxicity induced by PCS. The vascular damage induced by PCS was largely suppressed in the presence of probenecid, an inhibitor of organic anion transporters (OAT). In PCS-overloaded 5/6-nephrectomized rats, plasma MCP-1 levels, OPN expression, and ALP activity of the aortic arch were increased, accompanied by the induction of Nox4 expression. Collectively, the vascular toxicity of PCS can be attributed to its intracellular accumulation via OAT, which results in an enhanced NADPH oxidase expression and increased ROS production. In conclusion, we found for the first time that PCS could play an important role in the development of cardiovascular disease by inducing vascular toxicity in the CKD condition."},"publication_date":"2015-01","publication_name":{"en":"Pharmacology Research & Perspectives","ja":"Pharmacology Research & Perspectives"},"volume":"Vol.3","number":"No.1","starting_page":"e00092","ending_page":"e00092","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/prp2.92"],"issn":["2052-1707"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:88, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512957"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25414704","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84919462731&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325130","label":"url"}],"paper_title":{"en":"Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice","ja":"Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice"},"authors":{"en":[{"name":"Tanaka R"},{"name":"Ishima Yu"},{"name":"Enoki Y"},{"name":"Kimachi K"},{"name":"Shirai T"},{"name":"Watanabe H"},{"name":"Chuang VT"},{"name":"Maruyama T"},{"name":"Otagiri M"}],"ja":[{"name":"Tanaka R"},{"name":"異島 優"},{"name":"Enoki Y"},{"name":"Kimachi K"},{"name":"Shirai T"},{"name":"Watanabe H"},{"name":"Chuang VT"},{"name":"Maruyama T"},{"name":"Otagiri M"}]},"description":{"en":"Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral lung infections. We previously reported on the use of a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) for extending the half-life Trx, an endogenous protein with anti-oxidant properties. As a result, it was possible to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypothesized that HSA-Trx would attenuate the enhanced ROS production of species such as hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of HSA-Trx. In addition, the cytoprotective effects of HSA-Trx were examined in PR8 (H1N1) influenza virus-induced lung injured mice. The findings show that HSA-Trx reduced the number of total cells, neutrophils, and total protein in BALF of influenza virus-induced lung injured mice. The HSA-Trx treatment significantly decreased the level of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu(®) treatment also significantly suppressed the production of inflammatory cells and neutrophil infiltration, as well as the protein level in BALF and lung histopathological alterations caused by the influenza virus. The suppressive effect of Tamiflu(®) was slightly stronger than that of HSA-Trx. Interestingly, Tamiflu(®) significantly decreased virus proliferation, while HSA-Trx had no effect. These results indicate that HSA-Trx may be of therapeutic value for the treatment of various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the lung.","ja":"Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral lung infections. We previously reported on the use of a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) for extending the half-life Trx, an endogenous protein with anti-oxidant properties. As a result, it was possible to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypothesized that HSA-Trx would attenuate the enhanced ROS production of species such as hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of HSA-Trx. In addition, the cytoprotective effects of HSA-Trx were examined in PR8 (H1N1) influenza virus-induced lung injured mice. The findings show that HSA-Trx reduced the number of total cells, neutrophils, and total protein in BALF of influenza virus-induced lung injured mice. The HSA-Trx treatment significantly decreased the level of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu(®) treatment also significantly suppressed the production of inflammatory cells and neutrophil infiltration, as well as the protein level in BALF and lung histopathological alterations caused by the influenza virus. The suppressive effect of Tamiflu(®) was slightly stronger than that of HSA-Trx. Interestingly, Tamiflu(®) significantly decreased virus proliferation, while HSA-Trx had no effect. These results indicate that HSA-Trx may be of therapeutic value for the treatment of various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the lung."},"publication_date":"2014-11-05","publication_name":{"en":"Frontiers in Immunology","ja":"Frontiers in Immunology"},"volume":"Vol.5","starting_page":"561","ending_page":"561","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fimmu.2014.00561"],"issn":["1664-3224"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:89, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512958"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25255196","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84928384645&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325132","label":"url"}],"paper_title":{"en":"Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia","ja":"Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia"},"authors":{"en":[{"name":"Miyazaki Y"},{"name":"Taguchi K"},{"name":"Sou K"},{"name":"Watanabe H"},{"name":"Ishima Yu"},{"name":"Miyakawa T"},{"name":"Mitsuya H"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Miyazaki Y"},{"name":"Taguchi K"},{"name":"Sou K"},{"name":"Watanabe H"},{"name":"異島 優"},{"name":"Miyakawa T"},{"name":"Mitsuya H"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Bone marrow is a key element in the diagnosis of disorders of erythropoiesis, including anemia, and a potential target in their treatment. However, because efficient delivery of diagnostic and therapeutic agents to bone marrow is difficult, such delivery is achieved by administering drugs in large quantities that often have adverse effects. Here, we achieved selective delivery of recombinant human erythropoietin (rHuEPO) to bone marrow, via its encapsulation in liposomes with l-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) (liposome-EPO). The result, in a rabbit model of renal anemia, was a beneficial effect on hematopoiesis, better than with rHuEPO alone. Also, we determined that liposome-EPO delivery to bone marrow depended on specific uptake by bone marrow macrophages because of the presence of SA. These results indicate both that liposome-EPO is a new, promising erythropoietin-stimulating agent and that liposomes with SA have potential for diagnostic and therapeutic applications in diseases originating from bone marrow.","ja":"Bone marrow is a key element in the diagnosis of disorders of erythropoiesis, including anemia, and a potential target in their treatment. However, because efficient delivery of diagnostic and therapeutic agents to bone marrow is difficult, such delivery is achieved by administering drugs in large quantities that often have adverse effects. Here, we achieved selective delivery of recombinant human erythropoietin (rHuEPO) to bone marrow, via its encapsulation in liposomes with l-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) (liposome-EPO). The result, in a rabbit model of renal anemia, was a beneficial effect on hematopoiesis, better than with rHuEPO alone. Also, we determined that liposome-EPO delivery to bone marrow depended on specific uptake by bone marrow macrophages because of the presence of SA. These results indicate both that liposome-EPO is a new, promising erythropoietin-stimulating agent and that liposomes with SA have potential for diagnostic and therapeutic applications in diseases originating from bone marrow."},"publication_date":"2014-11-03","publication_name":{"en":"Molecular Pharmaceutics","ja":"Molecular Pharmaceutics"},"volume":"Vol.11","number":"No.11","starting_page":"4238","ending_page":"4248","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/mp500453a"],"issn":["1543-8392"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:90, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512959"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24185403","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84919399295&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325162","label":"url"}],"paper_title":{"en":"Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin","ja":"Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin"},"authors":{"en":[{"name":"Watanabe H"},{"name":"Sakaguchi Y"},{"name":"Sugimoto R"},{"name":"Kaneko KI"},{"name":"Iwata H"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Ishima Yu"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Watanabe H"},{"name":"Sakaguchi Y"},{"name":"Sugimoto R"},{"name":"Kaneko KI"},{"name":"Iwata H"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"異島 優"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Recent clinical studies have shown that increased serum levels of p-cresyl sulfate (PCS), a uremic toxin, are associated with the progression of chronic kidney disease (CKD) and cardiovascular outcomes. Using rat renal cortical slices, we previously reported that the rat organic anion transporter (OAT) could play a key role in the renal tubular secretion of PCS. However, no information is currently available regarding the transport of PCS via human OAT (hOAT) isoforms, hOAT1 and hOAT3. Uptake experiments of PCS were performed using HEK293 cells, which stably express hOAT1 or hOAT3. PCS was taken up by hOAT1/HEK293 and hOAT3/HEK293 cells in a time- and concentration-dependent manner. The apparent K m for the hOAT1-mediated transport of PCS was 128 μM, whereas in hOAT3/HEK293, saturation was not observed at the highest tested PCS concentration of 5 mM. Probenecid, an OAT inhibitor, inhibited PCS transport by hOAT1 and hOAT3. The uptake of p-aminohippurate by hOAT1 and estron-3-sulfate by hOAT3 was decreased with increasing PCS concentration. The apparent 50 % inhibitory concentrations for PCS were 690 and 485 μM for hOAT1 and hOAT3, respectively. PCS is a substrate for hOAT1 and hOAT3, and hOAT1 and hOAT3 appear to play a physiological role as a high-capacity PCS transporter. Since hOATs are expressed not only in the kidneys, but also in blood vessels and osteoblasts, etc., these findings are of great significance in terms of elucidating the renal clearance, tissue disposition of PCS and the mechanism of its toxicity in CKD.","ja":"Recent clinical studies have shown that increased serum levels of p-cresyl sulfate (PCS), a uremic toxin, are associated with the progression of chronic kidney disease (CKD) and cardiovascular outcomes. Using rat renal cortical slices, we previously reported that the rat organic anion transporter (OAT) could play a key role in the renal tubular secretion of PCS. However, no information is currently available regarding the transport of PCS via human OAT (hOAT) isoforms, hOAT1 and hOAT3. Uptake experiments of PCS were performed using HEK293 cells, which stably express hOAT1 or hOAT3. PCS was taken up by hOAT1/HEK293 and hOAT3/HEK293 cells in a time- and concentration-dependent manner. The apparent K m for the hOAT1-mediated transport of PCS was 128 μM, whereas in hOAT3/HEK293, saturation was not observed at the highest tested PCS concentration of 5 mM. Probenecid, an OAT inhibitor, inhibited PCS transport by hOAT1 and hOAT3. The uptake of p-aminohippurate by hOAT1 and estron-3-sulfate by hOAT3 was decreased with increasing PCS concentration. The apparent 50 % inhibitory concentrations for PCS were 690 and 485 μM for hOAT1 and hOAT3, respectively. PCS is a substrate for hOAT1 and hOAT3, and hOAT1 and hOAT3 appear to play a physiological role as a high-capacity PCS transporter. Since hOATs are expressed not only in the kidneys, but also in blood vessels and osteoblasts, etc., these findings are of great significance in terms of elucidating the renal clearance, tissue disposition of PCS and the mechanism of its toxicity in CKD."},"publication_date":"2014-10","publication_name":{"en":"Clinical and Experimental Nephrology","ja":"Clinical and Experimental Nephrology"},"volume":"Vol.18","number":"No.5","starting_page":"814","ending_page":"820","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10157-013-0902-9"],"issn":["1437-7799"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:91, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512960"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24769178","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84903649556&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325135","label":"url"}],"paper_title":{"en":"N-acetyl-l-methionine is a superior protectant of human serum albumin against photo-oxidation and reactive oxygen species compared to N-acetyl-l-tryptophan","ja":"N-acetyl-l-methionine is a superior protectant of human serum albumin against photo-oxidation and reactive oxygen species compared to N-acetyl-l-tryptophan"},"authors":{"en":[{"name":"Kouno Y"},{"name":"Anraku M"},{"name":"Yamasaki K"},{"name":"Okayama Y"},{"name":"Iohara D"},{"name":"Ishima Yu"},{"name":"Maruyama T"},{"name":"Kragh-Hansen U"},{"name":"Hirayama F"},{"name":"Otagiri M"}],"ja":[{"name":"Kouno Y"},{"name":"Anraku M"},{"name":"Yamasaki K"},{"name":"Okayama Y"},{"name":"Iohara D"},{"name":"異島 優"},{"name":"Maruyama T"},{"name":"Kragh-Hansen U"},{"name":"Hirayama F"},{"name":"Otagiri M"}]},"description":{"en":"Sodium octanoate (Oct) and N-acetyl-l-tryptophan (N-AcTrp) are widely used as stabilizers during pasteurization and storage of albumin products. However, exposure to light photo-degrades N-AcTrp with the formation of potentially toxic compounds. Therefore, we have examined the usefulness of N-acetyl-l-methionine (N-AcMet) in comparison with N-AcTrp for long-term stability, including photo stability, of albumin products. Recombinant human serum albumin (rHSA) with and without additives was photo-irradiated for 4weeks. The capability of the different stabilizers to scavenge reactive oxygen species (ROS) was examined by ESR spectrometry. Carbonyl contents were assessed by a spectrophotometric method using fluoresceinamine and Western blotting, whereas the structure of rHSA was examined by SDS-PAGE, far-UV circular dichroism and differential scanning calorimetry. Binding was determined by ultrafiltration. N-AcMet was found to be a superior ROS scavenger both before and after photo-irradiation. The number of carbonyl groups formed was lowest in the presence of N-AcMet. According to SDS-PAGE, N-AcMet stabilizes the monomeric form of rHSA, whereas N-AcTrp induces degradation of rHSA during photo-irradiation. The decrease in α-helical content of rHSA was the smallest in the presence of Oct, without or with N-AcMet. Photo-irradiation did not affect the denaturation temperature or calorimetric enthalpy of rHSA, when N-AcMet was present. The weakly bound N-AcMet is a superior protectant of albumin, because it is a better ROS-protector and structural stabilizer than N-AcTrp, and it is probable and also useful for other protein preparations. N-AcMet is an effective stabilizer of albumin during photo-irradiation, while N-Ac-Trp promotes photo-oxidative damage to albumin.","ja":"Sodium octanoate (Oct) and N-acetyl-l-tryptophan (N-AcTrp) are widely used as stabilizers during pasteurization and storage of albumin products. However, exposure to light photo-degrades N-AcTrp with the formation of potentially toxic compounds. Therefore, we have examined the usefulness of N-acetyl-l-methionine (N-AcMet) in comparison with N-AcTrp for long-term stability, including photo stability, of albumin products. Recombinant human serum albumin (rHSA) with and without additives was photo-irradiated for 4weeks. The capability of the different stabilizers to scavenge reactive oxygen species (ROS) was examined by ESR spectrometry. Carbonyl contents were assessed by a spectrophotometric method using fluoresceinamine and Western blotting, whereas the structure of rHSA was examined by SDS-PAGE, far-UV circular dichroism and differential scanning calorimetry. Binding was determined by ultrafiltration. N-AcMet was found to be a superior ROS scavenger both before and after photo-irradiation. The number of carbonyl groups formed was lowest in the presence of N-AcMet. According to SDS-PAGE, N-AcMet stabilizes the monomeric form of rHSA, whereas N-AcTrp induces degradation of rHSA during photo-irradiation. The decrease in α-helical content of rHSA was the smallest in the presence of Oct, without or with N-AcMet. Photo-irradiation did not affect the denaturation temperature or calorimetric enthalpy of rHSA, when N-AcMet was present. The weakly bound N-AcMet is a superior protectant of albumin, because it is a better ROS-protector and structural stabilizer than N-AcTrp, and it is probable and also useful for other protein preparations. N-AcMet is an effective stabilizer of albumin during photo-irradiation, while N-Ac-Trp promotes photo-oxidative damage to albumin."},"publication_date":"2014-09","publication_name":{"en":"Biochimica et Biophysica Acta (BBA) - General Subjects","ja":"Biochimica et Biophysica Acta (BBA) - General Subjects"},"volume":"Vol.1840","number":"No.9","starting_page":"2806","ending_page":"2812","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bbagen.2014.04.014"],"issn":["0304-4165"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:92, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512961"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24846171","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325134","label":"url"}],"paper_title":{"en":"Tuning of poly-s-nitrosated human serum albumin as superior antitumor nanomedicine","ja":"Tuning of poly-s-nitrosated human serum albumin as superior antitumor nanomedicine"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Fang J"},{"name":"Kragh-Hansen U"},{"name":"Yin H"},{"name":"Liao L"},{"name":"Katayama N"},{"name":"Watanabe H"},{"name":"Kai T"},{"name":"Suenaga A"},{"name":"Maeda H"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"Fang J"},{"name":"Kragh-Hansen U"},{"name":"Yin H"},{"name":"Liao L"},{"name":"Katayama N"},{"name":"Watanabe H"},{"name":"Kai T"},{"name":"Suenaga A"},{"name":"Maeda H"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Macromolecules have been developed as carriers of low-molecular-weight drugs in drug delivery systems (DDS) to improve their pharmacokinetic profile or to promote their uptake in tumor tissue via enhanced permeability and retention (EPR) effects. We have previously demonstrated that poly-nitric oxide (NO) conjugated human serum albumin (Poly-SNO-HSA) has the potential to be a DDS carrier capable of accumulating NO in tumors. However, the stability of Poly-SNO-HSA in the circulation has to be improved, and its optimal molecular size for using the EPR effects has to be evaluated. In the present study, we performed two tuning methods for refining Poly-SNO-HSA, namely, pegylation and dimerization. We observed that pegylation enhanced the stability of Poly-SNO-HSA both in vitro and in vivo, and that dimerization of Poly-SNO-HSA enhanced the antitumor activity via more efficient delivery of NO in Colon 26 tumor-bearing mice. Intriguingly, dimerization resulted in a 10 times higher antitumor activity. These data suggest that pegylation and dimerization of Poly-SNO-HSA are very important tuners to optimize NO stability and accumulation, and thereby effect, in tumors. Thus, polyethylene glycol-Poly-SNO-HSA dimer seems to be a very appealing and safe NO carrier and thereby a strong candidate as an antitumor drug in future development of cancer therapeutics.","ja":"Macromolecules have been developed as carriers of low-molecular-weight drugs in drug delivery systems (DDS) to improve their pharmacokinetic profile or to promote their uptake in tumor tissue via enhanced permeability and retention (EPR) effects. We have previously demonstrated that poly-nitric oxide (NO) conjugated human serum albumin (Poly-SNO-HSA) has the potential to be a DDS carrier capable of accumulating NO in tumors. However, the stability of Poly-SNO-HSA in the circulation has to be improved, and its optimal molecular size for using the EPR effects has to be evaluated. In the present study, we performed two tuning methods for refining Poly-SNO-HSA, namely, pegylation and dimerization. We observed that pegylation enhanced the stability of Poly-SNO-HSA both in vitro and in vivo, and that dimerization of Poly-SNO-HSA enhanced the antitumor activity via more efficient delivery of NO in Colon 26 tumor-bearing mice. Intriguingly, dimerization resulted in a 10 times higher antitumor activity. These data suggest that pegylation and dimerization of Poly-SNO-HSA are very important tuners to optimize NO stability and accumulation, and thereby effect, in tumors. Thus, polyethylene glycol-Poly-SNO-HSA dimer seems to be a very appealing and safe NO carrier and thereby a strong candidate as an antitumor drug in future development of cancer therapeutics."},"publication_date":"2014-07","publication_name":{"en":"Journal of Pharmaceutical Sciences","ja":"Journal of Pharmaceutical Sciences"},"volume":"Vol.103","number":"No.7","starting_page":"2184","ending_page":"2188","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/jps.24020"],"issn":["1520-6017"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:93, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512962"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24890462","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325133","label":"url"}],"paper_title":{"en":"Carbon Monoxide-Bound Red Blood Cell Resuscitation Ameliorates Hepatic Injury Induced by Massive Hemorrhage and Red Blood Cell Resuscitation via Hepatic Cytochrome P450 Protection in Hemorrhagic Shock Rats","ja":"Carbon Monoxide-Bound Red Blood Cell Resuscitation Ameliorates Hepatic Injury Induced by Massive Hemorrhage and Red Blood Cell Resuscitation via Hepatic Cytochrome P450 Protection in Hemorrhagic Shock Rats"},"authors":{"en":[{"name":"Ogaki S"},{"name":"Taguchi K"},{"name":"Watanabe H"},{"name":"Ishima Yu"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Ogaki S"},{"name":"Taguchi K"},{"name":"Watanabe H"},{"name":"異島 優"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Red blood cell (RBC) transfusions are the gold standard in cases of massive hemorrhage, but induce hepatic ischemia-reperfusion injury, a serious complication associated with hemorrhage and RBC resuscitation. Thus, the development of a novel resuscitable fluid that is not associated with hepatic ischemia-reperfusion injury would be desirable. It was reported that exogenous carbon monoxide (CO) treatment ameliorated hepatic ischemia-reperfusion injury accompanying liver transplantation. This suggests that transfusions with CO-bound RBC (CO-RBC) might protect against hepatic ischemia-reperfusion injury following massive hemorrhage and resuscitation compared with RBC resuscitation. To investigate this, we created a hemorrhagic shock model rat, followed by resuscitation with RBC and CO-RBC. Hepatic ischemia-reperfusion injury and the destruction of hepatic cytochrome P450 (CYP) were significantly ameliorated in the CO-RBC resuscitation group compared with the RBC resuscitation group. The free heme derived from the destruction of hepatic CYP was correlated with hepatic oxidation and injury, suggesting that CO-RBC was a major factor in the amelioration of hepatic ischemia-reperfusion injury induced by hemorrhage and resuscitation via hepatic CYP protection. These results indicate that CO-RBC has potential for use as a resuscitative fluid in blood transfusion and does not suffer from the limitations associated with the RBC transfusions that are currently in use.","ja":"Red blood cell (RBC) transfusions are the gold standard in cases of massive hemorrhage, but induce hepatic ischemia-reperfusion injury, a serious complication associated with hemorrhage and RBC resuscitation. Thus, the development of a novel resuscitable fluid that is not associated with hepatic ischemia-reperfusion injury would be desirable. It was reported that exogenous carbon monoxide (CO) treatment ameliorated hepatic ischemia-reperfusion injury accompanying liver transplantation. This suggests that transfusions with CO-bound RBC (CO-RBC) might protect against hepatic ischemia-reperfusion injury following massive hemorrhage and resuscitation compared with RBC resuscitation. To investigate this, we created a hemorrhagic shock model rat, followed by resuscitation with RBC and CO-RBC. Hepatic ischemia-reperfusion injury and the destruction of hepatic cytochrome P450 (CYP) were significantly ameliorated in the CO-RBC resuscitation group compared with the RBC resuscitation group. The free heme derived from the destruction of hepatic CYP was correlated with hepatic oxidation and injury, suggesting that CO-RBC was a major factor in the amelioration of hepatic ischemia-reperfusion injury induced by hemorrhage and resuscitation via hepatic CYP protection. These results indicate that CO-RBC has potential for use as a resuscitative fluid in blood transfusion and does not suffer from the limitations associated with the RBC transfusions that are currently in use."},"publication_date":"2014-07","publication_name":{"en":"Journal of Pharmaceutical Sciences","ja":"Journal of Pharmaceutical Sciences"},"volume":"Vol.103","number":"No.7","starting_page":"2199","ending_page":"2206","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/jps.24029"],"issn":["1520-6017"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:94, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512963"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24576052","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84898018008&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325136","label":"url"}],"paper_title":{"en":"Albumin fusion prolongs the antioxidant and anti-inflammatory activities of thioredoxin in mice with acetaminophen-induced hepatitis","ja":"Albumin fusion prolongs the antioxidant and anti-inflammatory activities of thioredoxin in mice with acetaminophen-induced hepatitis"},"authors":{"en":[{"name":"Tanaka R"},{"name":"Ishima Yu"},{"name":"Maeda H"},{"name":"Kodama A"},{"name":"Nagao S"},{"name":"Watanabe H"},{"name":"Chuang VT"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Tanaka R"},{"name":"異島 優"},{"name":"Maeda H"},{"name":"Kodama A"},{"name":"Nagao S"},{"name":"Watanabe H"},{"name":"Chuang VT"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Overdoses of acetaminophen (APAP) are a major cause of acute liver failure. N-Acetylcysteine (NAC) is the standard therapy for patients with such an overdose because oxidative stress plays an important role in the pathogenesis of APAP-induced hepatitis. However, NAC is not sufficiently efficacious. We previously developed a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx), designed to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx, an endogenous protein with antioxidative and anti-inflammatory properties. In this study, we investigated the therapeutic impact of HSA-Trx in mice with APAP-induced hepatitis. The systemic administration of HSA-Trx significantly improved the survival rate of mice treated with a lethal dose of APAP compared with saline. HSA-Trx strongly attenuated plasma transaminases in APAP-induced hepatitis mice compared with HSA or Trx, components of the fusion protein. HSA-Trx also markedly caused a diminution in the histopathological features of hepatic injuries and the number of apoptosis-positive hepatic cells. In addition, an evaluation of oxidative stress markers and plasma cytokine and chemokine levels clearly showed that HSA-Trx significantly improved the breakdown of hepatic redox conditions and inflammation caused by the APAP treatment. HSA-Trx also significantly decreased oxidative and nitrosative/nitrative stress induced by SIN-1 in vitro. Finally, HSA-Trx, but not the NAC treatment at 4 h after APAP injection, significantly inhibited the elevation in plasma transaminase levels. In conclusion, the findings suggest that HSA-Trx has considerable potential for use as a novel therapeutic agent for APAP-induced hepatitis, due to its long-lasting antioxidative and anti-inflammatory effects.","ja":"Overdoses of acetaminophen (APAP) are a major cause of acute liver failure. N-Acetylcysteine (NAC) is the standard therapy for patients with such an overdose because oxidative stress plays an important role in the pathogenesis of APAP-induced hepatitis. However, NAC is not sufficiently efficacious. We previously developed a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx), designed to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx, an endogenous protein with antioxidative and anti-inflammatory properties. In this study, we investigated the therapeutic impact of HSA-Trx in mice with APAP-induced hepatitis. The systemic administration of HSA-Trx significantly improved the survival rate of mice treated with a lethal dose of APAP compared with saline. HSA-Trx strongly attenuated plasma transaminases in APAP-induced hepatitis mice compared with HSA or Trx, components of the fusion protein. HSA-Trx also markedly caused a diminution in the histopathological features of hepatic injuries and the number of apoptosis-positive hepatic cells. In addition, an evaluation of oxidative stress markers and plasma cytokine and chemokine levels clearly showed that HSA-Trx significantly improved the breakdown of hepatic redox conditions and inflammation caused by the APAP treatment. HSA-Trx also significantly decreased oxidative and nitrosative/nitrative stress induced by SIN-1 in vitro. Finally, HSA-Trx, but not the NAC treatment at 4 h after APAP injection, significantly inhibited the elevation in plasma transaminase levels. In conclusion, the findings suggest that HSA-Trx has considerable potential for use as a novel therapeutic agent for APAP-induced hepatitis, due to its long-lasting antioxidative and anti-inflammatory effects."},"publication_date":"2014-04-07","publication_name":{"en":"Molecular Pharmaceutics","ja":"Molecular Pharmaceutics"},"volume":"Vol.11","number":"No.4","starting_page":"1228","ending_page":"1238","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/mp400690v"],"issn":["1543-8392"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:95, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512964"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24361613","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84891692691&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325161","label":"url"}],"paper_title":{"en":"Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity","ja":"Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity"},"authors":{"en":[{"name":"Kodama A"},{"name":"Watanabe H"},{"name":"Tanaka R"},{"name":"Kondo M"},{"name":"Chuang VT"},{"name":"Wu Q"},{"name":"Endo M"},{"name":"Ishima Yu"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Kodama A"},{"name":"Watanabe H"},{"name":"Tanaka R"},{"name":"Kondo M"},{"name":"Chuang VT"},{"name":"Wu Q"},{"name":"Endo M"},{"name":"異島 優"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"A strategy for preventing cisplatin nephrotoxicity due to enhanced oxidative stress and inflammatory response is highly desirable. Thioredoxin-1 (Trx), an endogenous redox-active protein, has a short retention time in the blood. A long acting form of Trx, human serum albumin-Trx (HSA-Trx), was produced by recombinant HSA fusion and its effectiveness in preventing cisplatin nephrotoxicity was examined. HSA-Trx was prepared in Pichia expression system. Cisplatin-induced nephropathy mouse model was established by a single administration of cisplatin. Compared to saline, Trx or N-acetylcysteine, an intravenous administration of HSA-Trx attenuated the cisplatin-induced elevation in serum creatinine, blood urea nitrogen and urinary N-acetyl-β-d-glucosaminidase along with the decrease in creatinine clearance. HSA-Trx caused a substantial reduction in the histological features of renal tubular injuries and the apoptosis-positive tubular cells. Changes in superoxide, 8-OHdG, glutathione and nitrotyrosine levels indicated that HSA-Trx significantly suppressed renal oxidative stress. HSA-Trx also suppressed the elevation of TNF-α, IL-1β and IL-6. Administered fluorescein isothiocyanate-labeled HSA-Trx was found partially localized in the proximal tubular cells whereas majority remained in the blood circulation. Specific cellular uptake and the scavenging of intracellular reactive oxygen species by HSA-Trx were observed in HK-2 cells. HSA-Trx could be a novel and effective approach for preventing cisplatin nephrotoxicity due to its prolonged anti-oxidative and anti-inflammatory action not only in extracellular compartment but also inside the proximal tubular cell. We report the renoprotective effect of HSA-Trx against cisplatin nephrotoxicity. This work would enhance developing therapeutics against acute kidney injuries including cisplatin nephrotoxicity.","ja":"A strategy for preventing cisplatin nephrotoxicity due to enhanced oxidative stress and inflammatory response is highly desirable. Thioredoxin-1 (Trx), an endogenous redox-active protein, has a short retention time in the blood. A long acting form of Trx, human serum albumin-Trx (HSA-Trx), was produced by recombinant HSA fusion and its effectiveness in preventing cisplatin nephrotoxicity was examined. HSA-Trx was prepared in Pichia expression system. Cisplatin-induced nephropathy mouse model was established by a single administration of cisplatin. Compared to saline, Trx or N-acetylcysteine, an intravenous administration of HSA-Trx attenuated the cisplatin-induced elevation in serum creatinine, blood urea nitrogen and urinary N-acetyl-β-d-glucosaminidase along with the decrease in creatinine clearance. HSA-Trx caused a substantial reduction in the histological features of renal tubular injuries and the apoptosis-positive tubular cells. Changes in superoxide, 8-OHdG, glutathione and nitrotyrosine levels indicated that HSA-Trx significantly suppressed renal oxidative stress. HSA-Trx also suppressed the elevation of TNF-α, IL-1β and IL-6. Administered fluorescein isothiocyanate-labeled HSA-Trx was found partially localized in the proximal tubular cells whereas majority remained in the blood circulation. Specific cellular uptake and the scavenging of intracellular reactive oxygen species by HSA-Trx were observed in HK-2 cells. HSA-Trx could be a novel and effective approach for preventing cisplatin nephrotoxicity due to its prolonged anti-oxidative and anti-inflammatory action not only in extracellular compartment but also inside the proximal tubular cell. We report the renoprotective effect of HSA-Trx against cisplatin nephrotoxicity. This work would enhance developing therapeutics against acute kidney injuries including cisplatin nephrotoxicity."},"publication_date":"2014-03","publication_name":{"en":"Biochimica et Biophysica Acta (BBA) - General Subjects","ja":"Biochimica et Biophysica Acta (BBA) - General Subjects"},"volume":"Vol.1840","number":"No.3","starting_page":"1152","ending_page":"1162","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bbagen.2013.12.007"],"issn":["0304-4165"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:96, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512965"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24498401","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84896864138&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325137","label":"url"}],"paper_title":{"en":"Differential effects of methoxy group on the interaction of curcuminoids with two major ligand binding sites of human serum albumin","ja":"Differential effects of methoxy group on the interaction of curcuminoids with two major ligand binding sites of human serum albumin"},"authors":{"en":[{"name":"Sato H"},{"name":"Chuang VT"},{"name":"Yamasaki K"},{"name":"Yamaotsu N"},{"name":"Watanabe H"},{"name":"Nagumo K"},{"name":"Anraku M"},{"name":"Kadowaki D"},{"name":"Ishima Yu"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Sato H"},{"name":"Chuang VT"},{"name":"Yamasaki K"},{"name":"Yamaotsu N"},{"name":"Watanabe H"},{"name":"Nagumo K"},{"name":"Anraku M"},{"name":"Kadowaki D"},{"name":"異島 優"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Curcuminoids are a group of compounds with a similar chemical backbone structure but containing different numbers of methoxy groups that have therapeutic potential due to their anti-inflammatory and anti-oxidant properties. They mainly bind to albumin in plasma. These findings influence their body disposition and biological activities. Spectroscopic analysis using site specific probes on human serum albumin (HSA) clearly indicated that curcumin (Cur), demethylcurcumin (Dmc) and bisdemethoxycurcumin (Bdmc) bind to both Site I (sub-site Ia and Ib) and Site II on HSA. At pH 7.4, the binding constants for Site I were relatively comparable between curcuminoids, while the binding constants for Site II at pH 7.4 were increased in order Cur < Dmc < Bdmc. Binding experiments using HSA mutants showed that Trp214 and Arg218 at Site I, and Tyr411 and Arg410 at Site II are involved in the binding of curcuminoids. The molecular docking of all curcuminoids to the Site I pocket showed that curcuminoids stacked with Phe211 and Trp214, and interacted with hydrophobic and aromatic amino acid residues. In contrast, each curcuminoid interacted with Site II in a different manner depending whether a methoxy group was present or absent. A detailed analysis of curcuminoids-albumin interactions would provide valuable information in terms of understanding the pharmacokinetics and the biological activities of this class of compounds.","ja":"Curcuminoids are a group of compounds with a similar chemical backbone structure but containing different numbers of methoxy groups that have therapeutic potential due to their anti-inflammatory and anti-oxidant properties. They mainly bind to albumin in plasma. These findings influence their body disposition and biological activities. Spectroscopic analysis using site specific probes on human serum albumin (HSA) clearly indicated that curcumin (Cur), demethylcurcumin (Dmc) and bisdemethoxycurcumin (Bdmc) bind to both Site I (sub-site Ia and Ib) and Site II on HSA. At pH 7.4, the binding constants for Site I were relatively comparable between curcuminoids, while the binding constants for Site II at pH 7.4 were increased in order Cur < Dmc < Bdmc. Binding experiments using HSA mutants showed that Trp214 and Arg218 at Site I, and Tyr411 and Arg410 at Site II are involved in the binding of curcuminoids. The molecular docking of all curcuminoids to the Site I pocket showed that curcuminoids stacked with Phe211 and Trp214, and interacted with hydrophobic and aromatic amino acid residues. In contrast, each curcuminoid interacted with Site II in a different manner depending whether a methoxy group was present or absent. A detailed analysis of curcuminoids-albumin interactions would provide valuable information in terms of understanding the pharmacokinetics and the biological activities of this class of compounds."},"publication_date":"2014-02-03","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"Vol.9","number":"No.2","starting_page":"e87919","ending_page":"e87919","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0087919"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:97, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512966"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24416365","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84896970499&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325160","label":"url"}],"paper_title":{"en":"Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases","ja":"Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases"},"authors":{"en":[{"name":"Nagumo K"},{"name":"Tanaka M"},{"name":"Chuang VT"},{"name":"Setoyama H"},{"name":"Watanabe H"},{"name":"Yamada N"},{"name":"Kubota K"},{"name":"Tanaka M"},{"name":"Matsushita K"},{"name":"Yoshida A"},{"name":"Jinnouchi H"},{"name":"Anraku M"},{"name":"Kadowaki D"},{"name":"Ishima Yu"},{"name":"Sasaki Y"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Nagumo K"},{"name":"Tanaka M"},{"name":"Chuang VT"},{"name":"Setoyama H"},{"name":"Watanabe H"},{"name":"Yamada N"},{"name":"Kubota K"},{"name":"Tanaka M"},{"name":"Matsushita K"},{"name":"Yoshida A"},{"name":"Jinnouchi H"},{"name":"Anraku M"},{"name":"Kadowaki D"},{"name":"異島 優"},{"name":"Sasaki Y"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"The degree of oxidized cysteine (Cys) 34 in human serum albumin (HSA), as determined by high performance liquid chromatography (HPLC), is correlated with oxidative stress related pathological conditions. In order to further characterize the oxidation of Cys34-HSA at the molecular level and to develop a suitable analytical method for a rapid and sensitive clinical laboratory analysis, the use of electrospray ionization time-of-flight mass spectrometer (ESI-TOFMS) was evaluated. A marked increase in the cysteinylation of Cys34 occurs in chronic liver and kidney diseases and diabetes mellitus. A significant positive correlation was observed between the Cys-Cys34-HSA fraction of plasma samples obtained from 229 patients, as determined by ESI-TOFMS, and the degree of oxidized Cys34-HSA determined by HPLC. The Cys-Cys34-HSA fraction was significantly increased with the progression of liver cirrhosis, and was reduced by branched chain amino acids (BCAA) treatment. The changes in the Cys-Cys34-HSA fraction were significantly correlated with the alternations of the plasma levels of advanced oxidized protein products, an oxidative stress marker for proteins. The binding ability of endogenous substances (bilirubin and tryptophan) and drugs (warfarin and diazepam) to HSA purified from chronic liver disease patients were significantly suppressed but significantly improved by BCAA supplementation. Interestingly, the changes in this physiological function of HSA in chronic liver disease were correlated with the Cys-Cys34-HSA fraction. In conclusion, ESI-TOFMS is a suitable high throughput method for the rapid and sensitive quantification of Cys-Cys34-HSA in a large number of samples for evaluating oxidative stress related chronic disease progression or in response to a treatment.","ja":"The degree of oxidized cysteine (Cys) 34 in human serum albumin (HSA), as determined by high performance liquid chromatography (HPLC), is correlated with oxidative stress related pathological conditions. In order to further characterize the oxidation of Cys34-HSA at the molecular level and to develop a suitable analytical method for a rapid and sensitive clinical laboratory analysis, the use of electrospray ionization time-of-flight mass spectrometer (ESI-TOFMS) was evaluated. A marked increase in the cysteinylation of Cys34 occurs in chronic liver and kidney diseases and diabetes mellitus. A significant positive correlation was observed between the Cys-Cys34-HSA fraction of plasma samples obtained from 229 patients, as determined by ESI-TOFMS, and the degree of oxidized Cys34-HSA determined by HPLC. The Cys-Cys34-HSA fraction was significantly increased with the progression of liver cirrhosis, and was reduced by branched chain amino acids (BCAA) treatment. The changes in the Cys-Cys34-HSA fraction were significantly correlated with the alternations of the plasma levels of advanced oxidized protein products, an oxidative stress marker for proteins. The binding ability of endogenous substances (bilirubin and tryptophan) and drugs (warfarin and diazepam) to HSA purified from chronic liver disease patients were significantly suppressed but significantly improved by BCAA supplementation. Interestingly, the changes in this physiological function of HSA in chronic liver disease were correlated with the Cys-Cys34-HSA fraction. In conclusion, ESI-TOFMS is a suitable high throughput method for the rapid and sensitive quantification of Cys-Cys34-HSA in a large number of samples for evaluating oxidative stress related chronic disease progression or in response to a treatment."},"publication_date":"2014-01-08","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"Vol.9","number":"No.1","starting_page":"e85216","ending_page":"e85216","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0085216"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:98, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512967"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23442250","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325164","label":"url"}],"paper_title":{"en":"Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression","ja":"Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression"},"authors":{"en":[{"name":"Tanaka R"},{"name":"Watanabe H"},{"name":"Kodama A"},{"name":"Chuang VT"},{"name":"Ishima Yu"},{"name":"Hamasaki K"},{"name":"Tanaka K"},{"name":"Mizushima T"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Tanaka R"},{"name":"Watanabe H"},{"name":"Kodama A"},{"name":"Chuang VT"},{"name":"異島 優"},{"name":"Hamasaki K"},{"name":"Tanaka K"},{"name":"Mizushima T"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Idiopathic pulmonary fibrosis (IPF) is thought to involve inflammatory cells and reactive oxygen species (ROS), such as superoxide anion radical (O2(·-)). There is currently no effective treatment of IPF. We previously developed a human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) designed to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx, an antioxidative and anti-inflammatory protein. In this study, we examined the therapeutic effect of HSA-Trx on an IPF animal model of bleomycin (BLM)-induced pulmonary fibrosis. A pharmacokinetic study of HSA-Trx or Trx in BLM mice showed that the plasma retention and lung distribution of Trxc was markedly improved by fusion with HSA. A weekly intravenous administration of HSA-Trx, but not Trx, ameliorated BLM-induced fibrosis, as evidenced by a histopathological analysis and pulmonary hydroxyproline levels. HSA-Trx suppressed active-transforming growth factor (TGF)-β levels in the lung and inhibited the increase of inflammatory cells in bronchoalveolar lavage fluid, pulmonary inflammatory cytokines, and oxidative stress markers. An in vitro EPR experiment using phosphate-buffered saline-stimulated neutrophils confirmed the O2(·-) scavenging ability of HSA-Trx. Furthermore, post-treatment of HSA-Trx had a suppressive effect against BLM-induced fibrosis. These results suggest that HSA-Trx has potential as a novel therapeutic agent for IPF, because of its long-acting antioxidative and anti-inflammatory modulation effects.","ja":"Idiopathic pulmonary fibrosis (IPF) is thought to involve inflammatory cells and reactive oxygen species (ROS), such as superoxide anion radical (O2(·-)). There is currently no effective treatment of IPF. We previously developed a human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) designed to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx, an antioxidative and anti-inflammatory protein. In this study, we examined the therapeutic effect of HSA-Trx on an IPF animal model of bleomycin (BLM)-induced pulmonary fibrosis. A pharmacokinetic study of HSA-Trx or Trx in BLM mice showed that the plasma retention and lung distribution of Trxc was markedly improved by fusion with HSA. A weekly intravenous administration of HSA-Trx, but not Trx, ameliorated BLM-induced fibrosis, as evidenced by a histopathological analysis and pulmonary hydroxyproline levels. HSA-Trx suppressed active-transforming growth factor (TGF)-β levels in the lung and inhibited the increase of inflammatory cells in bronchoalveolar lavage fluid, pulmonary inflammatory cytokines, and oxidative stress markers. An in vitro EPR experiment using phosphate-buffered saline-stimulated neutrophils confirmed the O2(·-) scavenging ability of HSA-Trx. Furthermore, post-treatment of HSA-Trx had a suppressive effect against BLM-induced fibrosis. These results suggest that HSA-Trx has potential as a novel therapeutic agent for IPF, because of its long-acting antioxidative and anti-inflammatory modulation effects."},"publication_date":"2013-05-01","publication_name":{"en":"The Journal of Pharmacology and Experimental Therapeutics","ja":"The Journal of Pharmacology and Experimental Therapeutics"},"volume":"Vol.345","number":"No.2","starting_page":"271","ending_page":"283","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1124/jpet.112.201814"],"issn":["1521-0103"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:99, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512968"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23402724","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84874615068&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325166","label":"url"}],"paper_title":{"en":"UW solution improved with high anti-apoptotic activity by S-nitrosated human serum albumin","ja":"UW solution improved with high anti-apoptotic activity by S-nitrosated human serum albumin"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Shinagawa T"},{"name":"Yoneshige S"},{"name":"Kragh-Hansen U"},{"name":"Ohya Y"},{"name":"Inomata Y"},{"name":"Kai T"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"Shinagawa T"},{"name":"Yoneshige S"},{"name":"Kragh-Hansen U"},{"name":"Ohya Y"},{"name":"Inomata Y"},{"name":"Kai T"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"S-Nitrosated human serum albumin (SNO-HSA) is useful in preventing liver ischemia/reperfusion injury, and SNO-HSA should thus be able to prevent cell injury during liver transplantation. However, the potential protective effect of SNO-HSA on a combination of cold and warm ischemia, which is obligatory when performing liver transplantation, has not been examined. Therefore, we evaluated the protective effect of SNO-HSA added to University of Wisconsin (UW) solution during cold or/and warm ischemia in situ and in vitro. First, we observed that apoptotic and necrotic cell death were increased during cold and warm ischemia, respectively. SNO-HSA, which possesses anti-apoptosis activity at low NO concentrations, can inhibit cold ischemia injury both in situ and in vitro. In contrast, SNO-HSA had no significant effect on warm liver ischemia injury which, however, can be reduced by UW solution. We also demonstrated that the cellular uptake of NO from SNO-HSA can occur during cold ischemia resulting in induction of heme oxygenase-1 within 3h of cold ischemia. Our results indicate that treatment with SNO-HSA or UW solution alone is not sufficient to inhibit liver injury during a period of both cold and warm ischemia. However, a combination of SNO-HSA and UW solution can be used to prevent the two types of ischemia. SNO-HSA-added UW solution could be very useful in transplantation, because the previously imposed constraints on preservation time can be removed. This is a great advantage in a situation as the present one with increased utilization of scarce donor organs for more recipients.","ja":"S-Nitrosated human serum albumin (SNO-HSA) is useful in preventing liver ischemia/reperfusion injury, and SNO-HSA should thus be able to prevent cell injury during liver transplantation. However, the potential protective effect of SNO-HSA on a combination of cold and warm ischemia, which is obligatory when performing liver transplantation, has not been examined. Therefore, we evaluated the protective effect of SNO-HSA added to University of Wisconsin (UW) solution during cold or/and warm ischemia in situ and in vitro. First, we observed that apoptotic and necrotic cell death were increased during cold and warm ischemia, respectively. SNO-HSA, which possesses anti-apoptosis activity at low NO concentrations, can inhibit cold ischemia injury both in situ and in vitro. In contrast, SNO-HSA had no significant effect on warm liver ischemia injury which, however, can be reduced by UW solution. We also demonstrated that the cellular uptake of NO from SNO-HSA can occur during cold ischemia resulting in induction of heme oxygenase-1 within 3h of cold ischemia. Our results indicate that treatment with SNO-HSA or UW solution alone is not sufficient to inhibit liver injury during a period of both cold and warm ischemia. However, a combination of SNO-HSA and UW solution can be used to prevent the two types of ischemia. SNO-HSA-added UW solution could be very useful in transplantation, because the previously imposed constraints on preservation time can be removed. This is a great advantage in a situation as the present one with increased utilization of scarce donor organs for more recipients."},"publication_date":"2013-04-01","publication_name":{"en":"Nitric Oxide: Biology and Chemistry","ja":"Nitric Oxide: Biology and Chemistry"},"volume":"Vol.30","starting_page":"36","ending_page":"42","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.niox.2013.01.004"],"issn":["1089-8611"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:100, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512969"},"force":{"see_also":[{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84875710102&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325170","label":"url"}],"paper_title":{"en":"p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase","ja":"p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase"},"authors":{"en":[{"name":"Watanabe H"},{"name":"Miyamoto Y"},{"name":"Honda D"},{"name":"Tanaka H"},{"name":"Wu Q"},{"name":"Endo M"},{"name":"Noguchi T"},{"name":"Kadowaki D"},{"name":"Ishima Yu"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Kataoka K"},{"name":"Kim-Mitsuyama S"},{"name":"Tanaka M"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Watanabe H"},{"name":"Miyamoto Y"},{"name":"Honda D"},{"name":"Tanaka H"},{"name":"Wu Q"},{"name":"Endo M"},{"name":"Noguchi T"},{"name":"Kadowaki D"},{"name":"異島 優"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Kataoka K"},{"name":"Kim-Mitsuyama S"},{"name":"Tanaka M"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"publication_date":"2013-04","publication_name":{"en":"Kidney International","ja":"Kidney International"},"volume":"Vol.83","number":"No.4","starting_page":"582","ending_page":"592","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/ki.2012.448"],"issn":["0085-2538"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:101, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512970"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23328494","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84873745129&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325168","label":"url"}],"paper_title":{"en":"Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment","ja":"Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Minomo A"},{"name":"Chuang VT"},{"name":"Suwa Y"},{"name":"Kragh-Hansen U"},{"name":"Narisoko T"},{"name":"Morioka H"},{"name":"Maruyama T"},{"name":"Otagiri M"}],"ja":[{"name":"異島 優"},{"name":"Minomo A"},{"name":"Chuang VT"},{"name":"Suwa Y"},{"name":"Kragh-Hansen U"},{"name":"Narisoko T"},{"name":"Morioka H"},{"name":"Maruyama T"},{"name":"Otagiri M"}]},"description":{"en":"4Z,15Z-bilirubin-IXα (BR), an endogenous toxic compound that is sparingly soluble in water, binds human serum albumin (HSA) with high affinity in a flexible manner. Our previous findings suggest that both Lys195 and Lys199 in subdomain IIA are important for the high-affinity binding of BR, and especially Lys199 in stand-alone domain II plays a prominent role in the renal elimination of BR. Our hypothesis is that HSA-domain II with high BR binding would be a useful therapeutic agent to treat hyperbilirubinemia in patients with impaired liver function. Unbound BR concentrations were determined using a modified HRP assay. To evaluate the effect of pan3_3-13 domain II mutant in promoting urinary BR excretion, the serum concentration and urinary excretion amount of BR were determined using bile duct ligation mice. After three or six rounds of panning, pan3_3-13 and pan6_4 were found to have a significantly higher affinity for BR than wild-type domain II. Administration of pan3_3-13 significantly reduced serum BR level and increased its urinary excretion in the disease model mice as compared to wild-type domain II treatment. These results suggest that pan3_3-13 has great potential as a therapeutic agent that promotes urinary BR excretion in hyperbilirubinemia. This is the first study to be applied to other HSA bound toxic compounds that are responsible for the progression of disease, thereby paving the way for the development of non-invasive and cost effective blood purification treatment methods.","ja":"4Z,15Z-bilirubin-IXα (BR), an endogenous toxic compound that is sparingly soluble in water, binds human serum albumin (HSA) with high affinity in a flexible manner. Our previous findings suggest that both Lys195 and Lys199 in subdomain IIA are important for the high-affinity binding of BR, and especially Lys199 in stand-alone domain II plays a prominent role in the renal elimination of BR. Our hypothesis is that HSA-domain II with high BR binding would be a useful therapeutic agent to treat hyperbilirubinemia in patients with impaired liver function. Unbound BR concentrations were determined using a modified HRP assay. To evaluate the effect of pan3_3-13 domain II mutant in promoting urinary BR excretion, the serum concentration and urinary excretion amount of BR were determined using bile duct ligation mice. After three or six rounds of panning, pan3_3-13 and pan6_4 were found to have a significantly higher affinity for BR than wild-type domain II. Administration of pan3_3-13 significantly reduced serum BR level and increased its urinary excretion in the disease model mice as compared to wild-type domain II treatment. These results suggest that pan3_3-13 has great potential as a therapeutic agent that promotes urinary BR excretion in hyperbilirubinemia. This is the first study to be applied to other HSA bound toxic compounds that are responsible for the progression of disease, thereby paving the way for the development of non-invasive and cost effective blood purification treatment methods."},"publication_date":"2013-04","publication_name":{"en":"Biochimica et Biophysica Acta (BBA) - General Subjects","ja":"Biochimica et Biophysica Acta (BBA) - General Subjects"},"volume":"Vol.1830","number":"No.4","starting_page":"2917","ending_page":"2923","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bbagen.2013.01.006"],"issn":["0304-4165"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:102, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512971"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23283135","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84874659901&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325171","label":"url"}],"paper_title":{"en":"A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy","ja":"A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy"},"authors":{"en":[{"name":"Kodama A"},{"name":"Watanabe H"},{"name":"Tanaka R"},{"name":"Tanaka H"},{"name":"Chuang VT"},{"name":"Miyamoto Y"},{"name":"Wu Q"},{"name":"Endo M"},{"name":"Hamasaki K"},{"name":"Ishima Yu"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Kodama A"},{"name":"Watanabe H"},{"name":"Tanaka R"},{"name":"Tanaka H"},{"name":"Chuang VT"},{"name":"Miyamoto Y"},{"name":"Wu Q"},{"name":"Endo M"},{"name":"Hamasaki K"},{"name":"異島 優"},{"name":"Fukagawa M"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"publication_date":"2013-03","publication_name":{"en":"Kidney International","ja":"Kidney International"},"volume":"Vol.83","number":"No.3","starting_page":"446","ending_page":"456","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/ki.2012.429"],"issn":["0085-2538"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:103, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512972"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23047897","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325173","label":"url"}],"paper_title":{"en":"S-nitrosated _-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis","ja":"S-nitrosated _-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Watanabe K"},{"name":"Akaike T"},{"name":"Sawa T"},{"name":"Kuroda T"},{"name":"Ogawa W"},{"name":"Watanabe H"},{"name":"Suenaga A"},{"name":"Kai T"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"Watanabe K"},{"name":"Akaike T"},{"name":"Sawa T"},{"name":"Kuroda T"},{"name":"Ogawa W"},{"name":"Watanabe H"},{"name":"Suenaga A"},{"name":"Kai T"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Treating infections with exogenous NO, which shows broad-spectrum antimicrobial activity, appears to be effective. Similar to NO biosynthesis, biosynthesis of α-1-acid glycoprotein variant A (AGPa), with a reduced cysteine (Cys149), increases markedly during inflammation and infection. We hypothesized that AGPa is an S-nitrosation target in acute-phase proteins. This study aimed to determine whether S-nitrosated AGPa (SNO-AGPa) may be the first compound of this novel antibacterial class against multidrug-resistant bacteria. AGPa was incubated with RAW264.7 cells activated by lipopolysaccharide and interferon-γ. The antimicrobial effects of SNO-AGPa were determined by measuring the turbidity of the bacterial suspensions in vitro and survival in a murine sepsis model in vivo, respectively. Results indicated that endogenous NO generated by activated RAW264.7 cells caused S-nitrosation of AGPa at Cys149. SNO-AGPa strongly inhibited growth of gram-positive, gram-negative, and multidrug-resistant bacteria and was an extremely potent bacteriostatic compound (IC(50): 10(-9) to 10(-6) M). The antibacterial mechanism of SNO-AGPa involves S-transnitrosation from SNO-AGPa to bacterial cells. Treatment with SNO-AGPa, but not with AGPa, markedly reduced bacterial counts in blood and liver in a mouse sepsis model. The sialyl residues of AGPa seem to suppress the antibacterial activity, since SNO-asialo AGPa was more potent than SNO-AGPa.","ja":"Treating infections with exogenous NO, which shows broad-spectrum antimicrobial activity, appears to be effective. Similar to NO biosynthesis, biosynthesis of α-1-acid glycoprotein variant A (AGPa), with a reduced cysteine (Cys149), increases markedly during inflammation and infection. We hypothesized that AGPa is an S-nitrosation target in acute-phase proteins. This study aimed to determine whether S-nitrosated AGPa (SNO-AGPa) may be the first compound of this novel antibacterial class against multidrug-resistant bacteria. AGPa was incubated with RAW264.7 cells activated by lipopolysaccharide and interferon-γ. The antimicrobial effects of SNO-AGPa were determined by measuring the turbidity of the bacterial suspensions in vitro and survival in a murine sepsis model in vivo, respectively. Results indicated that endogenous NO generated by activated RAW264.7 cells caused S-nitrosation of AGPa at Cys149. SNO-AGPa strongly inhibited growth of gram-positive, gram-negative, and multidrug-resistant bacteria and was an extremely potent bacteriostatic compound (IC(50): 10(-9) to 10(-6) M). The antibacterial mechanism of SNO-AGPa involves S-transnitrosation from SNO-AGPa to bacterial cells. Treatment with SNO-AGPa, but not with AGPa, markedly reduced bacterial counts in blood and liver in a mouse sepsis model. The sialyl residues of AGPa seem to suppress the antibacterial activity, since SNO-asialo AGPa was more potent than SNO-AGPa."},"publication_date":"2013-01-01","publication_name":{"en":"The FASEB journal","ja":"The FASEB journal"},"volume":"Vol.27","number":"No.1","starting_page":"391","ending_page":"398","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1096/fj.12-217794"],"issn":["1530-6860"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:104, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512973"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23063551","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84867767304&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325172","label":"url"}],"paper_title":{"en":"Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models","ja":"Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Hara M"},{"name":"Kragh-Hansen U"},{"name":"Inoue A"},{"name":"Suenaga A"},{"name":"Kai T"},{"name":"Watanabe H"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"異島 優"},{"name":"Hara M"},{"name":"Kragh-Hansen U"},{"name":"Inoue A"},{"name":"Suenaga A"},{"name":"Kai T"},{"name":"Watanabe H"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Human serum albumin (HSA) is the most abundant circulating protein and its S-nitrosated form serves as a reservoir of nitric oxide (NO). Previously, we prepared poly-S-nitrosated HSA (Poly-SNO-HSA) by incubation with Traut's Reagent and isopentyl nitrite and evaluated its potential as a novel anticancer agent through apoptosis involving the caspase-3 pathway. Recently, NO donors such as nitroglycerin were reported to revert the resistance to anticancer agents. Therefore, now we have evaluated the effect of the above type of Poly-SNO-HSA on the resistance to doxorubicin (dx) in human myelogenous leukemic cells (K562 cells). P-gp expression and dx accumulation in K562 and dx-resistant K562 cells (K562/dx cells) were quantified using Western blot and FACS analysis, respectively. Compared with parent K562 cells, higher expression of P-gp and lower accumulation of dx were shown in K562/dx cells. Poly-SNO-HSA caused increased dx accumulation in K562/dx cells by decreasing the expressions of P-gp and HIF-1α. Other experiments with the guanylate cyclase inhibitor ODQ and 8-Br-cGMP revealed that also a cGMP signaling pathway is involved in the Poly-SNO-HSA induced increase in dx accumulation. Furthermore, in vivo studies showed that co-treatment with Poly-SNO-HSA enhanced the anticancer effect of dx in K562/dx cells-bearing mice. Thus, in addition to its proapoptotic effect Poly-SNO-HSA can in an efficient manner revert drug resistance both in vitro and in vivo, and two pathways for this effect have been identified.","ja":"Human serum albumin (HSA) is the most abundant circulating protein and its S-nitrosated form serves as a reservoir of nitric oxide (NO). Previously, we prepared poly-S-nitrosated HSA (Poly-SNO-HSA) by incubation with Traut's Reagent and isopentyl nitrite and evaluated its potential as a novel anticancer agent through apoptosis involving the caspase-3 pathway. Recently, NO donors such as nitroglycerin were reported to revert the resistance to anticancer agents. Therefore, now we have evaluated the effect of the above type of Poly-SNO-HSA on the resistance to doxorubicin (dx) in human myelogenous leukemic cells (K562 cells). P-gp expression and dx accumulation in K562 and dx-resistant K562 cells (K562/dx cells) were quantified using Western blot and FACS analysis, respectively. Compared with parent K562 cells, higher expression of P-gp and lower accumulation of dx were shown in K562/dx cells. Poly-SNO-HSA caused increased dx accumulation in K562/dx cells by decreasing the expressions of P-gp and HIF-1α. Other experiments with the guanylate cyclase inhibitor ODQ and 8-Br-cGMP revealed that also a cGMP signaling pathway is involved in the Poly-SNO-HSA induced increase in dx accumulation. Furthermore, in vivo studies showed that co-treatment with Poly-SNO-HSA enhanced the anticancer effect of dx in K562/dx cells-bearing mice. Thus, in addition to its proapoptotic effect Poly-SNO-HSA can in an efficient manner revert drug resistance both in vitro and in vivo, and two pathways for this effect have been identified."},"publication_date":"2012-11-28","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.164","number":"No.1","starting_page":"1","ending_page":"7","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2012.10.003"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:105, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512974"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22898098","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84866623691&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325174","label":"url"}],"paper_title":{"en":"A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate","ja":"A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate"},"authors":{"en":[{"name":"Miyamoto Y"},{"name":"Iwao Y"},{"name":"Mera K"},{"name":"Watanabe H"},{"name":"Kadowaki D"},{"name":"Ishima Yu"},{"name":"Chuang VT"},{"name":"Sato K"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Miyamoto Y"},{"name":"Iwao Y"},{"name":"Mera K"},{"name":"Watanabe H"},{"name":"Kadowaki D"},{"name":"異島 優"},{"name":"Chuang VT"},{"name":"Sato K"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), a furan fatty acid uremic toxin (UT) and a substrate for organic ion transporters, contributes to the accumulation of CMPF in renal tubular cells. Although oxidative stress induced by UTs has been proposed as a mechanism of its toxicity in chronic kidney disease, little information is available regarding the redox property of CMPF and its relation to renal cell damage. The findings herein show that CMPF enhances the production of reactive oxygen species (ROS) in HK-2 cells in the presence of angiotensin II (A-II), an inducer of O(2)(·-). When iron is also present, CMPF and A-II induce the Fenton reaction, resulting in a further increase in ROS production. Such CMPF-induced oxidative stress increases TGF-β1 secretion in HK-2 cells, and a positive correlation between CMPF-induced ROS production and the secretion of active TGF-β1 was observed. CMPF caused a reduction in cell viability which was negatively correlated with intracellular ROS production. These negative effects of CMPF in HK-2 cells were completely suppressed by probenecid, an inhibitor of organic anion transport. Interestingly, in vitro ROS assays indicate that CMPF directly interacts with superoxide anion radicals (O(2)(·-)) and peroxy radicals (LOO) to produce CMPF radicals. The subsequent interaction of CMPF radicals with dissolved oxygen leads to the overproduction of O(2)(·-). Based on these findings, we conclude that CMPF, which accumulates in the renal cells, appears to play a prominent role as a pro-oxidant which subsequently leads to renal cellular damage via the overproduction of O(2)(·-).","ja":"3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), a furan fatty acid uremic toxin (UT) and a substrate for organic ion transporters, contributes to the accumulation of CMPF in renal tubular cells. Although oxidative stress induced by UTs has been proposed as a mechanism of its toxicity in chronic kidney disease, little information is available regarding the redox property of CMPF and its relation to renal cell damage. The findings herein show that CMPF enhances the production of reactive oxygen species (ROS) in HK-2 cells in the presence of angiotensin II (A-II), an inducer of O(2)(·-). When iron is also present, CMPF and A-II induce the Fenton reaction, resulting in a further increase in ROS production. Such CMPF-induced oxidative stress increases TGF-β1 secretion in HK-2 cells, and a positive correlation between CMPF-induced ROS production and the secretion of active TGF-β1 was observed. CMPF caused a reduction in cell viability which was negatively correlated with intracellular ROS production. These negative effects of CMPF in HK-2 cells were completely suppressed by probenecid, an inhibitor of organic anion transport. Interestingly, in vitro ROS assays indicate that CMPF directly interacts with superoxide anion radicals (O(2)(·-)) and peroxy radicals (LOO) to produce CMPF radicals. The subsequent interaction of CMPF radicals with dissolved oxygen leads to the overproduction of O(2)(·-). Based on these findings, we conclude that CMPF, which accumulates in the renal cells, appears to play a prominent role as a pro-oxidant which subsequently leads to renal cellular damage via the overproduction of O(2)(·-)."},"publication_date":"2012-11-01","publication_name":{"en":"Biochemical Pharmacology","ja":"Biochemical Pharmacology"},"volume":"Vol.84","number":"No.9","starting_page":"1207","ending_page":"1214","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.bcp.2012.07.033"],"issn":["1873-2968"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:106, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512975"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22488009","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325272","label":"url"}],"paper_title":{"en":"S-guanylation of human serum albumin is a unique posttranslational modification and results in a novel class of antibacterial agents","ja":"S-guanylation of human serum albumin is a unique posttranslational modification and results in a novel class of antibacterial agents"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Hoshino H"},{"name":"Shinagawa T"},{"name":"Watanabe K"},{"name":"Akaike T"},{"name":"Sawa T"},{"name":"Kragh-Hansen U"},{"name":"Kai T"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otagiri M"}],"ja":[{"name":"異島 優"},{"name":"Hoshino H"},{"name":"Shinagawa T"},{"name":"Watanabe K"},{"name":"Akaike T"},{"name":"Sawa T"},{"name":"Kragh-Hansen U"},{"name":"Kai T"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otagiri M"}]},"description":{"en":"8-Nitroguanosine 3',5'-cyclic monophosphate (8-nitro-cGMP) is a nitric oxide metabolite and an important second messenger. 8-Nitro-cGMP reacts with sulfhydryl groups forming a novel posttranslational modification, namely, S-guanylation. In this work, we found, by using a quantitative competition enzyme-linked immunosorbent assay procedure, that S-guanylated human serum albumin (S-cGMP-HSA) is a component of normal plasma, and that hemodialysis patients decrease its concentration, on an average, from 68 to 34 nM. End-stage renal disease is often accompanied by septicemia, and we found that S-cGMP-HSA possesses an in vitro antibacterial effect with half maximal inhibitory concentration of approximately 2 μM against Escherichia coli American Type Culture Collection. Our findings indicate that S-cGMP-HSA can be regarded as an endogenous antibacterial agent in healthy conditions and as a useful new class of antibacterial agents with a circulation time sufficient for in vivo biological activity. The clinical development of S-cGMP-HSA as a safe and strong antibacterial agent arisen from endogenous posttranslational modification would be expected.","ja":"8-Nitroguanosine 3',5'-cyclic monophosphate (8-nitro-cGMP) is a nitric oxide metabolite and an important second messenger. 8-Nitro-cGMP reacts with sulfhydryl groups forming a novel posttranslational modification, namely, S-guanylation. In this work, we found, by using a quantitative competition enzyme-linked immunosorbent assay procedure, that S-guanylated human serum albumin (S-cGMP-HSA) is a component of normal plasma, and that hemodialysis patients decrease its concentration, on an average, from 68 to 34 nM. End-stage renal disease is often accompanied by septicemia, and we found that S-cGMP-HSA possesses an in vitro antibacterial effect with half maximal inhibitory concentration of approximately 2 μM against Escherichia coli American Type Culture Collection. Our findings indicate that S-cGMP-HSA can be regarded as an endogenous antibacterial agent in healthy conditions and as a useful new class of antibacterial agents with a circulation time sufficient for in vivo biological activity. The clinical development of S-cGMP-HSA as a safe and strong antibacterial agent arisen from endogenous posttranslational modification would be expected."},"publication_date":"2012-09","publication_name":{"en":"Journal of Pharmaceutical Sciences","ja":"Journal of Pharmaceutical Sciences"},"volume":"Vol.101","number":"No.9","starting_page":"3222","ending_page":"3229","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/jps.23143"],"issn":["1520-6017"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:107, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512976"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22513409","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84862683519&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325271","label":"url"}],"paper_title":{"en":"Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin","ja":"Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin"},"authors":{"en":[{"name":"Watanabe H"},{"name":"Noguchi T"},{"name":"Miyamoto Y"},{"name":"Kadowaki D"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Miyamura S"},{"name":"Ishima Yu"},{"name":"Otagiri M"},{"name":"Maruyama T"}],"ja":[{"name":"Watanabe H"},{"name":"Noguchi T"},{"name":"Miyamoto Y"},{"name":"Kadowaki D"},{"name":"Kotani S"},{"name":"Nakajima M"},{"name":"Miyamura S"},{"name":"異島 優"},{"name":"Otagiri M"},{"name":"Maruyama T"}]},"description":{"en":"Recently, p-cresyl sulfate (PCS) has been identified as a protein-bound uremic toxin. Moreover, the serum-free concentration of PCS, which is associated with its efficacy of hemodialysis, appears to be a good predictor of survival in chronic kidney disease (CKD). We previously found that PCS interacts with indoxyl sulfate (IS), another sulfate-conjugated uremic toxin, during renal excretion via a common transporter. The purpose of this study was to further investigate the interaction between PCS and IS on the binding to human serum albumin (HSA). Here, we used ultrafiltration to show that there is only one high-affinity binding site for PCS, with a binding constant on the order of 10(5) M(-1) (i.e., comparable to that of IS). However, a binding constant of the low-affinity binding site for PCS is 2.5-fold greater than that for IS. Displacement of a fluorescence probe showed that PCS mainly binds to site II, which is the high-affinity site for PCS, on HSA. This finding was further supported by experiments using mutant HSA (R410A/Y411A) that displayed reduced site II ligand binding. A Klotz analysis showed that there could be competitive inhibition between PCS and IS on HSA binding. A similar interaction between PCS and IS on HSA was also observed under the conditions mimicking CKD stage 4 to 5. The present study suggests that competitive interactions between PCS and IS in both HSA binding and the renal excretion process could contribute to fluctuations in their free serum concentrations in patients with CKD.","ja":"Recently, p-cresyl sulfate (PCS) has been identified as a protein-bound uremic toxin. Moreover, the serum-free concentration of PCS, which is associated with its efficacy of hemodialysis, appears to be a good predictor of survival in chronic kidney disease (CKD). We previously found that PCS interacts with indoxyl sulfate (IS), another sulfate-conjugated uremic toxin, during renal excretion via a common transporter. The purpose of this study was to further investigate the interaction between PCS and IS on the binding to human serum albumin (HSA). Here, we used ultrafiltration to show that there is only one high-affinity binding site for PCS, with a binding constant on the order of 10(5) M(-1) (i.e., comparable to that of IS). However, a binding constant of the low-affinity binding site for PCS is 2.5-fold greater than that for IS. Displacement of a fluorescence probe showed that PCS mainly binds to site II, which is the high-affinity site for PCS, on HSA. This finding was further supported by experiments using mutant HSA (R410A/Y411A) that displayed reduced site II ligand binding. A Klotz analysis showed that there could be competitive inhibition between PCS and IS on HSA binding. A similar interaction between PCS and IS on HSA was also observed under the conditions mimicking CKD stage 4 to 5. The present study suggests that competitive interactions between PCS and IS in both HSA binding and the renal excretion process could contribute to fluctuations in their free serum concentrations in patients with CKD."},"publication_date":"2012-07-01","publication_name":{"en":"Drug Metabolism and Disposition","ja":"Drug Metabolism and Disposition"},"volume":"Vol.40","number":"No.7","starting_page":"1423","ending_page":"1428","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1124/dmd.112.045617"],"issn":["1521-009X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:108, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512977"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22351593","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84859795566&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325273","label":"url"}],"paper_title":{"en":"Quantitative evaluation of the role of cysteine and methionine residues in the antioxidant activity of human serum albumin using recombinant mutants","ja":"Quantitative evaluation of the role of cysteine and methionine residues in the antioxidant activity of human serum albumin using recombinant mutants"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Iwao Y"},{"name":"Yamada J"},{"name":"Noguchi T"},{"name":"Kragh-Hansen U"},{"name":"Mera K"},{"name":"Honda D"},{"name":"Suenaga A"},{"name":"Maruyama T"},{"name":"Otagiri M"}],"ja":[{"name":"異島 優"},{"name":"Iwao Y"},{"name":"Yamada J"},{"name":"Noguchi T"},{"name":"Kragh-Hansen U"},{"name":"Mera K"},{"name":"Honda D"},{"name":"Suenaga A"},{"name":"Maruyama T"},{"name":"Otagiri M"}]},"description":{"en":"The importance of cysteine (Cys) and methionine (Met) residues for the antioxidant activity of human serum albumin (HSA) was investigated using recombinant HSA mutants, in which Cys34 and/or the six Met residues had been mutated to Ala. The scavenging activities of the mutants against five reactive oxygen and nitrogen species were evaluated by a chemiluminescence assay, electron paramagnetic resonance spectroscopy, or a HPLC-flow reactor assay. Our results showed that the contributions of Cys34 and the Met residues to the antioxidant activity of HSA were 61% and 29% against O(2)(·-), 68% and 61% against H(2)O(2), 38% and 6% against HO(·), 36% and 13% against HOCl, and 51% and 1% against (·)NO, respectively. Thus, the findings propose in a direct way that Cys34 plays a more important role than the Met residues in the antioxidant activity of HSA.","ja":"The importance of cysteine (Cys) and methionine (Met) residues for the antioxidant activity of human serum albumin (HSA) was investigated using recombinant HSA mutants, in which Cys34 and/or the six Met residues had been mutated to Ala. The scavenging activities of the mutants against five reactive oxygen and nitrogen species were evaluated by a chemiluminescence assay, electron paramagnetic resonance spectroscopy, or a HPLC-flow reactor assay. Our results showed that the contributions of Cys34 and the Met residues to the antioxidant activity of HSA were 61% and 29% against O(2)(·-), 68% and 61% against H(2)O(2), 38% and 6% against HO(·), 36% and 13% against HOCl, and 51% and 1% against (·)NO, respectively. Thus, the findings propose in a direct way that Cys34 plays a more important role than the Met residues in the antioxidant activity of HSA."},"publication_date":"2012-05","publication_name":{"en":"IUBMB life","ja":"IUBMB life"},"volume":"Vol.64","number":"No.5","starting_page":"450","ending_page":"454","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/iub.567"],"issn":["1521-6551"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:109, {"insert":{"user_id":"B000320827","type":"published_papers","id":"30512978"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22225412","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84863147496&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325274","label":"url"}],"paper_title":{"en":"S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects","ja":"S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Chen D"},{"name":"Fang J"},{"name":"Maeda H"},{"name":"Minomo A"},{"name":"Kragh-Hansen U"},{"name":"Kai T"},{"name":"Maruyama T"},{"name":"Otagiri M"}],"ja":[{"name":"異島 優"},{"name":"Chen D"},{"name":"Fang J"},{"name":"Maeda H"},{"name":"Minomo A"},{"name":"Kragh-Hansen U"},{"name":"Kai T"},{"name":"Maruyama T"},{"name":"Otagiri M"}]},"description":{"en":"Macromolecules have been developed as carriers of low-molecular-weight drugs in drug delivery systems (DDS) to improve their pharmacokinetic profile or to promote their uptake in tumor tissue via enhanced permeability and retention (EPR) effects. In the present study, recombinant human serum albumin dimer (AL-Dimer), which was designed by linking two human serum albumin (HSA) molecules with the amino acid linker (GGGGS)(2), significantly accumulated in tumor tissue even more than HSA Monomer (AL-Monomer) and appearing to have good retention in circulating blood in murine colon 26 (C26) tumor-bearing mice. Moreover, we developed S-nitrosated AL-Dimer (SNO-AL-Dimer) as a novel DDS compound containing AL-Dimer as a carrier, and nitric oxide (NO) as (i) an anticancer therapeutic drug/cell death inducer and (ii) an enhancer of the EPR effect. We observed that SNO-AL-Dimer treatment induced apoptosis of C26 tumor cells in vitro, depending on the concentration of NO. In in vivo experiments, SNO-AL-Dimer was found to specifically deliver large amounts of cytotoxic NO into tumor tissue but not into normal organs in C26 tumor-bearing mice as compared with control (untreated tumor-bearing mice) and SNO-AL-Monomer-treated mice. Intriguingly, S-nitrosation improved the uptake of AL-Dimer in tumor tissue through augmenting the EPR effect. These data suggest that SNO-AL-Dimer behaves not only as an anticancer therapeutic drug, but also as a potentiator of the EPR effect. Therefore, SNO-AL-Dimer would be a very appealing carrier for utilization of the EPR effect in future development of cancer therapeutics.","ja":"Macromolecules have been developed as carriers of low-molecular-weight drugs in drug delivery systems (DDS) to improve their pharmacokinetic profile or to promote their uptake in tumor tissue via enhanced permeability and retention (EPR) effects. In the present study, recombinant human serum albumin dimer (AL-Dimer), which was designed by linking two human serum albumin (HSA) molecules with the amino acid linker (GGGGS)(2), significantly accumulated in tumor tissue even more than HSA Monomer (AL-Monomer) and appearing to have good retention in circulating blood in murine colon 26 (C26) tumor-bearing mice. Moreover, we developed S-nitrosated AL-Dimer (SNO-AL-Dimer) as a novel DDS compound containing AL-Dimer as a carrier, and nitric oxide (NO) as (i) an anticancer therapeutic drug/cell death inducer and (ii) an enhancer of the EPR effect. We observed that SNO-AL-Dimer treatment induced apoptosis of C26 tumor cells in vitro, depending on the concentration of NO. In in vivo experiments, SNO-AL-Dimer was found to specifically deliver large amounts of cytotoxic NO into tumor tissue but not into normal organs in C26 tumor-bearing mice as compared with control (untreated tumor-bearing mice) and SNO-AL-Monomer-treated mice. Intriguingly, S-nitrosation improved the uptake of AL-Dimer in tumor tissue through augmenting the EPR effect. These data suggest that SNO-AL-Dimer behaves not only as an anticancer therapeutic drug, but also as a potentiator of the EPR effect. Therefore, SNO-AL-Dimer would be a very appealing carrier for utilization of the EPR effect in future development of cancer therapeutics."},"publication_date":"2012-02-15","publication_name":{"en":"Bioconjugate Chemistry","ja":"Bioconjugate Chemistry"},"volume":"Vol.23","number":"No.2","starting_page":"264","ending_page":"271","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/bc2005363"],"issn":["1520-4812"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/published_papers.jsonl, jzUbQZMBYVtrs4O8011T) ====
==== begin registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/misc.jsonl) ====
line:1, {"insert":{"user_id":"B000320827","type":"misc"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=403535","label":"url"}],"paper_title":{"en":"血清アルブミンに存在する超硫黄の解析と創薬応用","ja":"血清アルブミンに存在する超硫黄の解析と創薬応用"},"authors":{"en":[{"name":"Ikeda Mayumi"},{"name":"Fukuta Tatsuya"},{"name":"岩尾 康範"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"池田 真由美"},{"name":"福田 達也"},{"name":"岩尾 康範"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"publication_date":"2024-01","publication_name":{"en":"Journal of the Pharmaceutical Society of Japan","ja":"薬学雑誌"},"volume":"Vol.144","number":"No.1","starting_page":"51","ending_page":"56","languages":["jpn"],"identifiers":{"doi":["10.1248/yakushi.23-00162-3"],"issn":["1347-5231"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:2, {"insert":{"user_id":"B000320827","type":"misc","id":"40052466"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392155","label":"url"}],"paper_title":{"en":"Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products","ja":"Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products"},"authors":{"en":[{"name":"Mohamed Ibrahim"},{"name":"Abdelhameed Mostafa Ramadan Eslam"},{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"Emam Abdallah Emam Sherif"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Omar Helmy Elgarhy"},{"name":"Hatem A Sarhan"},{"name":"Amal K Hussein"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Mohamed Ibrahim"},{"name":"ESLAM RAMADAN MOSTAFA ABDELHAMEED"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"Omar Helmy Elgarhy"},{"name":"Hatem A Sarhan"},{"name":"Amal K Hussein"},{"name":"石田 竜弘"}]},"publication_date":"2022-11","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"Vol.351","starting_page":"215","ending_page":"230","languages":["eng"],"identifiers":{"doi":["10.1016/j.jconrel.2022.09.031"],"issn":["0168-3659"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:3, {"insert":{"user_id":"B000320827","type":"misc","id":"36513541"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384612","label":"url"}],"paper_title":{"en":"The challenge to deliver oxaliplatin (l-OHP) to solid tumors: development of liposomal l-OHP formulations","ja":"The challenge to deliver oxaliplatin (l-OHP) to solid tumors: development of liposomal l-OHP formulations"},"authors":{"en":[{"name":"Matsuo Nana"},{"name":"ANDO Hidenori"},{"name":"Doi Yusuke"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 菜々"},{"name":"安藤 英紀"},{"name":"土井 祐輔"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2022-05-01","publication_name":{"en":"Chemical & Pharmaceutical Bulletin","ja":"Chemical & Pharmaceutical Bulletin"},"volume":"Vol.70","number":"No.5","starting_page":"351","ending_page":"358","languages":["eng"],"identifiers":{"doi":["10.1248/cpb.c22-00099"],"issn":["1347-5223"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:4, {"insert":{"user_id":"B000320827","type":"misc","id":"36164912"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383647","label":"url"}],"paper_title":{"en":"The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors","ja":"The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"Chuang Victor T G"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"Chuang Victor T G"},{"name":"石田 竜弘"}]},"publication_date":"2022-05-01","publication_name":{"en":"Chemical & Pharmaceutical Bulletin","ja":"Chemical & Pharmaceutical Bulletin"},"volume":"Vol.70","number":"No.5","starting_page":"330","ending_page":"333","languages":["eng"],"identifiers":{"doi":["10.1248/cpb.c21-01024"],"issn":["1347-5223"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:5, {"insert":{"user_id":"B000320827","type":"misc","id":"31958922"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374412","label":"url"}],"paper_title":{"en":"Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport System","ja":"Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport System"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"Maruyama Toru"},{"name":"Otagiri Masaki"},{"name":"石田 竜弘"}]},"publication_date":"2020-07-01","publication_name":{"en":"Chemical & Pharmaceutical Bulletin","ja":"Chemical & Pharmaceutical Bulletin"},"volume":"Vol.68","number":"No.7","starting_page":"583","ending_page":"588","languages":["eng"],"identifiers":{"doi":["10.1248/cpb.c20-00026"],"issn":["1347-5223"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:6, {"insert":{"user_id":"B000320827","type":"misc","id":"30513030"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366421","label":"url"}],"paper_title":{"en":"タンパクのPEG修飾によるPEG免疫応答の誘導","ja":"タンパクのPEG修飾によるPEG免疫応答の誘導"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2020-02-01","publication_name":{"en":"Journal of the Pharmaceutical Society of Japan","ja":"薬学雑誌"},"volume":"Vol.140","number":"No.2","starting_page":"163","ending_page":"169","languages":["jpn"],"identifiers":{"doi":["10.1248/yakushi.19-00187-5"],"issn":["1347-5231"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:7, {"insert":{"user_id":"B000320827","type":"misc","id":"30507452"},"force":{"see_also":[{"@id":"http://id.ndl.go.jp/bib/028929708","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390282763015033344/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=337619","label":"url"}],"paper_title":{"en":"Control of EPR effect by tumor-targeted NO donor via endogenous albumin transport system","ja":"内因性アルブミン輸送システムを利用した腫瘍選択的NO供与によるEPR効果の制御"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"},{"name":"小田切 優樹"}],"ja":[{"name":"異島 優"},{"name":"丸山 徹"},{"name":"石田 竜弘"},{"name":"小田切 優樹"}]},"description":{"en":"A unique phenomenon in solid tumors, enhanced permeability and retention(EPR) effect, is very famous for the development of macromolecular anticancer therapy. However, cancers with low vascular permeability posed a challenge for these EPR based therapeutic systems. An intrinsic vascular modulator such as nitric oxide(NO) could augment the intrinsic EPR effect. We have demonstrated that S-nitrosated human serum albumin dimer(SNO-HSA Dimer) becomes an enhancer of the EPR effect in various tumor-bearing mice models. Here, we summarized the enhanced effect of SNO-HSA Dimer on the anticancer effect of two types of macromolecular anticancer drugs, namely PEGylated liposomal doxorubicin(Doxil<sup>®</sup>) and albumin bound paclitaxel nanoparticle(Abraxane<sup>®</sup>). In C26-bearing mice with highly permeable vasculature, SNO-HSA Dimer could increase tumor accumulation of these anticancer drugs and thereby their anticancer effects. Interestingly, the tumor accumulation of Doxil<sup>®</sup> in B16-bearing mice, which are characterized by a low permeable vasculature, increased more 6-fold in the presence of SNO-HSA Dimer, and the improved accumulation of Doxil<sup>®</sup> led to increased survival and decreased tumor volume. On the other hand, SNO-HSA Dimer also augmented the tumor growth inhibition of Abraxane<sup>®</sup> in low vascular permeability B16-bearing mice. Furthermore, Abraxane<sup>®</sup> combined with SNO-HSA Dimer showed higher antitumor activity and improved survival rate of SUIT2 human pancreatic cancer orthotopic model. We also showed that the administration of SNO-HSA Dimer had no effect on blood pressure, heart rate and biochemical parameters, suggesting that SNO-HSA Dimer alone is very safe. Accordingly, we conclude that SNO-HSA Dimer is promising for regulating the EPR effect and enhanced therapeutic effects of many macromolecular anticancer drugs.","ja":"EPR効果は，高分子抗がん療法の開発の基礎となり得るが，低い血管透過性を有するがん領域では，このEPR効果のみでは十分な送達性が得られない．したがって，一酸化窒素(NO)のような血管調節分子で内因性EPR効果を増強することは極めて有望な戦略である．筆者らは，ヒト血清アルブミン二量体の<i>S</i>―ニトロソ化体(SNO―HSA Dimer)がEPR効果の増強剤であることを検討してきた．ここでは，すでに承認されたPEG化リポソーム・ドキソルビシン(Doxil®)およびアルブミン結合型パクリタキセル・ナノ粒子(Abraxane<sup>®</sup>)の2種類の高分子抗がん剤を用い，血管透過性が高いC26や血管透過性が低いB16担がんモデル，臨床病態に近いとされているSUIT2ヒト膵臓がん同所性モデルにて得られた結果を中心に報告する．"},"publication_date":"2018-03-25","publication_name":{"en":"Drug Delivery System","ja":"Drug Delivery System"},"volume":"Vol.33","number":"No.2","starting_page":"130","ending_page":"138","languages":["jpn"],"identifiers":{"doi":["10.2745/dds.33.130"],"issn":["0913-5006"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:8, {"insert":{"user_id":"B000320827","type":"misc","id":"30513031"},"force":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390001204641700864/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=335199","label":"url"}],"paper_title":{"en":"Accelerated blood clearance (ABC) 現象における動物種差","ja":"Accelerated blood clearance (ABC) 現象における動物種差"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2017-11","publication_name":{"en":"Drug Delivery System","ja":"Drug Delivery System"},"volume":"Vol.32","number":"No.5","starting_page":"396","ending_page":"401","languages":["jpn"],"identifiers":{"doi":["10.2745/dds.32.396"],"issn":["1881-2732"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:9, {"insert":{"user_id":"B000320827","type":"misc","id":"30513032"},"force":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390282679617948032/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=328447","label":"url"}],"paper_title":{"en":"ナノ粒子に対する補体活性化の功罪","ja":"ナノ粒子に対する補体活性化の功罪"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2017-08","publication_name":{"en":"Drug Delivery System","ja":"Drug Delivery System"},"volume":"Vol.32","number":"No.3","starting_page":"199","ending_page":"207","languages":["jpn"],"identifiers":{"doi":["10.2745/dds.32.199"],"issn":["1881-2732"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
line:10, {"insert":{"user_id":"B000320827","type":"misc","id":"30513033"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24490156","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84896099330&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325277","label":"url"}],"paper_title":{"en":"Poly-S-Nitrosated Albumin as a Safe and Effective Multifunctional Antitumor Agent: Characterization, Biochemistry and Possible Future Therapeutic Applications","ja":"Poly-S-Nitrosated Albumin as a Safe and Effective Multifunctional Antitumor Agent: Characterization, Biochemistry and Possible Future Therapeutic Applications"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Kragh-Hansen U"},{"name":"Maruyama T"},{"name":"Otagiri M"}],"ja":[{"name":"異島 優"},{"name":"Kragh-Hansen U"},{"name":"Maruyama T"},{"name":"Otagiri M"}]},"description":{"en":"Nitric oxide (NO) is a ubiquitous molecule involved in multiple cellular functions. Inappropriate production of NO may lead to disease states. To date, pharmacologically active compounds that release NO within the body, such as organic nitrates, have been used as therapeutic agents, but their efficacy is significantly limited by unwanted side effects. Therefore, novel NO donors with better pharmacological and pharmacokinetic properties are highly desirable. The S-nitrosothiol fraction in plasma is largely composed of endogenous S-nitrosated human serum albumin (Mono-SNO-HSA), and that is why we are testing whether this albumin form can be therapeutically useful. Recently, we developed SNO-HSA analogs such as SNO-HSA with many conjugated SNO groups (Poly-SNO-HSA) which were prepared using chemical modification. Unexpectedly, we found striking inverse effects between Poly-SNO-HSA and Mono-SNO-HSA. Despite the fact that Mono-SNO-HSA inhibits apoptosis, Poly-SNO-HSA possesses very strong proapoptotic effects against tumor cells. Furthermore, Poly-SNO-HSA can reduce or perhaps completely eliminate the multidrug resistance often developed by cancer cells. In this review, we forward the possibility that Poly-SNO-HSA can be used as a safe and effective multifunctional antitumor agent.","ja":"Nitric oxide (NO) is a ubiquitous molecule involved in multiple cellular functions. Inappropriate production of NO may lead to disease states. To date, pharmacologically active compounds that release NO within the body, such as organic nitrates, have been used as therapeutic agents, but their efficacy is significantly limited by unwanted side effects. Therefore, novel NO donors with better pharmacological and pharmacokinetic properties are highly desirable. The S-nitrosothiol fraction in plasma is largely composed of endogenous S-nitrosated human serum albumin (Mono-SNO-HSA), and that is why we are testing whether this albumin form can be therapeutically useful. Recently, we developed SNO-HSA analogs such as SNO-HSA with many conjugated SNO groups (Poly-SNO-HSA) which were prepared using chemical modification. Unexpectedly, we found striking inverse effects between Poly-SNO-HSA and Mono-SNO-HSA. Despite the fact that Mono-SNO-HSA inhibits apoptosis, Poly-SNO-HSA possesses very strong proapoptotic effects against tumor cells. Furthermore, Poly-SNO-HSA can reduce or perhaps completely eliminate the multidrug resistance often developed by cancer cells. In this review, we forward the possibility that Poly-SNO-HSA can be used as a safe and effective multifunctional antitumor agent."},"publication_date":"2013-12-30","publication_name":{"en":"BioMed Research International","ja":"BioMed Research International"},"volume":"Vol.2013","starting_page":"353892","ending_page":"353892","languages":["eng"],"identifiers":{"doi":["10.1155/2013/353892"],"issn":["2314-6141"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/misc.jsonl, kTUbQZMBYVtrs4O80136) ====
==== begin registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/books_etc.jsonl) ====
line:1, {"insert":{"user_id":"B000320827","type":"books_etc","id":"30513035"},"force":{"see_also":[{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85018582734&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=326919","label":"url"}],"book_title":{"en":"S-Nitroso Adducts of Albumin Analogs: Characterization, Categorization, and Possible Future Therapeutic Applications","ja":"S-Nitroso Adducts of Albumin Analogs: Characterization, Categorization, and Possible Future Therapeutic Applications"},"authors":{"en":[{"name":"Ishima Yu"},{"name":"Ulrich Kragh-Hansen"},{"name":"Masaki Otagiri"}],"ja":[{"name":"異島 優"},{"name":"Ulrich Kragh-Hansen"},{"name":"Masaki Otagiri"}]},"publication_date":"2016-11-11","languages":["eng"]},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/books_etc.jsonl, kzUbQZMBYVtrs4O81F1m) ====
==== begin registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/awards.jsonl) ====
line:1, {"insert":{"user_id":"B000320827","type":"awards"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=361988","label":"url"}],"award_name":{"en":"若手研究者学長表彰","ja":"若手研究者学長表彰"},"winners":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"association":{"en":"Tokushima University","ja":"徳島大学"},"award_date":"2019-12-04"},"priority":"input_data"}
line:2, {"insert":{"user_id":"B000320827","type":"awards","id":"38352110"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386255","label":"url"}],"award_name":{"en":"旭化成創剤研究奨励賞","ja":"旭化成創剤研究奨励賞"},"winners":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"award_title":{"en":"アルブミンの体内動態特性に基づくDDSキャリアの開発に関する研究","ja":"アルブミンの体内動態特性に基づくDDSキャリアの開発に関する研究"},"association":{"en":"日本薬剤学会","ja":"日本薬剤学会"},"award_date":"2022-05-27"},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/awards.jsonl, lTUbQZMBYVtrs4O81F3T) ====
==== begin registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/presentations.jsonl) ====
line:1, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768178"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393329","label":"url"}],"presentation_title":{"en":"Induction of neutralizing antibodies by immunization with inactivated human TNF-alpha in mice","ja":"Induction of neutralizing antibodies by immunization with inactivated human TNF-alpha in mice"},"presenters":{"en":[{"name":"Yamamoto Haruka"},{"name":"ANDO Hidenori"},{"name":"Yasukazu Omoto"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 遥香"},{"name":"安藤 英紀"},{"name":"大本 安一"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:2, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768179"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393328","label":"url"}],"presentation_title":{"en":"Development of a novel technique for antibody induction against membrane proteins by spleen immunization with membrane protein-loaded PEG-modified liposomes","ja":"Development of a novel technique for antibody induction against membrane proteins by spleen immunization with membrane protein-loaded PEG-modified liposomes"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:3, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768180"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393326","label":"url"}],"presentation_title":{"en":"An ionic liquids-based topical antitumor vaccine: a mechanism for induction of antitumor immunity via topical application of cancer-antigen peptides","ja":"An ionic liquids-based topical antitumor vaccine: a mechanism for induction of antitumor immunity via topical application of cancer-antigen peptides"},"presenters":{"en":[{"name":"Matsuzaki Takaaki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Yamanaka K"},{"name":"Hamamoto H"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松﨑 隆朗"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"Yamanaka K"},{"name":"Hamamoto H"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:4, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768181"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393325","label":"url"}],"presentation_title":{"en":"Differential organ-specific distribution of human serum albumin denatured by various modifications","ja":"Differential organ-specific distribution of human serum albumin denatured by various modifications"},"presenters":{"en":[{"name":"Hashimoto Aiko"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 愛子"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:5, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768182"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393324","label":"url"}],"presentation_title":{"en":"Neutralization of acidic tumor microenvironment by dosing of sodium potassium citrate (K/Na citrate) enhances antitumor effects of Abraxane®","ja":"Neutralization of acidic tumor microenvironment by dosing of sodium potassium citrate (K/Na citrate) enhances antitumor effects of Abraxane®"},"presenters":{"en":[{"name":"Uehara Riku"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上原 陸"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:6, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768183"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393323","label":"url"}],"presentation_title":{"en":"The mechanism investigation of intestinal absorption enhancement of drugs using ionic liquids","ja":"The mechanism investigation of intestinal absorption enhancement of drugs using ionic liquids"},"presenters":{"en":[{"name":"Fukuda Shoichiro"},{"name":"ANDO Hidenori"},{"name":"Maruyama Atsuya"},{"name":"Nakae Takashi"},{"name":"Tatsumi Noboru"},{"name":"Hamamoto Hidetoshi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 翔一郎"},{"name":"安藤 英紀"},{"name":"丸山 敦也"},{"name":"Nakae Takashi"},{"name":"Tatsumi Noboru"},{"name":"Hamamoto Hidetoshi"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:7, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768184"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393322","label":"url"}],"presentation_title":{"en":"Preparation, optimization, and evaluation of anionic DPPG-based LNPs for delivery of peptide antigens","ja":"Preparation, optimization, and evaluation of anionic DPPG-based LNPs for delivery of peptide antigens"},"presenters":{"en":[{"name":"Abdelhameed Mostafa Ramadan Eslam"},{"name":"ANDO Hidenori"},{"name":"Yamamoto Haruka"},{"name":"Fukumoto Mako"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Eslam Ramadan Mostafa Abdelhameed"},{"name":"安藤 英紀"},{"name":"山本 遥香"},{"name":"福本 真子"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:8, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768185"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393321","label":"url"}],"presentation_title":{"en":"Oral sodium bicarbonate enhances accumulation and antitumor effects of PEGylated liposomal doxorubicin (Doxil®)","ja":"Oral sodium bicarbonate enhances accumulation and antitumor effects of PEGylated liposomal doxorubicin (Doxil®)"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:9, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768186"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393320","label":"url"}],"presentation_title":{"en":"Transfusion of mouse B cells, embedded antigens with hydroxyl PEG-modified liposomes in vitro, induces cellular immune responses in mice","ja":"Transfusion of mouse B cells, embedded antigens with hydroxyl PEG-modified liposomes in vitro, induces cellular immune responses in mice"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:10, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768187"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393319","label":"url"}],"presentation_title":{"en":"Accelerated blood clearance of PEGylated liposomal antitumor agents after topical application of PEG derivatives containing cosmetics in a mouse model","ja":"Accelerated blood clearance of PEGylated liposomal antitumor agents after topical application of PEG derivatives containing cosmetics in a mouse model"},"presenters":{"en":[{"name":"Gaballa S A"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Emam Abdallah Emam Sherif"},{"name":"Ibrahim M"},{"name":"Mady F M"},{"name":"Naguib Y W"},{"name":"Khaled K A"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Gaballa S A"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"Sherif Emam Abdallah Emam"},{"name":"Ibrahim M"},{"name":"Mady F M"},{"name":"Naguib Y W"},{"name":"Khaled K A"},{"name":"石田 竜弘"}]},"event":{"en":"15th International Symposium on Nanomedicine","ja":"15th International Symposium on Nanomedicine"},"publication_date":"2022-12-07","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":true},"priority":"input_data"}
line:11, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768188"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393315","label":"url"}],"presentation_title":{"en":"Biological roles of supersulfide in human hair","ja":"Biological roles of supersulfide in human hair"},"presenters":{"en":[{"name":"Hirai Takeru"},{"name":"Tasaka Nanami"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"平井 傑琉"},{"name":"田坂 菜々美"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"Redox Week in Sendai 2022","ja":"Redox Week in Sendai 2022"},"publication_date":"2022-10-29","languages":["eng"],"location":{"en":"Sendai","ja":"Sendai"},"is_international_presentation":true},"priority":"input_data"}
line:12, {"insert":{"user_id":"B000320827","type":"presentations","id":"35922593"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383254","label":"url"}],"presentation_title":{"en":"Human serum albumin (HSA)-based nanocarriers efficiently deliver antigens to the spleen and induce antigen-specific humoral immunity","ja":"Human serum albumin (HSA)-based nanocarriers efficiently deliver antigens to the spleen and induce antigen-specific humoral immunity"},"presenters":{"en":[{"name":"Rina Yamade"},{"name":"Shimizu Taro"},{"name":"Naoki Hirakawa"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山出 莉奈"},{"name":"清水 太郎"},{"name":"平川 尚樹"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"14th International Symposium on Nanomedicine","ja":"14th International Symposium on Nanomedicine"},"publication_date":"2021-11-17","languages":["eng"],"is_international_presentation":true},"priority":"input_data"}
line:13, {"insert":{"user_id":"B000320827","type":"presentations","id":"35922594"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383253","label":"url"}],"presentation_title":{"en":"The induction level of anti-PEG IgM by PEGylated liposomes depends on the route of administration and the presence of nucleic acids","ja":"The induction level of anti-PEG IgM by PEGylated liposomes depends on the route of administration and the presence of nucleic acids"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Hiro Ueda"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"上田 大"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"14th International Symposium on Nanomedicine","ja":"14th International Symposium on Nanomedicine"},"publication_date":"2021-11-17","languages":["eng"],"is_international_presentation":true},"priority":"input_data"}
line:14, {"insert":{"user_id":"B000320827","type":"presentations","id":"36280254"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=364902","label":"url"}],"presentation_title":{"en":"Binding profile of quercetin and its derivatives to human serum albumin measured by multiplex drug-site mapping","ja":"Binding profile of quercetin and its derivatives to human serum albumin measured by multiplex drug-site mapping"},"presenters":{"en":[{"name":"Okuyama Hitomi"},{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Nishikawa Miyu"},{"name":"Ikushiro Shinichi"},{"name":"Mukai Rie"}],"ja":[{"name":"奥山 仁美"},{"name":"Ikeda Mayumi"},{"name":"異島 優"},{"name":"Nishikawa Miyu"},{"name":"Ikushiro Shinichi"},{"name":"向井 理恵"}]},"event":{"en":"ICoFF2019/ISNFF2019/ICPH2019","ja":"ICoFF2019/ISNFF2019/ICPH2019"},"publication_date":"2019-11-28","languages":["eng"],"location":{"en":"Kobe","ja":"Kobe"},"is_international_presentation":true},"priority":"input_data"}
line:15, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513066"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360901","label":"url"}],"presentation_title":{"en":"A novel S-sulfhydrated human serum albumin suppresses reactive oxygen species induced by kidney injuries","ja":"A novel S-sulfhydrated human serum albumin suppresses reactive oxygen species induced by kidney injuries"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Maruyama T"},{"name":"Akaike T"},{"name":"Otagiri M"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"Maruyama T"},{"name":"Akaike T"},{"name":"Otagiri M"},{"name":"石田 竜弘"}]},"event":{"en":"17th International Symposium on Blood Substitutes & Oxygen Therapeutics","ja":"17th International Symposium on Blood Substitutes & Oxygen Therapeutics"},"publication_date":"2019-11-22","languages":["eng"],"location":{"en":"Nara","ja":"Nara"},"is_international_presentation":true},"priority":"input_data"}
line:16, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513067"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360905","label":"url"}],"presentation_title":{"en":"Pre-treatment with Doxebo suppresses anti-PEG IgM immune responses through PEG-specific immune tolerance","ja":"Pre-treatment with Doxebo suppresses anti-PEG IgM immune responses through PEG-specific immune tolerance"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Miyahara Kohga"},{"name":"Kozma G"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Szebeni J"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"宮原 康嘉"},{"name":"Kozma G"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"Szebeni J"},{"name":"石田 竜弘"}]},"event":{"en":"17th International Symposium on Blood Substitutes & Oxygen Therapeutics","ja":"17th International Symposium on Blood Substitutes & Oxygen Therapeutics"},"publication_date":"2019-11-21","languages":["eng"],"location":{"en":"Nara","ja":"Nara"},"is_international_presentation":true},"priority":"input_data"}
line:17, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513068"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360897","label":"url"}],"presentation_title":{"en":"Human albumin based drug delivery: SNO-albumin dimer for cancer therapeutic application","ja":"Human albumin based drug delivery: SNO-albumin dimer for cancer therapeutic application"},"presenters":{"en":[{"name":"Otagiri M"},{"name":"Ishima Yu"},{"name":"Taguchi K"},{"name":"Maruyama T"}],"ja":[{"name":"Otagiri M"},{"name":"異島 優"},{"name":"Taguchi K"},{"name":"Maruyama T"}]},"event":{"en":"17th International Symposium on Blood Substitutes & Oxygen Therapeutics","ja":"17th International Symposium on Blood Substitutes & Oxygen Therapeutics"},"publication_date":"2019-11-21","languages":["eng"],"location":{"en":"Nara","ja":"Nara"},"is_international_presentation":true},"priority":"input_data"}
line:18, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513069"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359235","label":"url"}],"presentation_title":{"en":"Combination of cancer vaccines with liposomal oxaliplatin increased anti-cancer therapeutic efficacy by stimulating antitumor immunity","ja":"Combination of cancer vaccines with liposomal oxaliplatin increased anti-cancer therapeutic efficacy by stimulating antitumor immunity"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Takese Shunsuke"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"竹瀬 俊輔"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"Liposome Research Days 2019","ja":"Liposome Research Days 2019"},"publication_date":"2019-09-16","languages":["eng"],"location":{"en":"Sapporo","ja":"Sapporo"},"is_international_presentation":true},"priority":"input_data"}
line:19, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513070"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359223","label":"url"}],"presentation_title":{"en":"Immunization method to obtain antigen-specific antibodies by antigen delivery to splenic marginal zone B cells using PEGylated liposomes","ja":"Immunization method to obtain antigen-specific antibodies by antigen delivery to splenic marginal zone B cells using PEGylated liposomes"},"presenters":{"en":[{"name":"Shimazaki Yuna"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"島崎 優奈"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"Liposome Research Days 2019","ja":"Liposome Research Days 2019"},"publication_date":"2019-09-16","languages":["eng"],"location":{"en":"Sapporo","ja":"Sapporo"},"is_international_presentation":true},"priority":"input_data"}
line:20, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513071"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359159","label":"url"}],"presentation_title":{"en":"Quantitative determination of polysulfide in plasma proteins and biological human fluids using a novel Sulfide elimination from polysulfide (SEP) method","ja":"Quantitative determination of polysulfide in plasma proteins and biological human fluids using a novel Sulfide elimination from polysulfide (SEP) method"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"The 1st International Conference on Persulfide and Sulfur Metabolism in Biology and Medicine","ja":"The 1st International Conference on Persulfide and Sulfur Metabolism in Biology and Medicine"},"publication_date":"2019-09-10","languages":["eng"],"location":{"en":"Sendai","ja":"Sendai"},"is_international_presentation":true},"priority":"input_data"}
line:21, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513072"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354298","label":"url"}],"presentation_title":{"en":"Functional Elucidation of Polysulfides In Serum Albumin and Development of Biomimetic Donor of Polysulfides","ja":"Functional Elucidation of Polysulfides In Serum Albumin and Development of Biomimetic Donor of Polysulfides"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otagiri M"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"Watanabe H"},{"name":"Maruyama T"},{"name":"Otagiri M"},{"name":"石田 竜弘"}]},"event":{"en":"2019 CRS Annual Meeting & Exposition","ja":"2019 CRS Annual Meeting & Exposition"},"publication_date":"2019-07-22","languages":["eng"],"location":{"en":"Valencia","ja":"Valencia"},"is_international_presentation":true},"priority":"input_data"}
line:22, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513073"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=346972","label":"url"}],"presentation_title":{"en":"A Novel S-Sulfhydrated Serum Albumin Preparation Suppresses Melanin Synthesis","ja":"A Novel S-Sulfhydrated Serum Albumin Preparation Suppresses Melanin Synthesis"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"AAPS PharmSci 360","ja":"AAPS PharmSci 360"},"publication_date":"2018-11-06","languages":["eng"],"location":{"en":"Washington, D.C.","ja":"Washington, D.C."},"is_international_presentation":true},"priority":"input_data"}
line:23, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513074"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341384","label":"url"}],"presentation_title":{"en":"The effect of liposome co-incubation with cancer cells on the secretion, uptake propensity and expression of certain surface proteins of cancer cell-derived exosomes (extracellular vesicles)","ja":"The effect of liposome co-incubation with cancer cells on the secretion, uptake propensity and expression of certain surface proteins of cancer cell-derived exosomes (extracellular vesicles)"},"presenters":{"en":[{"name":"Sherif Emam Abdallah Emam"},{"name":"ANDO Hidenori"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Ishima Yu"},{"name":"Mahdy M A"},{"name":"Ghazy F S"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"異島 優"},{"name":"Mahdy M A"},{"name":"Ghazy F S"},{"name":"石田 竜弘"}]},"event":{"en":"2018 CRS Annual Meeting & Exposition","ja":"2018 CRS Annual Meeting & Exposition"},"publication_date":"2018-07-22","languages":["eng"],"location":{"en":"New York","ja":"New York"},"is_international_presentation":true},"priority":"input_data"}
line:24, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513075"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339941","label":"url"}],"presentation_title":{"en":"Reactive Sulfur Species in Human Hair Keratin Respond To Oxidative Stress","ja":"Reactive Sulfur Species in Human Hair Keratin Respond To Oxidative Stress"},"presenters":{"en":[{"name":"Tasaka Nanami"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田坂 菜々美"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"5th World Congress on Hydrogen Sulfide in Biology&Medicine","ja":"5th World Congress on Hydrogen Sulfide in Biology&Medicine"},"publication_date":"2018-06-02","languages":["eng"],"location":{"en":"Toronto","ja":"Toronto"},"is_international_presentation":true},"priority":"input_data"}
line:25, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513076"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339942","label":"url"}],"presentation_title":{"en":"A Novel S-Sulfhydrated Human Serum Albumin Preparation Suppresses Melanin Synhtesis","ja":"A Novel S-Sulfhydrated Human Serum Albumin Preparation Suppresses Melanin Synhtesis"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Tasaka Nanami"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"田坂 菜々美"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"5th World Congress on Hydrogen Sulfide in Biology&Medicine","ja":"5th World Congress on Hydrogen Sulfide in Biology&Medicine"},"publication_date":"2018-06-01","languages":["eng"],"location":{"en":"Toronto","ja":"Toronto"},"is_international_presentation":true},"priority":"input_data"}
line:26, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513077"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336848","label":"url"}],"presentation_title":{"en":"Development of the next-generation nab-paclitaxel therapy by using a novel nano EPR effect accelerator, S-nitrosated human serum albumin dimer","ja":"Development of the next-generation nab-paclitaxel therapy by using a novel nano EPR effect accelerator, S-nitrosated human serum albumin dimer"},"presenters":{"en":[{"name":"Ryo Kinoshita"},{"name":"Ishima Yu"},{"name":"Mayumi Ikeda"},{"name":"Hideaki Nakamura"},{"name":"Jun Fang"},{"name":"Hiroshi Maeda"},{"name":"Hiroshi Watanabe"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"Hideaki Nakamura"},{"name":"Jun Fang"},{"name":"Hiroshi Maeda"},{"name":"Hiroshi Watanabe"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"Controlled Release Society 2017","ja":"Controlled Release Society 2017"},"publication_date":"2017-07-18","languages":["eng"],"location":{"en":"Boston","ja":"Boston"},"is_international_presentation":true},"priority":"input_data"}
line:27, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513078"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325477","label":"url"}],"presentation_title":{"en":"S-Nitrosated human serum albumin dimer as a novel nano EPR enhancer applied to nanotechnology based anticancer drugs","ja":"S-Nitrosated human serum albumin dimer as a novel nano EPR enhancer applied to nanotechnology based anticancer drugs"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"Fang Jun"},{"name":"Maeda Hiroshi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"Fang Jun"},{"name":"Maeda Hiroshi"},{"name":"Otagiri Masaki"},{"name":"Maruyama Toru"}]},"event":{"en":"2016Controlled Release Society Annual Meeting & Exposition","ja":"2016Controlled Release Society Annual Meeting & Exposition"},"publication_date":"2016-07-17","languages":["eng"],"location":{"en":"Washington, D.C.","ja":"Washington, D.C."},"is_international_presentation":true},"priority":"input_data"}
line:28, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513079"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325482","label":"url"}],"presentation_title":{"en":"UW SOLUTION IMPROVED WITH HIGH ANTI-APOPTOTIC ACTIVITY BY S-NITROSATED HUMAN SERUM ALBUMIN","ja":"UW SOLUTION IMPROVED WITH HIGH ANTI-APOPTOTIC ACTIVITY BY S-NITROSATED HUMAN SERUM ALBUMIN"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Takuya Shinagawa"},{"name":"Shinji Yoneshige"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"異島 優"},{"name":"Takuya Shinagawa"},{"name":"Shinji Yoneshige"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide","ja":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide"},"publication_date":"2016-05-20","languages":["eng"],"location":{"en":"Sendai","ja":"Sendai"},"is_international_presentation":true},"priority":"input_data"}
line:29, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513080"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325481","label":"url"}],"presentation_title":{"en":"S-Nitrosated human serum albumin dimer as a novel nano EPR enhancer applied to nanotechnology-based anticancer drug","ja":"S-Nitrosated human serum albumin dimer as a novel nano EPR enhancer applied to nanotechnology-based anticancer drug"},"presenters":{"en":[{"name":"Ryo Kinoshita"},{"name":"Ishima Yu"},{"name":"Mayumi Ikeda"},{"name":"Jun Fang"},{"name":"Hiroshi Maeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"Jun Fang"},{"name":"Hiroshi Maeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide","ja":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide"},"publication_date":"2016-05-20","languages":["eng"],"location":{"en":"Sendai","ja":"Sendai"},"is_international_presentation":true},"priority":"input_data"}
line:30, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513081"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325480","label":"url"}],"presentation_title":{"en":"Anti-tumor effect of Poly-S-nitrosated Human Serum Albumin is enhanced by phosphodiesterase 5 inhibitors","ja":"Anti-tumor effect of Poly-S-nitrosated Human Serum Albumin is enhanced by phosphodiesterase 5 inhibitors"},"presenters":{"en":[{"name":"Mayumi Ikeda"},{"name":"Ishima Yu"},{"name":"Ryo Kinoshita"},{"name":"Hiroshi Watanabe"},{"name":"Tsuyoshi Ikeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"Hiroshi Watanabe"},{"name":"Tsuyoshi Ikeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide","ja":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide"},"publication_date":"2016-05-20","languages":["eng"],"location":{"en":"Sendai","ja":"Sendai"},"is_international_presentation":true},"priority":"input_data"}
line:31, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513082"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325479","label":"url"}],"presentation_title":{"en":"Sulfide Anti-Oxidant Buffer Enables Polysulfur to Be Detected by Methylene Blue Assay","ja":"Sulfide Anti-Oxidant Buffer Enables Polysulfur to Be Detected by Methylene Blue Assay"},"presenters":{"en":[{"name":"Mayumi Ikeda"},{"name":"Ishima Yu"},{"name":"Motonori Shibata"},{"name":"Hiroshi Watanabe"},{"name":"Ming Xian"},{"name":"Yuya Ouchi"},{"name":"Takaaki Akaike"},{"name":"Toru Maruyama"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"Motonori Shibata"},{"name":"Hiroshi Watanabe"},{"name":"Ming Xian"},{"name":"Yuya Ouchi"},{"name":"Takaaki Akaike"},{"name":"Toru Maruyama"}]},"event":{"en":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide","ja":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide"},"publication_date":"2016-05-20","languages":["eng"],"location":{"en":"Sendai","ja":"Sendai"},"is_international_presentation":true},"priority":"input_data"}
line:32, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513083"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325478","label":"url"}],"presentation_title":{"en":"Therapeutic potential of S-nitrosated 1-acid glycoprotein as a novel antibacterial agent","ja":"Therapeutic potential of S-nitrosated 1-acid glycoprotein as a novel antibacterial agent"},"presenters":{"en":[{"name":"Kotaro Matsusaka"},{"name":"Ishima Yu"},{"name":"Kaori Watanabe"},{"name":"Hiroshi Watanabe"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Kotaro Matsusaka"},{"name":"異島 優"},{"name":"Kaori Watanabe"},{"name":"Hiroshi Watanabe"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide","ja":"The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide"},"publication_date":"2016-05-20","languages":["eng"],"location":{"en":"Sendai","ja":"Sendai"},"is_international_presentation":true},"priority":"input_data"}
line:33, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513084"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325484","label":"url"}],"presentation_title":{"en":"Anti-tumor effect of Poly-S-nitrosated Human Serum Albumin is enhanced by phosphodiesterase 5 inhibitors","ja":"Anti-tumor effect of Poly-S-nitrosated Human Serum Albumin is enhanced by phosphodiesterase 5 inhibitors"},"presenters":{"en":[{"name":"Mayumi Ikeda"},{"name":"Ishima Yu"},{"name":"Ryo Kinoshita"},{"name":"Hiroshi Watanabe"},{"name":"Tsuyoshi Ikeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"Hiroshi Watanabe"},{"name":"Tsuyoshi Ikeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"Asian Federation for Pharmaceutical Sciences 2015","ja":"Asian Federation for Pharmaceutical Sciences 2015"},"publication_date":"2015-11-25","languages":["eng"],"location":{"en":"Bangkok","ja":"Bangkok"},"is_international_presentation":true},"priority":"input_data"}
line:34, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513085"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325483","label":"url"}],"presentation_title":{"en":"S-Nitrosated human serum albumin dimer as novel nano EPR enhancer applied to nano-anticancer drugs","ja":"S-Nitrosated human serum albumin dimer as novel nano EPR enhancer applied to nano-anticancer drugs"},"presenters":{"en":[{"name":"Ryo Kinoshita"},{"name":"Ishima Yu"},{"name":"Mayumi Ikeda"},{"name":"Jun Fang"},{"name":"Hiroshi Maeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"Jun Fang"},{"name":"Hiroshi Maeda"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"Asian Federation for Pharmaceutical Sciences 2015","ja":"Asian Federation for Pharmaceutical Sciences 2015"},"publication_date":"2015-11-25","languages":["eng"],"location":{"en":"Bangkok","ja":"Bangkok"},"is_international_presentation":true},"priority":"input_data"}
line:35, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513086"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325485","label":"url"}],"presentation_title":{"en":"Polythiolated- And Recombinant Mannosylated-Albumin As A Novel Cd68+/Cd206+ Kupffer Cell-Targeted Nano-Antioxidant For The Treatment Of Acute And Chronic Hepatitis Models","ja":"Polythiolated- And Recombinant Mannosylated-Albumin As A Novel Cd68+/Cd206+ Kupffer Cell-Targeted Nano-Antioxidant For The Treatment Of Acute And Chronic Hepatitis Models"},"presenters":{"en":[{"name":"Hitoshi Maeda"},{"name":"Shota Ichimizu"},{"name":"Hiroshi Watanabe"},{"name":"Ishima Yu"},{"name":"Ayaka Suenaga"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Hitoshi Maeda"},{"name":"Shota Ichimizu"},{"name":"Hiroshi Watanabe"},{"name":"異島 優"},{"name":"Ayaka Suenaga"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"19th North American ISSX Meeting and 29th JSSX Meeting","ja":"19th North American ISSX Meeting and 29th JSSX Meeting"},"publication_date":"2014-10-19","languages":["eng"],"location":{"en":"San Francisco","ja":"San Francisco"},"is_international_presentation":true},"priority":"input_data"}
line:36, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513087"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325492","label":"url"}],"presentation_title":{"en":"Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate","ja":"Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate"},"presenters":{"en":[{"name":"Hiroshi Watanabe"},{"name":"Yoshiaki Sakaguchi"},{"name":"Ryusei Sugimoto"},{"name":"Ishima Yu"},{"name":"Ken-ichi Kaneko"},{"name":"Hiroshi Iwata"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Hiroshi Watanabe"},{"name":"Yoshiaki Sakaguchi"},{"name":"Ryusei Sugimoto"},{"name":"異島 優"},{"name":"Ken-ichi Kaneko"},{"name":"Hiroshi Iwata"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"8th International Society on Uremia Research and Toxicity","ja":"8th International Society on Uremia Research and Toxicity"},"publication_date":"2014-03-13","languages":["eng"],"location":{"en":"Okinawa","ja":"Okinawa"},"is_international_presentation":true},"priority":"input_data"}
line:37, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513088"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325491","label":"url"}],"presentation_title":{"en":"S-nitrosated a-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis","ja":"S-nitrosated a-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis"},"presenters":{"en":[{"name":"Kaori Watanabe"},{"name":"Ishima Yu"},{"name":"Teruo Kuroda"},{"name":"Wakano Ogawa"},{"name":"Hiroshi Watanabe"},{"name":"Ayaka Suenaga"},{"name":"Toshiya Kai"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Kaori Watanabe"},{"name":"異島 優"},{"name":"Teruo Kuroda"},{"name":"Wakano Ogawa"},{"name":"Hiroshi Watanabe"},{"name":"Ayaka Suenaga"},{"name":"Toshiya Kai"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"Asian Federation for Pharmaceutical Sciences 2013","ja":"Asian Federation for Pharmaceutical Sciences 2013"},"publication_date":"2013-11-21","languages":["eng"],"location":{"en":"Cheju","ja":"Cheju"},"is_international_presentation":true},"priority":"input_data"}
line:38, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513089"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325490","label":"url"}],"presentation_title":{"en":"Therapeutic impact of human serum albumin-thioredoxin fusion protein, long-acting anti-oxidative and anti-inflammatory modulator, against acetaminophen-induced acute liver failure","ja":"Therapeutic impact of human serum albumin-thioredoxin fusion protein, long-acting anti-oxidative and anti-inflammatory modulator, against acetaminophen-induced acute liver failure"},"presenters":{"en":[{"name":"Ryota Tanaka"},{"name":"Hitoshi Maeda"},{"name":"Azusa Kodama"},{"name":"Hiroshi Watanabe"},{"name":"Ishima Yu"},{"name":"Toru Maruyama"},{"name":"Masaki Otagiri"}],"ja":[{"name":"Ryota Tanaka"},{"name":"Hitoshi Maeda"},{"name":"Azusa Kodama"},{"name":"Hiroshi Watanabe"},{"name":"異島 優"},{"name":"Toru Maruyama"},{"name":"Masaki Otagiri"}]},"event":{"en":"Asian Federation for Pharmaceutical Sciences 2013","ja":"Asian Federation for Pharmaceutical Sciences 2013"},"publication_date":"2013-11-21","languages":["eng"],"location":{"en":"Cheju","ja":"Cheju"},"is_international_presentation":true},"priority":"input_data"}
line:39, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513090"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325489","label":"url"}],"presentation_title":{"en":"A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy","ja":"A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy"},"presenters":{"en":[{"name":"Hiroshi Watanabe"},{"name":"Azusa Kodama"},{"name":"Ryota Tanaka"},{"name":"Hisae Tanaka"},{"name":"Victor Tuan Giam Chuang"},{"name":"Ishima Yu"},{"name":"Masafumi Fukagawa"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Hiroshi Watanabe"},{"name":"Azusa Kodama"},{"name":"Ryota Tanaka"},{"name":"Hisae Tanaka"},{"name":"Victor Tuan Giam Chuang"},{"name":"異島 優"},{"name":"Masafumi Fukagawa"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"Asian Federation for Pharmaceutical Sciences 2013","ja":"Asian Federation for Pharmaceutical Sciences 2013"},"publication_date":"2013-11-21","languages":["eng"],"location":{"en":"Cheju","ja":"Cheju"},"is_international_presentation":true},"priority":"input_data"}
line:40, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513091"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325488","label":"url"}],"presentation_title":{"en":"Poly-S-nitrosated Human Serum Albumin inhibits the Expression of P-glycoprotein Transporter in Human Multidrug-resistant Tumor","ja":"Poly-S-nitrosated Human Serum Albumin inhibits the Expression of P-glycoprotein Transporter in Human Multidrug-resistant Tumor"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Marie Hara"},{"name":"Hiroshi Watanabe"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"異島 優"},{"name":"Marie Hara"},{"name":"Hiroshi Watanabe"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"The 5th Asian Arden conference","ja":"The 5th Asian Arden conference"},"publication_date":"2013-08-06","languages":["eng"],"location":{"en":"愛知","ja":"愛知"},"is_international_presentation":true},"priority":"input_data"}
line:41, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513092"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325486","label":"url"}],"presentation_title":{"en":"Kupffer cell selective delivery of thiols by genetically engineered mannosylated-albumin as a new therapeutic strategy for hepatitis","ja":"Kupffer cell selective delivery of thiols by genetically engineered mannosylated-albumin as a new therapeutic strategy for hepatitis"},"presenters":{"en":[{"name":"Hitoshi Maeda"},{"name":"Hiroshi Watanabe"},{"name":"Ishima Yu"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Hitoshi Maeda"},{"name":"Hiroshi Watanabe"},{"name":"異島 優"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"The 5th Asian Arden conference","ja":"The 5th Asian Arden conference"},"publication_date":"2013-08-06","languages":["eng"],"location":{"en":"愛知","ja":"愛知"},"is_international_presentation":true},"priority":"input_data"}
line:42, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=403541","label":"url"}],"presentation_title":{"en":"アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製","ja":"アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製"},"presenters":{"en":[{"name":"Hashimoto Aiko"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 愛子"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"石田 竜弘"}]},"event":{"en":"第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2023-10-28","languages":["jpn"],"location":{"en":"Kochi","ja":"高知"},"is_international_presentation":false},"priority":"input_data"}
line:43, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402629","label":"url"}],"presentation_title":{"en":"化粧水の塗布による抗PEG IgMの誘導が抗がん剤封入PEG修飾リポソームの抗腫瘍効果に与える影響","ja":"化粧水の塗布による抗PEG IgMの誘導が抗がん剤封入PEG修飾リポソームの抗腫瘍効果に与える影響"},"presenters":{"en":[{"name":"Ishida Tatsuhiro"},{"name":"Sherif Armia"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"}],"ja":[{"name":"石田 竜弘"},{"name":"Sherif Armia"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"}]},"event":{"en":"第39回日本DDS学会学術集会","ja":"第39回日本DDS学会学術集会"},"publication_date":"2023-07-28","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:44, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402638","label":"url"}],"presentation_title":{"en":"がん細胞由来膜タンパク質を搭載したPEG修飾リポソームを脾臓に送達する技術を利用したがんワクチンの開発:細胞性免疫誘導の評価","ja":"がん細胞由来膜タンパク質を搭載したPEG修飾リポソームを脾臓に送達する技術を利用したがんワクチンの開発:細胞性免疫誘導の評価"},"presenters":{"en":[{"name":"Haruki Tanaka"},{"name":"ANDO Hidenori"},{"name":"Yamamoto Shunto"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田中 晴樹"},{"name":"安藤 英紀"},{"name":"山本 舜人"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第39回日本DDS学会学術集会","ja":"第39回日本DDS学会学術集会"},"publication_date":"2023-07-27","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:45, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402637","label":"url"}],"presentation_title":{"en":"末端構造の異なるPEG修飾リポソームの単独あるいは繰り返し投与における脾臓免疫細胞への移行性評価","ja":"末端構造の異なるPEG修飾リポソームの単独あるいは繰り返し投与における脾臓免疫細胞への移行性評価"},"presenters":{"en":[{"name":"Sohtaroh Kudoh"},{"name":"ANDO Hidenori"},{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"工藤 聡太郎"},{"name":"安藤 英紀"},{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第39回日本DDS学会学術集会","ja":"第39回日本DDS学会学術集会"},"publication_date":"2023-07-27","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:46, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402636","label":"url"}],"presentation_title":{"en":"NFBCを新規培養基材として用いた3D培養の有用性に関する研究:得られたエクソソームの細胞増殖と細胞内取り込みに与える影響の評価","ja":"NFBCを新規培養基材として用いた3D培養の有用性に関する研究:得られたエクソソームの細胞増殖と細胞内取り込みに与える影響の評価"},"presenters":{"en":[{"name":"Mako Fukumoto"},{"name":"ANDO Hidenori"},{"name":"Emam Abdallah Emam Sherif"},{"name":"Matsuo Nana"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福本 真子"},{"name":"安藤 英紀"},{"name":"Sherif Emam Abdallah Emam"},{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第39回日本DDS学会学術集会","ja":"第39回日本DDS学会学術集会"},"publication_date":"2023-07-27","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:47, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402635","label":"url"}],"presentation_title":{"en":"がん細胞由来膜タンパク質を搭載したPEG修飾リポソームを脾臓に送達する技術を利用したがんワクチンの開発:腫瘍増殖抑制効果の評価","ja":"がん細胞由来膜タンパク質を搭載したPEG修飾リポソームを脾臓に送達する技術を利用したがんワクチンの開発:腫瘍増殖抑制効果の評価"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第39回日本DDS学会学術集会","ja":"第39回日本DDS学会学術集会"},"publication_date":"2023-07-27","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:48, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402633","label":"url"}],"presentation_title":{"en":"アルカリ化剤の経口投与による腫瘍酸性環境改善とアブラキサン®の併用による抗腫瘍効果増強","ja":"アルカリ化剤の経口投与による腫瘍酸性環境改善とアブラキサン®の併用による抗腫瘍効果増強"},"presenters":{"en":[{"name":"Uehara Riku"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"江島 清"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上原 陸"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"江島 清"},{"name":"石田 竜弘"}]},"event":{"en":"第39回日本DDS学会学術集会","ja":"第39回日本DDS学会学術集会"},"publication_date":"2023-07-27","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:49, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402632","label":"url"}],"presentation_title":{"en":"イオン液体による難吸収性中分子化合物の腸管吸収促進効果の検討","ja":"イオン液体による難吸収性中分子化合物の腸管吸収促進効果の検討"},"presenters":{"en":[{"name":"Shoichiro Fukuda"},{"name":"ANDO Hidenori"},{"name":"中江 崇"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 翔一郎"},{"name":"安藤 英紀"},{"name":"中江 崇"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第39回日本DDS学会学術集会","ja":"第39回日本DDS学会学術集会"},"publication_date":"2023-07-27","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:50, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397450","label":"url"}],"presentation_title":{"en":"化粧水塗布時の含有PEGの皮膚透過と抗PEG IgM誘導に関する検討","ja":"化粧水塗布時の含有PEGの皮膚透過と抗PEG IgM誘導に関する検討"},"presenters":{"en":[{"name":"Mohamed Ibrahim"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Mohamed Ibrahim"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第38年会","ja":"日本薬剤学会第38年会"},"publication_date":"2023-05-17","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:51, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397416","label":"url"}],"presentation_title":{"en":"膜タンパク質搭載PEG修飾リポソームの脾臓送達による各種がん細胞上の膜タンパク質に対する抗体誘導","ja":"膜タンパク質搭載PEG修飾リポソームの脾臓送達による各種がん細胞上の膜タンパク質に対する抗体誘導"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第38年会","ja":"日本薬剤学会第38年会"},"publication_date":"2023-05-17","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:52, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397415","label":"url"}],"presentation_title":{"en":"抗ヒトTNFα抗体の生体内誘導を実現するTNFα由来ペプチドの免疫と抗体誘導評価","ja":"抗ヒトTNFα抗体の生体内誘導を実現するTNFα由来ペプチドの免疫と抗体誘導評価"},"presenters":{"en":[{"name":"Yamamoto Haruka"},{"name":"ANDO Hidenori"},{"name":"大本 安一"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 遥香"},{"name":"安藤 英紀"},{"name":"大本 安一"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第38年会","ja":"日本薬剤学会第38年会"},"publication_date":"2023-05-17","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:53, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397413","label":"url"}],"presentation_title":{"en":"NFBCを新規培養基材として用いた3D培養の有用性に関する研究:培養時のエクソソーム分泌性と得られたエクソソームの細胞増殖等に与える影響の評価","ja":"NFBCを新規培養基材として用いた3D培養の有用性に関する研究:培養時のエクソソーム分泌性と得られたエクソソームの細胞増殖等に与える影響の評価"},"presenters":{"en":[{"name":"Mako Fukumoto"},{"name":"ANDO Hidenori"},{"name":"Emam Abdallah Emam Sherif"},{"name":"Matsuo Nana"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福本 真子"},{"name":"安藤 英紀"},{"name":"Sherif Emam Abdallah Emam"},{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第38年会","ja":"日本薬剤学会第38年会"},"publication_date":"2023-05-17","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:54, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397412","label":"url"}],"presentation_title":{"en":"HPLCとICP-MSを組み合わせたオキサリプラチン遊離型とタンパク結合型の分離評価法の確立","ja":"HPLCとICP-MSを組み合わせたオキサリプラチン遊離型とタンパク結合型の分離評価法の確立"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第38年会","ja":"日本薬剤学会第38年会"},"publication_date":"2023-05-16","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:55, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397411","label":"url"}],"presentation_title":{"en":"イオン液体を基剤とした難吸収性中分子化合物の腸管吸収改善の検討","ja":"イオン液体を基剤とした難吸収性中分子化合物の腸管吸収改善の検討"},"presenters":{"en":[{"name":"Shoichiro Fukuda"},{"name":"ANDO Hidenori"},{"name":"Atsuya Maruyama"},{"name":"中江 崇"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 翔一郎"},{"name":"安藤 英紀"},{"name":"丸山 敦也"},{"name":"中江 崇"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第38年会","ja":"日本薬剤学会第38年会"},"publication_date":"2023-05-16","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:56, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397259","label":"url"}],"presentation_title":{"en":"免疫グロブリン中に含まれる超硫黄分子の検出とその機能解明","ja":"免疫グロブリン中に含まれる超硫黄分子の検出とその機能解明"},"presenters":{"en":[{"name":"Hirai Takeru"},{"name":"Osafune Hiroki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"平井 傑琉"},{"name":"長船 裕輝"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-28","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:57, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397258","label":"url"}],"presentation_title":{"en":"モデル抗原搭載アルブミンナノ粒子とアジュバントの併用によるがん治療効果検討","ja":"モデル抗原搭載アルブミンナノ粒子とアジュバントの併用によるがん治療効果検討"},"presenters":{"en":[{"name":"Yamade Rina"},{"name":"Shimizu Taro"},{"name":"Hirakawa Naoki"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山出 莉奈"},{"name":"清水 太郎"},{"name":"平川 尚樹"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-28","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:58, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397256","label":"url"}],"presentation_title":{"en":"ドキソルビシン封入リポソーム搭載脾臓細胞による抗腫瘍効果の検討","ja":"ドキソルビシン封入リポソーム搭載脾臓細胞による抗腫瘍効果の検討"},"presenters":{"en":[{"name":"Matsugi Yuki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松木 佑樹"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-28","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:59, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397255","label":"url"}],"presentation_title":{"en":"B細胞に搭載されたヒドロキシ末端PEG修飾リポソームは補体受容体を介して他の抗原提示細胞へと受け渡される","ja":"B細胞に搭載されたヒドロキシ末端PEG修飾リポソームは補体受容体を介して他の抗原提示細胞へと受け渡される"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-28","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:60, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397267","label":"url"}],"presentation_title":{"en":"血清アルブミンに存在する超硫黄の解析と創薬応用","ja":"血清アルブミンに存在する超硫黄の解析と創薬応用"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Fukuta Tatsuya"},{"name":"岩尾 康範"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"池田 真由美"},{"name":"福田 達也"},{"name":"岩尾 康範"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-26","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:61, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397266","label":"url"}],"presentation_title":{"en":"抗hTNFα抗体を生体内で誘導するhTNFαペプチド配列の探索と抗体誘導評価","ja":"抗hTNFα抗体を生体内で誘導するhTNFαペプチド配列の探索と抗体誘導評価"},"presenters":{"en":[{"name":"Yamamoto Haruka"},{"name":"ANDO Hidenori"},{"name":"大本 安一"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 遥香"},{"name":"安藤 英紀"},{"name":"大本 安一"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-26","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:62, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397264","label":"url"}],"presentation_title":{"en":"悪性リンパ腫に対するオキサリプラチン封入PEG修飾リポソームと抗体医薬の併用による抗腫瘍効果の検討","ja":"悪性リンパ腫に対するオキサリプラチン封入PEG修飾リポソームと抗体医薬の併用による抗腫瘍効果の検討"},"presenters":{"en":[{"name":"Sunami Takaya"},{"name":"ANDO Hidenori"},{"name":"Doi Yusuke"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"安倍 正博"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"角南 尚哉"},{"name":"安藤 英紀"},{"name":"土井 祐輔"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"安倍 正博"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-26","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:63, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397263","label":"url"}],"presentation_title":{"en":"アルブミン受容体の特性を生かしたアクティブターゲティング型DDSキャリアの開発","ja":"アルブミン受容体の特性を生かしたアクティブターゲティング型DDSキャリアの開発"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-26","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:64, {"insert":{"user_id":"B000320827","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=397262","label":"url"}],"presentation_title":{"en":"内因性超硫黄化タンパク質の発見","ja":"内因性超硫黄化タンパク質の発見"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"岩尾 康範"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"赤池 孝章"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"池田 真由美"},{"name":"岩尾 康範"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"赤池 孝章"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第143年会","ja":"日本薬学会第143年会"},"publication_date":"2023-03-26","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:65, {"insert":{"user_id":"B000320827","type":"presentations","id":"41505636"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=394063","label":"url"}],"presentation_title":{"en":"Investigation of the usefulness of human serum albumin nanoparticles as antigen delivery carriers to the spleen","ja":"Investigation of the usefulness of human serum albumin nanoparticles as antigen delivery carriers to the spleen"},"presenters":{"en":[{"name":"Yamade Rina"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山出 莉奈"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第2回英語セミナー","ja":"日本薬剤学会第2回英語セミナー"},"publication_date":"2023-02-02","languages":["eng"],"location":{"en":"Online","ja":"Online"},"is_international_presentation":false},"priority":"input_data"}
line:66, {"insert":{"user_id":"B000320827","type":"presentations","id":"40768189"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393314","label":"url"}],"presentation_title":{"en":"不活化ヒト TNFα 誘導体のマウスへの免疫による中和抗体の誘導評価","ja":"不活化ヒト TNFα 誘導体のマウスへの免疫による中和抗体の誘導評価"},"presenters":{"en":[{"name":"Yamamoto Haruka"},{"name":"ANDO Hidenori"},{"name":"大本 安一"},{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 遥香"},{"name":"安藤 英紀"},{"name":"大本 安一"},{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第1回日本抗体学会設立記念学術大会","ja":"第1回日本抗体学会設立記念学術大会"},"publication_date":"2022-11-26","languages":["jpn"],"location":{"en":"Kagoshima","ja":"鹿児島"},"is_international_presentation":false},"priority":"input_data"}
line:67, {"insert":{"user_id":"B000320827","type":"presentations","id":"40510327"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392885","label":"url"}],"presentation_title":{"en":"白金製剤と血漿タンパク質との相互作用:時間依存性に関する検討","ja":"白金製剤と血漿タンパク質との相互作用:時間依存性に関する検討"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬物動態学会第37回年会","ja":"日本薬物動態学会第37回年会"},"publication_date":"2022-11-08","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:68, {"insert":{"user_id":"B000320827","type":"presentations","id":"40408117"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392669","label":"url"}],"presentation_title":{"en":"全身性エリテマトーデスモデルマウス由来B細胞の取り込み能についての検討","ja":"全身性エリテマトーデスモデルマウス由来B細胞の取り込み能についての検討"},"presenters":{"en":[{"name":"Mizumachi Kenta"},{"name":"Shimizu Taro"},{"name":"Ueda Hiro"},{"name":"Takata Haruka"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"水町 健太"},{"name":"清水 太郎"},{"name":"上田 大"},{"name":"髙田 春風"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2022-11-05","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:69, {"insert":{"user_id":"B000320827","type":"presentations","id":"40408118"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392668","label":"url"}],"presentation_title":{"en":"Humira®(adalimumab)投与時の抗薬物抗体(ADA)誘導に関する検討:マウス型抗ヒトTNFαモノクローナル抗体をマウスに投与した際のADA誘導","ja":"Humira®(adalimumab)投与時の抗薬物抗体(ADA)誘導に関する検討:マウス型抗ヒトTNFαモノクローナル抗体をマウスに投与した際のADA誘導"},"presenters":{"en":[{"name":"Yamamoto Haruka"},{"name":"ANDO Hidenori"},{"name":"大本 安一"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 遥香"},{"name":"安藤 英紀"},{"name":"大本 安一"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2022-11-05","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:70, {"insert":{"user_id":"B000320827","type":"presentations","id":"40408119"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392667","label":"url"}],"presentation_title":{"en":"デキサメタゾンが及ぼすPEG修飾ナノ粒子による抗PEG抗体誘導への影響","ja":"デキサメタゾンが及ぼすPEG修飾ナノ粒子による抗PEG抗体誘導への影響"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Abe Shunji"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"阿部 舜史"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第16回次世代を担う若手医療薬科学シンポジウム","ja":"第16回次世代を担う若手医療薬科学シンポジウム"},"publication_date":"2022-10-29","languages":["jpn"],"location":{"en":"Wakayama","ja":"和歌山"},"is_international_presentation":false},"priority":"input_data"}
line:71, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066830"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392175","label":"url"}],"presentation_title":{"en":"膜タンパク質搭載PEG修飾リポソームの脾臓送達による抗膜タンパク質抗体誘導","ja":"膜タンパク質搭載PEG修飾リポソームの脾臓送達による抗膜タンパク質抗体誘導"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第43回生体膜と薬物の相互作用シンポジウム","ja":"第43回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2022-10-06","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:72, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066831"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392174","label":"url"}],"presentation_title":{"en":"PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討","ja":"PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第43回生体膜と薬物の相互作用シンポジウム","ja":"第43回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2022-10-06","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:73, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066832"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392173","label":"url"}],"presentation_title":{"en":"超硫黄分子のレドックス制御機構の解明と抗酸化剤への応用","ja":"超硫黄分子のレドックス制御機構の解明と抗酸化剤への応用"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"第30回DDSカンファランス","ja":"第30回DDSカンファランス"},"publication_date":"2022-09-16","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:74, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066833"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392172","label":"url"}],"presentation_title":{"en":"オキサリプラチン封入PEG修飾リポソームの悪性リンパ腫治療への展開","ja":"オキサリプラチン封入PEG修飾リポソームの悪性リンパ腫治療への展開"},"presenters":{"en":[{"name":"Sunami Takaya"},{"name":"ANDO Hidenori"},{"name":"Doi Yusuke"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Abe Masahiro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"角南 尚哉"},{"name":"安藤 英紀"},{"name":"土井 祐輔"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"安倍 正博"},{"name":"石田 竜弘"}]},"event":{"en":"第27回創剤フォーラム若手研究会","ja":"第27回創剤フォーラム若手研究会"},"publication_date":"2022-09-15","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:75, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066834"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392170","label":"url"}],"presentation_title":{"en":"イオン液体による薬物の腸管吸収促進メカニズムの検討","ja":"イオン液体による薬物の腸管吸収促進メカニズムの検討"},"presenters":{"en":[{"name":"Fukuda Shoichiro"},{"name":"ANDO Hidenori"},{"name":"Maruyama Atsuya"},{"name":"中江 崇"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 翔一郎"},{"name":"安藤 英紀"},{"name":"丸山 敦也"},{"name":"中江 崇"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第27回創剤フォーラム若手研究会","ja":"第27回創剤フォーラム若手研究会"},"publication_date":"2022-09-15","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:76, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066835"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392169","label":"url"}],"presentation_title":{"en":"重曹の経口投与によるDoxil®の腫瘍集積性向上と抗腫瘍効果増強","ja":"重曹の経口投与によるDoxil®の腫瘍集積性向上と抗腫瘍効果増強"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第27回創剤フォーラム若手研究会","ja":"第27回創剤フォーラム若手研究会"},"publication_date":"2022-09-15","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:77, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066836"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392168","label":"url"}],"presentation_title":{"en":"難水溶性薬物に対する溶解補助及び動態改善を企図した新規アルブミンナノ粒子の有用性評価","ja":"難水溶性薬物に対する溶解補助及び動態改善を企図した新規アルブミンナノ粒子の有用性評価"},"presenters":{"en":[{"name":"Nakano Ryuto"},{"name":"Hirakawa Naoki"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"中野 琉人"},{"name":"平川 尚樹"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"日本薬剤学会第3回超分子薬剤学FGシンポジウム","ja":"日本薬剤学会第3回超分子薬剤学FGシンポジウム"},"publication_date":"2022-09-12","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:78, {"insert":{"user_id":"B000320827","type":"presentations","id":"40066837"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392167","label":"url"}],"presentation_title":{"en":"B細胞に標的化されたヒドロキシ末端PEG修飾リポソームは補体受容体を介して他の免疫細胞へと受け渡される","ja":"B細胞に標的化されたヒドロキシ末端PEG修飾リポソームは補体受容体を介して他の免疫細胞へと受け渡される"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第3回超分子薬剤学FGシンポジウム","ja":"日本薬剤学会第3回超分子薬剤学FGシンポジウム"},"publication_date":"2022-09-12","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:79, {"insert":{"user_id":"B000320827","type":"presentations","id":"39818989"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391664","label":"url"}],"presentation_title":{"en":"超硫黄を介したヒト血清アルブミンの抗酸化作用","ja":"超硫黄を介したヒト血清アルブミンの抗酸化作用"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"岩尾 康範"},{"name":"Ishima Yu"}],"ja":[{"name":"池田 真由美"},{"name":"岩尾 康範"},{"name":"異島 優"}]},"event":{"en":"フォーラム2022:衛生薬学・環境トキシコロジー","ja":"フォーラム2022:衛生薬学・環境トキシコロジー"},"publication_date":"2022-08","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:80, {"insert":{"user_id":"B000320827","type":"presentations","id":"39818990"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391663","label":"url"}],"presentation_title":{"en":"ApoA-1 binding proteinの加齢に伴う血清中濃度の変化およびその抗炎症作用","ja":"ApoA-1 binding proteinの加齢に伴う血清中濃度の変化およびその抗炎症作用"},"presenters":{"en":[{"name":"Kohki TACHIBANA"},{"name":"Kusumoto Kohshi"},{"name":"前橋 梨花"},{"name":"樹山 友絵"},{"name":"永尾 綾菜"},{"name":"辻田 麻紀"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"Okuhira Keiichiro"}],"ja":[{"name":"立花 洸季"},{"name":"楠本 嵩志"},{"name":"前橋 梨花"},{"name":"樹山 友絵"},{"name":"永尾 綾菜"},{"name":"辻田 麻紀"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"奥平 桂一郎"}]},"event":{"en":"フォーラム2022:衛生薬学・環境トキシコロジー","ja":"フォーラム2022:衛生薬学・環境トキシコロジー"},"publication_date":"2022-08","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:81, {"insert":{"user_id":"B000320827","type":"presentations","id":"39818991"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391654","label":"url"}],"presentation_title":{"en":"毛髪中に含まれる超硫黄分子の検出および機能解明","ja":"毛髪中に含まれる超硫黄分子の検出および機能解明"},"presenters":{"en":[{"name":"Hirai Takeru"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"平井 傑琉"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"フォーラム2022:衛生薬学・環境トキシコロジー","ja":"フォーラム2022:衛生薬学・環境トキシコロジー"},"publication_date":"2022-08","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:82, {"insert":{"user_id":"B000320827","type":"presentations","id":"39818992"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391653","label":"url"}],"presentation_title":{"en":"様々な生体液に含まれる超硫黄分子の生理的意義の解明","ja":"様々な生体液に含まれる超硫黄分子の生理的意義の解明"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"Sakai Maki"},{"name":"Osafune Hiroki"},{"name":"岩尾 康範"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"池田 真由美"},{"name":"酒井 真紀"},{"name":"長船 裕輝"},{"name":"岩尾 康範"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"フォーラム2022:衛生薬学・環境トキシコロジー","ja":"フォーラム2022:衛生薬学・環境トキシコロジー"},"publication_date":"2022-08","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:83, {"insert":{"user_id":"B000320827","type":"presentations","id":"39818993"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391651","label":"url"}],"presentation_title":{"en":"血中の抗PEG抗体が筋肉内投与後のmRNA搭載LNPのタンパク質発現に与える影響に関する検討","ja":"血中の抗PEG抗体が筋肉内投与後のmRNA搭載LNPのタンパク質発現に与える影響に関する検討"},"presenters":{"en":[{"name":"Abe Shunji"},{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"阿部 舜史"},{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"遺伝子・デリバリー研究会第20回夏期セミナー","ja":"遺伝子・デリバリー研究会第20回夏期セミナー"},"publication_date":"2022-08-26","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:84, {"insert":{"user_id":"B000320827","type":"presentations","id":"39818994"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391650","label":"url"}],"presentation_title":{"en":"siRNA搭載PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討","ja":"siRNA搭載PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Ueda Hiro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"上田 大"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"遺伝子・デリバリー研究会第20回夏期セミナー","ja":"遺伝子・デリバリー研究会第20回夏期セミナー"},"publication_date":"2022-08-26","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:85, {"insert":{"user_id":"B000320827","type":"presentations","id":"39588967"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388778","label":"url"}],"presentation_title":{"en":"mRNA搭載LNP構成成分のPEG脂質が示す免疫原性及びアナフィラキシー様反応への影響","ja":"mRNA搭載LNP構成成分のPEG脂質が示す免疫原性及びアナフィラキシー様反応への影響"},"presenters":{"en":[{"name":"Abe Shunji"},{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"阿部 舜史"},{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本核酸医薬学会第7回年会","ja":"日本核酸医薬学会第7回年会"},"publication_date":"2022-08-01","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:86, {"insert":{"user_id":"B000320827","type":"presentations","id":"39588968"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388776","label":"url"}],"presentation_title":{"en":"核酸搭載リポソームの物理化学的性質が抗核酸抗体の誘導に与える影響の検討","ja":"核酸搭載リポソームの物理化学的性質が抗核酸抗体の誘導に与える影響の検討"},"presenters":{"en":[{"name":"Hiro Ueda"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"山吉 麻子"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上田 大"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"山吉 麻子"},{"name":"石田 竜弘"}]},"event":{"en":"日本核酸医薬学会第7回年会","ja":"日本核酸医薬学会第7回年会"},"publication_date":"2022-08-01","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:87, {"insert":{"user_id":"B000320827","type":"presentations","id":"39588969"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388775","label":"url"}],"presentation_title":{"en":"ナノフィブリル化バクテリアセルロースの経口摂取による腸内細菌叢の変動と肥満抑制効果の評価","ja":"ナノフィブリル化バクテリアセルロースの経口摂取による腸内細菌叢の変動と肥満抑制効果の評価"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"ANDO Hidenori"},{"name":"田島 健次"},{"name":"長澤 一樹"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"安藤 英紀"},{"name":"田島 健次"},{"name":"長澤 一樹"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"セルロース学会第29回年次大会","ja":"セルロース学会第29回年次大会"},"publication_date":"2022-07-21","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:88, {"insert":{"user_id":"B000320827","type":"presentations","id":"39588970"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388774","label":"url"}],"presentation_title":{"en":"ナノフィブリル化バクテリアセルロースを懸濁剤として用いたシクロスポリンA製剤の調製と乾癬治療効果の評価","ja":"ナノフィブリル化バクテリアセルロースを懸濁剤として用いたシクロスポリンA製剤の調製と乾癬治療効果の評価"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"ANDO Hidenori"},{"name":"田島 健次"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"安藤 英紀"},{"name":"田島 健次"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"石田 竜弘"}]},"event":{"en":"セルロース学会第29回年次大会","ja":"セルロース学会第29回年次大会"},"publication_date":"2022-07-21","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:89, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300597"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386243","label":"url"}],"presentation_title":{"en":"毛髪中に含まれる超硫黄分子の検出および機能解明","ja":"毛髪中に含まれる超硫黄分子の検出および機能解明"},"presenters":{"en":[{"name":"Hirai Takeru"},{"name":"Tasaka Nanami"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"平井 傑琉"},{"name":"田坂 菜々美"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"第49回日本毒性学会学術年会","ja":"第49回日本毒性学会学術年会"},"publication_date":"2022-07-01","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:90, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300598"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386242","label":"url"}],"presentation_title":{"en":"スルホサリチル酸を用いた新規アルブミンナノ粒子化法の開発と敗血症への応用","ja":"スルホサリチル酸を用いた新規アルブミンナノ粒子化法の開発と敗血症への応用"},"presenters":{"en":[{"name":"Tottori Yukina"},{"name":"Hirakawa Naoki"},{"name":"Kinoshita Ryo"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"十鳥 有希菜"},{"name":"平川 尚樹"},{"name":"木下 遼"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"第49回日本毒性学会学術年会","ja":"第49回日本毒性学会学術年会"},"publication_date":"2022-07-01","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:91, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300599"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386241","label":"url"}],"presentation_title":{"en":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序","ja":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序"},"presenters":{"en":[{"name":"Mukai Aina"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"向井 愛菜"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"第49回日本毒性学会学術年会","ja":"第49回日本毒性学会学術年会"},"publication_date":"2022-07-01","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:92, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300600"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386239","label":"url"}],"presentation_title":{"en":"皮膚角質層に含まれる超硫黄分子の検出","ja":"皮膚角質層に含まれる超硫黄分子の検出"},"presenters":{"en":[{"name":"Hashimoto Reina"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"橋本 怜奈"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"第49回日本毒性学会学術年会","ja":"第49回日本毒性学会学術年会"},"publication_date":"2022-07-01","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:93, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300601"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386240","label":"url"}],"presentation_title":{"en":"緑色蛍光タンパク質(EGFP)をモデル抗原として封入したPEG修飾エクソソームの脾臓送達による抗原特異的抗体の誘導","ja":"緑色蛍光タンパク質(EGFP)をモデル抗原として封入したPEG修飾エクソソームの脾臓送達による抗原特異的抗体の誘導"},"presenters":{"en":[{"name":"Kuramoto Reon"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"倉本 伶音"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第38回日本DDS学会学術集会","ja":"第38回日本DDS学会学術集会"},"publication_date":"2022-06-30","languages":["jpn"],"location":{"en":"Online","ja":"オンライン"},"is_international_presentation":false},"priority":"input_data"}
line:94, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300602"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386238","label":"url"}],"presentation_title":{"en":"オキサリプラチン封入PEG修飾リポソームの悪性リンパ腫に対する治療効果の検討","ja":"オキサリプラチン封入PEG修飾リポソームの悪性リンパ腫に対する治療効果の検討"},"presenters":{"en":[{"name":"Sunami Takaya"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Abe Masahiro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"角南 尚哉"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"安倍 正博"},{"name":"石田 竜弘"}]},"event":{"en":"第38回日本DDS学会学術集会","ja":"第38回日本DDS学会学術集会"},"publication_date":"2022-06-30","languages":["jpn"],"location":{"en":"Online","ja":"オンライン"},"is_international_presentation":false},"priority":"input_data"}
line:95, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300603"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386237","label":"url"}],"presentation_title":{"en":"アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製","ja":"アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製"},"presenters":{"en":[{"name":"Hashimoto Aiko"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 愛子"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"第38回日本DDS学会学術集会","ja":"第38回日本DDS学会学術集会"},"publication_date":"2022-06-30","languages":["jpn"],"location":{"en":"Online","ja":"オンライン"},"is_international_presentation":false},"priority":"input_data"}
line:96, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300604"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386236","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミンナノ粒子(HSAnp)を利用したDDSの新規開発とがんワクチンへの展開","ja":"ヒト血清アルブミンナノ粒子(HSAnp)を利用したDDSの新規開発とがんワクチンへの展開"},"presenters":{"en":[{"name":"Yamade Rina"},{"name":"Shimizu Taro"},{"name":"Hirakawa Naoki"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山出 莉奈"},{"name":"清水 太郎"},{"name":"平川 尚樹"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第38回日本DDS学会学術集会","ja":"第38回日本DDS学会学術集会"},"publication_date":"2022-06-30","languages":["jpn"],"location":{"en":"Online","ja":"オンライン"},"is_international_presentation":false},"priority":"input_data"}
line:97, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300605"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386235","label":"url"}],"presentation_title":{"en":"抗TNFαモノクローナル抗体(Humira)をマウスに投与した際の抗薬物抗体の誘導評価","ja":"抗TNFαモノクローナル抗体(Humira)をマウスに投与した際の抗薬物抗体の誘導評価"},"presenters":{"en":[{"name":"Yamamoto Haruka"},{"name":"ANDO Hidenori"},{"name":"大本 安一"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 遥香"},{"name":"安藤 英紀"},{"name":"大本 安一"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第38回日本DDS学会学術集会","ja":"第38回日本DDS学会学術集会"},"publication_date":"2022-06-30","languages":["jpn"],"location":{"en":"Online","ja":"オンライン"},"is_international_presentation":false},"priority":"input_data"}
line:98, {"insert":{"user_id":"B000320827","type":"presentations","id":"38300606"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386234","label":"url"}],"presentation_title":{"en":"抗原とオボアルブミンを共封入したPEG修飾リポソームの脾臓送達による抗原特異的抗体誘導の増強効果","ja":"抗原とオボアルブミンを共封入したPEG修飾リポソームの脾臓送達による抗原特異的抗体誘導の増強効果"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第38回日本DDS学会学術集会","ja":"第38回日本DDS学会学術集会"},"publication_date":"2022-06-30","languages":["jpn"],"location":{"en":"Online","ja":"オンライン"},"is_international_presentation":false},"priority":"input_data"}
line:99, {"insert":{"user_id":"B000320827","type":"presentations","id":"37120650"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=385750","label":"url"}],"presentation_title":{"en":"ガングリオシドを用いた抗核酸抗体誘導抑制効果の検討","ja":"ガングリオシドを用いた抗核酸抗体誘導抑制効果の検討"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Milad Qelliny"},{"name":"Shimizu Taro"},{"name":"Hiro Ueda"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"Milad Qelliny"},{"name":"清水 太郎"},{"name":"上田 大"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第37年会","ja":"日本薬剤学会第37年会"},"publication_date":"2022-05-27","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:100, {"insert":{"user_id":"B000320827","type":"presentations","id":"37120651"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=385749","label":"url"}],"presentation_title":{"en":"mRNA封入脂質ナノ粒子構成成分のPEGに対する抗PEG抗体の誘導及びアナフィラキシー様反応への影響","ja":"mRNA封入脂質ナノ粒子構成成分のPEGに対する抗PEG抗体の誘導及びアナフィラキシー様反応への影響"},"presenters":{"en":[{"name":"Abe Shunji"},{"name":"Takata Haruka"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"阿部 舜史"},{"name":"髙田 春風"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第37年会","ja":"日本薬剤学会第37年会"},"publication_date":"2022-05-26","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:101, {"insert":{"user_id":"B000320827","type":"presentations","id":"37120652"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=385748","label":"url"}],"presentation_title":{"en":"抗原封入PEG修飾リポソームを利用した抗体誘導におけるOVAのアジュバント効果の検証","ja":"抗原封入PEG修飾リポソームを利用した抗体誘導におけるOVAのアジュバント効果の検証"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第37年会","ja":"日本薬剤学会第37年会"},"publication_date":"2022-05-26","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:102, {"insert":{"user_id":"B000320827","type":"presentations","id":"37120653"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=385751","label":"url"}],"presentation_title":{"en":"アルブミンの体内動態特性に基づくDDSキャリアの開発に関する研究","ja":"アルブミンの体内動態特性に基づくDDSキャリアの開発に関する研究"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"日本薬剤学会第37年会","ja":"日本薬剤学会第37年会"},"publication_date":"2022-05-24","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:103, {"insert":{"user_id":"B000320827","type":"presentations","id":"36398377"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384351","label":"url"}],"presentation_title":{"en":"末端構造の異なるPEGで作製した抗原封入リポソームの静脈内投与による抗体誘導に関わる免疫細胞の評価","ja":"末端構造の異なるPEGで作製した抗原封入リポソームの静脈内投与による抗体誘導に関わる免疫細胞の評価"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"冨田 康治"},{"name":"前田 典之"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"冨田 康治"},{"name":"前田 典之"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第142年会","ja":"日本薬学会第142年会"},"publication_date":"2022-03-28","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:104, {"insert":{"user_id":"B000320827","type":"presentations","id":"36398378"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384350","label":"url"}],"presentation_title":{"en":"イオン液体を用いた経皮吸収ワクチンによる皮膚およびリンパ節における免疫細胞の活性化評価","ja":"イオン液体を用いた経皮吸収ワクチンによる皮膚およびリンパ節における免疫細胞の活性化評価"},"presenters":{"en":[{"name":"Matsuzaki Takaaki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"山中 勝弘"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松﨑 隆朗"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"山中 勝弘"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第142年会","ja":"日本薬学会第142年会"},"publication_date":"2022-03-28","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:105, {"insert":{"user_id":"B000320827","type":"presentations","id":"36398379"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384349","label":"url"}],"presentation_title":{"en":"脾臓中B細胞は補体受容体介在性に捕捉した抗原キャリアを他の抗原提示細胞へ輸送する","ja":"脾臓中B細胞は補体受容体介在性に捕捉した抗原キャリアを他の抗原提示細胞へ輸送する"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第142年会","ja":"日本薬学会第142年会"},"publication_date":"2022-03-28","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:106, {"insert":{"user_id":"B000320827","type":"presentations","id":"36398380"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384355","label":"url"}],"presentation_title":{"en":"ヒト膵がん細胞におけるニトロ化フェニル酪酸のオートファジー阻害効果","ja":"ヒト膵がん細胞におけるニトロ化フェニル酪酸のオートファジー阻害効果"},"presenters":{"en":[{"name":"別府 拓豪"},{"name":"西 弘二"},{"name":"井本 修平"},{"name":"Ishima Yu"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山﨑 啓之"}],"ja":[{"name":"別府 拓豪"},{"name":"西 弘二"},{"name":"井本 修平"},{"name":"異島 優"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山﨑 啓之"}]},"event":{"en":"日本薬学会第142年会","ja":"日本薬学会第142年会"},"publication_date":"2022-03-27","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:107, {"insert":{"user_id":"B000320827","type":"presentations","id":"36398381"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384352","label":"url"}],"presentation_title":{"en":"新型コロナウイルスに対する効率的な抗体誘導を目指した脾臓辺縁帯B細胞標的化ワクチン開発に関する検討","ja":"新型コロナウイルスに対する効率的な抗体誘導を目指した脾臓辺縁帯B細胞標的化ワクチン開発に関する検討"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Yamaguchi Sesshu"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"山口 雪洲"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第142年会","ja":"日本薬学会第142年会"},"publication_date":"2022-03-27","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:108, {"insert":{"user_id":"B000320827","type":"presentations","id":"36398382"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384354","label":"url"}],"presentation_title":{"en":"一酸化窒素とチオールを基軸とした新規NASH治療法の開発","ja":"一酸化窒素とチオールを基軸とした新規NASH治療法の開発"},"presenters":{"en":[{"name":"前田 仁志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}],"ja":[{"name":"前田 仁志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}]},"event":{"en":"日本薬学会第142年会","ja":"日本薬学会第142年会"},"publication_date":"2022-03-26","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:109, {"insert":{"user_id":"B000320827","type":"presentations","id":"36266352"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384018","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミンに対するケルセチンの結合特性が機能評価実験に及ぼす影響","ja":"ヒト血清アルブミンに対するケルセチンの結合特性が機能評価実験に及ぼす影響"},"presenters":{"en":[{"name":"奥山 仁美"},{"name":"内村 望空"},{"name":"坂尾 こず枝"},{"name":"池田 真由美"},{"name":"Ishima Yu"},{"name":"西川 美宇"},{"name":"生城 真一"},{"name":"Mukai Rie"}],"ja":[{"name":"奥山 仁美"},{"name":"内村 望空"},{"name":"坂尾 こず枝"},{"name":"池田 真由美"},{"name":"異島 優"},{"name":"西川 美宇"},{"name":"生城 真一"},{"name":"向井 理恵"}]},"event":{"en":"第26回 日本フードファクター学会 学術集会","ja":"第26回 日本フードファクター学会 学術集会"},"publication_date":"2021-11-20","languages":["jpn"],"location":{"en":"奈良県奈良市(奈良女子大学オンライン開催)","ja":"奈良県奈良市(奈良女子大学オンライン開催)"},"is_international_presentation":false},"priority":"input_data"}
line:110, {"insert":{"user_id":"B000320827","type":"presentations","id":"35251542"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382783","label":"url"}],"presentation_title":{"en":"抗原封入リポソームの脾臓免疫による抗体誘導に関するPEG末端構造の影響","ja":"抗原封入リポソームの脾臓免疫による抗体誘導に関するPEG末端構造の影響"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"前田 典之"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"前田 典之"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:111, {"insert":{"user_id":"B000320827","type":"presentations","id":"35251544"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382782","label":"url"}],"presentation_title":{"en":"表面物性の異なるナノフィブリル化バクテリアセルロースを用いたパクリタキセル製剤の開発と腹膜播種治療評価","ja":"表面物性の異なるナノフィブリル化バクテリアセルロースを用いたパクリタキセル製剤の開発と腹膜播種治療評価"},"presenters":{"en":[{"name":"Takata Masaki"},{"name":"ANDO Hidenori"},{"name":"Akagi Shunsuke"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"高田 正希"},{"name":"安藤 英紀"},{"name":"赤木 俊介"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:112, {"insert":{"user_id":"B000320827","type":"presentations","id":"35251545"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382780","label":"url"}],"presentation_title":{"en":"重曹経口投与による腫瘍内微小環境中性化にともなう遺伝子発現解析","ja":"重曹経口投与による腫瘍内微小環境中性化にともなう遺伝子発現解析"},"presenters":{"en":[{"name":"Uehara Riku"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上原 陸"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:113, {"insert":{"user_id":"B000320827","type":"presentations","id":"35251546"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382779","label":"url"}],"presentation_title":{"en":"Sulfane sulfur付加型HSAを用いた還元ストレス誘導を介するがん治療戦略","ja":"Sulfane sulfur付加型HSAを用いた還元ストレス誘導を介するがん治療戦略"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 菜々"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:114, {"insert":{"user_id":"B000320827","type":"presentations","id":"35251547"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382777","label":"url"}],"presentation_title":{"en":"核酸搭載PEG修飾カチオン性リポソームによる抗PEG抗体および抗核酸抗体誘導に及ぼすガングリオシド修飾の影響","ja":"核酸搭載PEG修飾カチオン性リポソームによる抗PEG抗体および抗核酸抗体誘導に及ぼすガングリオシド修飾の影響"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Qelliny Milad"},{"name":"Takata Haruka"},{"name":"Hiro UEDA"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Qelliny Milad"},{"name":"髙田 春風"},{"name":"上田 大"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:115, {"insert":{"user_id":"B000320827","type":"presentations","id":"35434465"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382804","label":"url"}],"presentation_title":{"en":"アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製","ja":"アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製"},"presenters":{"en":[{"name":"Hashimoto Aiko"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 愛子"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"第15回次世代を担う若手のための医療薬科学シンポジウム","ja":"第15回次世代を担う若手のための医療薬科学シンポジウム"},"publication_date":"2021-10-23","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:116, {"insert":{"user_id":"B000320827","type":"presentations","id":"34030862"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382680","label":"url"}],"presentation_title":{"en":"活性硫黄化が織りなすタンパク質の新たな生体防御機構","ja":"活性硫黄化が織りなすタンパク質の新たな生体防御機構"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"第28回日本血液代替物学会年次大会","ja":"第28回日本血液代替物学会年次大会"},"publication_date":"2021-10-14","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:117, {"insert":{"user_id":"B000320827","type":"presentations","id":"33869539"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382251","label":"url"}],"presentation_title":{"en":"ナノフィブリル化バクテリアセルロース(NFBC)を利用した3次元細胞培養に関する基礎的検討","ja":"ナノフィブリル化バクテリアセルロース(NFBC)を利用した3次元細胞培養に関する基礎的検討"},"presenters":{"en":[{"name":"ANDO Hidenori"},{"name":"Akagi Shunsuke"},{"name":"田島 健次"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"赤木 俊介"},{"name":"田島 健次"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"石田 竜弘"}]},"event":{"en":"セルロース学会第28回年次大会","ja":"セルロース学会第28回年次大会"},"publication_date":"2021-09-30","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:118, {"insert":{"user_id":"B000320827","type":"presentations","id":"33869540"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382250","label":"url"}],"presentation_title":{"en":"ナノフィブリル化バクテリアセルロース(NFBC)を用いた3次元培養によるヒト肝がんHepG2細胞の機能変動評価","ja":"ナノフィブリル化バクテリアセルロース(NFBC)を用いた3次元培養によるヒト肝がんHepG2細胞の機能変動評価"},"presenters":{"en":[{"name":"Akagi Shunsuke"},{"name":"ANDO Hidenori"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"赤木 俊介"},{"name":"安藤 英紀"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"セルロース学会第28回年次大会","ja":"セルロース学会第28回年次大会"},"publication_date":"2021-09-30","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:119, {"insert":{"user_id":"B000320827","type":"presentations","id":"33869541"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382249","label":"url"}],"presentation_title":{"en":"高い抗体産生誘導能を有する抗原搭載アルブミンナノ粒子の開発","ja":"高い抗体産生誘導能を有する抗原搭載アルブミンナノ粒子の開発"},"presenters":{"en":[{"name":"Yamade Rina"},{"name":"Hirakawa Naoki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山出 莉奈"},{"name":"平川 尚樹"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第2回超分子薬剤学FGシンポジウム","ja":"日本薬剤学会第2回超分子薬剤学FGシンポジウム"},"publication_date":"2021-09-25","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:120, {"insert":{"user_id":"B000320827","type":"presentations","id":"33967622"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382445","label":"url"}],"presentation_title":{"en":"Enhancement of the anti-tumor effect of B cell-based vaccines via increasing the loading amount of antigens by utilizing novel antigen carrier system","ja":"Enhancement of the anti-tumor effect of B cell-based vaccines via increasing the loading amount of antigens by utilizing novel antigen carrier system"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"2021 Tokushima Bioscience Retreat","ja":"2021 Tokushima Bioscience Retreat"},"publication_date":"2021-09-17","languages":["eng"],"location":{"en":"Tokushima","ja":"Tokushima"},"is_international_presentation":false},"priority":"input_data"}
line:121, {"insert":{"user_id":"B000320827","type":"presentations","id":"33624770"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=381822","label":"url"}],"presentation_title":{"en":"活性イオウ付加型ヒト血清アルブミンの腫瘍への送達は小疱形成を介した細胞死を誘導する","ja":"活性イオウ付加型ヒト血清アルブミンの腫瘍への送達は小疱形成を介した細胞死を誘導する"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 菜々"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"第29回DDSカンファランス","ja":"第29回DDSカンファランス"},"publication_date":"2021-09-03","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:122, {"insert":{"user_id":"B000320827","type":"presentations","id":"32883806"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376519","label":"url"}],"presentation_title":{"en":"新規脾臓免疫で誘導した抗体の多様性および結合性の評価","ja":"新規脾臓免疫で誘導した抗体の多様性および結合性の評価"},"presenters":{"en":[{"name":"ANDO Hidenori"},{"name":"Yamaguchi Sesshu"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"山口 雪洲"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-30","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:123, {"insert":{"user_id":"B000320827","type":"presentations","id":"32883807"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376517","label":"url"}],"presentation_title":{"en":"脾臓辺縁帯B細胞を標的としたペプチド封入リポソームによる免疫誘導に関する検討","ja":"脾臓辺縁帯B細胞を標的としたペプチド封入リポソームによる免疫誘導に関する検討"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Shimazaki Yuna"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"島崎 優奈"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-30","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:124, {"insert":{"user_id":"B000320827","type":"presentations","id":"32883808"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376513","label":"url"}],"presentation_title":{"en":"がん間質細胞を二重標的化する抗がん剤送達キャリアの開発と新規がんDDS戦略の構築","ja":"がん間質細胞を二重標的化する抗がん剤送達キャリアの開発と新規がんDDS戦略の構築"},"presenters":{"en":[{"name":"水田 夕稀"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"水田 夕稀"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"木下 遼"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-30","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:125, {"insert":{"user_id":"B000320827","type":"presentations","id":"32883809"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376522","label":"url"}],"presentation_title":{"en":"投与経路が及ぼすPEG修飾リポソーム投与時の抗PEG抗体誘導に与える影響に関する検討","ja":"投与経路が及ぼすPEG修飾リポソーム投与時の抗PEG抗体誘導に与える影響に関する検討"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Kawaguchi Yoshino"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"川口 桂乃"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-29","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:126, {"insert":{"user_id":"B000320827","type":"presentations","id":"32883810"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376512","label":"url"}],"presentation_title":{"en":"ヒト膵がん細胞に対するニトロ化フェニル酪酸の細胞死誘導メカニズムの解明","ja":"ヒト膵がん細胞に対するニトロ化フェニル酪酸の細胞死誘導メカニズムの解明"},"presenters":{"en":[{"name":"別府 拓豪"},{"name":"西 弘二"},{"name":"井本 修平"},{"name":"Ishima Yu"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山崎 啓之"}],"ja":[{"name":"別府 拓豪"},{"name":"西 弘二"},{"name":"井本 修平"},{"name":"異島 優"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山崎 啓之"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-29","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:127, {"insert":{"user_id":"B000320827","type":"presentations","id":"32883811"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376515","label":"url"}],"presentation_title":{"en":"イオン液体を用いたIL-23 特異的siRNAの経皮送達はイミキモド誘発乾癬モデルマウスの皮膚症状を改善する","ja":"イオン液体を用いたIL-23 特異的siRNAの経皮送達はイミキモド誘発乾癬モデルマウスの皮膚症状を改善する"},"presenters":{"en":[{"name":"Sakamoto Chika"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"坂元 智香"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"日本核酸医薬学会第6回年会","ja":"日本核酸医薬学会第6回年会"},"publication_date":"2021-06-27","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:128, {"insert":{"user_id":"B000320827","type":"presentations","id":"32939313"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376613","label":"url"}],"presentation_title":{"en":"ガングリオシドによるDNA搭載PEG修飾カチオン性リポソーム投与時のPEG及びDNAに対する抗体の産生への影響の検討","ja":"ガングリオシドによるDNA搭載PEG修飾カチオン性リポソーム投与時のPEG及びDNAに対する抗体の産生への影響の検討"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Milad Reda Qelliny"},{"name":"Shimizu Taro"},{"name":"Hiro UEDA"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"Milad Reda Qelliny"},{"name":"清水 太郎"},{"name":"上田 大"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本核酸医薬学会第6回年会 サテライト若手シンポジウム","ja":"日本核酸医薬学会第6回年会 サテライト若手シンポジウム"},"publication_date":"2021-06-25","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:129, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512560"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375623","label":"url"}],"presentation_title":{"en":"マクロファージ及び線維芽細胞を標的可能なレドックス応答性ナノラジカルスカベンジャーの開発と肝疾患治療への応用","ja":"マクロファージ及び線維芽細胞を標的可能なレドックス応答性ナノラジカルスカベンジャーの開発と肝疾患治療への応用"},"presenters":{"en":[{"name":"安田 健吾"},{"name":"Kinoshita Ryo"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"櫻木 美菜"},{"name":"水田 夕稀"},{"name":"山崎 啓之"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"渡邊 博志"},{"name":"丸山 徹"}],"ja":[{"name":"安田 健吾"},{"name":"木下 遼"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"櫻木 美菜"},{"name":"水田 夕稀"},{"name":"山崎 啓之"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"渡邊 博志"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:130, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512561"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375622","label":"url"}],"presentation_title":{"en":"様々なヒト血清アルブミン受容体を介した薬物キャリアの開発","ja":"様々なヒト血清アルブミン受容体を介した薬物キャリアの開発"},"presenters":{"en":[{"name":"Hashimoto Aiko"},{"name":"Hama Maichi"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 愛子"},{"name":"濱 眞壱"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:131, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512562"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375621","label":"url"}],"presentation_title":{"en":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序解明","ja":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序解明"},"presenters":{"en":[{"name":"Mukai Aina"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"向井 愛菜"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:132, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512563"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375620","label":"url"}],"presentation_title":{"en":"紫外線による皮膚角質中に含まれる活性イオウ分子種の変動","ja":"紫外線による皮膚角質中に含まれる活性イオウ分子種の変動"},"presenters":{"en":[{"name":"Hashimoto Reina"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 怜奈"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:133, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512564"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375619","label":"url"}],"presentation_title":{"en":"イオン液体を基剤としたLixisenatide製剤の開発と腸管吸収評価","ja":"イオン液体を基剤としたLixisenatide製剤の開発と腸管吸収評価"},"presenters":{"en":[{"name":"Sunami Takaya"},{"name":"ANDO Hidenori"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"角南 尚哉"},{"name":"安藤 英紀"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:134, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512565"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375618","label":"url"}],"presentation_title":{"en":"イオン液体を用いた難経口吸収性化合物の腸管吸収促進効果の検討","ja":"イオン液体を用いた難経口吸収性化合物の腸管吸収促進効果の検討"},"presenters":{"en":[{"name":"Atsuya MARUYAMA"},{"name":"ANDO Hidenori"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"丸山 敦也"},{"name":"安藤 英紀"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:135, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512566"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375617","label":"url"}],"presentation_title":{"en":"全身性エリテマトーデスモデルマウス由来マイクロパーティクルにおけるプロテオーム解析","ja":"全身性エリテマトーデスモデルマウス由来マイクロパーティクルにおけるプロテオーム解析"},"presenters":{"en":[{"name":"Hiro UEDA"},{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上田 大"},{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:136, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512567"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375616","label":"url"}],"presentation_title":{"en":"細胞ワクチンへの応用を目指した補体受容体標的化キャリアを用いる新規B細胞抗原刺激法の確立","ja":"細胞ワクチンへの応用を目指した補体受容体標的化キャリアを用いる新規B細胞抗原刺激法の確立"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Awata Mizuki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"粟田 瑞月"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:137, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512568"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375615","label":"url"}],"presentation_title":{"en":"効果的な細胞免疫療法の開発に向けたB細胞への新規抗原刺激法の有用性評価","ja":"効果的な細胞免疫療法の開発に向けたB細胞への新規抗原刺激法の有用性評価"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Awata Mizuki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"粟田 瑞月"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:138, {"insert":{"user_id":"B000320827","type":"presentations","id":"32512569"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375614","label":"url"}],"presentation_title":{"en":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administer","ja":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administer"},"presenters":{"en":[{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:139, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498654"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375599","label":"url"}],"presentation_title":{"en":"抗原封入リポソームの脾臓免疫による抗原特異的IgGの誘導とサブクラス多様性の評価","ja":"抗原封入リポソームの脾臓免疫による抗原特異的IgGの誘導とサブクラス多様性の評価"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"Yamaguchi Sesshu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"山口 雪洲"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:140, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498655"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375598","label":"url"}],"presentation_title":{"en":"効率的な体液性免疫誘導に向けたアルブミンナノキャリアの開発","ja":"効率的な体液性免疫誘導に向けたアルブミンナノキャリアの開発"},"presenters":{"en":[{"name":"Yamade Rina"},{"name":"Hirakawa Naoki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山出 莉奈"},{"name":"平川 尚樹"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:141, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498656"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375597","label":"url"}],"presentation_title":{"en":"経皮吸収型がんペプチドワクチンによるE.G7-OVA担がんマウスにおける腫瘍成長抑制効果","ja":"経皮吸収型がんペプチドワクチンによるE.G7-OVA担がんマウスにおける腫瘍成長抑制効果"},"presenters":{"en":[{"name":"Matsuzaki Takaaki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松﨑 隆朗"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:142, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498657"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375596","label":"url"}],"presentation_title":{"en":"菌由来セルロースナノファイバーを用いた細胞の三次元培養と機能性評価","ja":"菌由来セルロースナノファイバーを用いた細胞の三次元培養と機能性評価"},"presenters":{"en":[{"name":"Takata Masaki"},{"name":"Akagi Shunsuke"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"高田 正希"},{"name":"赤木 俊介"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:143, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498658"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375595","label":"url"}],"presentation_title":{"en":"重曹経口投与による腫瘍酸性環境の中性化とDoxil®の抗腫瘍効果の増強","ja":"重曹経口投与による腫瘍酸性環境の中性化とDoxil®の抗腫瘍効果の増強"},"presenters":{"en":[{"name":"Uehara Riku"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上原 陸"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:144, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498659"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375594","label":"url"}],"presentation_title":{"en":"新規脾臓免疫法による特異抗体の誘導とその多様性および結合親和性の評価","ja":"新規脾臓免疫法による特異抗体の誘導とその多様性および結合親和性の評価"},"presenters":{"en":[{"name":"Yamaguchi Sesshu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山口 雪洲"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:145, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498660"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375593","label":"url"}],"presentation_title":{"en":"マレイミド-チオール結合を介した抗がん剤封入リポソームの脾臓細胞への搭載とそのがん細胞障害性の評価","ja":"マレイミド-チオール結合を介した抗がん剤封入リポソームの脾臓細胞への搭載とそのがん細胞障害性の評価"},"presenters":{"en":[{"name":"Matsugi Yuki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松木 佑樹"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:146, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498661"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375592","label":"url"}],"presentation_title":{"en":"エクソソームの脾臓免疫で得た抗血清(ポリクローナル抗体)の結合性評価","ja":"エクソソームの脾臓免疫で得た抗血清(ポリクローナル抗体)の結合性評価"},"presenters":{"en":[{"name":"Kuramoto Reon"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"倉本 伶音"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:147, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498662"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375591","label":"url"}],"presentation_title":{"en":"PEG修飾タンパクの凝集体形成が及ぼす抗PEG抗体産生・血中滞留性への影響","ja":"PEG修飾タンパクの凝集体形成が及ぼす抗PEG抗体産生・血中滞留性への影響"},"presenters":{"en":[{"name":"Yuka FUKUDA"},{"name":"中島 祟樹"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"長野 一也"},{"name":"柴田 寛子"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 悠花"},{"name":"中島 祟樹"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"長野 一也"},{"name":"柴田 寛子"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:148, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498663"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375590","label":"url"}],"presentation_title":{"en":"経皮送達可能なsiRNA含有イオン液体製剤による新規乾癬治療","ja":"経皮送達可能なsiRNA含有イオン液体製剤による新規乾癬治療"},"presenters":{"en":[{"name":"Sakamoto Chika"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"坂元 智香"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:149, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498664"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375587","label":"url"}],"presentation_title":{"en":"物性の異なるナノフィブリル化バクテリアセルロースを用いた新規PTX製剤の開発と腹膜播種治療評価","ja":"物性の異なるナノフィブリル化バクテリアセルロースを用いた新規PTX製剤の開発と腹膜播種治療評価"},"presenters":{"en":[{"name":"Akagi Shunsuke"},{"name":"ANDO Hidenori"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"赤木 俊介"},{"name":"安藤 英紀"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:150, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498665"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375586","label":"url"}],"presentation_title":{"en":"免疫抑制剤フィンゴリモドによるABCトランスポーターの増加を介した泡沫化マクロファージへの脂質蓄積への影響","ja":"免疫抑制剤フィンゴリモドによるABCトランスポーターの増加を介した泡沫化マクロファージへの脂質蓄積への影響"},"presenters":{"en":[{"name":"Kohki TACHIBANA"},{"name":"Mai OGAWA"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"},{"name":"Okuhira Keiichiro"}],"ja":[{"name":"立花 洸季"},{"name":"小川 真依"},{"name":"石田 竜弘"},{"name":"異島 優"},{"name":"奥平 桂一郎"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:151, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498666"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375585","label":"url"}],"presentation_title":{"en":"核酸搭載PEG修飾リポソームが全身性エリテマトーデスの発症時期，増悪に与える影響","ja":"核酸搭載PEG修飾リポソームが全身性エリテマトーデスの発症時期，増悪に与える影響"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:152, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498667"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375584","label":"url"}],"presentation_title":{"en":"アルブミン結合型パクリタキセル製剤AbraxaneⓇの変性アルブミン受容体を介した薬物輸送メカニズム","ja":"アルブミン結合型パクリタキセル製剤AbraxaneⓇの変性アルブミン受容体を介した薬物輸送メカニズム"},"presenters":{"en":[{"name":"Hama Maichi"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"濵 眞壱"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:153, {"insert":{"user_id":"B000320827","type":"presentations","id":"32498668"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375583","label":"url"}],"presentation_title":{"en":"Cell-type tropism promotes the intratumor accumulation of PEGylated cancer cell-derived exosomes","ja":"Cell-type tropism promotes the intratumor accumulation of PEGylated cancer cell-derived exosomes"},"presenters":{"en":[{"name":"Emam Abdallah Emam Sherif"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-13","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:154, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578139"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373528","label":"url"}],"presentation_title":{"en":"ヒト膵がん細胞に対するニトロ化フェニル酪酸の細胞死誘導効果","ja":"ヒト膵がん細胞に対するニトロ化フェニル酪酸の細胞死誘導効果"},"presenters":{"en":[{"name":"別府 拓豪"},{"name":"西 弘二"},{"name":"井本 修平"},{"name":"Ishima Yu"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山崎 啓之"}],"ja":[{"name":"別府 拓豪"},{"name":"西 弘二"},{"name":"井本 修平"},{"name":"異島 優"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山崎 啓之"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-29","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:155, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578140"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373523","label":"url"}],"presentation_title":{"en":"難溶性薬物に対する溶解補助及び動態改善を企図した新規アルブミンナノ粒子の開発","ja":"難溶性薬物に対する溶解補助及び動態改善を企図した新規アルブミンナノ粒子の開発"},"presenters":{"en":[{"name":"Nakano Ryuto"},{"name":"Hirakawa Naoki"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"中野 琉人"},{"name":"平川 尚樹"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-29","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:156, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578141"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373522","label":"url"}],"presentation_title":{"en":"エクソソームの脾臓免疫により誘導した抗体のエクソソームタンパク質への結合評価","ja":"エクソソームの脾臓免疫により誘導した抗体のエクソソームタンパク質への結合評価"},"presenters":{"en":[{"name":"Kuramoto Reon"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"倉本 伶音"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-29","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:157, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578142"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373521","label":"url"}],"presentation_title":{"en":"高用量PEG修飾リポソーム投与時の抗PEG抗体誘導抑制機序に関する検討","ja":"高用量PEG修飾リポソーム投与時の抗PEG抗体誘導抑制機序に関する検討"},"presenters":{"en":[{"name":"Miyahara Kohga"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Janos Szebeni"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"宮原 康嘉"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"Janos Szebeni"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-29","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:158, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578143"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373520","label":"url"}],"presentation_title":{"en":"脾臓B細胞上の補体受容体を介した抗原送達法を利用する新規細胞免疫療法の開発","ja":"脾臓B細胞上の補体受容体を介した抗原送達法を利用する新規細胞免疫療法の開発"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimazaki Yuna"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"島崎 優奈"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-29","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:159, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578144"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373519","label":"url"}],"presentation_title":{"en":"活性イオウ付加アルブミンの設計と還元ストレス誘導による抗腫瘍効果の評価","ja":"活性イオウ付加アルブミンの設計と還元ストレス誘導による抗腫瘍効果の評価"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 菜々"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-29","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:160, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578145"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373518","label":"url"}],"presentation_title":{"en":"抗原封入リポソームの脾臓免疫で誘導された抗体の多様性・親和性評価","ja":"抗原封入リポソームの脾臓免疫で誘導された抗体の多様性・親和性評価"},"presenters":{"en":[{"name":"Yamaguchi Sesshu"},{"name":"ANDO Hidenori"},{"name":"Shimazaki Yuna"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山口 雪洲"},{"name":"安藤 英紀"},{"name":"島崎 優奈"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-29","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:161, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578146"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373526","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミン(HSA)を利用した脾臓への抗原送達による体液性免疫の誘導","ja":"ヒト血清アルブミン(HSA)を利用した脾臓への抗原送達による体液性免疫の誘導"},"presenters":{"en":[{"name":"Yamade Rina"},{"name":"Hirakawa Naoki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山出 莉奈"},{"name":"平川 尚樹"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-28","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:162, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578147"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373525","label":"url"}],"presentation_title":{"en":"イオン液体を用いたGLP-1受容体作動薬の腸管吸収性検討","ja":"イオン液体を用いたGLP-1受容体作動薬の腸管吸収性検討"},"presenters":{"en":[{"name":"Sunami Takaya"},{"name":"ANDO Hidenori"},{"name":"Maruyama Atsuya"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"角南 尚哉"},{"name":"安藤 英紀"},{"name":"丸山 敦也"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-28","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:163, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578148"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373529","label":"url"}],"presentation_title":{"en":"ヒト膵がん細胞におけるニトロ化ナテグリニドの細胞死誘導効果","ja":"ヒト膵がん細胞におけるニトロ化ナテグリニドの細胞死誘導効果"},"presenters":{"en":[{"name":"西 弘二"},{"name":"別府 拓豪"},{"name":"井本 修平"},{"name":"Ishima Yu"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山崎 啓之"}],"ja":[{"name":"西 弘二"},{"name":"別府 拓豪"},{"name":"井本 修平"},{"name":"異島 優"},{"name":"月川 健士"},{"name":"小田切 優樹"},{"name":"山崎 啓之"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-27","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:164, {"insert":{"user_id":"B000320827","type":"presentations","id":"31578149"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373527","label":"url"}],"presentation_title":{"en":"免疫抑制剤フィンゴリモドがマクロファージへの脂質蓄積に与える影響","ja":"免疫抑制剤フィンゴリモドがマクロファージへの脂質蓄積に与える影響"},"presenters":{"en":[{"name":"Kohki TACHIBANA"},{"name":"Mai OGAWA"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"},{"name":"Okuhira Keiichiro"}],"ja":[{"name":"立花 洸季"},{"name":"小川 真依"},{"name":"石田 竜弘"},{"name":"異島 優"},{"name":"奥平 桂一郎"}]},"event":{"en":"日本薬学会第141年会","ja":"日本薬学会第141年会"},"publication_date":"2021-03-27","languages":["jpn"],"location":{"en":"Hiroshima","ja":"広島"},"is_international_presentation":false},"priority":"input_data"}
line:165, {"insert":{"user_id":"B000320827","type":"presentations","id":"31070092"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=372568","label":"url"}],"presentation_title":{"en":"脾臓標的化リポソーム技術を用いた短期間で抗体を誘導する抗体産生誘導技術の開発","ja":"脾臓標的化リポソーム技術を用いた短期間で抗体を誘導する抗体産生誘導技術の開発"},"presenters":{"en":[{"name":"Yamaguchi Sesshu"},{"name":"Shimazaki Yuna"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山口 雪洲"},{"name":"島崎 優奈"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2020-12-07","languages":["jpn"],"location":{"en":"Matsue","ja":"松江"},"is_international_presentation":false},"priority":"input_data"}
line:166, {"insert":{"user_id":"B000320827","type":"presentations","id":"31070093"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=372567","label":"url"}],"presentation_title":{"en":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果","ja":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果"},"presenters":{"en":[{"name":"Mukai Aina"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"向井 愛菜"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2020-12-07","languages":["jpn"],"location":{"en":"Matsue","ja":"松江"},"is_international_presentation":false},"priority":"input_data"}
line:167, {"insert":{"user_id":"B000320827","type":"presentations","id":"31070094"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=372566","label":"url"}],"presentation_title":{"en":"脾臓細胞搭載抗がん剤封⼊カチオン性リポソームによるがん細胞障害性のin vitro評価","ja":"脾臓細胞搭載抗がん剤封⼊カチオン性リポソームによるがん細胞障害性のin vitro評価"},"presenters":{"en":[{"name":"Matsugi Yuki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松木 佑樹"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2020-12-07","languages":["jpn"],"location":{"en":"Matsue","ja":"松江"},"is_international_presentation":false},"priority":"input_data"}
line:168, {"insert":{"user_id":"B000320827","type":"presentations","id":"31070095"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=372565","label":"url"}],"presentation_title":{"en":"皮膚角質中に含まれる活性イオウ分子種の検出","ja":"皮膚角質中に含まれる活性イオウ分子種の検出"},"presenters":{"en":[{"name":"Hashimoto Reina"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 怜奈"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2020-12-07","languages":["jpn"],"location":{"en":"Matsue","ja":"松江"},"is_international_presentation":false},"priority":"input_data"}
line:169, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513093"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371690","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミンにおけるパースルフィド化の生理的意義の解明とその臨床応用","ja":"ヒト血清アルブミンにおけるパースルフィド化の生理的意義の解明とその臨床応用"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"澤 智裕"},{"name":"赤池 孝章"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"池田 真由美"},{"name":"澤 智裕"},{"name":"赤池 孝章"},{"name":"石田 竜弘"}]},"event":{"en":"第73回日本酸化ストレス学会・第20回日本NO学会合同学術集会","ja":"第73回日本酸化ストレス学会・第20回日本NO学会合同学術集会"},"publication_date":"2020-10-06","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:170, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513094"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371689","label":"url"}],"presentation_title":{"en":"酸化型ポリスルフィドタンパク質によるユニークな抗酸化作用機構","ja":"酸化型ポリスルフィドタンパク質によるユニークな抗酸化作用機構"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"Tasaka Nanami"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"池田 真由美"},{"name":"田坂 菜々美"},{"name":"石田 竜弘"}]},"event":{"en":"第73回日本酸化ストレス学会・第20回日本NO学会合同学術集会","ja":"第73回日本酸化ストレス学会・第20回日本NO学会合同学術集会"},"publication_date":"2020-10-06","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:171, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513095"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371491","label":"url"}],"presentation_title":{"en":"ストレプトゾトシン誘発Ⅰ型糖尿病モデルマウスにおける血清活性イオウ分子の変動","ja":"ストレプトゾトシン誘発Ⅰ型糖尿病モデルマウスにおける血清活性イオウ分子の変動"},"presenters":{"en":[{"name":"Sakai Maki"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"酒井 真紀"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第93回日本生化学会大会","ja":"第93回日本生化学会大会"},"publication_date":"2020-09-16","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:172, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513096"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371490","label":"url"}],"presentation_title":{"en":"生体液中の活性イオウ分子種含有タンパク質の同定と生理学的意義の解明","ja":"生体液中の活性イオウ分子種含有タンパク質の同定と生理学的意義の解明"},"presenters":{"en":[{"name":"Osafune Hiroki"},{"name":"Ikeda Mayumi"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"長船 裕輝"},{"name":"池田 真由美"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第93回日本生化学会大会","ja":"第93回日本生化学会大会"},"publication_date":"2020-09-16","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:173, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513097"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=368801","label":"url"}],"presentation_title":{"en":"抗がん剤搭載脾臓細胞によるがん細胞障害性評価に関する検討","ja":"抗がん剤搭載脾臓細胞によるがん細胞障害性評価に関する検討"},"presenters":{"en":[{"name":"Matsugi Yuki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松木 佑樹"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第36回日本DDS学会学術集会","ja":"第36回日本DDS学会学術集会"},"publication_date":"2020-08-28","languages":["jpn"],"location":{"en":"Kobe","ja":"神戸"},"is_international_presentation":false},"priority":"input_data"}
line:174, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513098"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=368800","label":"url"}],"presentation_title":{"en":"イオン液体を用いたsiRNAの経皮送達による新規乾癬治療法の開発","ja":"イオン液体を用いたsiRNAの経皮送達による新規乾癬治療法の開発"},"presenters":{"en":[{"name":"Sakamoto Chika"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"坂元 智香"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"第36回日本DDS学会学術集会","ja":"第36回日本DDS学会学術集会"},"publication_date":"2020-08-28","languages":["jpn"],"location":{"en":"Kobe","ja":"神戸"},"is_international_presentation":false},"priority":"input_data"}
line:175, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513099"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=368799","label":"url"}],"presentation_title":{"en":"ヒドロキシ末端PEG修飾リポソームによる抗原刺激を利用した新規B細胞ワクチンの開発","ja":"ヒドロキシ末端PEG修飾リポソームによる抗原刺激を利用した新規B細胞ワクチンの開発"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Awata Mizuki"},{"name":"Shimazaki Yuna"},{"name":"Yoshioka Chihiro"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"粟田 瑞月"},{"name":"島崎 優奈"},{"name":"吉岡 千尋"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第36回日本DDS学会学術集会","ja":"第36回日本DDS学会学術集会"},"publication_date":"2020-08-28","languages":["jpn"],"location":{"en":"Kobe","ja":"神戸"},"is_international_presentation":false},"priority":"input_data"}
line:176, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513100"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366524","label":"url"}],"presentation_title":{"en":"ヒト生体液におけるポリスルフィドプールの発見とその生理学的意義","ja":"ヒト生体液におけるポリスルフィドプールの発見とその生理学的意義"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"池田 真由美"},{"name":"石田 竜弘"}]},"event":{"en":"第47回日本毒性学会学術年会","ja":"第47回日本毒性学会学術年会"},"publication_date":"2020-06-29","languages":["jpn"],"location":{"en":"Sendai","ja":"仙台"},"is_international_presentation":false},"priority":"input_data"}
line:177, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513101"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=365115","label":"url"}],"presentation_title":{"en":"脾臓辺縁帯B細胞への抗原送達による抗体産生誘導技術の開発","ja":"脾臓辺縁帯B細胞への抗原送達による抗体産生誘導技術の開発"},"presenters":{"en":[{"name":"Yamaguchi Sesshu"},{"name":"Shimazaki Yuna"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山口 雪洲"},{"name":"島崎 優奈"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第35年会","ja":"日本薬剤学会第35年会"},"publication_date":"2020-05-14","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:178, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513102"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=365113","label":"url"}],"presentation_title":{"en":"インドシアニングリーンを用いたイオン液体の腸管吸収促進効果の検討","ja":"インドシアニングリーンを用いたイオン液体の腸管吸収促進効果の検討"},"presenters":{"en":[{"name":"Atsuya MARUYAMA"},{"name":"ANDO Hidenori"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"丸山 敦也"},{"name":"安藤 英紀"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第35年会","ja":"日本薬剤学会第35年会"},"publication_date":"2020-05-14","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:179, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513103"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=365112","label":"url"}],"presentation_title":{"en":"PEG修飾タンパクのPEG鎖長や修飾数が及ぼす抗PEG抗体産生と血中滞留性低下への影響","ja":"PEG修飾タンパクのPEG鎖長や修飾数が及ぼす抗PEG抗体産生と血中滞留性低下への影響"},"presenters":{"en":[{"name":"Yuka FUKUDA"},{"name":"中島 祟樹"},{"name":"長野 一也"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 悠花"},{"name":"中島 祟樹"},{"name":"長野 一也"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第35年会","ja":"日本薬剤学会第35年会"},"publication_date":"2020-05-14","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:180, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513104"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=365111","label":"url"}],"presentation_title":{"en":"アルブミン結合型パクリタキセル製剤であるAbraxane®の新たな腫瘍移行機序の発見","ja":"アルブミン結合型パクリタキセル製剤であるAbraxane®の新たな腫瘍移行機序の発見"},"presenters":{"en":[{"name":"Hama Maichi"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"濵 眞壱"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第35年会","ja":"日本薬剤学会第35年会"},"publication_date":"2020-05-14","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:181, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513105"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363099","label":"url"}],"presentation_title":{"en":"イオン液体によるインドシアニングリーンの経口吸収性改善の検討","ja":"イオン液体によるインドシアニングリーンの経口吸収性改善の検討"},"presenters":{"en":[{"name":"Maruyama Atsuya"},{"name":"ANDO Hidenori"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"丸山 敦也"},{"name":"安藤 英紀"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第140年会","ja":"日本薬学会第140年会"},"publication_date":"2020-03-28","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:182, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513106"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363095","label":"url"}],"presentation_title":{"en":"細胞ワクチン療法への利用に適したB細胞サブセットの同定に関する検討","ja":"細胞ワクチン療法への利用に適したB細胞サブセットの同定に関する検討"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Awata Mizuki"},{"name":"Shimazaki Yuna"},{"name":"Yoshioka Chihiro"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"粟田 瑞月"},{"name":"島崎 優奈"},{"name":"吉岡 千尋"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第140年会","ja":"日本薬学会第140年会"},"publication_date":"2020-03-28","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:183, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513107"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363093","label":"url"}],"presentation_title":{"en":"アルブミン結合型パクリタキセル製剤であるAbraxane®の新たな腫瘍移行機序の発見","ja":"アルブミン結合型パクリタキセル製剤であるAbraxane®の新たな腫瘍移行機序の発見"},"presenters":{"en":[{"name":"Hama Maichi"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"濵 眞壱"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第140年会","ja":"日本薬学会第140年会"},"publication_date":"2020-03-28","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:184, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513108"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363098","label":"url"}],"presentation_title":{"en":"糖尿病患者血清におけるサルフェン硫黄の変動","ja":"糖尿病患者血清におけるサルフェン硫黄の変動"},"presenters":{"en":[{"name":"Sakai Maki"},{"name":"Ikeda Mayumi"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"酒井 真紀"},{"name":"池田 真由美"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第140年会","ja":"日本薬学会第140年会"},"publication_date":"2020-03-26","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:185, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513109"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363097","label":"url"}],"presentation_title":{"en":"ヒト唾液α-amylase活性に及ぼすサルフェン硫黄の影響","ja":"ヒト唾液α-amylase活性に及ぼすサルフェン硫黄の影響"},"presenters":{"en":[{"name":"Osafune Hiroki"},{"name":"Ikeda Mayumi"},{"name":"Sakai Maki"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"長船 裕輝"},{"name":"池田 真由美"},{"name":"酒井 真紀"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第140年会","ja":"日本薬学会第140年会"},"publication_date":"2020-03-26","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:186, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513110"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363096","label":"url"}],"presentation_title":{"en":"毛髪キューティクルに存在するポリスルフィドの発見とイオウ供給による毛髪損傷抑制効果の検討","ja":"毛髪キューティクルに存在するポリスルフィドの発見とイオウ供給による毛髪損傷抑制効果の検討"},"presenters":{"en":[{"name":"Tasaka Nanami"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田坂 菜々美"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第140年会","ja":"日本薬学会第140年会"},"publication_date":"2020-03-26","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:187, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513111"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=362156","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミンに含まれるポリスルフィドの生理機能の解明","ja":"ヒト血清アルブミンに含まれるポリスルフィドの生理機能の解明"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"筑波大学 第8回環境生物学セミナー","ja":"筑波大学 第8回環境生物学セミナー"},"publication_date":"2019-12-26","invited":true,"languages":["jpn"],"location":{"en":"Tsukuba","ja":"つくば"},"is_international_presentation":false},"priority":"input_data"}
line:188, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513112"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=361899","label":"url"}],"presentation_title":{"en":"Targeting of albumin to pancreatic cancer via endogenous albumin transport system","ja":"Targeting of albumin to pancreatic cancer via endogenous albumin transport system"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"日本薬物動態学会第34回年会","ja":"日本薬物動態学会第34回年会"},"publication_date":"2019-12-10","invited":true,"languages":["eng"],"location":{"en":"Tsukuba","ja":"Tsukuba"},"is_international_presentation":false},"priority":"input_data"}
line:189, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513113"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360519","label":"url"}],"presentation_title":{"en":"タンパク質へのPEG修飾数やPEG鎖長が及ぼす抗PEG抗体産生への影響","ja":"タンパク質へのPEG修飾数やPEG鎖長が及ぼす抗PEG抗体産生への影響"},"presenters":{"en":[{"name":"Fukuda Yuka"},{"name":"中島 祟樹"},{"name":"長野 一也"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 悠花"},{"name":"中島 祟樹"},{"name":"長野 一也"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2019-11-09","languages":["jpn"],"location":{"en":"Takamatsu","ja":"高松"},"is_international_presentation":false},"priority":"input_data"}
line:190, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513114"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360518","label":"url"}],"presentation_title":{"en":"siRNA含有イオン液体製剤の経皮送達による乾癬治療","ja":"siRNA含有イオン液体製剤の経皮送達による乾癬治療"},"presenters":{"en":[{"name":"Sakamoto Chika"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"坂元 智香"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2019-11-09","languages":["jpn"],"location":{"en":"Takamatsu","ja":"高松"},"is_international_presentation":false},"priority":"input_data"}
line:191, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513115"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360517","label":"url"}],"presentation_title":{"en":"全身性エリテマトーデス病態時の脾臓免疫細胞によるマイクロパーティクルの取り込み変化の検討","ja":"全身性エリテマトーデス病態時の脾臓免疫細胞によるマイクロパーティクルの取り込み変化の検討"},"presenters":{"en":[{"name":"Ueda Hiro"},{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上田 大"},{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2019-11-09","languages":["jpn"],"location":{"en":"Takamatsu","ja":"高松"},"is_international_presentation":false},"priority":"input_data"}
line:192, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513116"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360515","label":"url"}],"presentation_title":{"en":"EPR増強剤の併用は膵臓癌に対するnab-パクリタキセルの治療効果を増強する","ja":"EPR増強剤の併用は膵臓癌に対するnab-パクリタキセルの治療効果を増強する"},"presenters":{"en":[{"name":"丸山 徹"},{"name":"Kinoshita Ryo"},{"name":"前田 仁志"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"Ishima Yu"}],"ja":[{"name":"丸山 徹"},{"name":"木下 遼"},{"name":"前田 仁志"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"異島 優"}]},"event":{"en":"第30回日本消化器癌発生学会総会","ja":"第30回日本消化器癌発生学会総会"},"publication_date":"2019-11-07","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:193, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513117"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360514","label":"url"}],"presentation_title":{"en":"難治性膵臓がんにおけるアルブミンナノ粒子のサイズ最適化の検討","ja":"難治性膵臓がんにおけるアルブミンナノ粒子のサイズ最適化の検討"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Hirakawa Naoki"},{"name":"Ishida Tatsuhiro"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"木下 遼"},{"name":"平川 尚樹"},{"name":"石田 竜弘"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第30回日本消化器癌発生学会総会","ja":"第30回日本消化器癌発生学会総会"},"publication_date":"2019-11-07","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:194, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513118"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360513","label":"url"}],"presentation_title":{"en":"Development of a novel tumor microenvironment-targeted drug deliver carrier","ja":"Development of a novel tumor microenvironment-targeted drug deliver carrier"},"presenters":{"en":[{"name":"水田 夕稀"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"馬場 秀夫"},{"name":"丸山 徹"}],"ja":[{"name":"水田 夕稀"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"木下 遼"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"馬場 秀夫"},{"name":"丸山 徹"}]},"event":{"en":"第30回日本消化器癌発生学会総会","ja":"第30回日本消化器癌発生学会総会"},"publication_date":"2019-11-07","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:195, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513119"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359158","label":"url"}],"presentation_title":{"en":"イオン液体を用いた新規インスリン含有経皮吸収製剤は糖尿病治療薬になりうる","ja":"イオン液体を用いた新規インスリン含有経皮吸収製剤は糖尿病治療薬になりうる"},"presenters":{"en":[{"name":"Sasai Masaki"},{"name":"Shimizu Taro"},{"name":"Okuhira Keiichiro"},{"name":"Ishima Yu"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"佐々井 雅樹"},{"name":"清水 太郎"},{"name":"奥平 桂一郎"},{"name":"異島 優"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"第28回DDSカンファランス","ja":"第28回DDSカンファランス"},"publication_date":"2019-09-06","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:196, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513120"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=358272","label":"url"}],"presentation_title":{"en":"アルブミン研究の新展開∼新たな生体防御機構解明へ∼","ja":"アルブミン研究の新展開∼新たな生体防御機構解明へ∼"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"九重セミナー第43回西日本薬剤学研究会","ja":"九重セミナー第43回西日本薬剤学研究会"},"publication_date":"2019-08-23","languages":["jpn"],"location":{"en":"Oita","ja":"大分"},"is_international_presentation":false},"priority":"input_data"}
line:197, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513121"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352786","label":"url"}],"presentation_title":{"en":"細胞膜透過型アルブミンの細胞内移行機序の解明∼マクロピノサイトーシス誘導とエンドソーム脱出経路∼","ja":"細胞膜透過型アルブミンの細胞内移行機序の解明∼マクロピノサイトーシス誘導とエンドソーム脱出経路∼"},"presenters":{"en":[{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"前田 仁志"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"二木 史朗"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"前田 仁志"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"二木 史朗"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第35回日本DDS学会学術集会","ja":"第35回日本DDS学会学術集会"},"publication_date":"2019-07-05","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:198, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513122"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352785","label":"url"}],"presentation_title":{"en":"マイクロパーティクルによる抗体産生誘導は全身性エリテマトーデスの症状進行に関与する","ja":"マイクロパーティクルによる抗体産生誘導は全身性エリテマトーデスの症状進行に関与する"},"presenters":{"en":[{"name":"Ueda Hiro"},{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上田 大"},{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第35回日本DDS学会学術集会","ja":"第35回日本DDS学会学術集会"},"publication_date":"2019-07-05","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:199, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513123"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352784","label":"url"}],"presentation_title":{"en":"脾臓への抗原デリバリー技術を利用した新規抗体産生技術の開発","ja":"脾臓への抗原デリバリー技術を利用した新規抗体産生技術の開発"},"presenters":{"en":[{"name":"Shimazaki Yuna"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"島崎 優奈"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第35回日本DDS学会学術集会","ja":"第35回日本DDS学会学術集会"},"publication_date":"2019-07-05","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:200, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513124"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352783","label":"url"}],"presentation_title":{"en":"抗体医薬を用いたがん治療に対するEPR増強剤SNO-HSA-dimerの効果","ja":"抗体医薬を用いたがん治療に対するEPR増強剤SNO-HSA-dimerの効果"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Ikeda Mayumi"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"第35回日本DDS学会学術集会","ja":"第35回日本DDS学会学術集会"},"publication_date":"2019-07-05","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:201, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513125"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352787","label":"url"}],"presentation_title":{"en":"慢性肝障害治療に対する肝クッパー細胞指向性1型インターフェロンの有用性評価","ja":"慢性肝障害治療に対する肝クッパー細胞指向性1型インターフェロンの有用性評価"},"presenters":{"en":[{"name":"皆吉 勇紀"},{"name":"前田 仁志"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"皆吉 勇紀"},{"name":"前田 仁志"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第35回日本DDS学会学術集会","ja":"第35回日本DDS学会学術集会"},"publication_date":"2019-07-04","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:202, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513126"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352578","label":"url"}],"presentation_title":{"en":"毛髪ケラチン中に存在するポリスルフィドの酸化ストレス応答","ja":"毛髪ケラチン中に存在するポリスルフィドの酸化ストレス応答"},"presenters":{"en":[{"name":"Tasaka Nanami"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田坂 菜々美"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第72回日本酸化ストレス学会学術集会","ja":"第72回日本酸化ストレス学会学術集会"},"publication_date":"2019-06-27","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:203, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513127"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352577","label":"url"}],"presentation_title":{"en":"亜鉛(Zn)/銅(Cu)の神経細胞死におけるSAPK/JNK経路の関与","ja":"亜鉛(Zn)/銅(Cu)の神経細胞死におけるSAPK/JNK経路の関与"},"presenters":{"en":[{"name":"田中 健一郎"},{"name":"下田 実可子"},{"name":"廣木 美果"},{"name":"久保田 真帆"},{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"川原 正博"}],"ja":[{"name":"田中 健一郎"},{"name":"下田 実可子"},{"name":"廣木 美果"},{"name":"久保田 真帆"},{"name":"池田 真由美"},{"name":"異島 優"},{"name":"川原 正博"}]},"event":{"en":"第46回日本毒性学会学術年会","ja":"第46回日本毒性学会学術年会"},"publication_date":"2019-06-27","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:204, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513128"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352424","label":"url"}],"presentation_title":{"en":"細胞培養系における血清アルブミン結合sulfane sulfurの役割","ja":"細胞培養系における血清アルブミン結合sulfane sulfurの役割"},"presenters":{"en":[{"name":"Inoue Arata"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"井上 改"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"}]},"event":{"en":"第19回日本NO学会学術集会","ja":"第19回日本NO学会学術集会"},"publication_date":"2019-06-14","languages":["jpn"],"location":{"en":"Fukuoka","ja":"福岡"},"is_international_presentation":false},"priority":"input_data"}
line:205, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513129"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352423","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミンに存在するポリスルフィドによるユニークな酸化ストレス応答","ja":"ヒト血清アルブミンに存在するポリスルフィドによるユニークな酸化ストレス応答"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Sakai Maki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"渡邊 博志"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"酒井 真紀"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"渡邊 博志"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"第19回日本NO学会学術集会","ja":"第19回日本NO学会学術集会"},"publication_date":"2019-06-14","languages":["jpn"],"location":{"en":"Fukuoka","ja":"福岡"},"is_international_presentation":false},"priority":"input_data"}
line:206, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513130"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351676","label":"url"}],"presentation_title":{"en":"血清アルブミンの酸化ストレス応答を模倣した新規抗酸化剤の設計","ja":"血清アルブミンの酸化ストレス応答を模倣した新規抗酸化剤の設計"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Okuhira Keiichiro"},{"name":"渡邊 博志"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"奥平 桂一郎"},{"name":"渡邊 博志"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第34年会","ja":"日本薬剤学会第34年会"},"publication_date":"2019-05-16","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:207, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513131"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351675","label":"url"}],"presentation_title":{"en":"難治性膵臓がんへの高い移行性を有するアルブミンナノ粒子の開発","ja":"難治性膵臓がんへの高い移行性を有するアルブミンナノ粒子の開発"},"presenters":{"en":[{"name":"Hirakawa Naoki"},{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Shimizu Taro"},{"name":"丸山 徹"},{"name":"Okuhira Keiichiro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"平川 尚樹"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"清水 太郎"},{"name":"丸山 徹"},{"name":"奥平 桂一郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第34年会","ja":"日本薬剤学会第34年会"},"publication_date":"2019-05-16","languages":["jpn"],"location":{"en":"Toyama","ja":"富山"},"is_international_presentation":false},"priority":"input_data"}
line:208, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513132"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=349982","label":"url"}],"presentation_title":{"en":"亜鉛/銅依存の神経細胞死におけるSAPK/JNKシグナルの関与","ja":"亜鉛/銅依存の神経細胞死におけるSAPK/JNKシグナルの関与"},"presenters":{"en":[{"name":"田中 健一郎"},{"name":"下田 実可子"},{"name":"葛西 美里"},{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"久保田 真帆"},{"name":"川原 正博"}],"ja":[{"name":"田中 健一郎"},{"name":"下田 実可子"},{"name":"葛西 美里"},{"name":"池田 真由美"},{"name":"異島 優"},{"name":"久保田 真帆"},{"name":"川原 正博"}]},"event":{"en":"日本薬学会第139年会","ja":"日本薬学会第139年会"},"publication_date":"2019-03-23","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:209, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513133"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=349980","label":"url"}],"presentation_title":{"en":"一酸化窒素を利用した血管透過性制御とがん治療応用","ja":"一酸化窒素を利用した血管透過性制御とがん治療応用"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Ikeda Mayumi"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第139年会","ja":"日本薬学会第139年会"},"publication_date":"2019-03-22","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:210, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513134"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=349976","label":"url"}],"presentation_title":{"en":"タンパクのPEG修飾による抗PEG免疫応答の誘導","ja":"タンパクのPEG修飾による抗PEG免疫応答の誘導"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第139年会","ja":"日本薬学会第139年会"},"publication_date":"2019-03-21","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:211, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513135"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=349641","label":"url"}],"presentation_title":{"en":"DDS担体としての血清アルブミンの有用性とがん治療への応用","ja":"DDS担体としての血清アルブミンの有用性とがん治療への応用"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"第2回徳島大学統合的がん創薬研究クラスター合同ミーティング","ja":"第2回徳島大学統合的がん創薬研究クラスター合同ミーティング"},"publication_date":"2019-02-05","languages":["jpn"],"location":{"en":"Awaji","ja":"淡路"},"is_international_presentation":false},"priority":"input_data"}
line:212, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513136"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347166","label":"url"}],"presentation_title":{"en":"共有結合型アルブミンナノ粒子を用いたセラノスティックナノDDS抗がん剤の開発","ja":"共有結合型アルブミンナノ粒子を用いたセラノスティックナノDDS抗がん剤の開発"},"presenters":{"en":[{"name":"Hirakawa Naoki"},{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Shimizu Taro"},{"name":"丸山 徹"},{"name":"Okuhira Keiichiro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"平川 尚樹"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"清水 太郎"},{"name":"丸山 徹"},{"name":"奥平 桂一郎"},{"name":"石田 竜弘"}]},"event":{"en":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2018-11-10","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:213, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513137"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347165","label":"url"}],"presentation_title":{"en":"イオン液体を用いた新規インスリン含有経皮吸収製剤の開発","ja":"イオン液体を用いた新規インスリン含有経皮吸収製剤の開発"},"presenters":{"en":[{"name":"Sasai Masaki"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"佐々井 雅樹"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2018-11-10","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:214, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513138"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347164","label":"url"}],"presentation_title":{"en":"高投与量Doxebo前処置によるABC現象の抑制に関する検討","ja":"高投与量Doxebo前処置によるABC現象の抑制に関する検討"},"presenters":{"en":[{"name":"Miyahara Kohga"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Szebeni Janos"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"宮原 康嘉"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"Szebeni Janos"},{"name":"石田 竜弘"}]},"event":{"en":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2018-11-10","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:215, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513139"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347163","label":"url"}],"presentation_title":{"en":"糖尿病患者における血清中サルフェン硫黄と抗酸化能の評価","ja":"糖尿病患者における血清中サルフェン硫黄と抗酸化能の評価"},"presenters":{"en":[{"name":"Sakai Maki"},{"name":"Ikeda Mayumi"},{"name":"今福 匡司"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"酒井 真紀"},{"name":"池田 真由美"},{"name":"今福 匡司"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2018-11-10","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:216, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513140"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347162","label":"url"}],"presentation_title":{"en":"辺縁帯B細胞標的化抗原デリバリーシステムによる抗腫瘍免疫応答増強効果","ja":"辺縁帯B細胞標的化抗原デリバリーシステムによる抗腫瘍免疫応答増強効果"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Watanabe Yuki"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"渡辺 優希"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2018-11-10","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:217, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513141"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347160","label":"url"}],"presentation_title":{"en":"生体液に含まれる活性イオウ分子種の検出","ja":"生体液に含まれる活性イオウ分子種の検出"},"presenters":{"en":[{"name":"Osafune Hiroki"},{"name":"Ikeda Mayumi"},{"name":"Sakai Maki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"長船 裕輝"},{"name":"池田 真由美"},{"name":"酒井 真紀"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2018-11-10","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:218, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513142"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347158","label":"url"}],"presentation_title":{"en":"Doxil前処置による養子免疫細胞のがん移行性向上に関する検討","ja":"Doxil前処置による養子免疫細胞のがん移行性向上に関する検討"},"presenters":{"en":[{"name":"Nakami Shoichi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"中見 祥一"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2018-11-10","languages":["jpn"],"location":{"en":"Yonago","ja":"米子"},"is_international_presentation":false},"priority":"input_data"}
line:219, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513143"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=346448","label":"url"}],"presentation_title":{"en":"生体液中の活性イオウ分子種の検出と機能解明","ja":"生体液中の活性イオウ分子種の検出と機能解明"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"赤池 孝章"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"赤池 孝章"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"第40回生体膜と薬物の相互作用シンポジウム","ja":"第40回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2018-10-18","languages":["jpn"],"location":{"en":"Sendai","ja":"仙台"},"is_international_presentation":false},"priority":"input_data"}
line:220, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513144"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=349718","label":"url"}],"presentation_title":{"en":"一酸化窒素ガスデリバリーのための超音波応答性ナノバブルの調製と虚血下肢における送達効果","ja":"一酸化窒素ガスデリバリーのための超音波応答性ナノバブルの調製と虚血下肢における送達効果"},"presenters":{"en":[{"name":"横山 桜子"},{"name":"笹山 瑞紀"},{"name":"真田 貴義"},{"name":"高橋 葉子"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"鈴木 亮"},{"name":"丸山 一雄"},{"name":"丸山 徹"},{"name":"根岸 洋一"}],"ja":[{"name":"横山 桜子"},{"name":"笹山 瑞紀"},{"name":"真田 貴義"},{"name":"高橋 葉子"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"鈴木 亮"},{"name":"丸山 一雄"},{"name":"丸山 徹"},{"name":"根岸 洋一"}]},"event":{"en":"第62回日本薬学会関東支部大会","ja":"第62回日本薬学会関東支部大会"},"publication_date":"2018-09-15","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:221, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513145"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=344901","label":"url"}],"presentation_title":{"en":"血清アルブミンに存在するサルフェン硫黄の酸化還元制御の解明と生体模倣的な硫黄送達システムの開発への応用","ja":"血清アルブミンに存在するサルフェン硫黄の酸化還元制御の解明と生体模倣的な硫黄送達システムの開発への応用"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"第12回次世代を担う若手医療薬科学シンポジウム","ja":"第12回次世代を担う若手医療薬科学シンポジウム"},"publication_date":"2018-09-15","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:222, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513146"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345802","label":"url"}],"presentation_title":{"en":"新規ナノEPR増強剤であるNO搭載型アルブミンダイマーと高分子抗がん剤の併用による次世代型難治性がん治療法の構築","ja":"新規ナノEPR増強剤であるNO搭載型アルブミンダイマーと高分子抗がん剤の併用による次世代型難治性がん治療法の構築"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"清水 太郎"},{"name":"石田 竜弘"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第1回超分子薬剤学FGシンポジウム","ja":"第1回超分子薬剤学FGシンポジウム"},"publication_date":"2018-09-12","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:223, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513147"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345799","label":"url"}],"presentation_title":{"en":"ガス状リガンドと相互作用するヒト血清アルブミンの臨床応用","ja":"ガス状リガンドと相互作用するヒト血清アルブミンの臨床応用"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Ikeda Mayumi"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"第1回超分子薬剤学FGシンポジウム","ja":"第1回超分子薬剤学FGシンポジウム"},"publication_date":"2018-09-12","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:224, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513148"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=344900","label":"url"}],"presentation_title":{"en":"ABC現象回避における末端マレイミドPEG-リン脂質の有用性に関する検討","ja":"ABC現象回避における末端マレイミドPEG-リン脂質の有用性に関する検討"},"presenters":{"en":[{"name":"Yamazaki Nio"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山﨑 仁王"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第27回DDSカンファランス","ja":"第27回DDSカンファランス"},"publication_date":"2018-09-07","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:225, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513149"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=344899","label":"url"}],"presentation_title":{"en":"がん化学・免疫併用療法におけるオキサリプラチン封入リポソームの有用性に関する検討","ja":"がん化学・免疫併用療法におけるオキサリプラチン封入リポソームの有用性に関する検討"},"presenters":{"en":[{"name":"Takese Shunsuke"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"竹瀬 俊輔"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第27回DDSカンファランス","ja":"第27回DDSカンファランス"},"publication_date":"2018-09-07","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:226, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513150"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354901","label":"url"}],"presentation_title":{"en":"多剤耐性菌および真菌に対するS‐ニトロソ化Alpha1―酸性糖蛋白質の効果","ja":"多剤耐性菌および真菌に対するS‐ニトロソ化Alpha1―酸性糖蛋白質の効果"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"金城 雄樹"},{"name":"丸山 徹"},{"name":"小田切 優樹"}],"ja":[{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"金城 雄樹"},{"name":"丸山 徹"},{"name":"小田切 優樹"}]},"event":{"en":"医療薬学フォーラム 2018","ja":"医療薬学フォーラム 2018"},"publication_date":"2018-06-23","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:227, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513151"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339952","label":"url"}],"presentation_title":{"en":"多剤耐性菌および真菌に対するS-ニトロソ化Alpha1-酸性糖蛋白質の効果","ja":"多剤耐性菌および真菌に対するS-ニトロソ化Alpha1-酸性糖蛋白質の効果"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"医療薬学フォーラム 2018","ja":"医療薬学フォーラム 2018"},"publication_date":"2018-06-23","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:228, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513152"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339951","label":"url"}],"presentation_title":{"en":"アルブミン付加製剤の基礎と未来","ja":"アルブミン付加製剤の基礎と未来"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"第34回日本DDS学会学術集会","ja":"第34回日本DDS学会学術集会"},"publication_date":"2018-06-22","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:229, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513153"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339947","label":"url"}],"presentation_title":{"en":"共有結合型アルブミンナノ粒子をキャリアとしたナノDDS抗がん剤の開発及び有用性評価","ja":"共有結合型アルブミンナノ粒子をキャリアとしたナノDDS抗がん剤の開発及び有用性評価"},"presenters":{"en":[{"name":"Hirakawa Naoki"},{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Shimizu Taro"},{"name":"丸山 徹"},{"name":"Okuhira Keiichiro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"平川 尚樹"},{"name":"木下 遼"},{"name":"異島 優"},{"name":"清水 太郎"},{"name":"丸山 徹"},{"name":"奥平 桂一郎"},{"name":"石田 竜弘"}]},"event":{"en":"第34回日本DDS学会学術集会","ja":"第34回日本DDS学会学術集会"},"publication_date":"2018-06-22","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:230, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513154"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339946","label":"url"}],"presentation_title":{"en":"脾臓標的化ワクチンによる免疫誘導における辺縁帯B細胞の役割","ja":"脾臓標的化ワクチンによる免疫誘導における辺縁帯B細胞の役割"},"presenters":{"en":[{"name":"Kawaguchi Yoshino"},{"name":"Shimazaki Yuna"},{"name":"Watanabe Yuki"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"川口 桂乃"},{"name":"島崎 優奈"},{"name":"渡辺 優希"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第34回日本DDS学会学術集会","ja":"第34回日本DDS学会学術集会"},"publication_date":"2018-06-22","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:231, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513155"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339948","label":"url"}],"presentation_title":{"en":"ヒドロキシ末端PEG修飾リポソームを用いた新規脾臓標的化ワクチンの開発に関する検討","ja":"ヒドロキシ末端PEG修飾リポソームを用いた新規脾臓標的化ワクチンの開発に関する検討"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Yoshioka Chihiro"},{"name":"Awata Mizuki"},{"name":"Kawaguchi Yoshino"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"吉岡 千尋"},{"name":"粟田 瑞月"},{"name":"川口 桂乃"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第34回日本DDS学会学術集会","ja":"第34回日本DDS学会学術集会"},"publication_date":"2018-06-21","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:232, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513156"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339939","label":"url"}],"presentation_title":{"en":"新規抗菌剤SNO-AGPの多剤耐性菌に対する克服効果","ja":"新規抗菌剤SNO-AGPの多剤耐性菌に対する克服効果"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"渡辺 佳織"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"渡辺 佳織"},{"name":"小田切 優樹"},{"name":"石田 竜弘"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会第33年会","ja":"日本薬剤学会第33年会"},"publication_date":"2018-06-01","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:233, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513157"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339938","label":"url"}],"presentation_title":{"en":"新規腫瘍DDSキャリアである共有結合型アルブミンナノ粒子の有用性評価","ja":"新規腫瘍DDSキャリアである共有結合型アルブミンナノ粒子の有用性評価"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"清水 太郎"},{"name":"石田 竜弘"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会第33年会","ja":"日本薬剤学会第33年会"},"publication_date":"2018-06-01","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:234, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513158"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354866","label":"url"}],"presentation_title":{"en":"一酸化窒素ガスを内封した超音波応答性ナノバブルのin vivoでの機能性評価","ja":"一酸化窒素ガスを内封した超音波応答性ナノバブルのin vivoでの機能性評価"},"presenters":{"en":[{"name":"笹山 瑞紀"},{"name":"真田 貴義"},{"name":"高橋 葉子"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"},{"name":"鈴木 亮"},{"name":"丸山 一雄"},{"name":"丸山 徹"},{"name":"根岸 洋一"}],"ja":[{"name":"笹山 瑞紀"},{"name":"真田 貴義"},{"name":"高橋 葉子"},{"name":"異島 優"},{"name":"石田 竜弘"},{"name":"鈴木 亮"},{"name":"丸山 一雄"},{"name":"丸山 徹"},{"name":"根岸 洋一"}]},"event":{"en":"日本薬剤学会第33年会","ja":"日本薬剤学会第33年会"},"publication_date":"2018-05-30","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:235, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513159"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339522","label":"url"}],"presentation_title":{"en":"生物由来健康食品に含まれる活性イオウ分子種の検出","ja":"生物由来健康食品に含まれる活性イオウ分子種の検出"},"presenters":{"en":[{"name":"Osafune Hiroki"},{"name":"Ikeda Mayumi"},{"name":"Sakai Maki"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"長船 裕輝"},{"name":"池田 真由美"},{"name":"酒井 真紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第71回日本酸化ストレス学会・第18回日本NO学会合同学術集会","ja":"第71回日本酸化ストレス学会・第18回日本NO学会合同学術集会"},"publication_date":"2018-05-18","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:236, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513160"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339521","label":"url"}],"presentation_title":{"en":"ポリスルフィド付加血清アルブミンによるメラニン産生の抑制","ja":"ポリスルフィド付加血清アルブミンによるメラニン産生の抑制"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第71回日本酸化ストレス学会・第18回日本NO学会合同学術集会","ja":"第71回日本酸化ストレス学会・第18回日本NO学会合同学術集会"},"publication_date":"2018-05-18","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:237, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513161"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339523","label":"url"}],"presentation_title":{"en":"アルブミン製剤中のサルフェン硫黄含有量の差異と抗酸化能の評価","ja":"アルブミン製剤中のサルフェン硫黄含有量の差異と抗酸化能の評価"},"presenters":{"en":[{"name":"Sakai Maki"},{"name":"Ikeda Mayumi"},{"name":"今福 匡司"},{"name":"Shimizu Taro"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"酒井 真紀"},{"name":"池田 真由美"},{"name":"今福 匡司"},{"name":"清水 太郎"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第71回日本酸化ストレス学会・第18回日本NO学会合同学術集会","ja":"第71回日本酸化ストレス学会・第18回日本NO学会合同学術集会"},"publication_date":"2018-05-17","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:238, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513162"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336345","label":"url"}],"presentation_title":{"en":"生理活性ガス運搬体としてのヒト血清アルブミン","ja":"生理活性ガス運搬体としてのヒト血清アルブミン"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Ikeda Mayumi"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"丸山 徹"},{"name":"小田切 優樹"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第138年会","ja":"日本薬学会第138年会"},"publication_date":"2018-03-28","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:239, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513163"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336349","label":"url"}],"presentation_title":{"en":"毛髪ケラチンに存在する活性イオウの発見と酸化ストレス応答","ja":"毛髪ケラチンに存在する活性イオウの発見と酸化ストレス応答"},"presenters":{"en":[{"name":"Tasaka Nanami"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田坂 菜々美"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第138年会","ja":"日本薬学会第138年会"},"publication_date":"2018-03-27","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:240, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513164"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336348","label":"url"}],"presentation_title":{"en":"ナノファイバーバイオセルロースを用いた新規パクリタキセル製剤の開発","ja":"ナノファイバーバイオセルロースを用いた新規パクリタキセル製剤の開発"},"presenters":{"en":[{"name":"Mochizuki Takashi"},{"name":"ANDO Hidenori"},{"name":"Fujita Kenji"},{"name":"田島 健次"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"望月 啓志"},{"name":"安藤 英紀"},{"name":"藤田 研司"},{"name":"田島 健次"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第138年会","ja":"日本薬学会第138年会"},"publication_date":"2018-03-27","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:241, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513165"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336347","label":"url"}],"presentation_title":{"en":"自然抗体としてのanti-PEG IgMがDoxilの血中濃度に与える影響","ja":"自然抗体としてのanti-PEG IgMがDoxilの血中濃度に与える影響"},"presenters":{"en":[{"name":"Kubo Yukiyo"},{"name":"Shimizu Taro"},{"name":"Ukawa Masami"},{"name":"藤本 麻葉"},{"name":"松本 陽子"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"久保 幸代"},{"name":"清水 太郎"},{"name":"鵜川 真実"},{"name":"藤本 麻葉"},{"name":"松本 陽子"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第138年会","ja":"日本薬学会第138年会"},"publication_date":"2018-03-27","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:242, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513166"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336346","label":"url"}],"presentation_title":{"en":"マクロファージによるPEG修飾体のin vitro取り込み量評価によるABC現象の発現予測に関する検討","ja":"マクロファージによるPEG修飾体のin vitro取り込み量評価によるABC現象の発現予測に関する検討"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Kubo Yukiyo"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"久保 幸代"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第138年会","ja":"日本薬学会第138年会"},"publication_date":"2018-03-27","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:243, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513167"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336350","label":"url"}],"presentation_title":{"en":"ポリスルフィド運搬体としてのヒト血清アルブミン","ja":"ポリスルフィド運搬体としてのヒト血清アルブミン"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Shimizu Taro"},{"name":"居原 秀"},{"name":"赤池 孝章"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"清水 太郎"},{"name":"居原 秀"},{"name":"赤池 孝章"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬学会第138年会","ja":"日本薬学会第138年会"},"publication_date":"2018-03-26","languages":["jpn"],"location":{"en":"Kanazawa","ja":"金沢"},"is_international_presentation":false},"priority":"input_data"}
line:244, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513168"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334560","label":"url"}],"presentation_title":{"en":"膵臓癌治療薬の送達性向上を企図した微小環境改善薬の開発","ja":"膵臓癌治療薬の送達性向上を企図した微小環境改善薬の開発"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"第5回TR推進合同フォーラム・ライフサイエンス技術交流会","ja":"第5回TR推進合同フォーラム・ライフサイエンス技術交流会"},"publication_date":"2017-11-01","languages":["jpn"],"location":{"en":"Fukuoka","ja":"福岡"},"is_international_presentation":false},"priority":"input_data"}
line:245, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513169"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334163","label":"url"}],"presentation_title":{"en":"新規抗がん剤としての活性イオウ付加アルブミンの設計","ja":"新規抗がん剤としての活性イオウ付加アルブミンの設計"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 菜々"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2017-10-22","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:246, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513170"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334162","label":"url"}],"presentation_title":{"en":"毛髪中に存在する活性イオウの発見とその生理的意義","ja":"毛髪中に存在する活性イオウの発見とその生理的意義"},"presenters":{"en":[{"name":"Tasaka Nanami"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田坂 菜々美"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2017-10-22","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:247, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513171"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334161","label":"url"}],"presentation_title":{"en":"抗PD-1抗体の併用はl-OHP liposomeによる抗腫瘍効果の個体差を減少させる","ja":"抗PD-1抗体の併用はl-OHP liposomeによる抗腫瘍効果の個体差を減少させる"},"presenters":{"en":[{"name":"Tagami Maho"},{"name":"Ikeda Ai"},{"name":"Takayama Takuma"},{"name":"Ishima Yu"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田神 舞帆"},{"name":"池田 愛"},{"name":"高山 拓磨"},{"name":"異島 優"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2017-10-22","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:248, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513172"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=332430","label":"url"}],"presentation_title":{"en":"マンノース受容体を標的とするナノ抗酸化剤の開発と急性及び慢性肝疾患への応用","ja":"マンノース受容体を標的とするナノ抗酸化剤の開発と急性及び慢性肝疾患への応用"},"presenters":{"en":[{"name":"前田 仁志"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"前田 仁志"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第26回DDSカンファランス","ja":"第26回DDSカンファランス"},"publication_date":"2017-09-01","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:249, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513173"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=332427","label":"url"}],"presentation_title":{"en":"PEG特異的細胞測定法を用いた抗PEG免疫反応の評価","ja":"PEG特異的細胞測定法を用いた抗PEG免疫反応の評価"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Kubo Yukiyo"},{"name":"Awata Mizuki"},{"name":"Kitayama Yuka"},{"name":"Mima Yu"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"久保 幸代"},{"name":"粟田 瑞月"},{"name":"北山 由佳"},{"name":"美馬 優"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第26回DDSカンファランス","ja":"第26回DDSカンファランス"},"publication_date":"2017-09-01","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:250, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513174"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325373","label":"url"}],"presentation_title":{"en":"siRNA搭載PEG修飾リポソームの静脈内投与後に腹腔から分泌されるanti-PEG IgM誘導機構の解明に関する検討","ja":"siRNA搭載PEG修飾リポソームの静脈内投与後に腹腔から分泌されるanti-PEG IgM誘導機構の解明に関する検討"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Kitayama Yuka"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"北山 由佳"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第33回日本DDS学会学術集会","ja":"第33回日本DDS学会学術集会"},"publication_date":"2017-07-07","languages":["jpn"],"location":{"en":"Kyoto","ja":"京都"},"is_international_presentation":false},"priority":"input_data"}
line:251, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513175"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325368","label":"url"}],"presentation_title":{"en":"酸化ストレスに応答するポリスルフィド化血清タンパク質の同定","ja":"酸化ストレスに応答するポリスルフィド化血清タンパク質の同定"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"第70回日本酸化ストレス学会学術集会","ja":"第70回日本酸化ストレス学会学術集会"},"publication_date":"2017-06-29","languages":["jpn"],"location":{"en":"Tsukuba","ja":"つくば"},"is_international_presentation":false},"priority":"input_data"}
line:252, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513176"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324525","label":"url"}],"presentation_title":{"en":"新規ナノEPR増強剤S-ニトロソ化ヒト血清アルブミンダイマーを用いた次世代型Abraxane療法の開発","ja":"新規ナノEPR増強剤S-ニトロソ化ヒト血清アルブミンダイマーを用いた次世代型Abraxane療法の開発"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"中村 秀明"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"中村 秀明"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第17回日本NO学会学術集会","ja":"第17回日本NO学会学術集会"},"publication_date":"2017-05-19","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:253, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513177"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324524","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミンに存在する活性イオウの検出とその機能解明","ja":"ヒト血清アルブミンに存在する活性イオウの検出とその機能解明"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Tasaka Nanami"},{"name":"Shimizu Taro"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"田坂 菜々美"},{"name":"清水 太郎"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"第17回日本NO学会学術集会","ja":"第17回日本NO学会学術集会"},"publication_date":"2017-05-19","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:254, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513178"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324511","label":"url"}],"presentation_title":{"en":"補体活性化能を持つポリマー修飾リポソームによる脾臓辺縁帯B細胞標的化に関する検討","ja":"補体活性化能を持つポリマー修飾リポソームによる脾臓辺縁帯B細胞標的化に関する検討"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Awata Mizuki"},{"name":"Yoshioka Chihiro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"粟田 瑞月"},{"name":"吉岡 千尋"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第32年会","ja":"日本薬剤学会第32年会"},"publication_date":"2017-05-13","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:255, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513179"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324510","label":"url"}],"presentation_title":{"en":"毛髪中における活性イオウの検出とその生物活性評価","ja":"毛髪中における活性イオウの検出とその生物活性評価"},"presenters":{"en":[{"name":"Tasaka Nanami"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"田坂 菜々美"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第32年会","ja":"日本薬剤学会第32年会"},"publication_date":"2017-05-13","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:256, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513180"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324509","label":"url"}],"presentation_title":{"en":"活性酸素スカベンジャーとしての血清アルブミンパースルフィド","ja":"活性酸素スカベンジャーとしての血清アルブミンパースルフィド"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"Shimizu Taro"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"異島 優"},{"name":"池田 真由美"},{"name":"清水 太郎"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第32年会","ja":"日本薬剤学会第32年会"},"publication_date":"2017-05-11","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:257, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513181"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324508","label":"url"}],"presentation_title":{"en":"活性イオウトラフィックタンパク質としてのヒト血清アルブミンの役割","ja":"活性イオウトラフィックタンパク質としてのヒト血清アルブミンの役割"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Tasaka Nanami"},{"name":"Shimizu Taro"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"田坂 菜々美"},{"name":"清水 太郎"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第32年会","ja":"日本薬剤学会第32年会"},"publication_date":"2017-05-11","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:258, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513182"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325493","label":"url"}],"presentation_title":{"en":"NASH病態におけるDDS戦略の限界と一酸化窒素による治療抵抗性の克服","ja":"NASH病態におけるDDS戦略の限界と一酸化窒素による治療抵抗性の克服"},"presenters":{"en":[{"name":"前田 仁志"},{"name":"Ishima Yu"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"柳澤 洋輝"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"前田 仁志"},{"name":"異島 優"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"柳澤 洋輝"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第38回生体膜と薬物の相互作用シンポジウム","ja":"第38回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2016-11-17","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:259, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513183"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324413","label":"url"}],"presentation_title":{"en":"新規酸化ストレス早期発見に向けた血清パースルフィド定量の有用性評価","ja":"新規酸化ストレス早期発見に向けた血清パースルフィド定量の有用性評価"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"Ishida Tatsuhiro"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"石田 竜弘"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第38回生体膜と薬物の相互作用シンポジウム","ja":"第38回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2016-11-17","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:260, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513184"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=321178","label":"url"}],"presentation_title":{"en":"PEGリポソームへのアルブミン修飾は，抗PEG抗体の産生を抑制する","ja":"PEGリポソームへのアルブミン修飾は，抗PEG抗体の産生を抑制する"},"presenters":{"en":[{"name":"Yamazaki Nio"},{"name":"Ishima Yu"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山﨑 仁王"},{"name":"異島 優"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"第55回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会","ja":"第55回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会"},"publication_date":"2016-11-06","languages":["jpn"],"location":{"en":"Okayama","ja":"岡山"},"is_international_presentation":false},"priority":"input_data"}
line:261, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513186"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325494","label":"url"}],"presentation_title":{"en":"ナノEPR増強剤であるNO付加アルブミンダイマーはAbraxane®の腫瘍移行を促進することで治療効果並びに安全性を向上させる","ja":"ナノEPR増強剤であるNO付加アルブミンダイマーはAbraxane®の腫瘍移行を促進することで治療効果並びに安全性を向上させる"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"中村 秀明"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"中村 秀明"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第31回日本薬物動態学会","ja":"第31回日本薬物動態学会"},"publication_date":"2016-10-13","languages":["jpn"],"location":{"en":"Nagano","ja":"長野"},"is_international_presentation":false},"priority":"input_data"}
line:262, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513187"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320434","label":"url"}],"presentation_title":{"en":"PEGリポソーム頻回投与時の課題であるABC現象は，アルブミン修飾によって克服可能であるか?","ja":"PEGリポソーム頻回投与時の課題であるABC現象は，アルブミン修飾によって克服可能であるか?"},"presenters":{"en":[{"name":"Yamazaki Nio"},{"name":"Ishima Yu"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山﨑 仁王"},{"name":"異島 優"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"ナノライフサイエンス・オープンセミナー2016","ja":"ナノライフサイエンス・オープンセミナー2016"},"publication_date":"2016-09-04","languages":["jpn"],"location":{"en":"大津市","ja":"大津市"},"is_international_presentation":false},"priority":"input_data"}
line:263, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513188"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325497","label":"url"}],"presentation_title":{"en":"組換え型高マンノース付加アルブミンを担体とした肝クッパー細胞指向性インターフェロンα2bの設計と肝保護効果","ja":"組換え型高マンノース付加アルブミンを担体とした肝クッパー細胞指向性インターフェロンα2bの設計と肝保護効果"},"presenters":{"en":[{"name":"皆吉 勇紀"},{"name":"前田 仁志"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"皆吉 勇紀"},{"name":"前田 仁志"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第32回日本DDS学会学術集会","ja":"第32回日本DDS学会学術集会"},"publication_date":"2016-06-30","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:264, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513189"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325496","label":"url"}],"presentation_title":{"en":"NASHモデルの病態生理に基づいた肝指向性ナノ抗酸化剤の有用性評価","ja":"NASHモデルの病態生理に基づいた肝指向性ナノ抗酸化剤の有用性評価"},"presenters":{"en":[{"name":"前田 仁志"},{"name":"Ishima Yu"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"前田 仁志"},{"name":"異島 優"},{"name":"皆吉 勇紀"},{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第32回日本DDS学会学術集会","ja":"第32回日本DDS学会学術集会"},"publication_date":"2016-06-30","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:265, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513190"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325495","label":"url"}],"presentation_title":{"en":"血中滞留型チオレドキシンは難治性の急性腎・肺障害連関を改善する","ja":"血中滞留型チオレドキシンは難治性の急性腎・肺障害連関を改善する"},"presenters":{"en":[{"name":"西田 健人"},{"name":"宮久 優子"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"深川 雅史"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"西田 健人"},{"name":"宮久 優子"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"深川 雅史"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第32回日本DDS学会学術集会","ja":"第32回日本DDS学会学術集会"},"publication_date":"2016-06-30","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:266, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513191"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325500","label":"url"}],"presentation_title":{"en":"ナノEPR増強剤であるNO付加アルブミンダイマーは 難治性癌における高分子抗癌剤抵抗性を改善する","ja":"ナノEPR増強剤であるNO付加アルブミンダイマーは 難治性癌における高分子抗癌剤抵抗性を改善する"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"中村 秀明"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"中村 秀明"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第31回年会","ja":"日本薬剤学会 第31回年会"},"publication_date":"2016-05-19","languages":["jpn"],"location":{"en":"Gifu","ja":"岐阜"},"is_international_presentation":false},"priority":"input_data"}
line:267, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513192"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325499","label":"url"}],"presentation_title":{"en":"S-ニトロソ化 α1-酸性糖タンパク質による癌治療への応用","ja":"S-ニトロソ化 α1-酸性糖タンパク質による癌治療への応用"},"presenters":{"en":[{"name":"松坂 幸太朗"},{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"松坂 幸太朗"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第31回年会","ja":"日本薬剤学会 第31回年会"},"publication_date":"2016-05-19","languages":["jpn"],"location":{"en":"Gifu","ja":"岐阜"},"is_international_presentation":false},"priority":"input_data"}
line:268, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513193"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325498","label":"url"}],"presentation_title":{"en":"ヘモグロビンを担体とした一酸化炭素デリバリーの非アルコール性脂肪肝炎に対する治療効果","ja":"ヘモグロビンを担体とした一酸化炭素デリバリーの非アルコール性脂肪肝炎に対する治療効果"},"presenters":{"en":[{"name":"柳澤 洋輝"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"柳澤 洋輝"},{"name":"前田 仁志"},{"name":"皆吉 勇紀"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第31回年会","ja":"日本薬剤学会 第31回年会"},"publication_date":"2016-05-19","languages":["jpn"],"location":{"en":"Gifu","ja":"岐阜"},"is_international_presentation":false},"priority":"input_data"}
line:269, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513194"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325502","label":"url"}],"presentation_title":{"en":"血清アルブミンによる一酸化窒素トラフィックシステムの解明と難治性癌治療への展開","ja":"血清アルブミンによる一酸化窒素トラフィックシステムの解明と難治性癌治療への展開"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"日本薬学会 第136年会","ja":"日本薬学会 第136年会"},"publication_date":"2016-03-26","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:270, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513195"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325501","label":"url"}],"presentation_title":{"en":"ヒト血清アルブミンにおける活性イオウ分子種の検出と構造・機能への影響","ja":"ヒト血清アルブミンにおける活性イオウ分子種の検出と構造・機能への影響"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"大内 雄也"},{"name":"Ming Xian"},{"name":"赤池 孝章"},{"name":"丸山 徹"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"大内 雄也"},{"name":"Ming Xian"},{"name":"赤池 孝章"},{"name":"丸山 徹"}]},"event":{"en":"日本薬学会 第136年会","ja":"日本薬学会 第136年会"},"publication_date":"2016-03-26","languages":["jpn"],"location":{"en":"Yokohama","ja":"横浜"},"is_international_presentation":false},"priority":"input_data"}
line:271, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513196"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325505","label":"url"}],"presentation_title":{"en":"Poly-S-二トロソ化ヒト血清アルブミンのHIF-1alpha抑制効果","ja":"Poly-S-二トロソ化ヒト血清アルブミンのHIF-1alpha抑制効果"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"井上 亜希"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"井上 亜希"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}]},"event":{"en":"第31回 日本DDS学会学術集会","ja":"第31回 日本DDS学会学術集会"},"publication_date":"2015-07-02","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:272, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513197"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325504","label":"url"}],"presentation_title":{"en":"急性及び慢性肝炎モデルマウスにおけるCD68+/CD206+クッパ―細胞由来活性酸素種を標的としたナノ抗酸化アルブミンの治療効果","ja":"急性及び慢性肝炎モデルマウスにおけるCD68+/CD206+クッパ―細胞由来活性酸素種を標的としたナノ抗酸化アルブミンの治療効果"},"presenters":{"en":[{"name":"前田 仁志"},{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"前田 仁志"},{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第31回 日本DDS学会学術集会","ja":"第31回 日本DDS学会学術集会"},"publication_date":"2015-07-02","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:273, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513198"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325503","label":"url"}],"presentation_title":{"en":"新規ナノEPR増強剤の一酸化窒素付加アルブミンダイマーによる腫瘍内環境改善作用","ja":"新規ナノEPR増強剤の一酸化窒素付加アルブミンダイマーによる腫瘍内環境改善作用"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第31回 日本DDS学会学術集会","ja":"第31回 日本DDS学会学術集会"},"publication_date":"2015-07-02","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:274, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513199"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325506","label":"url"}],"presentation_title":{"en":"高分子抗癌剤治療における新規ナノEPR増強剤としての一酸化窒素付加アルブミン二量体の有用性評価","ja":"高分子抗癌剤治療における新規ナノEPR増強剤としての一酸化窒素付加アルブミン二量体の有用性評価"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"Ikeda Mayumi"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"木下 遼"},{"name":"池田 真由美"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第15回 日本NO学会学術集会","ja":"第15回 日本NO学会学術集会"},"publication_date":"2015-06-27","languages":["jpn"],"location":{"en":"Osaka","ja":"大阪"},"is_international_presentation":false},"priority":"input_data"}
line:275, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513200"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325508","label":"url"}],"presentation_title":{"en":"遺伝子工学的手法を用いた血中滞留型BMP7の設計と持続的腎保護作用の評価","ja":"遺伝子工学的手法を用いた血中滞留型BMP7の設計と持続的腎保護作用の評価"},"presenters":{"en":[{"name":"戸田 翔太"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"戸田 翔太"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第58回 日本腎臓学会学術総会","ja":"第58回 日本腎臓学会学術総会"},"publication_date":"2015-06-05","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:276, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513201"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325507","label":"url"}],"presentation_title":{"en":"エリスロポエチン産生能を有するS-ニトロソ化アルブミンによる包括的腎疾患治療","ja":"エリスロポエチン産生能を有するS-ニトロソ化アルブミンによる包括的腎疾患治療"},"presenters":{"en":[{"name":"大城 俊"},{"name":"Ishima Yu"},{"name":"本田 尚子"},{"name":"渡邊 博志"},{"name":"深川 雅史"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"大城 俊"},{"name":"異島 優"},{"name":"本田 尚子"},{"name":"渡邊 博志"},{"name":"深川 雅史"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第58回 日本腎臓学会学術総会","ja":"第58回 日本腎臓学会学術総会"},"publication_date":"2015-06-05","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:277, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513202"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325512","label":"url"}],"presentation_title":{"en":"細胞内アルブミンデリバリーを企図した新規CPPの設計と有用性評価","ja":"細胞内アルブミンデリバリーを企図した新規CPPの設計と有用性評価"},"presenters":{"en":[{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"濱崎 慶輔"},{"name":"前田 仁志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"一水 翔太"},{"name":"渡邊 博志"},{"name":"濱崎 慶輔"},{"name":"前田 仁志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第30年会","ja":"日本薬剤学会 第30年会"},"publication_date":"2015-05-21","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:278, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513203"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325511","label":"url"}],"presentation_title":{"en":"腎指向型アルブミン-BMP7融合体による腎保護効果","ja":"腎指向型アルブミン-BMP7融合体による腎保護効果"},"presenters":{"en":[{"name":"戸田 翔太"},{"name":"渡邊 博志"},{"name":"弥永 直樹"},{"name":"濱崎 慶輔"},{"name":"國安 明彦"},{"name":"長谷川 功紀"},{"name":"後藤 久美子"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"戸田 翔太"},{"name":"渡邊 博志"},{"name":"弥永 直樹"},{"name":"濱崎 慶輔"},{"name":"國安 明彦"},{"name":"長谷川 功紀"},{"name":"後藤 久美子"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第30年会","ja":"日本薬剤学会 第30年会"},"publication_date":"2015-05-21","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:279, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513204"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325510","label":"url"}],"presentation_title":{"en":"NO付加ヒト血清アルブミンの抗腫瘍活性におけるPDE阻害剤の増強効果","ja":"NO付加ヒト血清アルブミンの抗腫瘍活性におけるPDE阻害剤の増強効果"},"presenters":{"en":[{"name":"Ikeda Mayumi"},{"name":"Ishima Yu"},{"name":"Kinoshita Ryo"},{"name":"渡邊 博志"},{"name":"池田 剛"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"池田 真由美"},{"name":"異島 優"},{"name":"木下 遼"},{"name":"渡邊 博志"},{"name":"池田 剛"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第30年会","ja":"日本薬剤学会 第30年会"},"publication_date":"2015-05-21","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:280, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513205"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325509","label":"url"}],"presentation_title":{"en":"組換え型高マンノース 付加アルブミンを担体とした 肝指向性インターフェロンα2bの設計と肝保護効果","ja":"組換え型高マンノース 付加アルブミンを担体とした 肝指向性インターフェロンα2bの設計と肝保護効果"},"presenters":{"en":[{"name":"皆吉 勇紀"},{"name":"前田 仁志"},{"name":"Ishima Yu"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"皆吉 勇紀"},{"name":"前田 仁志"},{"name":"異島 優"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第30年会","ja":"日本薬剤学会 第30年会"},"publication_date":"2015-05-21","languages":["jpn"],"location":{"en":"Nagasaki","ja":"長崎"},"is_international_presentation":false},"priority":"input_data"}
line:281, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513206"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325514","label":"url"}],"presentation_title":{"en":"尿毒症物質インドキシル硫酸の酸化修飾体に関する構造特性と生物活性","ja":"尿毒症物質インドキシル硫酸の酸化修飾体に関する構造特性と生物活性"},"presenters":{"en":[{"name":"丸山 徹"},{"name":"Ishima Yu"},{"name":"成底 徹"},{"name":"小谷 俊介"},{"name":"中島 誠"},{"name":"渡邊 博志"},{"name":"小田切 優樹"}],"ja":[{"name":"丸山 徹"},{"name":"異島 優"},{"name":"成底 徹"},{"name":"小谷 俊介"},{"name":"中島 誠"},{"name":"渡邊 博志"},{"name":"小田切 優樹"}]},"event":{"en":"日本薬学会第135年会","ja":"日本薬学会第135年会"},"publication_date":"2015-03-25","languages":["jpn"],"location":{"en":"Kobe","ja":"神戸"},"is_international_presentation":false},"priority":"input_data"}
line:282, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513207"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325513","label":"url"}],"presentation_title":{"en":"ドラッグデリバリーシステム担体としてのヒト血清アルブミン","ja":"ドラッグデリバリーシステム担体としてのヒト血清アルブミン"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"日本薬学会第135年会","ja":"日本薬学会第135年会"},"publication_date":"2015-03-25","languages":["jpn"],"location":{"en":"Kobe","ja":"神戸"},"is_international_presentation":false},"priority":"input_data"}
line:283, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513208"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325516","label":"url"}],"presentation_title":{"en":"S-ニトロソ化α1-酸性タンパク質による抗生物質の多剤耐性克服と機序解明","ja":"S-ニトロソ化α1-酸性タンパク質による抗生物質の多剤耐性克服と機序解明"},"presenters":{"en":[{"name":"丸山 徹"},{"name":"渡辺 佳織"},{"name":"Ishima Yu"},{"name":"小川 和加野"},{"name":"黒田 照夫"},{"name":"小田切 優樹"}],"ja":[{"name":"丸山 徹"},{"name":"渡辺 佳織"},{"name":"異島 優"},{"name":"小川 和加野"},{"name":"黒田 照夫"},{"name":"小田切 優樹"}]},"event":{"en":"第36回生体膜と薬物の相互作用シンポジウム","ja":"第36回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2014-11-20","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:284, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513209"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325515","label":"url"}],"presentation_title":{"en":"ベバシズマブの抗腫瘍活性に及ぼすPoly-S-二トロソ化ヒト血清アルブミンの併用効果","ja":"ベバシズマブの抗腫瘍活性に及ぼすPoly-S-二トロソ化ヒト血清アルブミンの併用効果"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"井上 亜希"},{"name":"方 軍"},{"name":"渡邊 博志"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"井上 亜希"},{"name":"方 軍"},{"name":"渡邊 博志"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第36回生体膜と薬物の相互作用シンポジウム","ja":"第36回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2014-11-20","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:285, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513210"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325520","label":"url"}],"presentation_title":{"en":"血清アルブミンを基盤とした一酸化窒素デリバリーシステムの創製と癌治療や虚血性疾患への応用","ja":"血清アルブミンを基盤とした一酸化窒素デリバリーシステムの創製と癌治療や虚血性疾患への応用"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"第30回日本DDS学会学術集会","ja":"第30回日本DDS学会学術集会"},"publication_date":"2014-07-30","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:286, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513211"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325519","label":"url"}],"presentation_title":{"en":"新規EPR増強剤の一酸化窒素付加アルブミンダイマーはDoxilの抗腫瘍効果を向上する","ja":"新規EPR増強剤の一酸化窒素付加アルブミンダイマーはDoxilの抗腫瘍効果を向上する"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第30回日本DDS学会学術集会","ja":"第30回日本DDS学会学術集会"},"publication_date":"2014-07-30","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:287, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513212"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325518","label":"url"}],"presentation_title":{"en":"横紋筋融解症AKIに対するアルブミン‐チオレドキシン融合体の有用性評価","ja":"横紋筋融解症AKIに対するアルブミン‐チオレドキシン融合体の有用性評価"},"presenters":{"en":[{"name":"西田 健人"},{"name":"大柿 滋"},{"name":"田中 遼大"},{"name":"小玉 あずさ"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"西田 健人"},{"name":"大柿 滋"},{"name":"田中 遼大"},{"name":"小玉 あずさ"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第30回日本DDS学会学術集会","ja":"第30回日本DDS学会学術集会"},"publication_date":"2014-07-30","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:288, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513213"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325517","label":"url"}],"presentation_title":{"en":"PEG化や2量体化により増強するS-ニトロソ化ヒト血清アルブミンの抗腫瘍活性","ja":"PEG化や2量体化により増強するS-ニトロソ化ヒト血清アルブミンの抗腫瘍活性"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第30回日本DDS学会学術集会","ja":"第30回日本DDS学会学術集会"},"publication_date":"2014-07-30","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:289, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513214"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325526","label":"url"}],"presentation_title":{"en":"S-ニトロソ化アルブミンは腎性貧血改善と腎保護作用を併せ持つ新規慢性腎臓病治療薬である","ja":"S-ニトロソ化アルブミンは腎性貧血改善と腎保護作用を併せ持つ新規慢性腎臓病治療薬である"},"presenters":{"en":[{"name":"本田 尚子"},{"name":"Ishima Yu"},{"name":"宮崎 裕理"},{"name":"渡邊 博志"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"本田 尚子"},{"name":"異島 優"},{"name":"宮崎 裕理"},{"name":"渡邊 博志"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第29年会","ja":"日本薬剤学会 第29年会"},"publication_date":"2014-05-20","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:290, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513215"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325524","label":"url"}],"presentation_title":{"en":"新規EPR増強剤の一酸化窒素付加アルブミンダイマーはDoxil®の抗腫瘍効果を向上する","ja":"新規EPR増強剤の一酸化窒素付加アルブミンダイマーはDoxil®の抗腫瘍効果を向上する"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"Ikeda Mayumi"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"池田 真由美"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第29年会","ja":"日本薬剤学会 第29年会"},"publication_date":"2014-05-20","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:291, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513216"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325523","label":"url"}],"presentation_title":{"en":"横紋筋融解症AKIに対するアルブミン‐チオレドキシン融合体の有用性評価","ja":"横紋筋融解症AKIに対するアルブミン‐チオレドキシン融合体の有用性評価"},"presenters":{"en":[{"name":"西田 健人"},{"name":"大柿 滋"},{"name":"田中 遼大"},{"name":"小玉 あずさ"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"西田 健人"},{"name":"大柿 滋"},{"name":"田中 遼大"},{"name":"小玉 あずさ"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第29年会","ja":"日本薬剤学会 第29年会"},"publication_date":"2014-05-20","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:292, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513217"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325522","label":"url"}],"presentation_title":{"en":"低酸素誘導オートファジーに対するPoly-S-ニトロソ化ヒト血清アルブミンの抑制効果","ja":"低酸素誘導オートファジーに対するPoly-S-ニトロソ化ヒト血清アルブミンの抑制効果"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"井上 亜希"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"井上 亜希"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第29年会","ja":"日本薬剤学会 第29年会"},"publication_date":"2014-05-20","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:293, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513218"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325521","label":"url"}],"presentation_title":{"en":"インフルエンザ肺炎に対するヒト血清アルブミン‐チオレドキシン融合タンパク質の有効性評価","ja":"インフルエンザ肺炎に対するヒト血清アルブミン‐チオレドキシン融合タンパク質の有効性評価"},"presenters":{"en":[{"name":"田中 遼大"},{"name":"Ishima Yu"},{"name":"榎木 裕紀"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}],"ja":[{"name":"田中 遼大"},{"name":"異島 優"},{"name":"榎木 裕紀"},{"name":"小田切 優樹"},{"name":"渡邊 博志"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会 第29年会","ja":"日本薬剤学会 第29年会"},"publication_date":"2014-05-20","languages":["jpn"],"location":{"en":"Saitama","ja":"さいたま"},"is_international_presentation":false},"priority":"input_data"}
line:294, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513219"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325533","label":"url"}],"presentation_title":{"en":"NO付加型ヒト血清アルブミンの臨床応用へのアプローチ","ja":"NO付加型ヒト血清アルブミンの臨床応用へのアプローチ"},"presenters":{"en":[{"name":"Ishima Yu"}],"ja":[{"name":"異島 優"}]},"event":{"en":"第14回 日本NO学会学術集会","ja":"第14回 日本NO学会学術集会"},"publication_date":"2014-05-16","languages":["jpn"],"location":{"en":"Saga","ja":"佐賀"},"is_international_presentation":false},"priority":"input_data"}
line:295, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513220"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325532","label":"url"}],"presentation_title":{"en":"ニトロインドキシル硫酸による酸化ストレス産生メカニズムの解析","ja":"ニトロインドキシル硫酸による酸化ストレス産生メカニズムの解析"},"presenters":{"en":[{"name":"Kinoshita Ryo"},{"name":"Ishima Yu"},{"name":"成底 徹"},{"name":"小谷 俊介"},{"name":"中島 誠"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"木下 遼"},{"name":"異島 優"},{"name":"成底 徹"},{"name":"小谷 俊介"},{"name":"中島 誠"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第14回 日本NO学会学術集会","ja":"第14回 日本NO学会学術集会"},"publication_date":"2014-05-16","languages":["jpn"],"location":{"en":"Saga","ja":"佐賀"},"is_international_presentation":false},"priority":"input_data"}
line:296, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513221"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325538","label":"url"}],"presentation_title":{"en":"多剤耐性菌に対するS-ニトロソ化α1酸性糖タンパク質の抗菌作用","ja":"多剤耐性菌に対するS-ニトロソ化α1酸性糖タンパク質の抗菌作用"},"presenters":{"en":[{"name":"渡邊 佳織"},{"name":"Ishima Yu"},{"name":"黒田 照夫"},{"name":"小川 和加野"},{"name":"渡邊 博志"},{"name":"甲斐 俊哉"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"渡邊 佳織"},{"name":"異島 優"},{"name":"黒田 照夫"},{"name":"小川 和加野"},{"name":"渡邊 博志"},{"name":"甲斐 俊哉"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬学会第134年会","ja":"日本薬学会第134年会"},"publication_date":"2014-03-27","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:297, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513222"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325536","label":"url"}],"presentation_title":{"en":"持続的抗酸化・抗炎症モジュレーターであるアルブミンーチオレドキシン融合体のアセトアミノフェン誘発急性肝障害に対する有用性評価","ja":"持続的抗酸化・抗炎症モジュレーターであるアルブミンーチオレドキシン融合体のアセトアミノフェン誘発急性肝障害に対する有用性評価"},"presenters":{"en":[{"name":"田中 遼大"},{"name":"Ishima Yu"},{"name":"前田 仁志"},{"name":"小玉 あずさ"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"田中 遼大"},{"name":"異島 優"},{"name":"前田 仁志"},{"name":"小玉 あずさ"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬学会第134年会","ja":"日本薬学会第134年会"},"publication_date":"2014-03-27","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:298, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513223"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325534","label":"url"}],"presentation_title":{"en":"インフルエンザ肺炎モデルマウスに対するヒト血清アルブミンーチオレドキシン融合タンパク質の有用性評価","ja":"インフルエンザ肺炎モデルマウスに対するヒト血清アルブミンーチオレドキシン融合タンパク質の有用性評価"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"田中 遼大"},{"name":"榎木 裕紀"},{"name":"小玉 あずさ"},{"name":"来海 和彦"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"田中 遼大"},{"name":"榎木 裕紀"},{"name":"小玉 あずさ"},{"name":"来海 和彦"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬学会第134年会","ja":"日本薬学会第134年会"},"publication_date":"2014-03-27","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:299, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513224"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325540","label":"url"}],"presentation_title":{"en":"一酸化窒素付加型アルブミンによる抗癌剤耐性克服効果とその機序解明","ja":"一酸化窒素付加型アルブミンによる抗癌剤耐性克服効果とその機序解明"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"原 茉梨絵"},{"name":"甲斐 俊哉"},{"name":"渡邊 博志"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"原 茉梨絵"},{"name":"甲斐 俊哉"},{"name":"渡邊 博志"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第35回生体膜と薬物の相互作用シンポジウム","ja":"第35回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2013-11-21","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:300, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513225"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325539","label":"url"}],"presentation_title":{"en":"遺伝子組換え型糖鎖付加アルブミンによるクッパー細胞選択的チオール送達は急性肝障害を改善する","ja":"遺伝子組換え型糖鎖付加アルブミンによるクッパー細胞選択的チオール送達は急性肝障害を改善する"},"presenters":{"en":[{"name":"前田 仁志"},{"name":"平田 憲史郎"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"前田 仁志"},{"name":"平田 憲史郎"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第35回生体膜と薬物の相互作用シンポジウム","ja":"第35回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2013-11-21","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:301, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513226"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325542","label":"url"}],"presentation_title":{"en":"S-NITROSATED -1-ACID GLYCOPROTEIN KILLS DRUG-RESISTANT BACTERIA AND AIDS SURVIVAL IN SEPSIS","ja":"S-NITROSATED -1-ACID GLYCOPROTEIN KILLS DRUG-RESISTANT BACTERIA AND AIDS SURVIVAL IN SEPSIS"},"presenters":{"en":[{"name":"Kaori Watanabe"},{"name":"Ishima Yu"},{"name":"Teruo Kuroda"},{"name":"Wakano Ogawa"},{"name":"Hiroshi Watanabe"},{"name":"Ayaka Suenaga"},{"name":"Toshiya Kai"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Kaori Watanabe"},{"name":"異島 優"},{"name":"Teruo Kuroda"},{"name":"Wakano Ogawa"},{"name":"Hiroshi Watanabe"},{"name":"Ayaka Suenaga"},{"name":"Toshiya Kai"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"日本薬物動態学会 第28回年会","ja":"日本薬物動態学会 第28回年会"},"publication_date":"2013-10-09","languages":["eng"],"location":{"en":"Tokyo","ja":"Tokyo"},"is_international_presentation":false},"priority":"input_data"}
line:302, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513227"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325541","label":"url"}],"presentation_title":{"en":"THERAPEUTIC IMPACT OF HUMAN SERUM ALBUMIN-THIOREDOXIN FUSION PROTEIN, LONG-ACTING ANTI-OXIDATIVE AND ANTI-INFLAMMATORY MODULATOR, AGAINST ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE","ja":"THERAPEUTIC IMPACT OF HUMAN SERUM ALBUMIN-THIOREDOXIN FUSION PROTEIN, LONG-ACTING ANTI-OXIDATIVE AND ANTI-INFLAMMATORY MODULATOR, AGAINST ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE"},"presenters":{"en":[{"name":"Ryota Tanaka"},{"name":"Hitoshi Maeda"},{"name":"Azusa Kodama"},{"name":"Hiroshi Watanabe"},{"name":"Ishima Yu"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}],"ja":[{"name":"Ryota Tanaka"},{"name":"Hitoshi Maeda"},{"name":"Azusa Kodama"},{"name":"Hiroshi Watanabe"},{"name":"異島 優"},{"name":"Masaki Otagiri"},{"name":"Toru Maruyama"}]},"event":{"en":"日本薬物動態学会 第28回年会","ja":"日本薬物動態学会 第28回年会"},"publication_date":"2013-10-09","languages":["eng"],"location":{"en":"Tokyo","ja":"Tokyo"},"is_international_presentation":false},"priority":"input_data"}
line:303, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513228"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325544","label":"url"}],"presentation_title":{"en":"S-ニトロソ化により獲得するα1-酸性糖タンパク質(AGP)の抗菌活性","ja":"S-ニトロソ化により獲得するα1-酸性糖タンパク質(AGP)の抗菌活性"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"渡辺 佳織"},{"name":"赤池 孝章"},{"name":"澤 智裕"},{"name":"黒田 照夫"},{"name":"小川 和加野"},{"name":"渡邊 博志"},{"name":"甲斐 俊哉"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"渡辺 佳織"},{"name":"赤池 孝章"},{"name":"澤 智裕"},{"name":"黒田 照夫"},{"name":"小川 和加野"},{"name":"渡邊 博志"},{"name":"甲斐 俊哉"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第24回日本生体防御学会学術集会","ja":"第24回日本生体防御学会学術集会"},"publication_date":"2013-07-10","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:304, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513229"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325548","label":"url"}],"presentation_title":{"en":"高分子抗癌剤の腫瘍集積性を高めるS-ニトロソ化アルブミンダイマーのEPR効果増強作用","ja":"高分子抗癌剤の腫瘍集積性を高めるS-ニトロソ化アルブミンダイマーのEPR効果増強作用"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第13回日本NO学会学術集会","ja":"第13回日本NO学会学術集会"},"publication_date":"2013-06-28","languages":["jpn"],"location":{"en":"Okinawa","ja":"沖縄"},"is_international_presentation":false},"priority":"input_data"}
line:305, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513230"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325545","label":"url"}],"presentation_title":{"en":"尿毒症物質インドキシル硫酸の生物活性に及ぼす活性酸化窒素種の影響","ja":"尿毒症物質インドキシル硫酸の生物活性に及ぼす活性酸化窒素種の影響"},"presenters":{"en":[{"name":"成底 徹"},{"name":"Ishima Yu"},{"name":"小谷 俊介"},{"name":"中島 誠"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"成底 徹"},{"name":"異島 優"},{"name":"小谷 俊介"},{"name":"中島 誠"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"第13回日本NO学会学術集会","ja":"第13回日本NO学会学術集会"},"publication_date":"2013-06-28","languages":["jpn"],"location":{"en":"Okinawa","ja":"沖縄"},"is_international_presentation":false},"priority":"input_data"}
line:306, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513231"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325554","label":"url"}],"presentation_title":{"en":"高分子抗癌剤の腫瘍集積性を高めるS-ニトロソ化アルブミンダイマーのEPR効果増強作用","ja":"高分子抗癌剤の腫瘍集積性を高めるS-ニトロソ化アルブミンダイマーのEPR効果増強作用"},"presenters":{"en":[{"name":"Ishima Yu"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"異島 優"},{"name":"方 軍"},{"name":"前田 浩"},{"name":"渡邊 博志"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会第28年会","ja":"日本薬剤学会第28年会"},"publication_date":"2013-05-23","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:307, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513232"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325551","label":"url"}],"presentation_title":{"en":"クッパー細胞選択的チオール送達によるアセトアミノフェン肝障害治療法の開発","ja":"クッパー細胞選択的チオール送達によるアセトアミノフェン肝障害治療法の開発"},"presenters":{"en":[{"name":"前田 仁志"},{"name":"平田 憲史郎"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"前田 仁志"},{"name":"平田 憲史郎"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"末永 綾香"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会第28年会","ja":"日本薬剤学会第28年会"},"publication_date":"2013-05-23","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
line:308, {"insert":{"user_id":"B000320827","type":"presentations","id":"30513233"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325549","label":"url"}],"presentation_title":{"en":"アルブミン-チオレドキシン融合体によるシスプラチン腎症予防効果","ja":"アルブミン-チオレドキシン融合体によるシスプラチン腎症予防効果"},"presenters":{"en":[{"name":"小玉 あずさ"},{"name":"田中 遼大"},{"name":"渡邊 博志"},{"name":"Ishima Yu"},{"name":"深川 雅史"},{"name":"小田切 優樹"},{"name":"丸山 徹"}],"ja":[{"name":"小玉 あずさ"},{"name":"田中 遼大"},{"name":"渡邊 博志"},{"name":"異島 優"},{"name":"深川 雅史"},{"name":"小田切 優樹"},{"name":"丸山 徹"}]},"event":{"en":"日本薬剤学会第28年会","ja":"日本薬剤学会第28年会"},"publication_date":"2013-05-23","languages":["jpn"],"location":{"en":"Nagoya","ja":"名古屋"},"is_international_presentation":false},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/310655/researchmap/presentations.jsonl, mTUbQZMBYVtrs4O81l2K) ====
====== BulkResult(B000320827, jzUbQZMBYVtrs4O8011T) : Begin ======
--- error
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:12Z","end_datetime":"2024-11-18T21:42:13Z","estimated_end_datetime":"2024-11-18T21:42:13Z","total_items":109,"process_items":109,"error_items":109}
{"no":1,"line":1,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":2,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":3,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":4,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":5,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":6,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":7,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"41379369","link":"https://api.researchmap.jp/Yu777/published_papers/41379369","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":8,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"41053474","link":"https://api.researchmap.jp/Yu777/published_papers/41053474","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":9,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"40510326","link":"https://api.researchmap.jp/Yu777/published_papers/40510326","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":10,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"39507274","link":"https://api.researchmap.jp/Yu777/published_papers/39507274","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":11,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":12,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"39656555","link":"https://api.researchmap.jp/Yu777/published_papers/39656555","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":13,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"36905618","link":"https://api.researchmap.jp/Yu777/published_papers/36905618","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":14,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"36366795","link":"https://api.researchmap.jp/Yu777/published_papers/36366795","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":15,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"36164913","link":"https://api.researchmap.jp/Yu777/published_papers/36164913","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":16,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"36292762","link":"https://api.researchmap.jp/Yu777/published_papers/36292762","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":17,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"39728153","link":"https://api.researchmap.jp/Yu777/published_papers/39728153","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":18,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"35684140","link":"https://api.researchmap.jp/Yu777/published_papers/35684140","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":19,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"35997017","link":"https://api.researchmap.jp/Yu777/published_papers/35997017","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":20,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"33247701","link":"https://api.researchmap.jp/Yu777/published_papers/33247701","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":21,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"32904113","link":"https://api.researchmap.jp/Yu777/published_papers/32904113","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":22,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"32439560","link":"https://api.researchmap.jp/Yu777/published_papers/32439560","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":23,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"32234603","link":"https://api.researchmap.jp/Yu777/published_papers/32234603","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":24,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"32065133","link":"https://api.researchmap.jp/Yu777/published_papers/32065133","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":25,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31973250","link":"https://api.researchmap.jp/Yu777/published_papers/31973250","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":26,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31973251","link":"https://api.researchmap.jp/Yu777/published_papers/31973251","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":27,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"32225139","link":"https://api.researchmap.jp/Yu777/published_papers/32225139","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":28,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31562212","link":"https://api.researchmap.jp/Yu777/published_papers/31562212","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":29,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31396057","link":"https://api.researchmap.jp/Yu777/published_papers/31396057","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":30,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512911","link":"https://api.researchmap.jp/Yu777/published_papers/30512911","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":31,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31853993","link":"https://api.researchmap.jp/Yu777/published_papers/31853993","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":32,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512910","link":"https://api.researchmap.jp/Yu777/published_papers/30512910","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":33,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512904","link":"https://api.researchmap.jp/Yu777/published_papers/30512904","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":34,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512905","link":"https://api.researchmap.jp/Yu777/published_papers/30512905","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":35,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512906","link":"https://api.researchmap.jp/Yu777/published_papers/30512906","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":36,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31858357","link":"https://api.researchmap.jp/Yu777/published_papers/31858357","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":37,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512907","link":"https://api.researchmap.jp/Yu777/published_papers/30512907","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":38,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31867757","link":"https://api.researchmap.jp/Yu777/published_papers/31867757","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":39,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512908","link":"https://api.researchmap.jp/Yu777/published_papers/30512908","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":40,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512909","link":"https://api.researchmap.jp/Yu777/published_papers/30512909","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":41,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31867758","link":"https://api.researchmap.jp/Yu777/published_papers/31867758","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":42,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"31867759","link":"https://api.researchmap.jp/Yu777/published_papers/31867759","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":43,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512912","link":"https://api.researchmap.jp/Yu777/published_papers/30512912","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":44,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512913","link":"https://api.researchmap.jp/Yu777/published_papers/30512913","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":45,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512914","link":"https://api.researchmap.jp/Yu777/published_papers/30512914","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":46,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512915","link":"https://api.researchmap.jp/Yu777/published_papers/30512915","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":47,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512916","link":"https://api.researchmap.jp/Yu777/published_papers/30512916","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":48,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512917","link":"https://api.researchmap.jp/Yu777/published_papers/30512917","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":49,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512918","link":"https://api.researchmap.jp/Yu777/published_papers/30512918","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":50,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512919","link":"https://api.researchmap.jp/Yu777/published_papers/30512919","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":51,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512920","link":"https://api.researchmap.jp/Yu777/published_papers/30512920","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":52,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512921","link":"https://api.researchmap.jp/Yu777/published_papers/30512921","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":53,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512922","link":"https://api.researchmap.jp/Yu777/published_papers/30512922","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":54,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512923","link":"https://api.researchmap.jp/Yu777/published_papers/30512923","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":55,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512924","link":"https://api.researchmap.jp/Yu777/published_papers/30512924","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":56,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512925","link":"https://api.researchmap.jp/Yu777/published_papers/30512925","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":57,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512926","link":"https://api.researchmap.jp/Yu777/published_papers/30512926","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":58,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512927","link":"https://api.researchmap.jp/Yu777/published_papers/30512927","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":59,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512928","link":"https://api.researchmap.jp/Yu777/published_papers/30512928","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":60,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512929","link":"https://api.researchmap.jp/Yu777/published_papers/30512929","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":61,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512930","link":"https://api.researchmap.jp/Yu777/published_papers/30512930","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":62,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512931","link":"https://api.researchmap.jp/Yu777/published_papers/30512931","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":63,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512932","link":"https://api.researchmap.jp/Yu777/published_papers/30512932","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":64,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512933","link":"https://api.researchmap.jp/Yu777/published_papers/30512933","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":65,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512934","link":"https://api.researchmap.jp/Yu777/published_papers/30512934","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":66,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512935","link":"https://api.researchmap.jp/Yu777/published_papers/30512935","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":67,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512936","link":"https://api.researchmap.jp/Yu777/published_papers/30512936","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":68,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512937","link":"https://api.researchmap.jp/Yu777/published_papers/30512937","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":69,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512938","link":"https://api.researchmap.jp/Yu777/published_papers/30512938","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":70,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512939","link":"https://api.researchmap.jp/Yu777/published_papers/30512939","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":71,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512940","link":"https://api.researchmap.jp/Yu777/published_papers/30512940","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":72,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512941","link":"https://api.researchmap.jp/Yu777/published_papers/30512941","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":73,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512942","link":"https://api.researchmap.jp/Yu777/published_papers/30512942","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":74,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512943","link":"https://api.researchmap.jp/Yu777/published_papers/30512943","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":75,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512944","link":"https://api.researchmap.jp/Yu777/published_papers/30512944","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":76,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512945","link":"https://api.researchmap.jp/Yu777/published_papers/30512945","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":77,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512946","link":"https://api.researchmap.jp/Yu777/published_papers/30512946","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":78,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512947","link":"https://api.researchmap.jp/Yu777/published_papers/30512947","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":79,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512948","link":"https://api.researchmap.jp/Yu777/published_papers/30512948","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":80,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512949","link":"https://api.researchmap.jp/Yu777/published_papers/30512949","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":81,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512950","link":"https://api.researchmap.jp/Yu777/published_papers/30512950","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":82,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512951","link":"https://api.researchmap.jp/Yu777/published_papers/30512951","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":83,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512952","link":"https://api.researchmap.jp/Yu777/published_papers/30512952","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":84,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512953","link":"https://api.researchmap.jp/Yu777/published_papers/30512953","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":85,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512954","link":"https://api.researchmap.jp/Yu777/published_papers/30512954","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":86,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512955","link":"https://api.researchmap.jp/Yu777/published_papers/30512955","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":87,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512956","link":"https://api.researchmap.jp/Yu777/published_papers/30512956","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":88,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512957","link":"https://api.researchmap.jp/Yu777/published_papers/30512957","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":89,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512958","link":"https://api.researchmap.jp/Yu777/published_papers/30512958","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":90,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512959","link":"https://api.researchmap.jp/Yu777/published_papers/30512959","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":91,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512960","link":"https://api.researchmap.jp/Yu777/published_papers/30512960","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":92,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512961","link":"https://api.researchmap.jp/Yu777/published_papers/30512961","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":93,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512962","link":"https://api.researchmap.jp/Yu777/published_papers/30512962","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":94,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512963","link":"https://api.researchmap.jp/Yu777/published_papers/30512963","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":95,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512964","link":"https://api.researchmap.jp/Yu777/published_papers/30512964","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":96,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512965","link":"https://api.researchmap.jp/Yu777/published_papers/30512965","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":97,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512966","link":"https://api.researchmap.jp/Yu777/published_papers/30512966","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":98,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512967","link":"https://api.researchmap.jp/Yu777/published_papers/30512967","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":99,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512968","link":"https://api.researchmap.jp/Yu777/published_papers/30512968","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":100,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512969","link":"https://api.researchmap.jp/Yu777/published_papers/30512969","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":101,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512970","link":"https://api.researchmap.jp/Yu777/published_papers/30512970","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":102,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512971","link":"https://api.researchmap.jp/Yu777/published_papers/30512971","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":103,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512972","link":"https://api.researchmap.jp/Yu777/published_papers/30512972","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":104,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512973","link":"https://api.researchmap.jp/Yu777/published_papers/30512973","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":105,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512974","link":"https://api.researchmap.jp/Yu777/published_papers/30512974","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":106,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512975","link":"https://api.researchmap.jp/Yu777/published_papers/30512975","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":107,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512976","link":"https://api.researchmap.jp/Yu777/published_papers/30512976","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":108,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512977","link":"https://api.researchmap.jp/Yu777/published_papers/30512977","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":109,"code":403,"action":"insert","action_type":"force","type":"published_papers","id":"30512978","link":"https://api.researchmap.jp/Yu777/published_papers/30512978","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}

--- success
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:12Z","end_datetime":"2024-11-18T21:42:13Z","estimated_end_datetime":"2024-11-18T21:42:13Z","total_items":109,"process_items":109,"error_items":109}
====== BulkResult(B000320827, jzUbQZMBYVtrs4O8011T) : End ======
====== BulkResult(B000320827, kTUbQZMBYVtrs4O80136) : Begin ======
--- error
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:27Z","end_datetime":"2024-11-18T21:42:27Z","estimated_end_datetime":"2024-11-18T21:42:28Z","total_items":10,"process_items":10,"error_items":10}
{"no":1,"line":1,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":2,"code":403,"action":"insert","action_type":"force","type":"misc","id":"40052466","link":"https://api.researchmap.jp/Yu777/misc/40052466","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":3,"code":403,"action":"insert","action_type":"force","type":"misc","id":"36513541","link":"https://api.researchmap.jp/Yu777/misc/36513541","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":4,"code":403,"action":"insert","action_type":"force","type":"misc","id":"36164912","link":"https://api.researchmap.jp/Yu777/misc/36164912","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":5,"code":403,"action":"insert","action_type":"force","type":"misc","id":"31958922","link":"https://api.researchmap.jp/Yu777/misc/31958922","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":6,"code":403,"action":"insert","action_type":"force","type":"misc","id":"30513030","link":"https://api.researchmap.jp/Yu777/misc/30513030","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":7,"code":403,"action":"insert","action_type":"force","type":"misc","id":"30507452","link":"https://api.researchmap.jp/Yu777/misc/30507452","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":8,"code":403,"action":"insert","action_type":"force","type":"misc","id":"30513031","link":"https://api.researchmap.jp/Yu777/misc/30513031","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":9,"code":403,"action":"insert","action_type":"force","type":"misc","id":"30513032","link":"https://api.researchmap.jp/Yu777/misc/30513032","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":10,"code":403,"action":"insert","action_type":"force","type":"misc","id":"30513033","link":"https://api.researchmap.jp/Yu777/misc/30513033","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}

--- success
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:27Z","end_datetime":"2024-11-18T21:42:27Z","estimated_end_datetime":"2024-11-18T21:42:28Z","total_items":10,"process_items":10,"error_items":10}
====== BulkResult(B000320827, kTUbQZMBYVtrs4O80136) : End ======
====== BulkResult(B000320827, kzUbQZMBYVtrs4O81F1m) : Begin ======
--- error
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:22Z","end_datetime":"2024-11-18T21:42:22Z","estimated_end_datetime":"2024-11-18T21:42:23Z","total_items":1,"process_items":1,"error_items":1}
{"no":1,"line":1,"code":403,"action":"insert","action_type":"force","type":"books_etc","id":"30513035","link":"https://api.researchmap.jp/Yu777/books_etc/30513035","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}

--- success
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:22Z","end_datetime":"2024-11-18T21:42:22Z","estimated_end_datetime":"2024-11-18T21:42:23Z","total_items":1,"process_items":1,"error_items":1}
====== BulkResult(B000320827, kzUbQZMBYVtrs4O81F1m) : End ======
====== BulkResult(B000320827, lTUbQZMBYVtrs4O81F3T) : Begin ======
--- error
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:37Z","end_datetime":"2024-11-18T21:42:37Z","estimated_end_datetime":"2024-11-18T21:42:38Z","total_items":2,"process_items":2,"error_items":2}
{"no":1,"line":1,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"awards","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":2,"code":403,"action":"insert","action_type":"force","type":"awards","id":"38352110","link":"https://api.researchmap.jp/Yu777/awards/38352110","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}

--- success
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:37Z","end_datetime":"2024-11-18T21:42:37Z","estimated_end_datetime":"2024-11-18T21:42:38Z","total_items":2,"process_items":2,"error_items":2}
====== BulkResult(B000320827, lTUbQZMBYVtrs4O81F3T) : End ======
====== BulkResult(B000320827, mTUbQZMBYVtrs4O81l2K) : Begin ======
--- error
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:32Z","end_datetime":"2024-11-18T21:42:33Z","estimated_end_datetime":"2024-11-18T21:42:35Z","total_items":308,"process_items":308,"error_items":308}
{"no":1,"line":1,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768178","link":"https://api.researchmap.jp/Yu777/presentations/40768178","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":2,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768179","link":"https://api.researchmap.jp/Yu777/presentations/40768179","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":3,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768180","link":"https://api.researchmap.jp/Yu777/presentations/40768180","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":4,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768181","link":"https://api.researchmap.jp/Yu777/presentations/40768181","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":5,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768182","link":"https://api.researchmap.jp/Yu777/presentations/40768182","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":6,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768183","link":"https://api.researchmap.jp/Yu777/presentations/40768183","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":7,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768184","link":"https://api.researchmap.jp/Yu777/presentations/40768184","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":8,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768185","link":"https://api.researchmap.jp/Yu777/presentations/40768185","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":9,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768186","link":"https://api.researchmap.jp/Yu777/presentations/40768186","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":10,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768187","link":"https://api.researchmap.jp/Yu777/presentations/40768187","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":11,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768188","link":"https://api.researchmap.jp/Yu777/presentations/40768188","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":12,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35922593","link":"https://api.researchmap.jp/Yu777/presentations/35922593","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":13,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35922594","link":"https://api.researchmap.jp/Yu777/presentations/35922594","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":14,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36280254","link":"https://api.researchmap.jp/Yu777/presentations/36280254","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":15,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513066","link":"https://api.researchmap.jp/Yu777/presentations/30513066","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":16,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513067","link":"https://api.researchmap.jp/Yu777/presentations/30513067","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":17,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513068","link":"https://api.researchmap.jp/Yu777/presentations/30513068","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":18,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513069","link":"https://api.researchmap.jp/Yu777/presentations/30513069","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":19,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513070","link":"https://api.researchmap.jp/Yu777/presentations/30513070","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":20,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513071","link":"https://api.researchmap.jp/Yu777/presentations/30513071","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":21,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513072","link":"https://api.researchmap.jp/Yu777/presentations/30513072","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":22,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513073","link":"https://api.researchmap.jp/Yu777/presentations/30513073","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":23,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513074","link":"https://api.researchmap.jp/Yu777/presentations/30513074","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":24,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513075","link":"https://api.researchmap.jp/Yu777/presentations/30513075","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":25,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513076","link":"https://api.researchmap.jp/Yu777/presentations/30513076","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":26,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513077","link":"https://api.researchmap.jp/Yu777/presentations/30513077","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":27,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513078","link":"https://api.researchmap.jp/Yu777/presentations/30513078","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":28,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513079","link":"https://api.researchmap.jp/Yu777/presentations/30513079","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":29,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513080","link":"https://api.researchmap.jp/Yu777/presentations/30513080","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":30,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513081","link":"https://api.researchmap.jp/Yu777/presentations/30513081","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":31,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513082","link":"https://api.researchmap.jp/Yu777/presentations/30513082","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":32,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513083","link":"https://api.researchmap.jp/Yu777/presentations/30513083","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":33,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513084","link":"https://api.researchmap.jp/Yu777/presentations/30513084","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":34,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513085","link":"https://api.researchmap.jp/Yu777/presentations/30513085","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":35,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513086","link":"https://api.researchmap.jp/Yu777/presentations/30513086","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":36,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513087","link":"https://api.researchmap.jp/Yu777/presentations/30513087","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":37,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513088","link":"https://api.researchmap.jp/Yu777/presentations/30513088","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":38,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513089","link":"https://api.researchmap.jp/Yu777/presentations/30513089","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":39,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513090","link":"https://api.researchmap.jp/Yu777/presentations/30513090","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":40,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513091","link":"https://api.researchmap.jp/Yu777/presentations/30513091","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":41,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513092","link":"https://api.researchmap.jp/Yu777/presentations/30513092","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":42,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":43,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":44,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":45,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":46,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":47,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":48,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":49,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":50,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":51,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":52,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":53,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":54,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":55,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":56,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":57,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":58,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":59,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":60,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":61,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":62,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":63,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":64,"code":403,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":65,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"41505636","link":"https://api.researchmap.jp/Yu777/presentations/41505636","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":66,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40768189","link":"https://api.researchmap.jp/Yu777/presentations/40768189","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":67,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40510327","link":"https://api.researchmap.jp/Yu777/presentations/40510327","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":68,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40408117","link":"https://api.researchmap.jp/Yu777/presentations/40408117","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":69,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40408118","link":"https://api.researchmap.jp/Yu777/presentations/40408118","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":70,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40408119","link":"https://api.researchmap.jp/Yu777/presentations/40408119","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":71,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066830","link":"https://api.researchmap.jp/Yu777/presentations/40066830","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":72,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066831","link":"https://api.researchmap.jp/Yu777/presentations/40066831","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":73,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066832","link":"https://api.researchmap.jp/Yu777/presentations/40066832","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":74,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066833","link":"https://api.researchmap.jp/Yu777/presentations/40066833","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":75,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066834","link":"https://api.researchmap.jp/Yu777/presentations/40066834","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":76,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066835","link":"https://api.researchmap.jp/Yu777/presentations/40066835","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":77,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066836","link":"https://api.researchmap.jp/Yu777/presentations/40066836","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":78,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"40066837","link":"https://api.researchmap.jp/Yu777/presentations/40066837","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":79,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39818989","link":"https://api.researchmap.jp/Yu777/presentations/39818989","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":80,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39818990","link":"https://api.researchmap.jp/Yu777/presentations/39818990","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":81,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39818991","link":"https://api.researchmap.jp/Yu777/presentations/39818991","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":82,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39818992","link":"https://api.researchmap.jp/Yu777/presentations/39818992","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":83,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39818993","link":"https://api.researchmap.jp/Yu777/presentations/39818993","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":84,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39818994","link":"https://api.researchmap.jp/Yu777/presentations/39818994","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":85,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39588967","link":"https://api.researchmap.jp/Yu777/presentations/39588967","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":86,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39588968","link":"https://api.researchmap.jp/Yu777/presentations/39588968","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":87,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39588969","link":"https://api.researchmap.jp/Yu777/presentations/39588969","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":88,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"39588970","link":"https://api.researchmap.jp/Yu777/presentations/39588970","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":89,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300597","link":"https://api.researchmap.jp/Yu777/presentations/38300597","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":90,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300598","link":"https://api.researchmap.jp/Yu777/presentations/38300598","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":91,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300599","link":"https://api.researchmap.jp/Yu777/presentations/38300599","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":92,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300600","link":"https://api.researchmap.jp/Yu777/presentations/38300600","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":93,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300601","link":"https://api.researchmap.jp/Yu777/presentations/38300601","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":94,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300602","link":"https://api.researchmap.jp/Yu777/presentations/38300602","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":95,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300603","link":"https://api.researchmap.jp/Yu777/presentations/38300603","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":96,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300604","link":"https://api.researchmap.jp/Yu777/presentations/38300604","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":97,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300605","link":"https://api.researchmap.jp/Yu777/presentations/38300605","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":98,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"38300606","link":"https://api.researchmap.jp/Yu777/presentations/38300606","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":99,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"37120650","link":"https://api.researchmap.jp/Yu777/presentations/37120650","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":100,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"37120651","link":"https://api.researchmap.jp/Yu777/presentations/37120651","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":101,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"37120652","link":"https://api.researchmap.jp/Yu777/presentations/37120652","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":102,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"37120653","link":"https://api.researchmap.jp/Yu777/presentations/37120653","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":103,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36398377","link":"https://api.researchmap.jp/Yu777/presentations/36398377","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":104,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36398378","link":"https://api.researchmap.jp/Yu777/presentations/36398378","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":105,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36398379","link":"https://api.researchmap.jp/Yu777/presentations/36398379","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":106,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36398380","link":"https://api.researchmap.jp/Yu777/presentations/36398380","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":107,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36398381","link":"https://api.researchmap.jp/Yu777/presentations/36398381","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":108,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36398382","link":"https://api.researchmap.jp/Yu777/presentations/36398382","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":109,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"36266352","link":"https://api.researchmap.jp/Yu777/presentations/36266352","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":110,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35251542","link":"https://api.researchmap.jp/Yu777/presentations/35251542","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":111,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35251544","link":"https://api.researchmap.jp/Yu777/presentations/35251544","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":112,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35251545","link":"https://api.researchmap.jp/Yu777/presentations/35251545","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":113,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35251546","link":"https://api.researchmap.jp/Yu777/presentations/35251546","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":114,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35251547","link":"https://api.researchmap.jp/Yu777/presentations/35251547","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":115,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"35434465","link":"https://api.researchmap.jp/Yu777/presentations/35434465","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":116,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"34030862","link":"https://api.researchmap.jp/Yu777/presentations/34030862","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":117,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"33869539","link":"https://api.researchmap.jp/Yu777/presentations/33869539","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":118,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"33869540","link":"https://api.researchmap.jp/Yu777/presentations/33869540","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":119,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"33869541","link":"https://api.researchmap.jp/Yu777/presentations/33869541","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":120,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"33967622","link":"https://api.researchmap.jp/Yu777/presentations/33967622","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":121,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"33624770","link":"https://api.researchmap.jp/Yu777/presentations/33624770","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":122,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32883806","link":"https://api.researchmap.jp/Yu777/presentations/32883806","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":123,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32883807","link":"https://api.researchmap.jp/Yu777/presentations/32883807","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":124,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32883808","link":"https://api.researchmap.jp/Yu777/presentations/32883808","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":125,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32883809","link":"https://api.researchmap.jp/Yu777/presentations/32883809","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":126,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32883810","link":"https://api.researchmap.jp/Yu777/presentations/32883810","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":127,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32883811","link":"https://api.researchmap.jp/Yu777/presentations/32883811","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":128,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32939313","link":"https://api.researchmap.jp/Yu777/presentations/32939313","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":129,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512560","link":"https://api.researchmap.jp/Yu777/presentations/32512560","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":130,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512561","link":"https://api.researchmap.jp/Yu777/presentations/32512561","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":131,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512562","link":"https://api.researchmap.jp/Yu777/presentations/32512562","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":132,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512563","link":"https://api.researchmap.jp/Yu777/presentations/32512563","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":133,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512564","link":"https://api.researchmap.jp/Yu777/presentations/32512564","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":134,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512565","link":"https://api.researchmap.jp/Yu777/presentations/32512565","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":135,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512566","link":"https://api.researchmap.jp/Yu777/presentations/32512566","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":136,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512567","link":"https://api.researchmap.jp/Yu777/presentations/32512567","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":137,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512568","link":"https://api.researchmap.jp/Yu777/presentations/32512568","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":138,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32512569","link":"https://api.researchmap.jp/Yu777/presentations/32512569","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":139,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498654","link":"https://api.researchmap.jp/Yu777/presentations/32498654","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":140,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498655","link":"https://api.researchmap.jp/Yu777/presentations/32498655","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":141,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498656","link":"https://api.researchmap.jp/Yu777/presentations/32498656","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":142,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498657","link":"https://api.researchmap.jp/Yu777/presentations/32498657","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":143,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498658","link":"https://api.researchmap.jp/Yu777/presentations/32498658","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":144,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498659","link":"https://api.researchmap.jp/Yu777/presentations/32498659","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":145,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498660","link":"https://api.researchmap.jp/Yu777/presentations/32498660","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":146,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498661","link":"https://api.researchmap.jp/Yu777/presentations/32498661","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":147,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498662","link":"https://api.researchmap.jp/Yu777/presentations/32498662","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":148,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498663","link":"https://api.researchmap.jp/Yu777/presentations/32498663","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":149,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498664","link":"https://api.researchmap.jp/Yu777/presentations/32498664","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":150,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498665","link":"https://api.researchmap.jp/Yu777/presentations/32498665","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":151,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498666","link":"https://api.researchmap.jp/Yu777/presentations/32498666","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":152,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498667","link":"https://api.researchmap.jp/Yu777/presentations/32498667","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":153,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"32498668","link":"https://api.researchmap.jp/Yu777/presentations/32498668","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":154,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578139","link":"https://api.researchmap.jp/Yu777/presentations/31578139","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":155,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578140","link":"https://api.researchmap.jp/Yu777/presentations/31578140","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":156,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578141","link":"https://api.researchmap.jp/Yu777/presentations/31578141","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":157,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578142","link":"https://api.researchmap.jp/Yu777/presentations/31578142","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":158,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578143","link":"https://api.researchmap.jp/Yu777/presentations/31578143","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":159,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578144","link":"https://api.researchmap.jp/Yu777/presentations/31578144","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":160,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578145","link":"https://api.researchmap.jp/Yu777/presentations/31578145","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":161,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578146","link":"https://api.researchmap.jp/Yu777/presentations/31578146","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":162,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578147","link":"https://api.researchmap.jp/Yu777/presentations/31578147","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":163,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578148","link":"https://api.researchmap.jp/Yu777/presentations/31578148","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":164,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31578149","link":"https://api.researchmap.jp/Yu777/presentations/31578149","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":165,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31070092","link":"https://api.researchmap.jp/Yu777/presentations/31070092","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":166,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31070093","link":"https://api.researchmap.jp/Yu777/presentations/31070093","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":167,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31070094","link":"https://api.researchmap.jp/Yu777/presentations/31070094","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":168,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"31070095","link":"https://api.researchmap.jp/Yu777/presentations/31070095","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":169,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513093","link":"https://api.researchmap.jp/Yu777/presentations/30513093","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":170,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513094","link":"https://api.researchmap.jp/Yu777/presentations/30513094","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":171,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513095","link":"https://api.researchmap.jp/Yu777/presentations/30513095","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":172,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513096","link":"https://api.researchmap.jp/Yu777/presentations/30513096","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":173,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513097","link":"https://api.researchmap.jp/Yu777/presentations/30513097","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":174,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513098","link":"https://api.researchmap.jp/Yu777/presentations/30513098","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":175,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513099","link":"https://api.researchmap.jp/Yu777/presentations/30513099","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":176,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513100","link":"https://api.researchmap.jp/Yu777/presentations/30513100","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":177,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513101","link":"https://api.researchmap.jp/Yu777/presentations/30513101","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":178,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513102","link":"https://api.researchmap.jp/Yu777/presentations/30513102","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":179,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513103","link":"https://api.researchmap.jp/Yu777/presentations/30513103","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":180,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513104","link":"https://api.researchmap.jp/Yu777/presentations/30513104","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":181,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513105","link":"https://api.researchmap.jp/Yu777/presentations/30513105","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":182,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513106","link":"https://api.researchmap.jp/Yu777/presentations/30513106","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":183,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513107","link":"https://api.researchmap.jp/Yu777/presentations/30513107","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":184,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513108","link":"https://api.researchmap.jp/Yu777/presentations/30513108","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":185,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513109","link":"https://api.researchmap.jp/Yu777/presentations/30513109","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":186,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513110","link":"https://api.researchmap.jp/Yu777/presentations/30513110","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":187,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513111","link":"https://api.researchmap.jp/Yu777/presentations/30513111","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":188,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513112","link":"https://api.researchmap.jp/Yu777/presentations/30513112","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":189,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513113","link":"https://api.researchmap.jp/Yu777/presentations/30513113","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":190,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513114","link":"https://api.researchmap.jp/Yu777/presentations/30513114","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":191,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513115","link":"https://api.researchmap.jp/Yu777/presentations/30513115","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":192,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513116","link":"https://api.researchmap.jp/Yu777/presentations/30513116","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":193,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513117","link":"https://api.researchmap.jp/Yu777/presentations/30513117","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":194,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513118","link":"https://api.researchmap.jp/Yu777/presentations/30513118","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":195,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513119","link":"https://api.researchmap.jp/Yu777/presentations/30513119","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":196,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513120","link":"https://api.researchmap.jp/Yu777/presentations/30513120","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":197,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513121","link":"https://api.researchmap.jp/Yu777/presentations/30513121","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":198,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513122","link":"https://api.researchmap.jp/Yu777/presentations/30513122","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":199,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513123","link":"https://api.researchmap.jp/Yu777/presentations/30513123","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":200,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513124","link":"https://api.researchmap.jp/Yu777/presentations/30513124","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":201,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513125","link":"https://api.researchmap.jp/Yu777/presentations/30513125","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":202,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513126","link":"https://api.researchmap.jp/Yu777/presentations/30513126","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":203,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513127","link":"https://api.researchmap.jp/Yu777/presentations/30513127","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":204,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513128","link":"https://api.researchmap.jp/Yu777/presentations/30513128","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":205,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513129","link":"https://api.researchmap.jp/Yu777/presentations/30513129","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":206,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513130","link":"https://api.researchmap.jp/Yu777/presentations/30513130","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":207,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513131","link":"https://api.researchmap.jp/Yu777/presentations/30513131","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":208,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513132","link":"https://api.researchmap.jp/Yu777/presentations/30513132","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":209,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513133","link":"https://api.researchmap.jp/Yu777/presentations/30513133","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":210,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513134","link":"https://api.researchmap.jp/Yu777/presentations/30513134","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":211,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513135","link":"https://api.researchmap.jp/Yu777/presentations/30513135","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":212,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513136","link":"https://api.researchmap.jp/Yu777/presentations/30513136","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":213,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513137","link":"https://api.researchmap.jp/Yu777/presentations/30513137","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":214,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513138","link":"https://api.researchmap.jp/Yu777/presentations/30513138","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":215,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513139","link":"https://api.researchmap.jp/Yu777/presentations/30513139","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":216,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513140","link":"https://api.researchmap.jp/Yu777/presentations/30513140","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":217,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513141","link":"https://api.researchmap.jp/Yu777/presentations/30513141","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":218,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513142","link":"https://api.researchmap.jp/Yu777/presentations/30513142","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":219,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513143","link":"https://api.researchmap.jp/Yu777/presentations/30513143","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":220,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513144","link":"https://api.researchmap.jp/Yu777/presentations/30513144","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":221,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513145","link":"https://api.researchmap.jp/Yu777/presentations/30513145","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":222,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513146","link":"https://api.researchmap.jp/Yu777/presentations/30513146","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":223,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513147","link":"https://api.researchmap.jp/Yu777/presentations/30513147","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":224,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513148","link":"https://api.researchmap.jp/Yu777/presentations/30513148","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":225,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513149","link":"https://api.researchmap.jp/Yu777/presentations/30513149","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":226,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513150","link":"https://api.researchmap.jp/Yu777/presentations/30513150","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":227,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513151","link":"https://api.researchmap.jp/Yu777/presentations/30513151","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":228,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513152","link":"https://api.researchmap.jp/Yu777/presentations/30513152","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":229,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513153","link":"https://api.researchmap.jp/Yu777/presentations/30513153","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":230,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513154","link":"https://api.researchmap.jp/Yu777/presentations/30513154","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":231,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513155","link":"https://api.researchmap.jp/Yu777/presentations/30513155","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":232,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513156","link":"https://api.researchmap.jp/Yu777/presentations/30513156","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":233,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513157","link":"https://api.researchmap.jp/Yu777/presentations/30513157","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":234,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513158","link":"https://api.researchmap.jp/Yu777/presentations/30513158","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":235,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513159","link":"https://api.researchmap.jp/Yu777/presentations/30513159","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":236,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513160","link":"https://api.researchmap.jp/Yu777/presentations/30513160","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":237,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513161","link":"https://api.researchmap.jp/Yu777/presentations/30513161","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":238,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513162","link":"https://api.researchmap.jp/Yu777/presentations/30513162","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":239,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513163","link":"https://api.researchmap.jp/Yu777/presentations/30513163","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":240,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513164","link":"https://api.researchmap.jp/Yu777/presentations/30513164","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":241,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513165","link":"https://api.researchmap.jp/Yu777/presentations/30513165","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":242,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513166","link":"https://api.researchmap.jp/Yu777/presentations/30513166","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":243,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513167","link":"https://api.researchmap.jp/Yu777/presentations/30513167","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":244,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513168","link":"https://api.researchmap.jp/Yu777/presentations/30513168","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":245,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513169","link":"https://api.researchmap.jp/Yu777/presentations/30513169","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":246,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513170","link":"https://api.researchmap.jp/Yu777/presentations/30513170","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":247,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513171","link":"https://api.researchmap.jp/Yu777/presentations/30513171","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":248,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513172","link":"https://api.researchmap.jp/Yu777/presentations/30513172","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":249,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513173","link":"https://api.researchmap.jp/Yu777/presentations/30513173","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":250,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513174","link":"https://api.researchmap.jp/Yu777/presentations/30513174","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":251,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513175","link":"https://api.researchmap.jp/Yu777/presentations/30513175","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":252,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513176","link":"https://api.researchmap.jp/Yu777/presentations/30513176","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":253,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513177","link":"https://api.researchmap.jp/Yu777/presentations/30513177","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":254,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513178","link":"https://api.researchmap.jp/Yu777/presentations/30513178","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":255,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513179","link":"https://api.researchmap.jp/Yu777/presentations/30513179","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":256,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513180","link":"https://api.researchmap.jp/Yu777/presentations/30513180","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":257,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513181","link":"https://api.researchmap.jp/Yu777/presentations/30513181","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":258,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513182","link":"https://api.researchmap.jp/Yu777/presentations/30513182","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":259,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513183","link":"https://api.researchmap.jp/Yu777/presentations/30513183","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":260,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513184","link":"https://api.researchmap.jp/Yu777/presentations/30513184","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":261,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513186","link":"https://api.researchmap.jp/Yu777/presentations/30513186","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":262,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513187","link":"https://api.researchmap.jp/Yu777/presentations/30513187","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":263,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513188","link":"https://api.researchmap.jp/Yu777/presentations/30513188","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":264,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513189","link":"https://api.researchmap.jp/Yu777/presentations/30513189","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":265,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513190","link":"https://api.researchmap.jp/Yu777/presentations/30513190","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":266,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513191","link":"https://api.researchmap.jp/Yu777/presentations/30513191","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":267,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513192","link":"https://api.researchmap.jp/Yu777/presentations/30513192","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":268,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513193","link":"https://api.researchmap.jp/Yu777/presentations/30513193","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":269,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513194","link":"https://api.researchmap.jp/Yu777/presentations/30513194","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":270,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513195","link":"https://api.researchmap.jp/Yu777/presentations/30513195","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":271,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513196","link":"https://api.researchmap.jp/Yu777/presentations/30513196","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":272,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513197","link":"https://api.researchmap.jp/Yu777/presentations/30513197","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":273,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513198","link":"https://api.researchmap.jp/Yu777/presentations/30513198","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":274,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513199","link":"https://api.researchmap.jp/Yu777/presentations/30513199","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":275,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513200","link":"https://api.researchmap.jp/Yu777/presentations/30513200","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":276,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513201","link":"https://api.researchmap.jp/Yu777/presentations/30513201","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":277,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513202","link":"https://api.researchmap.jp/Yu777/presentations/30513202","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":278,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513203","link":"https://api.researchmap.jp/Yu777/presentations/30513203","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":279,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513204","link":"https://api.researchmap.jp/Yu777/presentations/30513204","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":280,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513205","link":"https://api.researchmap.jp/Yu777/presentations/30513205","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":281,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513206","link":"https://api.researchmap.jp/Yu777/presentations/30513206","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":282,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513207","link":"https://api.researchmap.jp/Yu777/presentations/30513207","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":283,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513208","link":"https://api.researchmap.jp/Yu777/presentations/30513208","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":284,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513209","link":"https://api.researchmap.jp/Yu777/presentations/30513209","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":285,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513210","link":"https://api.researchmap.jp/Yu777/presentations/30513210","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":286,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513211","link":"https://api.researchmap.jp/Yu777/presentations/30513211","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":287,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513212","link":"https://api.researchmap.jp/Yu777/presentations/30513212","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":288,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513213","link":"https://api.researchmap.jp/Yu777/presentations/30513213","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":289,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513214","link":"https://api.researchmap.jp/Yu777/presentations/30513214","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":290,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513215","link":"https://api.researchmap.jp/Yu777/presentations/30513215","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":291,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513216","link":"https://api.researchmap.jp/Yu777/presentations/30513216","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":292,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513217","link":"https://api.researchmap.jp/Yu777/presentations/30513217","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":293,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513218","link":"https://api.researchmap.jp/Yu777/presentations/30513218","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":294,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513219","link":"https://api.researchmap.jp/Yu777/presentations/30513219","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":295,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513220","link":"https://api.researchmap.jp/Yu777/presentations/30513220","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":296,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513221","link":"https://api.researchmap.jp/Yu777/presentations/30513221","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":297,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513222","link":"https://api.researchmap.jp/Yu777/presentations/30513222","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":298,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513223","link":"https://api.researchmap.jp/Yu777/presentations/30513223","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":299,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513224","link":"https://api.researchmap.jp/Yu777/presentations/30513224","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":300,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513225","link":"https://api.researchmap.jp/Yu777/presentations/30513225","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":301,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513226","link":"https://api.researchmap.jp/Yu777/presentations/30513226","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":302,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513227","link":"https://api.researchmap.jp/Yu777/presentations/30513227","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":303,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513228","link":"https://api.researchmap.jp/Yu777/presentations/30513228","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":304,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513229","link":"https://api.researchmap.jp/Yu777/presentations/30513229","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":305,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513230","link":"https://api.researchmap.jp/Yu777/presentations/30513230","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":306,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513231","link":"https://api.researchmap.jp/Yu777/presentations/30513231","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":307,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513232","link":"https://api.researchmap.jp/Yu777/presentations/30513232","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}
{"no":1,"line":308,"code":403,"action":"insert","action_type":"force","type":"presentations","id":"30513233","link":"https://api.researchmap.jp/Yu777/presentations/30513233","errors":[{"code":403,"error":"forbidden","error_description":"追加する権限がないか、所属名がクライアントIDの機関と一致しません。"}]}

--- success
{"code":400,"status":"error","start_datetime":"2024-11-18T21:42:32Z","end_datetime":"2024-11-18T21:42:33Z","estimated_end_datetime":"2024-11-18T21:42:35Z","total_items":308,"process_items":308,"error_items":308}
====== BulkResult(B000320827, mTUbQZMBYVtrs4O81l2K) : End ======